Renin inhibitors

FIELD OF THE INVENTION

The present invention relates to compounds that may be used to inhibit renin, as well as compositions of matter and kits comprising these compounds. The invention also relates to methods for inhibiting renin and treatment methods using compounds according to the present invention.

BACKGROUND OF THE INVENTION

The renin-angiotensin-aldosterone system (“RAAS”) is one of the hormonal mechanisms involved in regulating pressure/volume homeostasis and also in the development of hypertension, a condition that can progress to more serious cardiovascular diseases such as congestive heart failure. Activation of RAAS begins with secretion of the enzyme renin from juxtaglomerular cells in the kidney.

Renin, a member of the aspartyl protease family, passes from the kidneys into the blood where it cleaves angiotensinogen to generate the decapeptide angiotensin I. Angiotensin I is then cleaved in the lungs, the kidneys and other organs by the angiotensin-converting enzyme (ACE) to form the octapeptide angiotensin II. Angiotensin II, which is known to work on at least two receptor subtypes (AT₁and AT₂), increases blood pressure both directly by arterial vasoconstriction and indirectly by liberating from the adrenal glands the sodium-ion-retaining hormone aldosterone. Angiotensin II also produces other physiological effects such as promoting sodium and fluid retention, inhibiting renin secretion, increasing sympathetic nervous system activity, stimulating vasopressin secretion, causing a positive cardiac inotropic effect and modulating other hormonal systems.

Modulation of the RAAS represents a major advance in the treatment of cardiovascular diseases. In particular, the rationale to develop renin inhibitors lies in its specificity (Kleinert H. D., Cardiovasc. Drugs, 1995, 9, 645). The only substrate known for renin is angiotensinogen, which can only be processed (under physiological conditions) by renin. Inhibitors of the enzymatic activity of renin are therefore expected to bring about a reduction in the formation of angiotensin I and angiotensin II.

In view of the foregoing, renin is an attractive target for the discovery of new therapeutics for cardiovascular disease, hypertension, congestive heart failure, myocardial infarction, renal protection, inflammation, neurological diseases, cancer and other diseases. Accordingly, there is a need to find new renin inhibitors for use as therapeutic agents to treat human diseases.

SUMMARY OF THE INVENTION

The present invention relates to compounds that have activity for inhibiting renin. The present invention provides compounds, pharmaceutical compositions, articles of manufacture and kits comprising these compounds, and also methods of using and method of preparing these compounds.

In one aspect, the invention is directed to compounds having the formula:

embedded image

wherein

1 is 0, 1, 2, or 3;

A₁, A₂, A₃, A₄, and A₅are each independently selected from the group consisting of C and N, provided that two of A₁, A₁, A₃, A₄, and A₅are N;

R₁is selected from the group consisting of (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, amino, (C_1-10)alkylamino, sulfonamido, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, amino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl. (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted;

R₂is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-4)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_3-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted, provided that R₂is absent when A₂is a nitrogen that forms part of a double bond;

R₃and R₄are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamide, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted, and R₂and R₃, and R₃and R₄, may be taken together to form a 5, 6, 7, 8 membered saturated, unsaturated or aromatic ring, provided that R₃and R₄are each independently absent when A₃and A₄, respectively, is a nitrogen that forms part of a double bond;

R₅is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-4)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted, and R₄and R₅may be taken together to form a 5, 6, 7, 8 membered saturated, unsaturated or aromatic ring, provided that R₅is absent when A₅is a nitrogen that forms part of a double bond;

R₆is selected from the group consisting of hydrogen, hydroxyl, unsubstituted and substituted (C_1-6)alkyl, —COOR₉, and —CH₂OR₉, where R₉is selected from the group consisting of hydrogen, (C_1-6)alkyl, (C₆)aryl, (C_5-6)heteroaryl, (C_3-6)cycloalkyl, and hetero(C_2-5)cycloalkyl, each unsubstituted or substituted; and

R₇is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted; and

provided that

- when A₂and A₅are both N, A₁, A₃and A₄are C, R₃and R₄are taken together to form a substituted phenyl, and R₂is a substituted alkyl, R₁is not (C_1-10)alkoxy, (C_4-12)aryloxy, or hetero(C_1-10)aryloxy,
- when A₂and A₅are both N, A₁, A₃and A₄are C, R₃and R₄are taken together to form a substituted pyrimidinyl, and R₂is a substituted alkyl, at least one of the substituents on R, contains one or more heteroatoms,
- when A₁and A₃are each N, A₂, A₄and A₅are each C, and R₄and R₅are taken together to form an unstituted phenyl, R₁is not a phenyl,
- R₂and R₅are not both absent,
- R₂and R₅are not both hydrogen, and
- only one of R₂and R₃, R₃and R₄, and R₄and R₅are taken together to form a ring.

In another aspect, the invention relates to pharmaceutical compositions that comprise a renin inhibitor according to the present invention as an active ingredient and a pharmaceutical acceptable excipient. Pharmaceutical compositions according to the invention may optionally comprise 0.001%-100% of one or more inhibitors of this invention. These pharmaceutical compositions may be administered or coadministered by a wide variety of routes, including for example, orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery (for example by catheter or stent), subcutaneously, intraadiposally, intraarticularly, or intrathecally. The compositions may also be administered or coadministered in slow release dosage forms.

In another aspect, the invention provides kits and other articles of manufacture for treating disease states associated with renin. In one embodiment, a kit is provided that comprises a composition comprising at least one renin inhibitor of the present invention in combination with instructions. The instructions may indicate the disease state for which the composition is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition. The kit may also comprise packaging materials. The packaging material may comprise a container for housing the composition. The kit may also optionally comprise additional components, such as syringes for administration of the composition. The kit may comprise the composition in single or multiple dose forms.

In another aspect, the invention provides an article of manufacture that comprises a composition comprising at least one renin inhibitor of the present invention in combination with packaging materials. The packaging material may comprise a container for housing the composition. The container may optionally comprise a label indicating the disease state for which the composition is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition. The article of manufacture may also optionally comprise additional components, such as syringes for administration of the composition. The article of manufacture may comprise the composition in single or multiple dose forms.

In another aspect, the invention is related to methods for preparing the compounds, compositions and kits according to the present invention. For example, several synthetic schemes are provided herein for synthesizing compounds according to the present invention.

In another aspect, the invention is related to reagents that may be used in the preparation of the compounds according to the invention.

In another aspect, the invention is related to methods for using compounds, compositions, kits and articles of manufacture according to the present invention. In one embodiment, the compounds, compositions, kits and articles of manufacture are used to inhibit renin.

In one embodiment, the compounds, compositions, kits and articles of manufacture are used to treat a disease state for which renin possess activity that contributes to the pathology and/or symptomology of the disease state. In another embodiment, a compound is administered to a subject wherein renin activity within the subject is altered, preferably reduced.

In another embodiment, a prodrug of a compound is administered to a subject that is converted to the compound in vivo where it inhibits renin.

In another embodiment, a method of inhibiting renin is provided that comprises contacting a renin with a compound according to the present invention.

In another embodiment, a method of inhibiting renin is provided that comprises causing a compound according to the present invention to be present in a subject in order to inhibit renin in vivo.

In another embodiment, a method of inhibiting renin is provided that comprises administering a first compound to a subject that is converted in vivo to a second compound wherein the second compound inhibits renin in vivo. It is noted that the compounds of the present invention may be the first or second compounds.

In another embodiment, a therapeutic method is provided that comprises administering a compound according to the present invention.

In another embodiment, a method of treating a condition in a patient that is known to be mediated by renin, or which is known to be treated by renin inhibitors, comprising administering to the patient a therapeutically effective amount of a compound according to the present invention.

In another embodiment, a method is provided for treating a disease state for which renin possess activity that contributes to the pathology and/or symptomology of the disease state, the method comprising: causing a compound according to the present invention to be present in a subject in a therapeutically effective amount for the disease state.

In another embodiment, a method is provided for treating a disease state for which renin possess activity that contributes to the pathology and/or symptomology of the disease state, the method comprising: administering a first compound to a subject that is converted in viva to a second compound such that the second compound is present in the subject in a therapeutically effective amount for the disease state. It is noted that the compounds of the present invention may be the first or second compounds.

In another embodiment, a method is provided for treating a disease state for which renin possess activity that contributes to the pathology and/or symptomology of the disease state, the method comprising: administering a compound according to the present invention to a subject such that the compound is present in the subject in a therapeutically effective amount for the disease state.

In another embodiment, a method is provided for using a compound according to the present invention in order to manufacture a medicament for use in the treatment of a disease state that is known to be mediated by renin, or that is known to be treated by renin inhibitors.

It is noted in regard to all of the above embodiments that the present invention is intended to encompass all pharmaceutically acceptable ionized forms (e.g., salts) and solvates (e.g., hydrates) of the compounds, regardless of whether such ionized forms and solvates are specified since it is well know in the art to administer pharmaceutical agents in an ionized or solvated form. It is also noted that unless a particular stereochemistry is specified, recitation of a compound is intended to encompass all possible stereoisomers (e.g., enantiomers or diastereomers depending on the number of chiral centers), independent of whether the compound is present as an individual isomer or a mixture of isomers. Further, unless otherwise specified, recitation of a compound is intended to encompass all possible resonance forms and tautomers. With regard to the claims, the language “compound of or having the formula” is intended to encompass the compound and all pharmaceutically acceptable ionized forms and solvates, all possible stereoisomers, all possible resonance forms and tautomers, all pharmaceutically acceptable salts and their polymorphs, unless otherwise specifically specified in the particular claim.

It is further noted that prodrugs may also be administered which are altered in vivo and become a compound according to the present invention. The various methods of using the compounds of the present invention are intended, regardless of whether prodrug delivery is specified, to encompass the administration of a prodrug that is converted in vivo to a compound according to the present invention. It is also noted that certain compounds of the present invention may be altered in vivo prior to inhibit renin and thus may themselves be prodrugs for another compound. Such prodrugs of another compound may or may not themselves independently have renin inhibitory activity.

BRIEF DESCRIPTION OF THE FIGURE

FIG. 1 illustrates SEQ ID NO: 1 and SEQ ID NO: 2 referred to in this application.

DEFINITIONS

Unless otherwise stated, the following terms used in the specification and claims shall have the following meanings for the purposes of this Application.

“*” is used through out the Specification and in the Claims to indicate the point of attachment of a substituent to the remainder of the molecule on which the substituent is drawn.

“Alicyclic” means a moiety comprising a non-aromatic ring structure. Alicyclic moieties may be saturated or partially unsaturated with one, two or more double or triple bonds. Alicyclic moieties may also optionally comprise heteroatoms such as nitrogen, oxygen and sulfur. The nitrogen atoms can be optionally quaternerized or oxidized and the sulfur atoms can be optionally oxidized. Examples of alicyclic moieties include, but are not limited to moieties with C_3-8rings such as cyclopropane, cyclohexane, cyclopentane, cyclopentene, cyclopentadiene, cyclohexane, cyclohexene, cyclohexadiene, cycloheptane, cycloheptene, cycloheptadiene, cyclooctane, cyclooctene, and cyclooctadiene.

“Aliphatic” means a moiety characterized by a straight or branched chain arrangement of constituent carbon atoms and may be saturated or partially unsaturated with one, two or more double or triple bonds.

“Alkoxy” means the radical —O-alkyl; the alkyl group is as defined in this Application and can be optionally substituted.

“Alkyl” represented by itself means a straight or branched, saturated or unsaturated, aliphatic radical having a chain of carbon atoms, optionally with oxygen (See “oxaalkyl”) or nitrogen atoms (See “azaalkyl”) between the carbon atoms. C_Xalkyl and C_X-Yalkyl are typically used where X and Y indicate the number of carbon atoms in the chain. For example, C_1-6alkyl includes alkyls that have a chain of between 1 and 6 carbons (e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, pentyl, hexyl, vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methylallyl, ethynyl, 1-propynyl, 2-propynyl, ethyloxymethyl, (—CH₂—O—CH₂CH₃), ethylaminomethyl (—CH₂—NH—CH₂CH₃) and the like). Alkyl represented along with another radical (e.g., as in arylalkyl, heteroarylalkyl) means a straight or branched, saturated or unsaturated aliphatic divalent radical having the number of atoms indicated or when no atoms are indicated means a bond (e.g., (C_6-10)aryl(C_1-3)alkyl includes, benzyl, phenylethyl, 1-phenylethyl, 3-phenylpropyl, 2-thienylmethyl, 2-pyridinylmethyl and the like).

“Alkenyl” means a straight or branched, carbon chain that contains at least one carbon-carbon double bond. Examples of alkenyl include vinyl, allyl, isopropenyl, pentenyl, hexenyl, heptenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl, and the like.

“Alkynyl” means a straight or branched, carbon chain that contains at least one carbon-carbon triple bond. Examples of alkynyl include ethynyl, propargyl, 3-methyl-1-pentynyl, 2-heptynyl and the like.

“Alkylene”, unless indicated otherwise, means a straight or branched, saturated or unsaturated, aliphatic, divalent radical. C_Xalkylene and C_X-Yalkylene are typically used where X and Y indicate the number of carbon atoms in the chain. For example, C_1-6alkylene includes methylene (—CH₂—), ethylene (—CH₂CH₂—), trimethylene (—CH₂CH₂CH₂—), tetramethylene (—CH₂CH₂CH₂CH₂—), 2-butenylene (—CH₂CH═CHCH₂—), 2-methyltetramethylene (—CH₂CH(CH₃)CH₂CH₂—), pentamethylene (—CH₂CH₂CH₂CH₁CH₂—) and the like.

“Alkenylene” means a straight or branched, divalent carbon chain having one or more carbon-carbon double bonds. Examples of alkenylene include ethene-1,2-diyl, propene-1,3-diyl, methylene-1,1-diyl, and the like.

“Alkynylene” means a straight or branched, divalent carbon chain having one or more carbon-carbon triple bonds. Examples of alkynylene include ethyne-1,2-diyl, propyne-1,3-diyl, and the like.

“Alkylidene” means a straight or branched saturated or unsaturated, aliphatic radical connected to the parent molecule by a double bond. C_Xalkylidene and C_X-Yalkylidene are typically used where X and Y indicate the number of carbon atoms in the chain. For example, C_1-6alkylidene includes methylidene (═CH₂), ethylidene (═CHCH₃), isopropylidene (═C(CH₃)₂), propylidene (═CHCH₂CH₃), allylidene (═CH—CH═CH₂), and the like.

“Amino” means the radical —NR_aR_b, where R_aand R_bare each independently hydrogen or a non-hydrogen substituent. Representative amino groups include, without limits, —NH₂, —NHCH₃, —N(CH₃)₂, —NH(C_1-10)alkyl, —N((C_1-10)alkyl)₂, —NHaryl, —NHheteroaryl, —N(aryl)₂, —N(heteroaryl)₂, and the like. Optionally, R_aand R_btogether with the nitrogen may also form a ring. Unless indicated otherwise, the compounds of the invention containing amino moieties may include protected derivatives thereof. Suitable protecting groups for amino moieties include acetyl, tert-butoxycarbonyl, benzyloxycarbonyl, and the like.

“Amido” refers to the group —C(O)NR_aR_b, where R_aand R_bare each independently hydrogen or a non-hydrogen substituent. Representative amino groups include, without limits, —C(O)NH₂, —C(O)NHCH₃, —C(O)N(CH₃)₂, —C(O)NH(C_1-10)alkyl, —C(O)N((C_1-10)alkyl)₂, —C(O)NHaryl, —C(O)NHheteroaryl, —C(O)N(aryl)₂, —C(O)N(heteroaryl)₂, and the like.

“Animal” includes humans, non-human mammals (e.g., dogs, cats, rabbits, cattle, horses, sheep, goats, swine, deer, and the like) and non-mammals (e.g., birds, reptiles and the like).

“Aromatic” means a moiety wherein the constituent atoms make up an unsaturated ring system, all atoms in the ring system are sp²hybridized and the total number of pi electrons is equal to 4n+2. An aromatic ring may be such that the ring atoms are only carbon atoms or may include carbon and non-carbon atoms (see Heteroaryl).

“Aryl” means a monocyclic or polycyclic ring assembly where all the ring atoms are carbon atoms, and at least one of the rings comprising the ring assembly is an aromatic ring. If one or more ring atoms is not carbon (e.g., N, 5), the ring assembly is a heteroaryl. C_Xaryl and C_X-Yaryl are typically used where X and Y indicate the number of carbon atoms in the ring.

“Azaalkyl” means an alkyl, as defined above, except where one or more substituted or unsubstituted nitrogen atoms (—N—) are positioned between carbon atoms of the alkyl. For example, an (C_2-6) azaalkyl refers to a chain comprising between 2 and 6 carbons and one or more nitrogen atoms positioned between the carbon atoms.

“Bicyclic” means a two-ringed ring assembly where the two rings are fused together, linked by a single bond or linked by two bridging atoms.

“Bicycloalkyl” means a saturated or partially unsaturated fused bicyclic or bridged polycyclic ring assembly.

“Bicycloaryl” means a ring assembly of two rings, wherein the rings are linked by a single bond or fused and at least one of the rings comprising the ring assembly is an aromatic ring. C_Xbicycloaryl and C_X-Ybicycloaryl are typically used where X and Y indicate the number of carbon atoms in the bicyclic ring assembly and directly attached to the ring.

“Bridging ring” as used herein refers to a ring that is bonded to another ring to form a compound having a bicyclic structure where two ring atoms that are common to both rings are not directly bound to each other. Non-exclusive examples of common compounds having a bridging ring include borneol, norbornane, 7-oxabicyclo[2.2.1]heptane, and the like. One or both rings of the bicyclic system may also comprise heteroatoms.

“Carbamoyl” means the radical —OC(O)NR_aR_bwhere R_aand R_bare each independently hydrogen or a non-hydrogen substituent.

“Carbocycle” means a ring consisting of carbon atoms.

“Carbocyclic ketone derivative” means a carbocyclic derivative wherein the ring contains a —C(═O)— moiety.

“Carbonyl” typically means a divalent radical —C(═O)—. It is noted that the term “carbonyl” when referring to a monovalent substituent can alternatively refer to a substituted carbonyl or acyl group, —C(═O)R_a, where R_ais hydrogen or a non-hydrogen substituent on the carbonyl carbon, forming different carbonyl-containing groups including acids, acid halides, aldehydes, amides, esters, and ketones.

“Carboxy” typically means a divalent radical —C(O)O—. It is noted that the term “carboxy” when referring to a monovalent substituent means a substituted carboxy, —C(O)OR, where R_ais hydrogen or a non-hydrogen substituent on the carboxyl group forming different carboxy containing groups including acids and esters. It is further noted that compounds of the invention containing carboxy moieties may include protected derivatives thereof, i.e., where the oxygen is substituted with a protecting group. Suitable protecting groups for carboxy moieties include benzyl, tert-butyl, and the like.

“Cyano” means the radical —CN.

“Cycloalkyl” means a radical comprising a non-aromatic, saturated or partially unsaturated, monocyclic, fused or bridged polycyclic ring assembly. C_Xcycloalkyl and C_X-Ycycloalkyl are typically used where X and Y indicate the number of carbon atoms in the ring assembly. For example, C_3-10cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, 2,5-cyclohexadienyl, bicyclo[2.2.2]octyl, adamantan-1-yl, decahydronaphthyl, oxocyclohexyl, dioxocyclohexyl, thiocyclohexyl, 2-oxobicyclo[2.2.1]hept-1-yl, and the like.

“Cycloalkylene” means a divalent radical comprising a saturated or partially unsaturated, monocyclic or polycyclic ring assembly. C_Xcycloalkylene and C_X-Ycycloalkylene are typically used where X and Y indicate the number of carbon atoms in the ring assembly.

“Cyclyl” means a mono- or polycyclic radical, typically a mono-, bi- or tricyclic, unsaturated, partially saturated or saturated ring system with typically 3 to 22, more typically 3 to 14, most typically 3-7, ring atoms and is unsubstituted or substituted by one or more substituents independently selected typically from the substituents as defined in this Application.

“Disease” specifically includes any unhealthy condition of an animal or part thereof and includes an unhealthy condition that may be caused by, or incident to, medical or veterinary therapy applied to that animal, i.e., the “side effects” of such therapy.

“Fused ring” as used herein refers to a multi-ring assembly wherein the rings comprising the ring assembly are so linked that the ring atoms that are common to two rings are directly bound to each other. The fused ring assemblies may be saturated, partially saturated, carbocyclics, heterocyclics, aromatics, heteroaromatics, and the like. Non-exclusive examples of common fused rings include decalin, naphthalene, anthracene, phenanthrene, indole, benzofuran, purine, quinoline, and the like.

“Halo” means fluoro, chloro, bromo or iodo.

“Halo-substituted alkyl”, as an isolated group or part of a larger group, means “alkyl” substituted by one or more “halo” atoms, as such terms are defined in this Application. Halo-substituted alkyl includes haloalkyl, dihaloalkyl, trihaloalkyl, perhaloalkyl and the like (e.g., halo-substituted (C_1-3)alkyl includes chloromethyl, dichloromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, perfluoroethyl, 2,2,2-trifluoro-1,1-dichloroethyl, and the like).

“Heteroalkyl” means alkyl, as defined in this Application, provided that one or more of the atoms within the alkyl chain is a heteroatom.

“Heteroaryl” means a monocyclic or polycyclic ring assembly wherein at least one ring atom is a heteroatom and the remaining ring atoms are carbon, and at least one of the rings comprising the ring assembly is an aromatic ring. Monocyclic heteroaryl groups include, but are not limited to, cyclic aromatic groups having five or six ring atoms, wherein at least one ring atom is a heteroatom and the remaining ring atoms are carbon. The nitrogen atoms of such heteroaryl rings can be optionally quaternerized and the sulfur atoms of such heteroaryl rings can be optionally oxidized. Heteroaryl groups of this invention include, but are not limited to, those derived from furan, imidazole, isothiazole, isoxazole, oxadiazole, oxazole, 1,2,3-oxadiazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrroline, triazole, 1,3,4-thiadiazole, triazole and tetrazole. “Heteroaryl” also includes polycyclic ring assemblies, wherein a heteroaromatic ring is fused or linked by a bond to one or more rings independently selected from the group consisting of an aromatic ring, a cycloalkyl ring, a cycloalkenyl ring, a heterocycloalkyl ring and another heteroaromatic ring. Bicyclic or tricyclic heteroaryls include, but are not limited to, those derived from benzo[b]furan, benzo[b]thiophene, benzimidazole, imidazo[4,5-c]pyridine, quinazoline, thieno[2,3-c]pyridine, thieno[3,2-b]pyridine, thieno[2,3-b]pyridine, indolizine, imidazo[1,2a]pyridine, quinoline, isoquinoline, phthalazine, quinoxaline, naphthyridine, quinolizine, indole, isoindole, indazole, indoline, benzoxazole, benzopyrazole, benzothiazole, imidazo[1,5-a]pyridine, pyrazolo[1,5-a]pyridine, imidazo[1,2-a]pyrimidine, imidazo[1,2-c]pyrimidine, imidazo[1,5-a]pyrimidine, imidazo[1,5-c]pyrimidine, pyrrolo[2,3-b]pyridine, pyrrolo[2,3-c]pyridine, pyrrolo[3,2-c]pyridine, pyrrolo[3,2-b]pyridine, pyrrolo[2,3-d]pyrimidine, pyrrolo[3,2-d]pyrimidine, pyrrolo[2,3-b]pyrazine, pyrazolo[1,5-a]pyridine, pyrrolo[1,2-b]pyridazine, pyrrolo[1,2-c]pyrimidine, pyrrolo[1,2-a]pyrimidine, pyrrolo[1,2-a]pyrazine, triazo[1,5-a]pyridine, pteridine, purine, carbazole, acridine, phenazine, phenothiazene, phenoxazine, 1,2-dihydropyrrolo[3,2,1-hi]indole, indolizine, pyrido[1,2-a]indole and 2(1H)-pyridinone. The polycylic heteroaryl ring assembly can be attached to the parent molecule through either the heteroaryl group itself or the aryl, cycloalkyl, cycloalkenyl or heterocycloalkyl group to which it is fused. The heteroaryl groups of this invention can be substituted or unsubstituted.

“Heterobicycloaryl” means bicycloaryl, as defined in this Application, provided that one or more of the atoms within the ring assembly is a heteroatom. For example, hetero(C_4-12)bicycloaryl as used in this Application includes, but is not limited to, indoline, 2-amino-4-oxo-3,4-dihydropteridin-6-yl, tetrahydroisoquinolinyl, and the like.

“Heterocycloalkyl” means cycloalkyl, as defined in this Application, provided that one or more of the atoms forming the ring is a heteroatom. Non-exclusive examples of heterocycloalkyl include piperidyl, 4-morpholyl, 4-piperazinyl, pyrrolidinyl, perhydropyrrolizinyl, 1,3-dioxanyl, 1,4-dioxanyl and the like.

“Heteroatom” refers to an atom that is not a carbon atom. Particular examples of heteroatoms include, but are not limited to nitrogen, oxygen, and sulfur.

“Heteroatom moiety” includes a moiety where the atom by which the moiety is attached is not a carbon. Examples of heteroatom moieties include —NR═, —NR—, —N⁺(O⁻)═, —O—, —S— or —S(O)₂—, wherein R is hydrogen or a non-hydrogen substituent.

“Heterobicycloalkyl” means bicycloalkyl, as defined in this Application, provided that one or more of the atoms within the ring is a heteroatom. For example hetero(C_9-12)bicycloalkyl as used in this application includes, but is not limited to, 3-aza-bicyclo[4.1.0]hept-3-yl, 2-aza-bicyclo[3.1.0]hex-2-yl, 3-aza-bicyclo[3.1.0]hex-3-yl, and the like.

“Heterocyclyl” refers to a mono- or polycyclic radical, typically a mono-, bi- or tricyclic, unsaturated, partially saturated or saturated ring system with typically 3 to 22, more typically 3 to 14, most typically 3-7, ring atoms, and with one or more, preferably one to four, heteroatoms independently selected from nitrogen, oxygen, sulfur, S(═O)—, —S(═O)₂—, and is unsubstituted or substituted by one or more substituents independently selected typically from the substituents defined in this Application.

“Heterocycloalkylene” means cycloalkylene, as defined in this Application, provided that one or more of the ring member carbon atoms is replaced by a heteroatom.

“Hydroxy” means the radical —OH.

“IC₅₀” refers to the molar concentration of an inhibitor that produces 50% inhibition of the target enzyme.

“Iminoketone derivative” means a derivative comprising the moiety —C(═NR)—, wherein R is hydrogen or a non-hydrogen substituent attached to the nitrogen.

“Isomers” mean any compounds having identical molecular formulae but differing in the nature or sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers.” Stereoisomers that are not mirror images of one another are termed “diastereomers” and stereoisomers that are nonsuperimposable mirror images are termed “enantiomers” or sometimes “optical isomers.” A carbon atom bonded to four different substituents (where no two are the same) is termed a “chiral center.” A compound with one chiral center has two enantiomeric forms of opposite chirality. A mixture of equal amounts of the two enantiomeric forms is termed a “racemic mixture.” A compound that has more than one chiral center has 2^n-1enantiomeric pairs, where n is the number of chiral centers. Compounds with more than one chiral center may exist as ether an individual diastereomer or as a mixture of diastereomers, termed a “diastereomeric mixture.” When one chiral center is present a stereoisomer may be characterized by the absolute configuration of that chiral center. Absolute configuration refers to the arrangement in space of the substituents attached to the chiral center. Enantiomers are characterized by the absolute configuration of their chiral centers and described by the R- and S-s sequencing rules of Cahn, Ingold and Prelog. Conventions for stereochemical nomenclature, methods for the determination of stereochemistry and the separation of stereoisomers are well known in the art (e.g., see “Advanced Organic Chemistry”, 4th edition, March, Jerry, John Wiley & Sons, New York, 1992).

“Leaving group” means a moiety that can be displaced by another moiety, such as by nucleophilic attack, during a chemical reaction. Leaving groups are well known in the art and include, for example, halides and OSO₂R′ where R′ is, for example, alkyl, haloalkyl, or aryl optionally substituted by halo, alkyl, alkoxy, amino, and the like. Non-limiting examples of leaving groups include chloro, bromo, iodo, mesylate, tosylate, and other similar groups.

“Moiety” means an interconnected group of atoms, generally referred to by its most characteristic structural component. For example, a “carbonyl moiety” refers to groups that contain a carbonyl group.

“Nitro” means the radical —NO₂.

“Oxaalkyl” means an alkyl, as defined above, except where one or more oxygen atoms (—O—) are positioned between carbon atoms of the alkyl. For example, an (C_2-6)oxaalkyl refers to a chain comprising between 2 and 6 carbons wherein one or more oxygen atoms is positioned between two carbon atoms.

“Oxy” typically means the radical —O—. It is noted that the term “oxy” when referring to a monovalent radical can alternatively refer to a substituents oxy group, —OR—, where R is hydrogen or a non-hydrogen substituent on the'oxy radical forming oxy-containing groups including hydroxy, alkoxy, aryloxy, heteroaryloxy and carbonyloxy.

“Pharmaceutically acceptable” means that which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary use as well as human pharmaceutical use.

“Pharmaceutically acceptable salts” means salts of compounds of the present invention which are pharmaceutically acceptable, as defined above, and which possess the desired pharmacological activity. Such salts include acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or with organic acids such as acetic acid, propionic acid, hexanoic acid, heptanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, o-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, p-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]oct-2-ene-1-carboxylic acid, glucoheptonic acid, 4,4′-methylenebis(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid and the like.

Pharmaceutically acceptable salts also include base addition salts which may be formed when acidic protons present are capable of reacting with inorganic or organic bases. Acceptable inorganic bases include sodium hydroxide, sodium carbonate, potassium hydroxide, aluminum hydroxide and calcium hydroxide. Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine and the like.

“Prodrug” means a compound that is convertible in vivo metabolically into an inhibitor according to the present invention. The prodrug itself may or may not also have renin inhibitory activity. For example, an inhibitor comprising a hydroxy group may be administered as an ester that is converted by hydrolysis in viva to the hydroxy compound. Suitable esters that may be converted in viva into hydroxy compounds include acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis-b-hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates, methanesulfonates, ethanesulfonates, benzenesulfonates, p-toluenesulfonates, cyclohexylsulfamates, quinates, esters of amino acids, and the like. Similarly, an inhibitor comprising an amine group may be administered as an amide or as an N-alkyl (particularly N-methyl or N-ethyl) that is converted by hydrolysis or oxidation in viva to the amine compound.

“Protected derivatives” means derivatives of inhibitors in which a reactive site or sites are blocked with protecting groups. Protected derivatives are useful in the preparation of inhibitors or in themselves may be active as inhibitors. Examples of protected group includes, but are not limited to, acetyl, tetrahydropyran, methoxymethyl ether, β-methoxyethoxymethyl ether, p-methoxybenzyl, methylthiomethyl ether, pivaloyl, silyl ether, carbobenzyloxy, benzyl, tert-butoxycarbonyl, p-methoxyphenyl, 9-fluorenylmethyloxycarbonyl, acetals, ketals, acylals, dithianes, methylesters, benzyl esters, tert-butyl esters, and silyl esters. A comprehensive list of suitable protecting groups can be found in T. W. Greene, Protecting Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, Inc. 1999.

“Ring” means a carbocyclic or a heterocyclic system.

“Substituent convertible to hydrogen in vivo” means any group that is convertible to a hydrogen atom by enzymological or chemical means including, but not limited to, hydrolysis, reduction and oxidation. Examples include hydrolyzable groups, such as acyl groups, groups having an oxycarbonyl group, amino acid residues, peptide residues, o-nitrophenylsulfenyl, trimethylsilyl, tetrahydro-pyranyl, diphenylphosphinyl, and the like. Examples of acyl groups include formyl, acetyl, trifluoroacetyl, and the like. Examples of groups having an oxycarbonyl group include ethoxycarbonyl, t-butoxycarbonyl (—(O)CO—C(CH₃)₃), benzyloxycarbonyl, p-methoxybenzyloxycarbonyl, vinyloxycarbonyl, β-(p-toluenesulfonyl)ethoxycarbonyl, and the like. Examples of suitable amino acid residues include amino acid residues per se and amino acid residues that are protected with a protecting group. Suitable amino acid residues include, but are not limited to, residues of Gly (glycine), Ala (alanine; —C(O)CH(NH₂)CH₃), Arg (arginine), Asn (asparagine), Asp (aspartic acid), Cys (cysteine), Glu (glutamic acid), H is (histidine), Ile (isoleucine), Leu (leucine; —C(O)CH(NH₂)CH₂CH(CH₃)₂), Lys (lysine), Met (methionine), Phe (phenylalanine), Pro (praline), Ser (serine), Thr (threonine), Trp (tryptophan), Tyr (tyrosine), Val (valine), Nva (norvaline), Hse (homoserine), 4-Hyp (4-hydroxyproline), 5-Hyl (5-hydroxylysine), Orn (ornithine) and β-Ala. Examples of suitable protecting groups include those typically employed in peptide synthesis, including acyl groups (such as formyl and acetyl), arylmethyloxycarbonyl groups (such as benzyloxycarbonyl and p-nitrobenzyloxycarbonyl), t-butoxycarbonyl groups (—(O)CO—C(CH₃)₃), and the like. Suitable peptide residues include peptide residues comprising two to five, and optionally two to three, of the aforesaid amino acid residues. Examples of such peptide residues include, but are not limited to, residues of such peptides as Ala-Ala (—C(O)CH(NH)CH₃—C(O)CH(NH₂)CH₃)), Gly-Phe, Nva-Nva, Ala-Phe, Gly-Gly, Gly-Gly-Gly, Ala-Met, Met-Met, Leu-Met and Ala-Leu. The residues of these amino acids or peptides can be present in stereochemical configurations of the D-form, the L-form or mixtures thereof. In addition, the amino acid or peptide residue may have an asymmetric carbon atom. Examples of suitable amino acid residues having an asymmetric carbon atom include residues of Ala, Leu, Phe, Trp, Nva, Val, Met, Ser, Lys, Thr and Tyr. Peptide residues having an asymmetric carbon atom include peptide residues having one or more constituent amino acid residues having an asymmetric carbon atom. Examples of suitable amino acid protecting groups include those typically employed in peptide synthesis, including acyl groups (such as formyl and acetyl), arylmethyloxycarbonyl groups (such as benzyloxycarbonyl and p-nitrobenzyloxycarbonyl), t-butoxycarbonyl groups (—(O)CO—C(CH₃)₃), and the like. Other examples of substituents “convertible to hydrogen in vivo” include reductively eliminable hydrogenolyzable groups. Examples of suitable reductively eliminable hydrogenolyzable groups include, but are not limited to, arylsulfonyl groups (such as o-toluenesulfonyl); methyl groups substituted with phenyl or benzyloxy (such as benzyl, trityl and benzyloxymethyl); arylmethoxycarbonyl groups (such as benzyloxycarbonyl and o-methoxy-benzyloxycarbonyl); and halogenoethoxycarbonyl groups (such as β,β,β-trichloroethoxycarbonyl and β-iodoethoxycarbonyl). Further examples of substituents “convertible to hydrogen in vivo” include enzymatic oxidizable groups such as N-alkyls, particularly N-methyl and N-ethyl.

“Optionally substituted” refers to the optional replacement of hydrogen with a monovalent or divalent radical. “Unsubstituted” means that a given moiety consist of only hydrogen atoms bound at available valences. “Substituted” refers to the replacement of hydrogen with a monovalent or divalent radical. The substituents of an “optionally substituted” group may include, without limitation, one or more substituents independently selected from the group or designated subsets thereof, aldehyde, (C_1-10)alkyl, alkylene, alkylidene, amide, amino, aminoalkyl, aryl, bicycloalkyl, bicycloaryl, carbamoyl, carbocyclyl, carboxyl, carbonyl group, cycloalkyl, cycloalkylene, ester, halo, heterobicycloalkyl, heterocycloalkylene, heteroaryl, heterobicycloaryl, heterocycloalkyl, oxo, hydroxy, iminoketone, ketone, nitro, oxaalkyl, and oxoalkyl moieties, each of which may optionally also be substituted or unsubstituted.

In one particular embodiment, examples of substituents include, but are not limited to, hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-14)aryloxy, (C_1-13)heteroaryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, (C_1-10)haloalkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-5)alkyl, (C_3-12)heterocycloalkyl(C_1-10)alkyl, aryl(C_1-10)alkyl, (C_1-10)heteroaryl(C_1-5)alkyl, (C_9-12)bicycloaryl(C_1-5)alkyl, (C_8-12)heterobicycloaryl(C_1-5)alkyl, (C_3-12)cycloalkyl, (C_3-12)heterocycloalkyl, (C_9-12)bicycloalkyl, (C_3-12)heterobicycloalkyl, (C_4-12)aryl, (C_1-10)heteroaryl, (C_9-12)bicycloaryl and (C_4-12)heterobicycloaryl, the substituents are as defined herein. In addition, the substituent is itself optionally substituted by a further substituent. In one particular embodiment, examples of the further substituent include, but are not limited to, hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, (C_1-10)heteroaryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, (C_1-10)haloalkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-5)alkyl, (C_3-12)heterocycloalkyl(C_1-10)alkyl, aryl(C_1-10)alkyl, (C_1-10)heteroaryl(C_1-5)alkyl, (C_9-12)bicycloaryl(C_1-5)alkyl, (C_8-12)heterobicycloaryl(C_1-5)alkyl, (C_3-12)cycloalkyl, (C_3-12)heterocycloalkyl, (C_9-12)bicycloalkyl, (C_3-12)heterobicycloalkyl, (C_4-12)aryl, (C_1-10)heteroaryl, (C_9-12)bicycloaryl and (C_4-12)heterobicycloaryl, the substituents are as defined herein.

“Sulfinyl” means the radical —S(O)—. It is noted that the term “sulfinyl” when referring to a monovalent substituent can alternatively refer to a substituted sulfinyl group, —S(═O)R, where R is hydrogen or a non-hydrogen substituent on the sulfur atom forming different sulfinyl groups including sulfinic acids, sulfinamides, sulfinyl esters, and sulfoxides.

“Sulfonyl” means the radical —S(O)₂—. It is noted that the term “sulfonyl” when referring to a monovalent substituent can alternatively refer to a substituted sulfonyl group, —S(═O)₂R, where R is hydrogen or a non-hydrogen substituent on the sulfur atom forming different sulfonyl groups including sulfonic acids, sulfonamides, sulfonate esters, and sulfones.

“Therapeutically effective amount” means that amount which, when administered to an animal for treating a disease, is sufficient to effect such treatment for the disease.

“Thiocarbonyl” means the radical —C(S)—. It is noted that the term thiocarbonyl when referring to a monovalent substituent can alternatively refer to a substituted thiocarbonyl group, —C(═S)₂R, where R is hydrogen or a non-hydrogen substituent on the carbon atom forming different thiocarbonyl groups including thioacids, thioamides, thioesters, and thioketones.

“Treatment” or “treating” means any administration of a compound of the present invention and includes:

(1) preventing the disease from occurring in an animal which may be predisposed to the disease but does not yet experience or display the pathology or symptomatology of the disease,

(2) inhibiting the disease in an animal that is experiencing or displaying the pathology or symptomatology of the diseased (i.e., arresting further development of the pathology and/or symptomatology), or

(3) ameliorating the disease in an animal that is experiencing or displaying the pathology or symptomatology of the diseased (i.e., reversing the pathology and/or symptomatology).

It is noted in regard to all of the definitions provided herein that the definitions should be interpreted as being open ended in the sense that further substituents beyond those specified may be included. Hence, a C₁alkyl indicates that there is one carbon atom but does not indicate what are the substituents on the carbon atom. Hence, a C₁alkyl comprises methyl (i.e., —CH₃) as well as —CR_aR_bR_cwhere R_a, R_b, and R_cmay each independently be hydrogen or any other substituent where the atom attached to the carbon is not a hydrogen atom. Hence, —CF₃, —CH₁₀H and —CH₂CN, for example, are all C₁alkyls.

It is noted in regard to all of the definitions provided herein that the definitions should be interpreted as being open ended in the sense that further substituents beyond those specified may be included. Hence, a C₁alkyl indicates that there is one carbon atom but does not indicate what are the substituents on the carbon atom. Hence, a C₁alkyl comprises methyl (i.e., —CH₃) as well as —CR_aR_bR_cwhere R_a, R_b, and R_cmay each independently be hydrogen or any other substituent where the atom attached to the carbon is a heteroatom or cyano. Hence, CF₃, CH₂OH and CH₂CN, for example, are all C₁alkyls.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to compounds, pharmaceutical compositions, kits and articles of manufacture that may be used to inhibit renin. The present invention also relates to methods for inhibiting renin and treatment methods using compounds according to the present invention. The present invention further relates to methods for the preparation of the renin inhibitors of the invention, and to compounds that are useful for the preparation of the renin inhibitors of the invention.

It is noted that the compounds of the present invention may also possess inhibitory activity for other aspartyl proteases (e.g., pepsin, gastricsin, napsin, BACE 1 & 2 and cathepsin D and E) and thus may be used to address disease states associated with these other family members. In addition, the compounds of the present invention may be useful as inhibitors of plasmepsins to treat malaria and as inhibitors of Candida albicans secreted aspartyl proteases to treat fungal infections.

In one aspect, the invention is directed to compounds that are active against renin.

In one embodiment, compounds of the present invention are of the formula:

embedded image

wherein

l is 0, 1, 2, or 3;

A₁, A₂, A₃, A₄, and A₅are each independently selected from the group consisting of C and N, provided that two of A₁, A₂, A₃, A₄, and A₅are N;

R₁is selected from the group consisting of (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, amino, (C_1-10)alkylamino, sulfonamido, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, amino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted;

R₂is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-4)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted, provided that R₂is absent when A₂is a nitrogen that forms part of a double bond;

R₃and R₄are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamide, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted, and R₂and R₃, and R₃and R₄, may be taken together to form a 5, 6, 7, 8 membered saturated, unsaturated or aromatic ring, provided that R₃and R₄are each independently absent when A₃and A₄, respectively, is a nitrogen that forms part of a double bond;

provided that

- when A₂and A₅are both N, A₁, A₃and A₄are C, R₃and R₄are taken together to form a substituted phenyl, and R₂is a substituted alkyl, R₁is not (C_1-10)alkoxy, (C_4-12)aryloxy, or hetero(C_1-10)aryloxy,
- when A₂and A₅are both N, A₁, A₃and A₄are C, R₃and R₄are taken together to form a substituted pyrimidinyl, and R₂is a substituted alkyl, at least one of the substituents on R₂contains one or more heteroatoms,
- when A₁and A₃are each N, A₁, A₄and A₅are each C, and R₄and R₅are taken together to form an unstituted phenyl, R₂is not a phenyl,
- R, and R₅are not both absent,
- R₂and R₅are not both hydrogen, and
- only one of R₂and R₃, R₃and R₄, and R₄and R₅are taken together to form a ring.

In another embodiment, the compounds of the invention are of the formula selected from the following group:

embedded image

wherein

l is 0, 1, 2, or 3;

each A₀is independently selected from the group consisting of CR₁₀R₁₀′, NR₈, O, and S;

R₁is selected from the group consisting of (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, amino, (C_1-10) alkylamino, sulfonamido, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, amino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted;

R₂is selected from the group consisting of (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-4)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted, provided that

- when R₁is a substituted alkyl and the fused ring to which R₂is attached is a substituted benzimidazole, R₁is not (C_1-10)alkoxy, (C_4-12)aryl, or hetero(C_1-10)aryl,
- when R₂is a substituted alkyl, and the fused ring to which R₂is attached is a substituted pyrimidinylimadazole, at least one of the substituents on R₂contains one or more heteroatoms, and
- when the fused ring to which R₂is attached is an unsubstituted benzimidazole, is not phenyl;

R₃and R₄are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted;

R₇is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_3-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted;

R₈is selected from the group consisting of hydrogen, hydroxyl, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyloxy, carbonyl, aminocarbonyl, oxycarbonyl, amino, (C_1-10)alkylamino, sulfonamido, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted, or R₈is absent when the nitrogen to which it is bound forms part of a double bond; and

R₁₀and R₁₀′ are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted, or R₁₀is absent when the carbon to which it is bound forms part of a double bond.

In another embodiment, the compounds of the invention are of the formula

embedded image

wherein

1 is 0, 1, 2, or 3;

each A₀is independently selected from the group consisting of CR₁₀R₁₀′, NR₈, O, and S;

R₁is selected from the group consisting of (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, amino, (C_1-10)alkylamino, sulfonamido, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, amino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted;

R₂is selected from the group consisting of (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-4)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero (C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted, provided that

- when R₂is a substituted alkyl and the fused ring to which R₂is attached is a substituted benzimidazole, R₁is not (C_1-10)alkoxy, (C_4-12)aryl, or hetero(C_1-10)aryl,
- when R₂is a substituted alkyl and the fused ring to which R₂is attached is a substituted pyrimidinylimadazole, at least one of the substituents on R₂contains one or more heteroatoms;

R₇is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_4-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl(C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted;

R₁₀and R₁₀′ are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted, or R₁₀′ is absent when the carbon to which it is bound forms part of a double bond.

In other embodiment, the compounds of the invention are of a formula selected from the following group:

embedded image

wherein

l is 0, 1, 2, or 3;

p is 0, 1, 2, 3, or 4;

R₁is selected from the group consisting of (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, amino, (C_1-10)alkylamino, sulfonamido, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, amino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted;

R₂is selected from the group consisting of (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, sulfonyl, sulfinyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-4)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulflnyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl(C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted, provided that

- when R₂is a substituted alkyl and the fused ring to which R₂is attached is a substituted benzimidazole, R₁is not (C_1-10)alkoxy, (C_4-12)aryl, or hetero(C_1-10)aryl, and
- when R₂is a substituted alkyl and the fused ring to which R₂is attached is a substituted pyrimidinylimadazole, at least one of the substituents on R₂contains one or more heteroatoms;

R₇is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-12)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted;

each R₁₀or R₁₀′ is independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl, (C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bioycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted.

In another embodiment, the compounds of the invention are of the formula

embedded image

wherein

l is 0, 1, 2, or 3;

p is 0, 1, 2, 3, or 4;

R₁is selected from the group consisting of (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, amino, (C_1-10)alkylamino, sulfonamido, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, amino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted;

R₂is selected from the group consisting of hydrogen, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-4)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted, provided that when R₂is a substituted alkyl and the benzimidazole ring to which R₂is attached is substituted, R₁is not (C_1-10)alkoxy, (C_4-12)aryl or hetero(C_1-10)aryl;

R₇is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamide, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-14cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted; and

each R₁₀is independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted.

In still another embodiment, the compounds of the invention are of the formula:

embedded image

wherein

l is 0, 1, 2, or 3;

p is 0, 1, 2, 3, or 4;

R₁is selected from the group consisting of (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, amino, (C_1-10)alkylamino, sulfonamido, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, amino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-10)bicycloaryl, each unsubstituted or substituted;

R₂is selected from the group consisting of (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-4)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-10)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted, provided that when R₂is a substituted alkyl and the benzimidazole ring to which R2 is attached is substituted, R₁is not (C_1-10)alkoxy, (C_4-12)aryl or hetero(C_1-10)aryl;

In yet another embodiment, the compounds of the invention are of the formula:

embedded image

wherein

l is 0, 1, 2, or 3;

each A₀is independently selected from the group consisting of CR₁₀R₁₀′, NR₈, O, and S;

R₁is selected from the group consisting of (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, amino, (C_1-10)alkylamino, sulfonamido, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, amino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_1-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted;

R₂is selected from the group consisting of (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_4-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted, provided that when the fused ring to which R₂is attached is an unsubstituted benzimadazole, R₁is not phenyl;

R₁₀and R₁₀′ are each selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted, or R₁₀′ is absent when the carbon to which it is bound forms part of a double bond.

In yet another embodiment, the compounds of the invention are of a formula selected from the following group:

embedded image

wherein

l is 0, 1, 2, or 3;

p is 0, 1, 2, 3, or 4;

R₁is selected from the group consisting of (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, amino, (C_1-10)alkylamino, sulfonamido, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, amino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted;

R₈is selected from the group consisting of hydrogen, hydroxyl, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyloxy, carbonyl, aminocarbonyl, oxycarbonyl, amino, (C_1-10)alkylamino, sulfonamido, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_3-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted, or R₈is absent when the nitrogen to which it is bound forms part of a double bond; and

each R₁₀and R₁₀′ is independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted.

In another embodiment, the compounds of the invention are of the formula:

embedded image

wherein

l is 0, 1, 2, or 3;

p is 0, 1, 2, 3, or 4;

R₁is selected from the group consisting of (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, amino, (C_1-10)alkylamino, sulfonamido, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, amino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-16)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted;

R₁₀is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl(C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted.

In yet another embodiment, the compounds of the invention are of the formula:

embedded image

wherein

l is 0, 1, 2, or 3;

p is 0, 1, 2, 3, or 4;

R₁is selected from the group consisting of (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, amino, (C_1-10)alkylamino, sulfonamido, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_4-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_1-10)bicycloaryl, each unsubstituted or substituted;

R₁₀is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbon yloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl, (C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted.

R₁

In some variations of the above embodiments, R₁is selected from the group consisting of amino, (C_1-10)alkylamino, (C_1-10)alkyl, hetero(C_1-10)alkyl, amino(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, each unsubstituted or substituted. In some other variations, R₁is selected from the group consisting of (C_1-6)alkyl and amino, each unsubstituted or substituted. In some other variations, R₁is unsubstituted or substituted (C_1-6)alkyl. In yet other variations, R₁is unsubstituted or substituted amino.

In particular variations of the above embodiments, R₁is —NHR₁₁. In some variations of these particular variations, R₁₁is selected from the group consisting of (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted with 1-3 substitutents.

In other variations, R₁₁is selected from the group consisting of (C_1-6)alkyl, hydroxy(C_1-6)alkyl, carbonyl(C_1-6)alkyl, (C_3-12)cycloalkyl(C_1-6)alkyl, hetero(C_3-12)cycloalkyl(C_1-6)alkyl, aryl(C_1-6)alkyl, hetero(C_1-10)aryl(C_1-6)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted with 1-3 substituents.

In still other variations, R_1iis selected from the following group: methyl, ethyl, propyl,

embedded image

each unsubstituted or substituted with 1-3 substituents.

In some variations, the substituents on R₁₁, when present, are each independently selected from the group consisting of halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-10)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or further substituted. In other variations, the substituents on R₁₁are each independently selected from the group consisting of halo, perhalo(C_1-6)alkyl, (C_1-6)alkyl, aryl, aryl(C_1-6)alkyl, heteroaryl(C_1-6)alkyl, (C_1-6)alkoxy, and (C_1-6)alkylcarbonyl, each unsubstituted or further substituted. In still other variations, the substituents on R₁₁are each independently selected from the group consisting of chloro, methyl, trifluoromethyl, isobutyl, phenyl, phenylmethyl, and methoxy. In other variation, one of the substituents on R₁₁is chloro. In yet other variation, one of the substituents on R₁₁is methyl.

In other particular variations of the above embodiments, R₁is of the formula

embedded image

where

m is 0, 1 or 2;

n is 0 or 1;

R₁₄and R₁₅are each individually selected from the group consisting of hydrogen, hydroxyl, (C_1-6)alkyl, hydroxy(C_1-6)alkyl, (C_1-6)alkoxy, aryl(C_1-6)alkyl, heteroaryl(C_1-6)alkyl, cycloalkyl(C_1-6)alkyl, and (C_1-6)heteracycloalkyl(C_1-6)alkyl, provided that only one of R₁₄and R₁₅is hydroxyl;

R₁₆is selected from the group consisting of hydrogen, cyano, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, heteroaryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted, and any two substitutents bound to adjacent atoms of R₁₆may be taken together to form a 5, 6, or 7 membered, unsubstituted or substituted, saturated, unsaturated or aromatic ring;

R₁₆′ is selected from the group consisting of hydrogen, unsubstituted (C_1-6)alkyl and substituted (C_1-6)alkyl; and

R₁₇is selected from the group consisting of hydrogen, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted; and

provided that

- R₁₄and R₁₅may be taken together to form a 5, 6, or 7 membered, unsubstituted or substituted, saturated, unsaturated or aromatic ring,
- R₁₅and R₁₆may be taken together to form a 5, 6, or 7 membered, unsubstituted or substituted, saturated, unsaturated or aromatic ring,
- R₁₆and R₁₆′ may be taken together to form a 3, 4, 5, or 6 membered, unsubstituted or substituted, saturated, unsaturated or aromatic ring, and
- R₁₆and R₁₇may be taken together to form a 5, 6, or 7 membered, unsubstituted or substituted, aryl or heteroaryl.

In yet another particular variations of the above embodiments, R₁is of the formula

embedded image

where

R₁₆is selected from the group consisting of (C_1-6)alkyl, amino(C_1-6)alkyl, alkoxy(C_1-6)alkyl, aryl(C_1-6)alkyl, heteroaryl(C_1-6)alkyl, and aryloxy(C_1-6)alkyl, aryl, heteroaryl, cycloalkyl(C_1-6)alkyl and heterocycloalkyl(C_1-6)alkyl, each unsubstituted or substituted;

R₁₆′ is selected from the group consisting of hydrogen, unsubstituted or substituted (C_1-6)alkyl;

R₁₇is selected from the group consisting of hydrogen, (C_1-6)alkyl, hydroxyl(C_1-6)alkyl, alkoxy(C_1-4alkyl, halo(C_1-6)alkyl, amino(C_1-6)alkyl, each unsubstituted or substituted; and

provided that

- R₁₆and R₁₆′ may be taken together to form a 3, 4, 5, or 6 membered, unsubstituted or substituted, saturated, unsaturated or aromatic ring, and
- R₁₆and R₁₇may be taken together to form a 5, 6, or 7 membered, unsubstituted or substituted, aryl or heteroaryl.

Of the immediately preceding particular variations, in some variations, R₁₆is selected from the group consisting of methyl, ethyl, isopropyl, isobutyl, sec-butyl, tertbutyl, phenylmethyl, cyclohexyl, pyridylmethyl, 1-chloromethyl, each individually unsubstituted or substituted. In other variations, R₁₆and R₁₇are taken together to form a 5, 6, or 7 membered, unsubstituted or substituted cycloalkyl or heterocycloalkyl. In still other variations, R₁₆and R₁₇are taken together to form an unsubstituted or substituted pyrrolindyl. In yet still other variations, R₁₆and R₁₆′ are taken together to form a 3, 4, 5, or 6 membered, unsubstituted or substituted cycloalkyl or heterocycloalkyl, each individually unsubstituted or substituted. In still further variations, R₁₆and R₁₆′ are taken together to form a cyclobutyl or cyclopropyl ring, each individually unsubstituted or substituted.

In all these variations, the substituents on R₁₆, R₁₇, or the rings formed by taking together R₁₆and R₁₆′ or R₁₆and R₁₇, are each individually selected from the group consisting of halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or further substituted.

In another particular variations of the above embodiments, R₁is a substituted alkyl of the formula

embedded image

where

R₁₅is selected from the group consisting of hydrogen, hydroxyl, (C_1-6)alkyl, hydroxy(C_1-6)alkyl, (C_1-6)alkoxy, aryl(C_1-6)alkyl, heteroaryl(C_1-6)alkyl, cycloalkyl(C_1-6)alkyl, and (C_1-6)heterocycloalkyl(C_1-6)alkyl, provided that only one of R₁₄and R₁₅is hydroxyl; R₁₆is a (C_1-10)alkyl or a cyclic moiety selected from the group consisting of (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, wherein said (C_1-10)alkyl and cyclic moiety are each independently unsubstituted or substituted with I-3 substituents, or R₁₅and R₁₆are taken together to form a 5, 6, or 7 membered, unsubstituted or substituted, saturated, unsaturated or aromatic ring, and the substituents bonded to R₁₆or to the ring formed by taking together R₁₅and R₁₆are each independently selected from the group consisting of halo, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonyl, (C_1-10)alkyl, halo(C_1-10)alkyl, perhalo(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, each unsubstituted or substituted, and any two substitutents bonded to adjacent atoms may be taken together to form a 5, 6, or 7 membered, unsubstituted or substituted, saturated, unsaturated or aromatic ring; and

R₁₇is selected from the group consisting of hydrogen, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted.

Of the immediately preceding particular variations, in some variations, R₁₅and R₁₆are taken together to form a ring selected from the group consisting of (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted.

In some variations, the ring formed by taking R₁₅and R₁₆together is a pyrrolidinyl of the formula

embedded image

where R₁₃is selected from the group consisting of hydrogen, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, amido, carboxamido, sulfonamido, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted.

In some variations, R₁₃is selected from the group consisting of hydrogen, unsubstituted (C_1-6)alkyl, R₁₈substituted (C_1-6)alkyl,

embedded image

where

k is 0, 1, or 2;

each R₁₈is independently selected from the group consisting of hydrogen, oxy, cyano, nitro, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)arYl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or is further substituted with 1-3 substituents,

where

- the I-3 substituents bonded to R₁₈are each independently selected from the group consisting of halo, nitro, cyano, thio, oxy, hydroxy, oxo, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or further substituted.

Particularly, R₁₈is selected from the group consisting of nitro, cyano, and

embedded image

each unsubstituted or substituted with 1-3 substituents.

More particularly, R₁₈is selected from the group consisting of

embedded image

each unsubstituted or substituted with 1-3 substituents.

Most particularly, R₁₈is selected from the group consisting of

embedded image

each unsubstituted or substituted with 1-3 substituents.

It is noted that when R₁₈is substituted, in some variations, the 1-3 substituents bonded to R₁₈are each independently selected from the group consisting of halo, nitro, cyano, thio, oxy, hydroxy, oxo, carbonyloxy, (C_1-10)alkoxy, (C_1-10)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-10)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or further substituted.

In other variations, the 1-3 substituents bonded to R₁₈are each independently selected from the group consisting of halo, cyano, oxo, (C_1-6)alkyl, halo(C_1-6)alkyl, perhalo(C_1-6)alkyl, (C₆)aryl, (C_1-6)heteroaryl, (C_1-6)alkoxy, aryloxy, heteroaryloxy, and (C_1-6)alkylthio, each unsubstituted or further substituted.

In still other variations, the substitutents on R₁₈are each independently selected from the group consisting of methyl, ethyl, propyl, isopropyl, trifluoromethyl, butyl, isobutyl, t-butyl, oxo, phenyl, pyridinyl, methoxy, phenoxy, proylthio, methoxycarbonyl, difluoromethoxy, and

embedded image

Compounds SYR145132U, 144392B and 144393B on the “160 benzimidazoles Apr. 11, 2007” List]

In yet other particular variations of the above embodiments, R₁is of the formula

embedded image

and R₁₆is a cyclic moiety selected from the group consisting of (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted with 1-3 substituents,

where

- each said 1-3 substituents on R₁₆is independently selected from the group consisting of halo, hydroxy, oxo, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonyl, (C_1-10)alkyl, halo(C_1-10)alkyl, perhalo(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, each unsubstituted or substituted, or any two substituents bonded to adjacent atoms of the cyclic moiety are taken together to form a 5, 6, or 7 membered, unsubstituted or substituted, saturated, unsaturated or aromatic ring.

In some variations, R₁₆is selected from the group consisting of

embedded image

each unsubstituted or substituted with said 1-3 substituents.

In other variations, R₁₆is selected from the group consisting of

embedded image

each unsubstituted or substituted with 1-3 substituents.

It is noted that when R₁₆is substituted, the substituents bonded to R₁₆are each independently selected from the group consisting of halo, hydroxy, oxo, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonyl, (C_1-10)alkyl, halo(C_1-10)alkyl, perhalo(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-10)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, each unsubstituted or further substituted with 1-3 substituents. Particularly, the substituents on R₁₆are each independently selected from the group consisting of halo, hydroxy, (C_1-10)alkoxy, (C_4-12)aryloxy, (C_1-6)alkyl, hydroxy(C_1-6)alkyl, alkoxy(C_1-6)alkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, hydroxycyclo(C_3-6)alkyl, alkoxycyclo(C_3-6)alkyl, amido, carboxamido, sulfonamide, carbamate, urea, each unsubstituted or further substituted. More particularly, the substituents on R₁₆are each independently selected from the group consisting of halo, hydroxyl, unsubstituted or substituted (C_1-6)alkyl, and unsubstituted or substituted (C_1-10)alkoxy. Further, any two substituents bonded to adjacent ring atoms of the R₁₆cyclic moiety may be taken together to form a five, six or seven membered, unsubstituted or substituted, saturated, unsaturated or aromatic ring.

Subgenus Where R16 is Alkyamino: ZLP-1 and ZLP-4 Provisional Claim 40

In yet other particular variations of the above embodiments, R₁is of the formula

embedded image

and R₁₆is a substituted methyl of the formula

embedded image

where

R₁₉is selected from the group consisting of hydrogen, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, sulfonamido, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted;

R₂₀is selected from the group consisting of hydrogen, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, sulfonamido, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_1-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted; or

- R₁₉and R₂₀are taken together to form a 5, 6, or 7 membered, unsubstituted or substituted, saturated, unsaturated or aromatic ring.
  - (ZLP4) The compound according to provisional claim 40.

Of the immediately preceding variations, in some variations,

R₁₉is selected from the group consisting of hydrogen, unsubstituted (C_1-6)alkyl, and substituted (C_1-6)alkyl;

R₂₀is selected from the group consisting of hydrogen, (C_1-6)alkyl,

embedded image

where

- each R₂₁is independently selected from the group consisting of hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, sulfonyl, sulftnyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted with 1-3 substituents,

where

- the substituents on R₂₁are each independently selected from the group consisting of halo, nitro, cyano, thio, oxy, hydroxy, oxo, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted, or when R₁₁is a ring selected from the group consisting of (C_3-12)cycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, hetero(C_3-12)cycloalkyl, any two substituents bonded to adjacent ring atoms of R₂₁may be taken to form a 5, 6, or 7 membered, unsubstituted or substituted, unsaturated, saturated or aromatic ring.

In other variations, R₂₁are each independently selected from the group consisting of (C_1-6)alkyl, isopropyl, and

embedded image

each unsubstituted or substituted with 1-3 substituents.

In other variations, R₂₁are each independently selected from the group consisting of (C_1-6)alkyl, isopropyl,

embedded image

each unsubstituted or substituted with 1-3 substituents.

In still other variations, R₂₁are each independently selected from the group consisting of

embedded image

each unsubstituted or substituted with 1-3 substituents.

It is noted that when R₂₁is substituted, the substituents on R₂₁are each independently selected from the group consisting of halo, nitro, cyano, thio, oxy, hydroxy, oxo, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted.

Particularly, the substitutents on R₂₁are each independently selected from the group consisting of halo, nitro, cyano, oxo, (C_1-6)alkyl, halo(C_1-6)alkyl, perhalo(C_1-6)alkyl, amido, alkoxycarbonyl, (C₆)aryl, (C_1-5)heteroaryl, (C_1-6)cycloalkyl, (C_1-6)heterocycloalkyl, (C_1-6)alkoxy, aryloxy, heteroaryloxy, and (C_1-6)alkylthio, each unsubstituted or further substituted.

More particularly, the substitutents on R₂₁are each independently selected from the group consisting of oxo, chloro, fluoro, cyano, nitro, methyl, ethyl, propyl, isopropyl, tertbutyl, phenyl, substituted phenyl, halo substituted phenyl, piperidinyl, thiophene, methoxy, difluoromethoxy, trifluoromethoxy, ethoxy, phenoxy, methoxycarbonyl, ethoxycarbonyl, (C_1-6)alkylthio,

embedded image

embedded image

and

embedded image

each unsubstituted or further substituted.

Most particularly, the substitutents on R₂₁is selected from the group consisting of methoxy, phenyl, chloro, and

embedded image

It is also noted that, in all of the above variations regarding the substituents on R₂₁, any two substituents bonded to adjacent ring atoms of R₂₁may be taken to form a 5, 6, or 7 membered, unsubstituted or substituted, unsaturated, saturated or aromatic ring.

PROTHETIC EXAMPLES

In other particular variations of the above embodiments, R₁is of the formula

embedded image

R₁₆is a substituted methyl of the formula

embedded image

and R₁₉and R₂₀are taken together to form a ring of the formula

embedded image

where

R₂₃is selected from the group consisting of hydrogen, unsubstituted (C_1-6)alkyl, R₁₄substituted (C_1-6)alkyl,

embedded image

where

- k is 0, 1, or 2;
- each R₂₄is independently selected from the group consisting of oxy, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted with 1-3 substituents.
- where
  - the substituents on R₂₄are each independently selected from the group consisting of halo, nitro, cyano, thio, oxy, oxo, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted.

In some variations, R₂₄is selected from the group consisting of (C_1-6)alkyl,

embedded image

each unsubstituted or substituted with 1-3 substituents.

In other variations, R₂₄is selected from the group consisting of (C_1-6)alkyl,

embedded image

each unsubstituted or substituted with 1-3 substituents.

In still other variations, R₂₄is selected from the group consisting of

embedded image

each unsubstituted or substituted with 1-3 substituents.

It is noted that when R24 is substituted, the substitutents on R₂₄are each independently selected from the group consisting of halo, cyano, oxo, (C_1-6)alkyl, halo(C_1-6)alkyl, perhalo(C_1-6)alkyl, (C₆)aryl, (C_1-6)heteroaryl, (C_1-6)alkoxy, aryloxy, heteroaryloxy, and (C_1-6)alkylthio, each unsubstituted or further substituted. More particularly, the substitutents on R₂₄are each independently selected from the group consisting of methyl, ethyl, propyl, isopropyl, tertbutyl, phenyl, substituted phenyl, halosubstituted phenyl, piperidinyl, thiophene, methoxy, difluoromethoxy, trifluoromethoxy, ethoxy, phenoxy, methoxycarbonyl, ethoxycarbonyl,

embedded image

(C_1-6)alkylthio, and

embedded image

each unsubstituted or substituted.

(ZLP2 compounds from the “160 Benzimidazoles Apr. 11, 2007” List, Only 4 Examples)

In yet other particular variations of the above embodiments, R₁is of the formula

embedded image

and R₁₆is a substituted methyl of the formula

embedded image

where

R₂₆is selected from the group consisting of hydrogen, carbonyl, oxycarbonyl, aminocarbonyl, sulfonyl, sulfinyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, aza(C_1-10)alkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted with 1-3 substituents

where

the substituents on R₂₆are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, oxo, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, aza(C_1-10)alkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_3-12)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or further substituted, and any two substituents bonded to adjacent atoms of R₂₆may be taken together to form a 5, 6, or 7 membered, unsubstituted or substituted, saturated, unsaturated or aromatic ring.

In some variations, R₂₆is selected from the group consisting of hydrogen, (C_1-6)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero (C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted with said 1-3 substituents.

In other variations, R₂₆is selected from the group consisting of hydrogen, (C_1-6)alkyl,

embedded image

each unsubstituted or substituted with said 1-3 substituents.

In still other variations, R₂₆is selected from the group consisting of

embedded image

each unsubstituted or substituted with said 1-3 substituents.

It is further noted that when R₂₆is substituted, the substituents on R₂₆are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, oxo, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, aza(C_1-10)alkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or further substituted.

In some variations, the substituents on R₂₆are each independently selected from the group consisting of oxo, (C_1-6)alkyl, alkylthio, (C_1-6)alkoxy, haloalkyl, perhaloalkyl, (C_1-6)alkoxy, aryloxy, (C_1-6)alkoxycarbonyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, each unsubstituted or further substituted.

It is further noted that any two substituents bonded to adjacent atoms of R₂₆may be taken together to form a 5, 6, or 7 membered, unsubstituted or substituted, saturated, unsaturated or aromatic ring.

Claiming the BenzimidazolesMay 312007_—143 Samples and Prophetic Examples

In yet other particular variations of the above embodiments, R₁is of the formula

embedded image

and R₁₆is a substituted methyl of the formula

embedded image

where

R₂₈is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, aza(C_1-10)alkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted with 1-3 substituents

where

the substituents on R²⁸are each independently selected from the group consisting of halo, nitro, cyano, thio, oxy, hydroxy, oxo, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-30)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or further substituted; and any two substituents bonded to adjacent atoms of R₂₈may be taken together to form a five, six or seven membered saturated, unsaturated or aromatic ring, each unsubstituted or substituted.

In some variations, R₂₈is selected from the group consisting of (C_1-6)alkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl, aryl(C_1-6)alkyl, heteroaryl(C_1-6)alkyl, cycloalkyl(C_1-6)alkyl, and heterocycloalkyl(C_1-6)alkyl, each unsubstituted or substituted with 1-3 substituents.

In some variations, R²⁸is selected from the group consisting of aryl and heteroaryl, each unsubstituted or substituted with 1-3 substituents.

In still other variations, R²⁸is selected from the group consisting of

embedded image

each unsubstituted or substituted with 1-3 substituents.

In yet other variations, R₂₈is selected from the group consisting of

embedded image

each unsubstituted or substituted with 1-3 substituents.

In other variations, R₂₈is an unsubstituted or a substituted phenyl.

In other variations, R₂₈is a unsubstituted or substituted naphthyl of the formula

embedded image

In still other variations, R₂₈is selected from the group consisting of substituted six-membered aryls and heteroaryls, where the aryls and heteroaryls are substituted with 1-3 substituents, and one of said 1-3 substituents is bonded to the ring atom at the para-position relative to the point where R₂₈is attached to the remainder of the molecular.

It is noted that in all the above variations of R₂₈, when it is substituted, the substituents are each independently selected from the group consisting of halo, nitro, cyano, thio, oxy, oxo, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)alkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_4-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_3-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or further substituted. It is further noted that any two substituents bonded to adjacent atoms of R₂₈may be taken together to form a five, six or seven membered saturated, unsaturated or aromatic ring, each unsubstituted or further substituted.

In some variations, the substituents on R₂₈are each independently selected from the group consisting of halo, oxo, alkoxy, aryloxy, (C_1-6)alkyl, hydroxyalkyl, alkoxyalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, hydroxycyclo(C_3-6)alkyl, alkoxycyclo(C_3-6)alkyl, amido, carboxamido, sulfonamide, carbamate, urea, each unsubstituted or further substituted, and any two substituents bonded to adjacent atoms of R₂₈may be taken together to form a five, six or seven membered, saturated, unsaturated or aromatic ring, each unsubstituted or substituted.

In other variations, the substituents on R₂₈are each independently selected from the group consisting of fluoro, chloro, bromo, tertbutyl, amino, oxo,

embedded image

where

v is 0, 1, 2 or 3;

each R₃₀is independently selected from the group consisting of hydrogen, halo, hydroxyl, cyano, amino, oxo, (C_1-6)alkyl, alkylamino, alkylaminooxy, aminocarbonyl, alkoxycarbonyl, (C_1-6)alkoxy, alkoxyalkyl, heterocycloalkyl, aryl, heteroaryl, alkylsulfonyl, amidosulfonyl, aminosulfonyl, sulfonyl, amino, amido, carboxamido, carbamate, and urea, each unsubstituted or substituted, and any two of R₃₀bound to adjacent ring atoms may be taken together to form a 5 or 6 membered, unsubstituted or substituted, saturated, unsaturated or aromatic ring; and

each R₃₁or R₃₁′ is independently selected from the group consisting of hydrogen, (C_1-6)alkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, hydroxycyclo(C_3-6)alkyl, alkoxycyclo(C_3-6)alkyl, each unsubstituted or substituted, and any two of R₃₀and R₃₁bonded to adjacent atoms and any two of R₃₁and R₃₁′ bonded to the same atom may be taken to form a 5, 6 or 7 membered, unsubstituted or substituted, saturated, unsaturated or aromatic ring.

In some other variations, the substituents on R₂₃are each independently selected from the group consisting of tertbutyl,

embedded image

where

V is 0, 1, 2 or 3;

each R₃₀is independently selected from the group consisting of hydrogen, halo, hydroxyl, cyano, amino, oxo, (C_1-6)alkyl, alkylamino, alkylaminooxy, aminocarbonyl, alkoxycarbonyl, (C_1-6)alkoxy, alkoxyalkyl, heterocycloalkyl, aryl, heteroaryl, alkylsulfonyl, amidosulfonyl, aminosulfonyl, sulfonyl, amino, amido, carboxamido, carbamate, and urea, each unsubstituted or substituted, and any two R₃₀bonded to adjacent ring atoms may be taken together to form a 5 or 6 membered, unsubstituted or substituted, saturated, unsaturated or aromatic ring;

each R₅₀is independently selected from the group consisting of H, methyl, methoxy, chloro, and fluoro.

In other variations, the substituents on R₂₈are each independently selected from the group consisting of tertbutyl,

embedded image

where

v is 0, 1, 2 or 3;

each R₃₀is independently selected from the group consisting of hydrogen, halo, cyano, amino, oxo, (C_1-6)alkyl, alkylamino, alkylaminooxy, aminocarbonyl, alkoxycarbonyl, (C_1-6)alkoxy, alkoxyalkyl, heterocycloalkyl, aryl, heteroaryl, alkylsulfonyl, amidosulfonyl, aminosulfonyl, sulfonyl, amino, amido, carboxamido, carbamate, and urea, each unsubstituted or substituted, and any two R₃₀bonded to adjacent ring atoms may be taken together to form a 5 or 6 membered, unsubstituted or substituted, saturated, unsaturated or aromatic ring;

each R₃₁is independently selected from the group consisting of hydrogen, (C_1-6)alkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, hydroxycyclo(C_3-6)alkyl, alkoxycyclo(C_3-6)alkyl, each unsubstituted or substituted, and any two of R₃₀and R₃₁bonded to adjacent ring atoms may be taken together to form a 5 or 6 membered, unsubstituted or substituted, saturated, unsaturated or aromatic ring; and

each R₅₀is independently selected from the group consisting of H, methyl, methoxy, chloro, and fluoro.

In yet other variations, R₃₀is selected from the group consisting of hydrogen, halo, hydroxyl, cyano, oxo, (C_1-6)alkyl, —NHC(O)CH₃, alkylsulfonyl, amino, —C(O)NH—(C_1-6)alkyl, —C(O)NH—(C_1-6)alkyl(C_1-6)alkoxy, (C_1-6)alkoxy, hydroxy(C_1-6)alkylamino, (C_1-6)alkoxy(C_1-6)alkyl, and —NH—(C_1-6)alkyl, heterocycloalkylacyl, amido, carboxamido, phenyl, and (C_1-4)heteroaryl.

In still other variations, R₃₀is selected from the group consisting of hydrogen, hydroxyl, halo, hydroxyl, cyano, oxo, (C_1-6)alkyl, hydroxy(C_1-6)alkyl, phenyl, (C_1-6)alkoxy(C_1-6)alkyl, amino, sulfonyl, (C_1-6)alkoxy, (C_1-6)alkylsulfonyl, morpholinyl,

embedded image

wherein

R₃₄is selected from the group consisting of hydrogen, hydroxyl, halo, and hydroxymethyl;

R₃₅is selected from the group consisting of hydrogen and unsubstituted or substituted (C_1-6)alkyl;

R₃₆is selected from the group consisting of hydroxyl, unsubstituted or substituted (C_1-6)alkyl; and

R₃₇is selected from the group consisting of hydrogen, (C_1-6)alkyl, cycloalkyl, hydroxy(C_1-6)alkyl, alkoxy(C_1-6)alkyl, hydroxycyloalkyl, alkoxycycloalkyl, halo(C_1-6)alkyl, and halocycloalkyl, each unsubstituted or substituted.

In some further variations, R₃₀is selected from the group consisting hydrogen, hydroxyl, fluoro, chloro, cyano, oxo, methyl, propyl, isopropyl, tertbutyl, phenyl, hydroxyethyl, methoxymethyl, methoxyethyl, ethoxypropyl, —NH₂, —N(CH₃)₂, —NH(CH₃), cyclopropylamino, methoxy, ethoxy, isopropyloxy, cyclopropylmethyloxy, methylsulfonyl, morpholinyl,

embedded image

In still some further variations, R₃₀is selected from the group consisting hydrogen, hydroxyl, fluoro, chloro, cyano, oxo, methyl, n-propyl, isopropyl, tertbutyl, hydroxyethyl, methoxymethyl, methoxyethyl, —NH₂, —N(CH₃)₂, methoxy, ethoxy, isopropyloxy, methylsulfonyl, morpholinyl,

embedded image

In some variations of the above embodiments and variations, R³¹is selected from the group consisting of hydrogen, hydroxyl, and unsubstituted or substituted (C_1-6)alkyl.

In yet other particular variations of the above embodiments, R₁is of the formula

embedded image

where

v is 0, 1, 2, or 3; and

R₃₀is selected from the group consisting of hydroxyl, chloro,

embedded image

In still other particular variations of the above embodiments, R₁is of the formula

embedded image

where

v is 0, 1, 2, or 3;

R₁₅is selected from the group consisting of hydrogen, hydroxyl, (C_1-4)alkyl, hydroxy(C_1-4)alkyl, (C_1-4)alkoxy, aryl(C_1-4)alkyl, heteroaryl(C_1-4alkyl, cycloalkyl(C_1-4)alkyl, and (C_1-4)heterocycloalkyl(C_1-4)alkyl;

R₁₇is selected from the group consisting of hydrogen, (C_1-6)alkyl, halo(C_1-6)alkyl, hydroxy(C_1-6)alkyl, carbonyl(C_1-6)alkyl, sulfonyl(C_1-6)alkyl, sulfinyl(C_1-6)alkyl, (C_1-6)azaalkyl, (C_3-12)cycloalkyl(C_1-6)alkyl, hetero(C_3-2)cycloalkyl(C_1-6)alkyl, (C_4-12)aryl(C_1-6)alkyl, hetero(C_1-10)aryl(C_1-6)alkyl, (C_9-12)bicycloaryl(C_1-6)alkyl, hetero(C_8-12)bicycloaryl(C_1-6)alkyl, hetero(C_1-6)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted;

R₃₀is selected from the group consisting of hydrogen, fluoro, methyl, propyl, hydroxyethyl, and methoxyethyl; and

R₃₁is selected from the group consisting of hydrogen and (C_1-6)alkyl.

In other particular variations of the above embodiments, R₁is of the formula

embedded image

where

R₁₅is selected from the group consisting of hydrogen, hydroxyl, (C_1-4)alkyl, hydroxy(C_1-4)alkyl, (C_1-4)alkoxy, aryl(C_1-4)alkyl, heteroaryl(C_1-4)alkyl, cycloalkyl(C_1-4)alkyl, and (C_1-4)heterocycloalkyl(C_1-4)alkyl;

R₁₇is selected from the group consisting of hydrogen, (C_1-6)alkyl, halo(C_1-6)alkyl, hydroxy(C_1-6)alkyl, carbonyl(C_1-6)alkyl, sulfonyl(C_1-6)alkyl, sulfinyl(C_1-6)alkyl, (C_1-6)azaalkyl, (C_3-12)cycloalkyl(C_1-6)alkyl, hetero(C_3-12)cycloalkyl(C_1-6)alkyl, (C_4-12)aryl(C_1-6)alkyl, hetero(C_1-10)aryl(C_1-6)alkyl, (C_9-12)bicycloaryl(C_1-6)alkyl, hetero(C_8-12)bicycloaryl(C_1-6)alkyl, hetero(C_1-6)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted;

R₃₀is selected from the group consisting of hydrogen, hydroxyl,

embedded image

R₁₅

In some further variations of the above embodiments and variations, when present, R₁₅is selected from the group consisting of hydrogen, hydroxyl, (C_1-6)alkyl, hydroxyl(C_1-6)alkyl, aryl(C_1-6)alkyl, heteroaryl(C_1-6)alkyl. In other further variations, R₁₅is selected from the group consisting of hydrogen, hydroxyl, and benzyl. In still other further variations, R₁₅is hydrogen.

R₁₇

In some further variations of the above embodiments and variations, when present, R₁₇is selected from the group consisting of hydrogen, (C_1-6)alkyl, hydroxyl(C_1-6)alkyl, alkoxy(C_1-6)alkyl, halo(C_1-6)alkyl, amino(C_1-6)alkyl, each unsubstituted or substituted. In other further variations, R₁₇is hydrogen.

R₂

In some further variations of the above embodiments and variations, when present, R₂is (C_1-4)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, (C_1-6)alkoxy(C_1-10)alkyl carbonyl(C_1-4)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, each unsubstituted or substituted.

In particular variations, R₂is -L-R₂₅, where

L is a linker providing 1, 2, 3, 4, 5 or 6 atom separation between the ring atom and R²⁵to which L is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur; and

R₂₅is selected from the group consisting of cyano, halo, hydroxyl, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, amido, carboxamido, sulfonamido, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, (C_1-10)haloalkyl, (C_1-10)perhaloalkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, aryl, and heteroaryl, each unsubstituted or substituted.

In other variations, L is (C_1-4)alkyl, unsubstituted or substituted. In yet other variations, L is —(CH₂)₃—. In still other variations, L is —(CH₂)₂—. In yet still other variations, L is —(CH₂)—.

In variations of the above embodiments and variations, R₂₅is selected from the group consisting of cyano, halo, haloalkyl, perhaloalkyl, hydroxyl, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, carboxamido, amido, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, aryl and heteroaryl, each unsubstituted or substituted. In other variations, R₂₅is selected from the group consisting of —F, —Cl, —CN, —CF₃, —OR₂₇, —C(O)NR₂₇R₂₇′, —OC(O)NR₂₇R₂₇′, —O(CH₂)_nOR₂₇NR₂₇R₂₇′, —NHC(O)OR₂₇, —NHC(O)R₂₇, —NHS(O)₂R₂₇, (C_4-14)aryl, and (C_1-13)heteroaryl, where n is 1 or 2, and R₂₇and R₂₇′ are each independently selected from the group consisting of H, perhalo(C_1-7)alkyl, (C_1-7)alkyl, hydroxyl(C_1-7)alkyl, (C₆)aryl and (C_1-5)heteroaryl, each unsubstituted or substituted. In still other variations, R₂₅is selected from the group consisting of —OH, —F, —CF₃, —CN, —OCH₃, —OCH₂CH₃, —OCF₃, —OC(O)NHCH₃, —OC(O)NHCH₃, —(O)NHCH₃, —C(O)NHCH₂CH₃, —NHS(O)₂CH₃, —NHC(O)CH₂OH, —NHC(O)CH₃, —OCH₂OCH₃, —OCH₂OCH₂CH₃, —O(CH₂)₂OH, —O(CH₂)₂OCH₃, —O(CH₂)₂OCH₂CH₃, —OCH₂CH(OH)CH₂OCH₃, —OCH₂CH(OH)CH₂OH, —(C_1-5)heteroaryl, —(CH₂)₂(C_1-5)heteroaryl, —(CH₂)₂(C_1-5)heteroaryl,

embedded image

each unsubstituted or substituted. In some particular variations, R₂₅is selected from the group consisting of —F, —CF₃, —CN, —OH, and —OCH₃,

In some particular variations of the above embodiments and variations, R₂is selected from the group consisting of —(CH₂)₂F, —(CH₂)₃OCH₃, (CH₂)₃OH, —(CH₂)₃OEt, —(CH₂)₃OCF₃, —(CH₂)₃CF₃, —(CH₂)₃CN, —(CH₂)₃OC(O)NHCH₃, —(CH₂)₃NHC(O)OCH₃, —(CH₂)₂NHC(O)CH₃, —(CH₂)₂CN, —(CH₂)₂CF₃, —(CH₂)₃NHC(O)OCH₃, —(CH₂)₂OCONHCH₃, —(CH₂)₂C(O)NHCH₃, —(CH₂)₂OCF₃, —(CH₂)₂NHS(O)₂CH₃, —(CH₂)₂CONHCH₂CH₃, —(CH₂)₂C(O)NHCH₂OH, —(CH₂)₂(C_1-4)heteroaryl, —CH₂CONHCH₃, —CH₂CONHCH₂CH₃, and —(CH₂)₂(C_1-4)heteroaryl, each unsubstituted or substituted.

In other particular variations, R₂is selected from the group consisting of —(CH₂)₂F, —(CH₂)₃CF₃, —(CH₂)₃OCH₃, —(CH₂)₃OH, —(CH₂)₃CN,

embedded image

where W₁and W₂are each independently —CH— or —N—. In some variations, W₁is —CH—. In other variations, W₁is —N—. In still other variations, both W₁and W₂are —CH—.

In still other particular variations, R₂is —(CH₂)₃OCH₃.

R₆

In some particular variations of the above embodiments and variations, R₆is selected from the group consisting of hydrogen, hydroxyl, (C_1-3)alkyl, (C_1-3)alkoxy, (C_1-3)alkoxy(C_1-3)alkyl, and —COOR where R is alkyl, cycloalkyl, cycloheteroalkyl, aryl and heteroaryl, each unsubstituted or substituted. In other particular variations, R₆is selected from the group consisting of hydrogen and hydroxyl.

R₇

In some particular variations of the above embodiments and variations, R₇is selected from the group consisting of hydrogen, halo, cyano, thio, oxy, hydroxy, carbonyloxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, (C_1-10)alkyl, carbonyl(C_1-3)alkyl, sulfonyl(C_1-3)alkyl, amino(C_1-10)alkyl, (C_3-4)cycloalkyl(C_1-10)alkyl, hetero(C_3-7)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, heteroaryl(C_1-10)alkyl, and aminocarbonyloxy, each unsubstituted or substituted. In other particular variations, R₇is selected from the group consisting of hydrogen, methyl, ethyl, and methoxy.

R₁₀

In some variations of the above embodiments and variations, R₁₀and R₁₀′ are each independently selected from the group consisting of hydrogen, cyano, nitro, oxo, halo, hydroxyl, carbonyloxy, (C_1-10)alkoxy, carbonyl, amino, (C_1-10)alkylamino, sulfonamido, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, hetero(C_1-10)alkyl, each unsubstituted or substituted.

In other variations, R₁₀and R₁₀′ are each independently selected from the group consisting of hydrogen, (C_1-6)alkyl, cyano, oxo, and halo.

In still other variations, R₁₀and R₁₀′ are each independently selected from the group consisting of hydrogen, methyl, isopropyl, chloro, fluoro, oxo, nitro, and methoxy.

In some particular variations when R₁₀is bound to a benzimidazole of the formula

embedded image

R₁₀is selected from the group consisting of hydrogen, 4-methyl, 5-methyl, 6-methyl, 6-isopropyl, 4-fluoro, 5-fluoro, 6-fluoro, 7-fluoro, 4-chloro, 5-chloro, 6-chloro, 7-chloro, 4-cyano, 6-cyano, 7-cyano, 5-nitro, 6-nitro, 4-methoxy, 6-methoxy, and 7-methoxy.

In other particular variations, R₁₀is selected from the group consisting of hydrogen, 4-methyl, 5-methyl, 6-methyl, 6-fluoro, 4-chloro, 6-chloro, and 7-chloro. In other particular variations, R₁₀is selected from the group consisting of hydrogen and 4-chloro. In other particular variations, R₁₀is selected from the group consisting of hydrogen and 4-methyl. In still other particular variations, R₁₀is selected from the group consisting of hydrogen and 7-chloro.

Particular examples of compounds according to the present invention include, but are not limited to:

3-(1H-benzo[d]imidazol-2-yl)-N-(3-chloro-4-methylphenyl)piperidine-1-carboxamide;
3-(1H-benzo[d]imidazol-2-yl)-N-benzoylpiperidine-1-carboxamide;
3-(1H-benzo[d]imidazol-2-yl)-N-(naphthalen-2-yl)piperidine-1-carboxamide;
3-(1H-benzo[d]imidazol-2-yl)-N-benzoylpiperidine-1-carboxamide;
3-(1H-benzo[d]imidazol-2-yl)-N-(3,5-dimethylphenyl)piperidine-1-carboxamide;
3-(1H-benzo[d]imidazol-2-yl)-N-(4-chloro-3-(trifluoromethyl)phenyl)piperidine-1-carboxamide;
3-(1H-benzo[d]imidazol-2-yl)-N-phenylpiperidine-1-carboxamide;
3-(1H-benzo[d]imidazol-2-yl)-N-(2,3-dihydro-1H-inden-5-yl)piperidine-1-carboxamide;
3-(1H-benzo[d]imidazol-2-yl)-N-cyclohexylpiperidine-1-carboxamide;
N-(benzo[d][1,3]dioxol-5-yl)-3-(1H-benzo[d]imidazol-2-yl)piperidine-1-carboxamide;
(2S)-methyl 2-(3-(1H-benzo[d]imidazol-2-yl)piperidine-1-carboxamido)-3-phenylpropanoate;
(2R)-methyl 2-(3-(1H-benzo[d]imidazol-2-yl)piperidine-1-carboxamido)-3-phenylpropanoate;
ethyl 3-(3-(1H-benzo[d]imidazol-2-yl)piperidine-1-carboxamido)propanoate;
3-(1H-benzo[d]imidazol-2-yl)-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)piperidine-1-carboxamide;
3-(1H-benzo[d]imidazol-2-yl)-N-(biphenyl-2-yl)piperidine-1-carboxamide;
3-(1H-benzo[d]imidazol-2-yl)-N-propylpiperidine-1-carboxamide;
N-(benzo[c][1,2,5]thiadiazol-4-yl)-3-(1H-benzo[d]imidazol-2-yl)piperidine-1-carbothioamide;
(2S)-methyl 2-(3-(1H-benzo[d]imidazol-2-yl)piperidine-1-carboxamido)-4-methylpentanoate;
3-(1H-benzo[d]imidazol-2-yl)-N-(pyridin-3-yl)piperidine-1-carboxamide;
3-(1H-benzo[d]imidazol-2-yl)-N-(furan-2-ylmethyl)piperidine-1-carboxamide;
(S)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)-3-phenylpropan-1-one;
(3R)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-amino-4-(4-chlorophenyl)butan-1-one;
(3R)-3-amino-4-(4-chlorophenyl)-1-(3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(3S)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-amino-3-(4-(trifluoromethyl)phenyl)propan-1-one;
(3S)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-amino-3-(2-nitrophenyl)propan-1-one;
(3R)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-amino-4-(2-chlorophenyl)butan-1-one;
(3S)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-amino-3-(2,3-dimethoxyphenyl)propan-1-one;
(3R)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-amino-4-(benzo[b]thiophen-3-yl)butan-1-one;
(3S)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-amino-3-(3-chlorophenyl)propan-1-one;
(3S)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-amino-3-(3,5-dimethoxyphenyl)propan-1-one;
(3R)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-amino-5-phenylpentan-1-one;
(3S)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-amino-3-(4-nitrophenyl)propan-1-one;
(3R)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-amino-4-(4-bromophenyl)butan-1-one;
(3S)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-amino-3-(2,4-dichlorophenyl)propan-1-one;
(3R)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-amino-4-(3,4-dichlorophenyl)butan-1-one;
(3S)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-amino-3-(2,3-dichlorophenyl)propan-1-one;
(3R)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-amino-4-(naphthalen-1-yl)butan-1-one;
(3R)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-amino-4-(4-nitropentyl)butan-1-one;
(3S)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-amino-3-(3-nitrophenyl)propan-1-one;
(3S)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-amino-3-(3-bromophenyl)propan-1-one;
(3R)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-amino-4-o-tolylbutan-1-one;
(3R)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-amino-4-m-tolylbutan-1-one;
(3R)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl-3-amino-4-(naphthalen-2-yl)butan-1-one;
(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)(pyrrolidin-2-yl)methanone
(2S)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-amino-4-methylpentan-1-one;
(2S)-1-(3 (1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-amino-3-methylbutan-1-one;
(2S,3S)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-amino-3-methylpentan-1-one;
(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)((S)-1-(piperidin-4-yl)pyrrolidin-2-yl)methanone;
(2R)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-aminopropan-1-one;
(2R)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-aminobutan-1-one;
(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)(piperidin-3-yl)methanone;
(2S)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-aminopropan-1-one;
(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)((R)-pyrrolidin-2-yl)methanone;
(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)(azetidin-3-yl)methanone;
(2S)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-amino-3,3-dimethylbutan-1-one;
(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)(1S,2S)-2-aminocyclopentyl)methanone;
(2R)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-amino-3-phenylpropan-1-one;
(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)(1-aminocyclobutyl)methanone;
(2R)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl-2-amino-3-chloropropan-1-one;
(2S)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-amino-2-cyclohexylethanone;
(2S)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl-2-amino-3-(pyridin-2-yl)propan-1-one;
(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)(1-aminocyclopropyl)methanone;
1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-(methylamino)-3-phenylpropan-1-one;
(3R)-3-amino-1-(3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-phenylpropan-1-one;
(3S)-3-amino-1-(3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-phenylpropan-1-one;
(3S)-3-amino-4-(4-chlorophenyl)-1-(3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-4-(4-chlorophenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(S)-3-amino-4-(4-chlorophenyl)-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(S)-3-amino-4-(4-chlorophenyl)-1-0)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-1((R)-3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-amino-4-(biphenyl-4-yl)butan-1-one;
(R)-3-Amino-4-(biphenyl-4-yl)-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
4-(biphenyl-4-yl)-3-hydroxy-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one;
(R)-3-amino-4-(4-chlorophenyl)-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-4-(3,4-difluorophenyl)-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-4-(3,4-dichlorophenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(pyridin-4-yl)butan-1-one;
(R)-3-amino-4-(3-chlorophenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(S)-3-amino-3-(3-bromophenyl)-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)propan-1-one;
(R)-3-amino-1((R)-3-(5,5-dichloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one;
(R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(pyridin-3-yl)butan-1-one;
(S)-3-amino-3-(3-chlorophenyl)-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)propan-1-one;
(S)-3-amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-(3-(trifluoromethyl)phenyl)propan-1-one;
3-((S)-1-amino-3-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-oxopropyl)benzonitrile;
(R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(2,4,5-trifluorophenyl)butan-1-one;
(R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-phenylbutan-1-one;
(S)-3-amino-4-(benzyloxy)-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(S)-3-amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-phenylpropan-1-one;
(R)-3-amino-4-(4-tert-butylphenyl)-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-4-(4-bromophenyl)-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(2R,3R)-3-amino-2-hydroxy-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-phenylpropan-1-one;
4-amino-3-(4-chlorophenyl)-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-(piperidin-4-yl)propan-1-one;
(R)-3-amino-1((R)-3-(6-fluoro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one;
(R)-3-amino-1((R)-3-(5-fluoro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one;
(R)-3-Amino-1-((R)-3-(7-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalene-2-yl)butan-1-one;
(R)-3-amino-4-(biphenyl-4-yl)-1((R)-3-(7-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-1((R)-3-(6-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one;
(R)-3-amino-1-(3-(5-methoxy-3-(3-methoxypropyl)-3H-imidazo[4,5-b]pyridin-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one;
(R)-2-(1-(3-amino-4-(naphthalen-2-yl)butanoyl)piperidin-3-yl)-3-(3-methoxypropyl)-3H-imidazo[4,5-b]pyridin-5(4H)-one;
(R)-3-amino-1-(3-(5-chloro-3-(3-methoxypropyl)-3H-imidazo[4,5-b]pyridin-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one;
(R)-3-amino-4-(biphenyl-4-yl)-1((R)-3-(3-(3-methoxypropyl)-3H-imidazo[4,5-c]pyridin-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-1((R)-3-(4-methoxy-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one;
(R)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-5-methyl-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one;
(R)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-4-methyl-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one;
(R)-3-amino-1-((R)-3-(4-methoxy-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one;
(R)-3-amino-1-((R)-3-(7-methoxy-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one;
2-((R)-1-((R)-3-amino-4-(naphthalen-2-yl)butanoyl)piperidin-3-yl)-1-(3-methoxypropyl)-1H-benzo[d]imidazole-6-carbonitrile;
(R)-3-amino-1-((R)-3-(6-methoxy-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one;
methyl 2-O-((R)-3-amino-4-(naphthalen-2-yl)butanoyl)piperidin-3-yl)-1-(3-methoxypropyl)-1H-benzo[d]imidazole-6-carboxylate;
methyl 2-O-((R)-3-amino-4-(naphthalen-2-yl)butanoyl)piperidin-3-yl)-1-(3-methoxypropyl)-1H-benzo[d]imidazole-7-carboxylate;
(3R)-3-amino-1-(3-(6-(hydroxymethyl)-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one;
(R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-6-nitro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one;
(R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-7-nitro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one;
(R)-3-amino-1((R)-3-(6-isopropyl-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one;
(R)-3-amino-1-((R)-3-(5-isopropyl-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one;
(R)-3-amino-4-(biphenyl-4-yl)-1((R)-3-(4-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(S)-3-amino-1((R)-3(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-(pyridin-3-yl)propan-1-one;
(S)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-(4-methoxypyridin-3-yl)propan-1-one;
(S)-3-amino-3-(3-methoxyphenyl)-1-(R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-yl)propan-1-one;
(R)-3-amino-4-(biphenyl-3-yl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
Methyl 4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-carboxylate;
(R)-3-amino-4-(biphenyl-4-yl)-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4-(pyridin-3-yl)phenyl)butan-1-one;
(R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4-(pyridin-4-yl)phenyl)butan-1-one;
(R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4′-(morpholine-4-carbonyl)biphenyl-4-yl)butan-1-one;
(R)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4′-morpholinobiphenyl-4-yl)butan-1-one;
N-(4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-yl)acetamide;
(R)-3-amino-4-(2′-(methoxymethyl)biphenyl-4-yl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-4-(4-(3-chloropyridin-4-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-4-(4-(2,6-dimethoxypyridin-3-yl)phenyl)-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-4-(4-(2-chloropyridin-4-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-N-cyclopropyl)biphenyl-4-carboxamide;
(R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4-(6-morpholinopyridin-3-yl)phenyl)butan-1-one;
(R)-3-amino-4-(4-(6-aminopyridin-3-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[c]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-4-(4-(3,5-dimethyl-1H-pyrazol-4-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-4-(4-(6-ethoxypyridin-3-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-4-(4-(imidazo[1,2-a]pyridin-6-yl)phenyl)-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-4-(4-(benzo[c][1,2,5]oxadiazol-5-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-4-(4-(1H-pyrazol-5-yl)phenyl)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-4-(4-(6-isopropoxypyridin-3-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-4-(4-(6-(cyclopropylmethoxy)pyridin-3-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4-(3-methoxypyridin-4-yl)phenyl)butan-1-one;
(R)-3-amino-4-(4-(furan-3-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-4-(4-(furan-2-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-4-(4-(6-(dimethylamino)pyridin-3-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4-(2-methoxypyridin-4-yl)phenyl)butan-1-one;
(R)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4-(pyrimidin-5-yl)phenyl)butan-1-one;
(R)-3-amino-4-(4-(2-fluoropyridin-4-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-4-(4-(2-fluoropyridin-3-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-4-(4-(1H-pyrrol-3-yl)phenyl)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-4-(4-(1H-pyrrol-2-yl)phenyl)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-4-(4-(2-aminopyrimidin-5-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-4-(2′-chlorobiphenyl-4-yl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-4-(4′-methoxybiphenyl-4-yl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(2′-methylbiphenyl-4-yl)butan-1-one;
(R)-3-amino-4-(3′-methoxybiphenyl-4-yl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-4-(2′-methoxybiphenyl-4-yl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-4-(2′-fluorobiphenyl-4-yl)-1-((R)-3-(1-(3-methoxypropyl)-1H-1-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-4-(4′-(dimethylamino)biphenyl-4-yl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4-(4-methoxypyridin-3-yl)phenyl)butan-1-one;
(R)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4-(2-methoxypyridin-3-yl)phenyl)butan-1-one;
4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-carbonitrile;
(R)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4′-(methylsulfonyl)biphenyl-4-yl)butan-1-one;
(R)-3-amino-4-(4-(3,5-dimethylisoxazol-4-yl)phenyl-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-4-(4-(2-chloropyridin-3-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-carboxamide;
5-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)pyrimidine-2,4(1H,3H)-dione;
(R)-3-amino-4-(4′-aminobiphenyl-4-yl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
1-(4′-((R)-2-amino-4((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-yl)-3-cyclopropylurea;
1-(4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-yl)urea;
1-(4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-yl)-3-ethylurea;
3-(4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-yl)-1,1-dimethylurea;
1-(4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-yl)-3-methylurea;
methyl 4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-ylcarbamate;
4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-N-(2-methoxyethyl)biphenyl-4-carboxamide;
4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-N-(2-ethoxyethyl)biphenyl-4-carboxamide;
4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-N-(2-isopropoxyethyl)biphenyl-4-carboxamide;
4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-N-(3-methoxypropyl)biphenyl-4-carboxamide;
4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-N-(2,3-dihydroxypropyl)biphenyl-4-carboxamide;
4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-N-(2-hydroxyethyl)biphenyl-4-carboxamide;
4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-N-(1-hydroxy-2-methylpropan-2-yl)biphenyl-4-carboxamide;
4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-N-(1,3-dihydroxypropan-2-yl)biphenyl-4-carboxamide;
(R)-3-amino-4-(4′-((R)-3-hydroxypyrrolidine-1-carbonyl)biphenyl-4-yl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-N—((R)-1-hydroxypropan-2-yl)biphenyl-4-carboxamide;
4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-N—((S)-1-hydroxypropan-2-yl)biphenyl-4-carboxamide;
4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-N-(2-hydroxy-2-methylpropyl)biphenyl-4-carboxamide;
4-(4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenylcarbonyl)piperazin-2-one;
4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-fluoro-N-(2-hydroxyethyl) biphenyl-4-carboxamide;
4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-fluoro-N-(2-methoxyethyl)biphenyl-4-carboxamide;
4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-2-chloro-N-(2-hydroxyethyl)biphenyl-4-carboxamide;
4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-2-chloro-N-(2-methoxyethyl)biphenyl-4-carboxamide;
5-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-N-(2-hydroxyethyl)picolinamide;
5-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-N-(2-methoxyethyl)picolinamide;
5-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-N-(1-hydroxy-2-methylpropan-2-yl)thiophene-2-carboxamide;
N-(4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-yl)-2-methoxyacetamide;
N-(4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-yl)-2-hydroxy-2-methylpropanamide;
N-(4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-yl)-2-hydroxyacetamide;
(R)-3-amino-4-(4-(2-ethoxythiazol-4-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4-(2-methoxythiazol-4-yl)phenyl)butan-1-one;
(R)-3-amino-4-(4-(2-isopropylthiazol-4-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
4-((R)-2-amino-4-((R)-3(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-N-cyclohexylbenzamide;
(R)-3-amino-4-(4-(1,2-dimethyl-1H-imidazol-5-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
5-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-1,3-dimethylpyrimidine-2,4(1H,3H)-dione;
4-(4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-yl)-3-methyl-1H-1,2,4-triazol-5(4H)-one;
1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)pyridin-2(1H)-one;
(R)-4-(4-(1H-imidazol-1-yl)phenyl)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)pyrrolidin-2-one;
1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-3-methylpyrimidine-2,4(1H,3H)-dione;
1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-3-methylpyrimidine-2,4(1H,3H)-dione;
1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-3-methylpyrimidine-2,4(1H,3H)-dione;
1-(4-((R)-2-Amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-3-methylpyrimidine-2,4(1H,3H)-dione;
1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-3-(2-methoxyethyl)-1H-benzo[d]imidazol-2(3H)-one;
1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl-4-oxobutyl)phenyl)-5-methyl-1H-benzo[d]imidazol-2(3H)-one;
1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-6-methyl-1H-benzo[d]imidazol-2(31-1)-one;
1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-4-fluoro-1H-benzo[d]imidazol-2(3H)-one;
1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-7-fluoro-1H-benzo[d]imidazol-2(3H)-one;
1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-5,6-dimethyl-1H-benzo[d]imidazol-2(3H)-one;
1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one;
1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-3-propyl-1H-benzo[d]imidazol-2(3H)-one;
1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-3-(2-hydroxyethyl)-1H-benzo[d]imidazol-2(3H)-one;
1-(4-((R)-2-amino-4-((R)-3(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-5-fluoro-1H-benzo[d]imidazol-2(3H)-one;
1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-6-fluoro-1H-benzo[d]imidazol-2(3H)-one;
1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-4-methyl-1H-benzo[d]imidazol-2(3H)-one;
1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-7-methyl-1H-benzo[d]imidazol-2(3H)-one;
1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-34)-4-oxobutyl)phenyl)-5-methoxy-1H-benzo[d]imidazol-2(3H)-one;
1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-6-methoxy-1H-benzo[d]imidazol-2(3H)-one
2-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)isoquinolin-1(2H)-one;
2-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)isoquinolin-1(2H)-one;
(R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4-(4-phenylpiperazin-1-yl)phenyl)butan-1-one;
(R)-4-(4-(4-acetylpiperazin-1-yl)phenyl)-3-amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
4-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-1-phenylpiperazin-2-one;
(R)-3-amino-4-(4-(4-hydroxypiperidin-1-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-4-(4-(4-(hydroxymethyl)piperidin-1-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-4-(4-(4-(hydroxymethyl)piperidin-1-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
methyl 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)piperidine-4-carboxylate;
(R)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4-phenoxyphenyl)butan-1-one;
N-(2-(2-((R)-1((R)-3-amino-4-(naphthalen-2-yl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-yl)ethyl)acetamide;
(R)-3-amino-2-benzyl-4-(4-chlorophenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-4,5,6,7-tetrahydro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one;
methyl 4′-((2R)-2-amino-4-(3-(5-tert-butyl-1-(3-methoxypropyl)-1H-imidazol-2-yl)-3-hydroxypiperidin-1-yl)-4-oxobutyl)biphenyl-4-carboxylate;
(R)-3-amino-1((R)-3-(2-(3-methoxypropyl)-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one;
(R)-3-amino-1-((S)-3-(2-methyl-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one;
(R)-3-amino-1((R)-3-(2-methyl-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one;
(3R)-3-amino-1-(3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)-5-methylpiperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one;
(R)-3-amino-4-(4-chlorophenyl)-14(S)-3-hydroxy-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-4-(4-chlorophenyl)-1((R)-3-hydroxy-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-2-naphthamide;
1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(2-methoxyphenyl)urea;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-5-phenylfuran-2-carboxamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-5-phenylthiophene-2-carboxamide;
1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(4-methoxyphenyl)urea;
1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(3-methoxyphenyl)urea;
1-((S)-2-amino-44 (R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(3,4-dichlorophenyl)urea;
1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(3-chlorophenyl)urea;
1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(2-chlorophenyl)urea;
1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)urea;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-4-(thiophen-2-yl)benzamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-5-(2-fluorophenyl)furan-2-carboxamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-4-(thiophen-3-yl)benzamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3,4-dichlorobenzamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)benzofuran-2-carboxamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-carboxamide;
1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(2-(trifluoromethoxy)phenyl)urea;
1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(2,3-dihydro-1H-inden-5-yl)urea;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-5-(2,4-dichlorophenyl)furan-2-carboxamide;
1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(5-tert-butyl-2-methoxyphenyl)urea;
1-((S)-2-amino-4-((R)-3-O-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-phenylurea;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-phenoxybenzamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-2,3-dihydrobenzofuran-5-carboxamide;
1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(2-phenoxyphenyl)urea;
1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(2,5-dimethoxyphenyl)urea;
1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl-4-oxobutyl)-3-(2-(difluoromethoxy)phenyl)urea;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-5-(2-nitrophenyl)furan-2-carboxamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-5-(2,5-dichlorophenyl)furan-2-carboxamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-5-(2,3-dichlorophenyl)furan-2-carboxamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-4-phenoxybenzamide;
1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-yl)-4-oxobutyl)-3-(2,4-dimethoxyphenyl)urea;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-4-methoxybenzamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-4-chlorobenzenesulfonamide;
methyl 3-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutylcarbamoyl)benzoate;
1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(4-chlorophenyl)urea;
1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(2-(methylthio)phenyl)urea;
1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(2-methoxyphenyl)urea;
1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(2-propylphenyl)urea;
1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(2-methoxy-5-methylphenyl)urea;
1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(3-phenoxyphenyl)urea;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-2,6-dichlorobenzamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-2,6-dichlorobenzenesulfonamide;
1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(biphenyl-2-yl)urea;
1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(4-methoxy-2-methylphenyl)urea;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3,4-dimethylbenzamide;
ethyl 4-(5-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutylcarbamoyl)furan-2-yl)benzoate;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-5-(3,5-dichlorophenyl)furan-2-carboxamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-5-(3-chlorophenyl)furan-2-carboxamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[c]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-5-(3-nitrophenyl)furan-2-carboxamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-chlorobenzamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-2-phenoxynicotinamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-chlorobenzenesulfonamide;
1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(2-isopropylphenyl)urea;
1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(2-tert-butylphenyl)urea;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)benzamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-5-(4-fluorophenyl)furan-2-carboxamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3,4-dichlorobenzenesulfonamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-2-chlorobenzenesulfonamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-2-(propylthio)nicotinamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-4-chlorobenzamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-methoxybenzamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-1-naphthamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)propane-2-sulfonamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-6-(piperidin-1-yl)picolinamide;
methyl 4-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutylcarbamoyl)benzoate;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-methoxybenzenesulfonamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)benzenesulfonamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)benzamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-fluorobenzamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-2-cyclohexylacetamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-2-chlorobenzamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-4-methoxybenzenesulfonamide;
1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(2,5-di methoxyphenethyl)urea;
1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-cyclohexylurea;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-2-methoxybenzenesulfonamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)furan-2-carboxamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)cyclohexanecarboxamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-2-methoxybenzamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)morpholine-4-carboxamide;
methyl 2-(3-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)ureido)benzoate;
ethyl 2-(3-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)ureido)benzoate;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)cyclopentanecarboxamide;
1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-cyclopentylurea;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)isobutyramide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)pyrrolidine-1-carboxamide;
N—((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)propane-2-sulfonamide;
1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(2-cyanophenyl)urea;
((3R,4S)-4-amino-1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)sulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3S,4R)-3-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidin-1-ylsulfonyl)-1H-benzo[d]imidazol-2(3H)-one;
((3R,4S)-4-amino-1-(4-bromo-2,6-dichlorophenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(2,4,6-trichlorophenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(naphthalen-2-ylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(4-bromo-2-chlorophenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,3S)-4-amino-1-(2,5-dichlorophenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(4-chloro-2,5-dimethylphenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(2,4,5-trichlorophenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(2-chlorophenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(2,6-dichlorophenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(biphenyl-4-ylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(2-chloro-4-fluorophenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(2,4-dichlorophenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(3-chlorophenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(5-phenylfuran-2-carbonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-(3-chloro-2-methylphenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(naphthalen-1-yl)sulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(2,3-dihydrobenzofuran-5-ylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(2-chloro-5(trifluoromethyl)phenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(3-methoxyphenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(3-phenoxybenzoyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(2-chloro-6-methylphenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(1-methyl-1H-indol-5-ylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(3,4-dichlorophenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-1-(2-naphthoyl)-4-aminopyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[b]imidazol-2-yl)piperidin-1-ylmethanone;
((3R,4S)-4-amino-1-(2,3-dichlorophenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(3-(2-methylthiazol-4-yl)phenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(3,4-dichlorobenzoyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(2-phenoxynicotinoyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
(3S,4R)-3-amino-N-(3-methoxyphenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidine-1-carboxamide;
((3R,4S)-4-amino-1-(3-phenoxyphenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(4-methoxyphenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(4-chlorophenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(isopropylsulfonyl)pyrrolidin-3-yl)-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(3,4-dimethoxyphenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
methyl 2-((3S,4R)-3-amino-4((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidin-1-ylsulfonyl)benzoate;
((3R,4S)-4-amino-1-(4-tert-butylphenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(3-chlorobenzoyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-1-(1-naphthoyl)-4-aminopyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
methyl 3-((3S,4R)-3-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidine-1-carbonyl)benzoate;
(3S,4R)-3-amino-N-(3-chlorophenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidine-1-carboxamide;
((3R,4S)-4-amino-1-(2-methoxyphenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
N-(4-((3S,4R)-3-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidin-1-ylsulfonyl)phenyl)acetamide;
((3R,4S)-4-amino-1-(4-methoxy-2-nitrophenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
1-(4-((3S,4R)-3-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidin-1-ylsulfonyl)phenyl)pyrrolidin-2-one;
((3R,4S)-4-amino-1-(2,4-dimethylphenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(phenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4 S)-4-amino-1-benzoylpyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
(3S,4R)-3-amino-N-cyclohex yl-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidine-1-carboxamide;
((3R,4S)-4-amino-1-(2-methoxybenzoyl)pyrrolidin-3-yl)((R)-3(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
(3S,4R)-3-amino-N-(4-chlorophenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidine-1-carboxamide;
3S,4R)-3-amino-N-(2-chlorophenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidine-1-carboxamide;
(3S,4R)-2-chlorophenyl 3-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidine-1-carboxylate;
4-((3S,4R)-3-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidin-1-ylsulfonyl)-3-chlorobenzonitrile;
((3R,4S)-4-amino-1-(1-methyl-1H-indol-4-ylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,45)-4-amino-1-(3-fluorobenzoyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(4-methoxybenzoyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,48)-4-amino-1-(cyclopentanecarbonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
1-(3S,4R)-3-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidin-1-yl)-2-methylpropan-1-one;
1-(3S,4R)-3-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidin-1-yl)-2-cyclohexylethanone;
((3R,4S)-4-amino-1-(2-chlorobenzoyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
(3S,4R)-3-amino-N-cyclopentyl-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidine-1-carboxamide;
(3S,4R)-3-amino-N-(2-methoxyphenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidine-1-carboxamide;
((3R,4S)-4-amino-1-(5-bromo-2-methoxyphenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(2-(trifluoromethyl)phenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
2-((3S,4R)-3-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidin-1-ylsulfonyl)-4-methylbenzonitrile;
(3S,4R)-3-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)-N-phenylpyrrolidine-1-carboxamide;
((3R,4S)-4-amino-1-(cyclohexanecarbonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(benzofuran-2-carbonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
(3S,4R)-4-chlorophenyl 3-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidine-1-carboxylate;
(3S,4R)-3-(trifluoromethyl)phenyl 3-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidine-1-carboxylate;
((3R,4S)-4-amino-1-(3-(5-methyl-1,2,4-oxadiazol-3-yl)phenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(2-methoxy-5-methylphenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(2-methoxy-4-nitrophenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(5-chloro-2-methoxyphenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(2,5-dimethoxyphenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(2,6-dichlorobenzoyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[9]imidazol-2-yl)piperidin-1-yl)methanone;
((3S,4R)-3-amino-N-(4-methoxyphenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidine-1-carboxamide;
((3R,4S)-4-amino-1-(4-chlorobenzoyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1,1-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(pyrrolidine-1-carbonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(2-(propylthio)nicotinoyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(3-(difluoromethoxy)phenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,48)-4-amino-1-(furan-2-carbonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(3-methoxybenzoyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
methyl 4-((3S,4R)-3-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidine-1-carbonyl)benzoate;
((3R,4S)-4-amino-1-(morpholine-4-carbonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
methyl 2-((3S,4R)-3-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidine-1-carbonyl)benzoate;
((3R,4S)-4-amino-1-(2,6-dichlorophenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(2,6-difluorophenylsulfonyl)pyrrolidin-3-yl)((R)-3(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
2-((3S,4R)-3-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidin-1-ylsulfonyl)benzonitrile;
((3R,4S)-4-amino-1-(3-fluorophenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
N-(3-((3S,4R)-3-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidin-1-ylsulfonyl)phenyl)acetamide;
((3R,4S)-4-amino-1-(3-(2-methylpyrimidin-4-yl)phenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
((3R,4S)-4-amino-1-(3-(5-methyl-1,3,4-oxadiazol-2-yl)phenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone;
methyl 2-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutoxy)benzoate;
(R)-3-amino-4-(3-methoxyphenoxy)-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-4-(1H-benzo[d]imidazol-2-yloxy)-3-amino-1((R)-3(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-4-(4-(2-((S)-3-hydroxypyrrolidin-1-yl)thiazol-4-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
1-(4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-yl)imidazolidin-2-one;
(R)-3-amino-4-(4-(2-hydroxypyridin-4-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
6-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[c]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-2H-benzo[b][1,4]oxazin-3(4H)-one;
6-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-2H-benzo[b][1,4]oxazin-3(4H)-one;
(R)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4-(4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)phenyl)butan-1-one;
1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-6-fluoro-1H-benzo[d]imidazol-2(3H)-one;
1-(4′-((R)-2-amino-4-((R)-3-(4-fluoro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-yl)imidazolidin-2-one
7-(4-((R)-2-amino-4-((R)-3-(4-fluoro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-2H-benzo[b][1,4]thiazin-3(4H)-one
7-(4-((R)-2-amino-4-((R)-3-(4-fluoro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-2H-benzo[b][1,4]oxazin-3(4H)-one
(R)-3-amino-1((R)-3-(4-fluoro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4-(2-hydroxypyridin-4-yl)phenyl)butan-1-one
N-(2-(2-((R)-1((R)-3-amino-4-(4-(6-hydroxypyridin-3-yl)phenyl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-yl)ethyl)acetamide
N-(2-(2-((R)-1((R)-3-amino-4-(4-(6-aminopyridin-3-yl)phenyl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-yl)ethyl)acetamide
3-(2-((R)-1((R)-3-amino-4-(4-(4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)phenyl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-yl)propanamide
N-(2-(2-((R)-1-((R)-3-amino-4-(4-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)phenyl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-yl)ethyl)acetamide
N-(2-(2-((R)-1-((R)-3-amino-4-(4-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)phenyl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-yl)ethyl)acetamide
N-(2-(2-((R)-1((R)-3-amino-4-(4-(2-aminopyrimidin-5-yl)phenyl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-yl)ethyl)acetamide
(R)-3-amino-1-((R)-3-(4-fluoro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4-(6-hydroxypyridin-3-yl)phenyl)butan-1-one
(R)-3-amino-4-(4-(6-aminopyridin-3-yl)phenyl)-1((R)-3-(4-fluoro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one
(R)-3-amino-1-((R)-3-(4-fluoro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4-(4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)phenyl)butan-1-one
(R)-3-amino-4-(4-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)phenyl)-1-((R)-3-(4-fluoro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one
(R)-3-amino-4-(4-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)phenyl)-1((R)-3-(4-fluoro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one
(R)-3-amino-4-(4-(2-aminopyrimidin-5-yl)phenyl)-1-((R)-3-(4-fluoro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one
methyl 4′-((R)-4-((R)-3-(1-(2-acetamidoethyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-amino-4-oxobutyl)biphenyl-4-ylcarbamate
5-(4-((R)-2-amino-4-((R)-3-(4-fluoro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)indolin-2-one
6-(4-((R)-2-amino-4-((R)-3-(4-fluoro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)indolin-2-one
5-(4-((R)-2-amino-4-((R)-3-(4-fluoro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)benzo[d]oxazol-2(3H)-one
N-(2-(2-((R)-1((R)-3-amino-4-(4-(2-hydroxypyridin-4-yl)phenyl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-yl)ethyl)acetamide
N-(2-(2-((R)-1((R)-3-amino-4-(4′-(2-oxoimidazolidin-1-yl)biphenyl-4-yl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-yl)ethyl)acetamide
(R)-3-amino-4-(4-(2-aminobenzo[d]oxazol-5-yl)phenyl)-1((R)-3-(4-fluoro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one
N-(2-(2-((R)-1((R)-3-amino-4-(4-(2-oxo-2,3-dihydrobenzo[b][1,4]oxathiin-6-yl)phenyl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-yl)ethyl)acetamide
N-(2-(2-((R)-1((R)-3-amino-4-(4-(2-oxoindolin-5-yl)phenyl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-yl)ethyl)acetamide
N-(2-(2-((R)-1((R)-3-amino-4-(4-(2-oxoindolin-6-yl)phenyl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-yl)ethyl)acetamide
N-(2-(2-((R)-1-((R)-3-amino-4-(4-(2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-yl)ethyl)acetamide
5-(4-((R)-2-amino-4-((R)-3-(4-fluoro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)benzo[d]oxazol-2(3H)-one
(R)-3-amino-4-(4-(2-aminobenzo[d]oxazol-5-yl)phenyl)-1-((R)-3-(4-fluoro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one
N-(2-(2-((R)-1((R)-3-amino-4-(4-(2-aminopyrimidin-5-yl)phenyl)butanoyl)piperidin-3-yl)-4-chloro-1H-benzo[d]imidazol-1-yl)ethyl)acetamide
N-(2-(2-((R)-1((R)-3-amino-4-(4-(6-aminopyridin-3-yl)phenyl)butanoyl)piperidin-3-yl)-4-methyl-1H-benzo[d]imidazol-1-yl)ethyl)acetamide
N-(2-(2-((R)-1-((R)-3-amino-4-(4-(2-aminopyrimidin-5-yl)phenyl)butanoyl)piperidin-3-yl)-4-methyl-1H-benzo[d]imidazol-1-yl)ethyl)acetamide
N-(2-(2-((R)-1((R)-3-amino-4-(4-(6-hydroxypyridin-3-yl)phenyl)butanoyl)piperidin-3-yl)-4-methyl-1H-benzo[d]imidazol-1-yl)ethyl)acetamide
N-(2-(2-((R)-1((R)-3-amino-4-(4-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)phenyl)butanoyl)piperidin-3-yl)-4-methyl-1H-benzo[d]imidazol-1-yl-ethyl)acetamide
N-(2-(2-((R)-1((R)-3-amino-4-(4-(4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)phenyl)butanoyl)piperidin-3-yl)-4-methyl-1H-benzo[d]imidazol-1-yl)ethyl)acetamide
N-(2-(2-((R)-1-((R)-3-amino-4-(4-(6-hydroxypyridin-3-yl)phenyl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-yl)ethyl)acetamide
N-(2-(2-((R)-1-((R)-3-amino-4-(4-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)phenyl)butanoyl)piperidin-3-yl)-4-methyl-1H-benzo[d]imidazol-1-yl)ethyl)acetamide
N-(2-(2-((R)-1-((R)-3-amino-4-(4-(6-hydroxypyridin-3-yl)phenyl)butanoyl)piperidin-3-yl)-4-chloro-1H-benzo[d]imidazol-1-yl)ethyl)acetamide
N-(2-(2-((R)— 1-((R)-3-amino-4-(4-(6-aminopyridin-3-yl)phenyl)butanoyl)piperidin-3-yl)-4-chloro-1H-benzo[d]imidazol-1-yl)ethyl)acetamide
3-(2-((R)-1-((R)-3-amino-4-(4-(6-aminopyridin-3-yl)phenyl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-yl)propanamide;
3-(2-((R)-1((R)-3-amino-4-(4-(2-aminopyrimidin-5-yl)phenyl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-yl)propanamide;
3-(2-((R)-1-((R)-3-amino-4-(4-(4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)phenyl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-yl)propanamide;
3-(2-((R)-1((R)-3-amino-4-(4-(4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)phenyl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-yl)propanamide;
3-(2-((R)-1((R)-3-amino-4-(4-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)phenyl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-yl)propanamide;
3-(2-((R)-1-((R)-3-amino-4-(biphenyl-4-yl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-yl)propanamide;
3-(2-((R)-1((R)-4-(4′-acetamidobiphenyl-4-yl)-3-aminobutanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-yl)propanamide;
3-(2-((R)-1((R)-3-amino-4-(4′-methoxybiphenyl-4-yl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-yl)propanamide;
3-(2-((R)-1((R)-3-amino-4-(4-(pyridin-4-yl)phenyl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-yl)propanamide;
3-(2-((R)-1((R)-3-amino-4-(4′-chlorobiphenyl-4-yl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-yl)propanamide;
(R)-3-amino-4-(4-(2,3-dihydrobenzofuran-5-yl)phenyl)-1((R)-3-(4-fluoro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one;
N-(4′-((R)-2-amino-4-((R)-3-(4-fluoro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-yl)acetamide;
(R)-3-amino-1((R)-3-(4-fluoro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4′-methoxybiphenyl-4-yl)butan-1-one;
(R)-3-amino-4-(4-(2,3-dihydrobenzofuran-5-yl)phenyl)-1-((Z)-3-(1-(3-methoxypropyl)-4-methyl-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one
(R)-3-amino-4-(4-(benzofuran-5-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-4-methyl-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one
5-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-4-methyl-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)indolin-2-one
7-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-4-methyl-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-2H-benzo[b][1,4]thiazin-3(4H)-one
7-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-4-methyl-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-2H-benzo[b][1,4]oxazin-3(4H)-one
5-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-4-methyl-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-1-methylindolin-2-one
(R)-4-(4-(1H-indazol-5-yl)phenyl)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-4-methyl-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one
(R)-3-amino-4-(4-(3-amino-1H-indazol-5-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-4-methyl-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one
3-(2-((R)-1((R)-3-amino-4-(4-(2,3-dihydrobenzofuran-5-yl)phenyl)butanoyl)piperidin-3-yl)-4-methyl-1H-benzo[d]imidazol-1-yl)-N-methylpropanamide
(3R)-3-amino-1-(3-(5-chloro-3-(3-methoxypropyl)-3H-imidazo[4,5-b]pyridin-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one;
(3R)-3-amino-1-(3-(5-methoxy-3-(3-methoxypropyl)-3H-imidazo[4,5-b]pyridin-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one;
(R)-3-amino-4-(4-(6-hydroxypyridin-3-yl)phenyl)-1-((R)-3-(3-(3-methoxypropyl)-7-methyl-3H-imidazo[4,5-b]pyridin-2-yl)piperidin-1-yl)butan-1-one;
(R)-3-amino-4-(biphenyl-4-yl)-1((R)-3-(3-(3-methoxypropyl)-7-methyl-3H-imidazo[4,5-b]pyridin-2-yl)piperidin-1-yl)butan-1-one;
3-((3S,4R)-3-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidin-1-yl)benzonitrile;
3-((3S,4R)-3-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidin-1-yl)benzonitrile;
((3R,4S)-4-amino-1-(4-nitrophenyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone; and
(R)-3-amino-4-(4-(2-aminopyrimidin-5-yl)phenyl)-1((R)-3-(1-(2-fluoroethyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one.

It is noted that the compounds of the present invention may be in the form of a pharmaceutically acceptable salt. It is further note that the compounds of the present invention may be in a mixture of stereoisomers, or the compound may comprise a single stereoisomer.

In another aspect, the present invention is related to a pharmaceutical composition comprising as an active ingredient a compound according to any one of the above embodiments and variations. In one embodiment, the composition is a solid formulation adapted for oral administration. In another embodiment, the composition is a liquid formulation adapted for oral administration. In yet another embodiment, the composition is a tablet. In still another embodiment, the composition is a liquid formulation adapted for parenteral administration.

In another embodiment, the pharmaceutical composition comprises a compound according to any one of the above embodiments and variations, wherein the composition is adapted for administration by a route selected from the group consisting of orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery (for example by catheter or stent), subcutaneously, intraadiposally, intraarticularly, and intrathecally.

In another aspect, the invention is related to a kit which comprises a compound of any one of the above embodiments and variations; and instructions which comprise one or more forms of information selected from the group consisting of indicating a disease state for which the composition is to be administered, storage information for the composition, dosing information and instructions regarding how to administer the composition. In one particular variation, the kit comprises the compound in a multiple dose form.

In still another aspect, the invention is related to an article of manufacture comprising a compound of any one of the above embodiments and variations and packaging materials. In one embodiment, the packaging material comprises a container for housing the compound. In another embodiment, the container comprises a label indicating one or more members of the group consisting of a disease state for which the compound is to be administered, storage information, dosing information and/or instructions regarding how to administer the compound. In another embodiment, the article of manufacture comprises the compound in a multiple dose form.

In a further aspect, the invention is related to a therapeutic method comprising administering a compound to a subject.

In one embodiment, the method comprises contacting renin with a compound of any one of the above embodiments and variations.

In yet another embodiment is a method of inhibiting renin which comprises causing a compound of any one of the above embodiments and variations to be present in a subject in order to inhibit renin in vivo.

A further embodiment is a method of inhibiting renin which comprises administering a first compound to a subject that is converted in vivo to a second compound wherein the second compound inhibits renin in vivo, the second compound being a compound according to any one of the above embodiments and variations.

Another further embodiment is a method of treating a disease state for which renin possesses activity contributes to the pathology and/or symptomology of the disease state. In one variation, the method comprises causing a compound of any one of the above embodiments and variations to be present in a subject in a therapeutically effective amount for the disease state. In another variation, the method comprises administering a compound of any one of the above embodiments and variations to a subject, wherein the compound is present in the subject in a therapeutically effective amount for the disease state. In a further variation, the method comprises administering a first compound to a subject that is converted in vivo to a second compound wherein the second compound inhibits renin in viva, the second compound being a compound according to any one of the above embodiments and variations.

In one variation of the above embodiments and variations, the disease state is selected from the group consisting of cardiovascular disease, hypertension, congestive heart failure, myocardial infarction, renal protection, inflammation, neurological disease and cancer.

Another aspect of the invention is directed to method of preparing the compounds of the invention.

In one embodiment, the method of preparing the compounds includes

coupling a compound of the formula

embedded image

to a compound of the formula

embedded image

under conditions that form an intermediate of the formula

embedded image

wherein

R₃and R₄are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamide, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted, and R₃and R₄may be taken together to form a 5, 6, 7, 8 membered saturated, unsaturated or aromatic ring;

R₁₆is a (C_1-10)alkyl or a cyclic moiety selected from the group consisting of (C_3-14cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, wherein said (C_1-10)alkyl, and cyclic moiety are each independently unsubstituted or substituted with 1-3 substituents that are each independently selected from the group consisting of carbonyl, oxycarbonyl, aminocarbonyl, sulfonyl, (C_1-10)alkyl, halo(C_1-10)alkyl, perhalo(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycIoalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, each unsubstituted or substituted, and any two substitutents bonded to adjacent atoms of R₁₆may be taken together to form a 5, 6, or 7 membered, unsubstituted or substituted, saturated, unsaturated or aromatic ring; and

provided that

- when R₃and R₄are taken together to form a substituted pyrimidinyl and R₂is a substituted alkyl, at least one of the substituents on R₂contains one or more heteroatoms.

In some variations of the preceding embodiment, the method of preparing the compounds of the invention further includes

deprotecting the intermediate of the formula

embedded image

under conditions that form a compound of the formula

embedded image

In other variations of the preceding embodiment, the method of preparing the compounds of the invention further includes:

coupling a compound of the formula

embedded image

to a compound of the formula X—R₂, where X is a leaving group,

under conditions that form a compound of the formula

embedded image

In other variations of the preceding embodiment, the method of preparing the compounds of the invention further includes

coupling

embedded image

under conditions that form a compound of the formula

embedded image

In other variations of the preceding embodiment of the method of preparing the compounds of the invention, R₃and R₄are taken together to form an unsubstituted or substituted phenyl.

In some particular variations of the method of preparing the compounds of the invention, R₁₆is a substituted methyl selected from the group consisting of:

embedded image

where

R₁₉is selected from the group consisting of hydrogen, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, sulfonamido, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-10)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted;

R₂₀is selected from the group consisting of hydrogen, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, sulfonamido, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted, provided that R₁₉and R₂₀may be taken together to form a 5, 6, or 7 membered, unsubstituted or substituted, saturated, unsaturated or aromatic ring.

R₂₆is selected from the group consisting of hydrogen, carbonyl, oxycarbonyl, aminocarbonyl, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, aza(C_1-10)alkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted with 1-3 substituents that are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, aza(C_1-10)alkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted with 1-3 substituents, and any two substituents bonded to adjacent atoms of R₂₆may be taken together to form a 5, 6, or 7 membered, unsubstituted or substituted, saturated, unsaturated or aromatic ring;

In more particular variations of the method of preparing the compound of the invention, R₁₆is a substituted methyl of the formula

embedded image

where R₂₈is selected from the group consisting of

embedded image

each unsubstituted or substituted with 1-3 substituents that are each independently selected from the group consisting of halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-17)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or substituted, and any two substituents bonded to adjacent atoms of R₂₈may be taken together to form a five, six or seven membered saturated, unsaturated or aromatic ring, each unsubstituted or substituted.

In some variations, R₂₈is an unsubstituted or a substituted phenyl. In other variations, R₂₈is a unsubstituted or substituted naphthyl of the formula

embedded image

In still other variations, R₂₈is selected from the group consisting of substituted six-membered aryls and heteroaryls, where the aryls and heteroaryls are substituted with 1-3 substituents, and one of said 1-3 substituents is bonded to the ring atom at the para-position relative to the point where R²⁸is attached to the remainder of the molecular.

It is noted that for all the above variations, when R₂₈is substituted, the substituents on R₂₈are each independently selected from the group consisting of halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C_1-10)alkoxy, (C_4-12)aryloxy, hetero(C_1-10)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C_1-10)alkylamino, sulfonamide, imino, sulfonyl, sulfinyl, (C_1-10)alkyl, halo(C_1-10)alkyl, hydroxy(C_1-10)alkyl, carbonyl(C_1-10)alkyl, thiocarbonyl(C_1-10)alkyl, sulfonyl(C_1-10)alkyl, sulfinyl(C_1-10)alkyl, (C_1-10)azaalkyl, (C_1-10)oxaalkyl, (C_1-10)oxoalkyl, imino(C_1-10)alkyl, (C_3-12)cycloalkyl(C_1-10)alkyl, hetero(C_3-12)cycloalkyl(C_1-10)alkyl, (C_4-12)aryl(C_1-10)alkyl, hetero(C_1-10)aryl(C_1-10)alkyl, (C_9-12)bicycloaryl(C_1-10)alkyl, hetero(C_8-12)bicycloaryl(C_1-10)alkyl, hetero(C_1-10)alkyl, (C_3-12)cycloalkyl, hetero(C_3-12)cycloalkyl, (C_9-12)bicycloalkyl, hetero(C_3-12)bicycloalkyl, (C_4-12)aryl, hetero(C_1-10)aryl, (C_9-12)bicycloaryl and hetero(C_4-12)bicycloaryl, each unsubstituted or further substituted, and any two substituents bonded to adjacent atoms of R₂₈may be taken together to form a five, six or seven membered saturated, unsaturated or aromatic ring, each unsubstituted or substituted.

In some variation, the substituents on R₂₈are each independently selected from the group consisting of halo, alkoxy, aryloxy, (C_1-6)alkyl, hydroxyalkyl, alkoxyalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, hydroxycyclo(C_3-6)alkyl, alkoxycyclo(C_3-6)alkyl, amido, carboxamido, sulfonamide, carbamate, urea, each unsubstituted or further substituted, and any two substituents bonded to adjacent atoms of R₂₈may be taken together to form a five, six or seven membered, saturated, unsaturated or aromatic ring, each unsubstituted or substituted.

In other variations, the substituents on R₂₈are each independently selected from the group consisting of fluoro, chloro, bromo, tertbutyl, amino

embedded image

where

v is 0, 1, 2 or 3;

In still other variations, the substituents on R₂₈are each independently selected from the group consisting of tertbutyl,

embedded image

where

v is 0, 1, 2 or 3;

each R₃₀is independently selected from the group consisting of hydrogen, halo, hydroxyl, cyano, amino, oxo, (C_1-6)alkyl, alkylamino, alkylaminooxy, aminocarbonyl, alkoxycarbonyl, (C_1-6)alkoxy, alkoxyalkyl, heterocycloalkyl, aryl, heteroaryl, alkylsulfonyl, amidosulfonyl, aminosulfonyl, sulfonyl, amino, amino, carboxamido, carbamate, and urea, each unsubstituted or substituted, and any two R₃₀bonded to adjacent ring atoms may be taken together to form a 5 or 6 membered, unsubstituted or substituted, saturated, unsaturated or aromatic ring;

each R₅₀is independently selected from the group consisting of H, methyl, methoxy, chloro, and fluoro.

In still other variations, the substituents on R₂₈are each independently selected from the group consisting of tertbutyl,

embedded image

where

v is 0, 1, 2 or 3;

each R₃₀is independently selected from the group consisting of hydrogen, halo, cyano, amino, oxo, (C_1-6)alkyl, alkylamino, alkylaminooxy, aminocarbonyl, alkoxycarbonyl, (C_1-6)alkyl, alkoxyalkyl, heterocycloalkyl, aryl, heteroaryl, alkylsulfonyl, amidosulfonyl, aminosulfonyl, sulfonyl, amino, amido, carboxamido, carbamate, and urea, each unsubstituted or substituted, and any two R₃₀bonded to adjacent ring atoms may be taken together to form a 5 or 6 membered, unsubstituted or substituted, saturated, unsaturated or aromatic ring;

each R₅₀is independently selected from the group consisting of H, methyl, methoxy, chloro, and fluoro.

In some variations of the preceding variations of the method of preparing compounds of the invention, R₃₀is selected from the group consisting of hydrogen, halo, hydroxyl, cyano, oxo, (C_1-6)alkyl, —NHC(O)CH₃, alkylsulfonyl, amino, —C(O)NH—(C_1-6)alkyl, —C(O)NH—(C_1-6)alkyl(C_1-6)alkoxy, (C_1-6)alkoxy, hydroxy(C_1-6)alkylamino, (C_1-6)alkoxy(C_1-6)alkyl, and —NH—(C_1-6)alkyl, heterocycloalkylacyl, amido, carboxamido, phenyl, and (C_1-4)heteroaryl.

In other variations, R₃₀is selected from the group consisting of hydrogen, hydroxyl, halo, hydroxyl, cyano, oxo, (C_1-6)alkyl, hydroxy(C_1-6)alkyl, phenyl, (C_1-6)alkoxy(C_1-6)alkyl, amino, sulfonyl, (C_1-6)alkoxy, (C_1-6)alkylsulfonyl, morpholinyl,

embedded image

wherein

R₃₄is selected from the group consisting of hydrogen, hydroxyl, halo, and hydroxymethyl;

R₃₅is selected from the group consisting of hydrogen and unsubstituted or substituted (C_1-6)alkyl;

R₃₆is selected from the group consisting of hydroxyl, unsubstituted or substituted (C_1-6)alkyl; and

In still other variations, R₃₀is selected from the group consisting hydrogen, hydroxyl, fluoro, chloro, cyano, oxo, methyl, propyl, isopropyl, tertbutyl, phenyl, hydroxyethyl, methoxymethyl, methoxyethyl, ethoxypropyl, —NH₂, —N(CH₃)₂, —NH(CH₃), cyclopropylamino, methoxy, ethoxy, isopropyloxy, cyclopropylmethyloxy, methylsulfonyl, morpholinyl,

embedded image

In still further variations, R₃₀is selected from the group consisting hydrogen, hydroxyl, fluoro, chloro, cyano, oxo, methyl, n-propyl, isopropyl, tertbutyl, hydroxyethyl, methoxymethyl, methoxyethyl, —NH₂, —N(CH₃)₂, methoxy, ethoxy, isopropyloxy, methylsulfonyl, morpholinyl,

embedded image

In some variations of the method of preparing the compounds of the invention, R₃₁is selected from the group consisting of hydrogen, hydroxyl, and unsubstituted or substituted (C_1-6)alkyl.

Salts, Hydrates, and Prodrugs of Renin Inhibitors

It should be recognized that the compounds of the present invention may be present and optionally administered in the form of salts, hydrates and prodrugs that are converted in vivo into the compounds of the present invention.

A “pharmaceutically acceptable salt”, as used herein, is intended to encompass any compound according to the present invention that is utilized in the form of a salt thereof, especially where the salt confers on the compound improved pharmacokinetic properties as compared to the free form of compound or a different salt form of the compound. The pharmaceutically acceptable salt form may also initially confer desirable pharmacokinetic properties on the compound that it did not previously possess, and may even positively affect the pharmacodynamics of the compound with respect to its therapeutic activity in the body. An example of a pharmacokinetic property that may be favorably affected is the manner in which the compound is transported across cell membranes, which in turn may directly and positively affect the absorption, distribution, biotransformation and excretion of the compound. While the route of administration of the pharmaceutical composition is important, and various anatomical, physiological and pathological factors can critically affect bioavailability, the solubility of the compound is usually dependent upon the character of the particular salt form thereof, which it utilized. One of skill in the art will appreciate that an aqueous solution of the compound will provide the most rapid absorption of the compound into the body of a subject being treated, while lipid solutions and suspensions, as well as solid dosage forms, will result in less rapid absorption of the compound.

It is within the scope of the present invention to convert the compounds of the present invention into and use them in the form of their pharmaceutically acceptable salts derived from various organic and inorganic acids and bases in accordance with procedures well known in the art.

When the compounds of the present invention possess a free base form, the compounds can be prepared as a pharmaceutically acceptable acid addition salt by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid, e.g., hydrohalides such as hydrochloride, hydrobromide, hydroiodide; other mineral acids and their corresponding salts such as sulfate, nitrate, phosphate, etc.; and alkyl and monoarylsulfonates such as ethanesulfonate, toluenesulfonate and benzenesulfonate; and other organic acids and their corresponding salts such as acetate, tartrate, maleate, succinate, citrate, benzoate, salicylate and ascorbate. Further acid addition salts of the present invention include, but are not limited to: adipate, alginate, arginate, aspartate, bisulfate, bisulfite, bromide, butyrate, camphorate, camphorsulfonate, caprylate, chloride, chlorobenzoate, cyclopentanepropionate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, fumarate, galacterate (from mucic acid), galacturonate, glucoheptoate, gluconate, glutamate, glycerophosphate, hemisuccinate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isethionate, iso-butyrate, lactate, lactobionate, malate, malonate, mandelate, metaphosphate, methanesulfonate, methylbenzoate, monohydrogenphosphate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, oleate, pamoate, pectinate, persulfate, phenylacetate, 3-phenylpropionate, phosphate, phosphonate and phthalate. It should be recognized that the free base forms will typically differ from their respective salt forms somewhat in physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free base forms for the purposes of the present invention.

When the compounds of the present invention possess a free acid form, a pharmaceutically acceptable base addition salt can be prepared by reacting the free acid form of the compound with a pharmaceutically acceptable inorganic or organic base. Examples of such bases are alkali metal hydroxides including potassium, sodium and lithium hydroxides; alkaline earth metal hydroxides such as barium and calcium hydroxides; alkali metal alkoxides, e.g., potassium ethanolate and sodium propanolate; and various organic bases such as ammonium hydroxide, piperidine, diethanolamine and N-methylglutamine. Also included are the aluminum salts of the compounds of the present invention. Further base salts of the present invention include, but are not limited to: copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium and zinc salts. Organic base salts include, but are not limited to, salts of primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, e.g., arginine, betaine, caffeine, chloroprocaine, choline, N,N′-dibenzylethylenediamine (benzathine), dicyclohexylamine, diethanolamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, iso-propylamine, lidocaine, lysine, meglumine, N-methyl-D-glucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethanolamine, triethylamine, trimethylamine, tripropylamine and tris-(hydroxymethyl)-methylamine (tromethamine). It should be recognized that the free acid forms will typically differ from their respective salt forms somewhat in physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid forms for the purposes of the present invention.

Compounds of the present invention that comprise basic nitrogen-containing groups may be quaternized with such agents as (C_1-4) alkyl halides, e.g., methyl, ethyl, iso-propyl and tert-butyl chlorides, bromides and iodides; di(C_1-4) alkyl sulfates, e.g., dimethyl, diethyl and diamyl sulfates; (C_10-18) alkyl halides, e.g., decyl, dodecyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; and aryl (C_1-4) alkyl halides, e.g., benzyl chloride and phenethyl bromide. Such salts permit the preparation of both water-soluble and oil-soluble compounds of the present invention.

Compounds of the invention further include prodrug derivatives of the compounds. It is noted that in many instances, the prodrugs themselves also fall within the scope of the range of compounds according to the present invention.

Various forms of prodrugs are well known in the art. For examples of such prodrug derivatives, see, e.g.,

- a) Design of Prodrugs, Bundgaard, A. Ed., Elsevier, 1985 and Method in Enzymology, Widder, K. et al., Ed.; Academic, 1985, vol. 42, p. 309-396;
- b) Bundgaard, H. “Design and Application of Prodrugs” in A Textbook of Drug Design and Development, Krosgaard-Larsen and H. Bundgaard, Ed., 1991, Chapter 5, p. 113-191; and
- c) Bundgaard, H., Advanced Drug Delivery Review, 1992, 8, 1-38.
  
  Each of which is incorporated herein by reference.

Pharmaceutically acceptable prodrugs of the compounds of this invention include, but are not limited to, esters, carbonates, thiocarbonates, N-acyl derivatives, N-acyloxyalkyl derivatives, quaternary derivatives of tertiary amines, N-Mannich bases, Schiff bases, amino acid conjugates, phosphate esters, metal salts and sulfonate esters.

Compounds of the present invention may also be conveniently prepared, or formed during the process of the invention, as solvates (e.g., hydrates). Hydrates of compounds of the present invention may be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents such as dioxin, tetrahydrofuran or methanol.

Indications for Use of Renin Inhibitors

Renin inhibitors of the present invention may be used to treat and/or prevent high blood pressure, cardiovascular diseases, congestive heart failure, myocardial infarction, renal protection, inflammation, neurological disease and cancer.

Renin is a proteolytic enzyme synthesized and stored principally in the juxtaglomerular apparatus. When renin is released into the blood from the kidney, the renin-angiotensin-aldosterone system (“RAAS”) is activated. Renin acts on the alpha-2 globulin angiotensinogen (synthesized in the liver) to generate angiotensin I. This non-pressor decapeptide is converted to angiotensin II by angiotensin-converting enzyme (ACE). The major pharmacological effects of angiotensin II are vasoconstriction and stimulation of the adrenal cortex to release aldosterone, a hormone which causes sodium retention. Vasoconstriction and conservation of sodium both contribute to increased blood pressure. Angiotensin II also produces other physiological effects such as inhibiting renin secretion, increasing sympathetic nervous system activity, stimulating vasopressin secretion, causing a positive cardiac inotropic effect and modulating other hormonal systems. Thus, the renin-angiotensin system plays an important role in normal cardiovascular homeostasis and in some forms of elevated blood pressure (hypertension).

The reduction of the activity of renin in a subject through inhibition may therefore be used to therapeutically address the diseases and conditions caused by the overactivation of RAAS.

Thus, renin inhibiting compounds of the present invention may be used as agents for control of hypertension, may also be used to treat and/or prevent congestive heart failure and hyperaldosteronism, vascular diseases related to diabetes, and renal diseases such as acute or chronic renal failure. In addition, the renin inhibiting compounds may also be used as diagnostic agents for identification of cases of hypertension due to renin excess.

In addition, the compounds of the present invention may be useful as inhibitors of plasmepsins to treat malaria and as inhibitors of Candida albicans secreted aspartyl proteases to treat fungal infections.

It is further noted that additional diseases beyond those disclosed herein may also be identified as the biological roles that renin and the RAAS system play in various pathways become more fully understood.

Combination Therapy

A wide variety of therapeutic agents may have a therapeutic additive or synergistic effect when used in combination with renin inhibitors according to the present invention. Such therapeutic agents may additively or synergistically combine with the renin inhibitors to reduce or alleviate the effects and symptoms of cardiovascular disease.

The compounds according to the present invention may be used in combination with other therapeutic agents, wherein the cells are treated with a compound according to the present invention before, at the same time, and/or after the cells are treated with the one or more additional cardiovascular therapeutics; these treatments are referred to herein as combination therapy. It is noted that administration of one agent before another is referred to herein as sequential therapy, even if the agents are also administered together. It is noted that combination therapy is intended to cover methods where agents are administered before or after each other (sequential therapy) as well as when the agents are administered at the same time.

Representative classes of cardiovascular agents that may be used with the renin inhibitors of the present invention include, but are not limited to, diuretics, adrenergic blocking agents, vasodilators, calcium channel blockers, angiotensin converting enzyme (ACE) inhibitors, potassium channel activators, antiserotoninergic agents, thromboxane synthetase inhibitors, angiotensin II antagonists, angiotensin II receptor blockers, and other agents useful for treating (in a human or other mammal) hypertension, congestive heart failure, or vascular diseases related to diabetes, or for treating renal diseases such as acute or chronic renal failure.

Representative diuretics include hydrochlorothiazide, polythiazide, piretanide, torasemide, bumetanide, amiloride, chlorothiazide, indapamide, acetazolamide, amiloride, bumetanide, benzthiazide, ethacrynic acid, furosemide, indacrinone, metolazone, spironolactone, triamterene, chlorthalidone and the like or a pharmaceutically acceptable salt thereof.

Representative adrenergic blocking agents include phentolamine, phenoxybenzamine, prazosin, terazosin, tolazine, atenolol, metoprolol, albuterol, nadolol, propranolol, timolol, carteolol and the like or a pharmaceutically acceptable salt thereof.

Representative vasodilators include hydralazine, minoxidil, diazoxide, nitroprusside, flusequinan and the like or a pharmaceutically acceptable salt thereof.

Representative calcium channel blockers include aminone, bencyclane, diltiazem, fendiline, flunarizine, nicardipine, nimodipine, perhexylene, verapamil, gallopamil, nifedipine and the like or a pharmaceutically acceptable salt thereof.

Representative ACE inhibitors include ramipril, aptopril, enalapril, lisinopril, fosinopril, captopril and the like or a pharmaceutically acceptable salt thereof.

Representative potassium channel activators include pinacidil, glibenclamide, glimepiride, diaoxide, cromocalim, and the like or a pharmaceutically acceptable salt thereof.

Representative antiserotoninergic agents include ketanserin and the like or a pharmaceutically acceptable salt thereof.

Representative angiotensin II antagonists include DUP527 and the like or a pharmaceutically acceptable salt thereof.

Representative angiotensin II receptor blockers (angiotensin II receptor antagonists (ARBs)) include losartan, irbesartan, valsartan, omapatrilat, gemopatrilat and the like or a pharmaceutically acceptable salt thereof.

Other representative cardiovascular agents include sympatholytic agents such as methyldopa, clonidine, guanabenz, reserpine and the like or a pharmaceutically acceptable salt thereof.

Dosage, Host and Safety

The compounds of the present invention are stable and can be used safely. In particular, the compounds of the present invention are useful as renin inhibitors for a variety of subjects (e.g., humans, non-human mammals and non-mammals). The optimal dose may vary depending upon such conditions as, for example, the type of subject, the body weight of the subject, the route of administration, and specific properties of the particular compound being used. In general, the daily dose for oral administration to an adult (body weight of about 60 kg) is about 1 to 1000 mg, about 3 to 300 mg, or about 10 to 200 mg. It will be appreciated that the daily dose can be given in a single administration or in multiple (e.g., 2 or 3) portions a day.

Compositions Comprising Renin Inhibitors

A wide variety of compositions and administration methods may be used in conjunction with the compounds of the present invention. Such compositions may include, in addition to the compounds of the present invention, conventional pharmaceutical excipients, and other conventional, pharmaceutically inactive agents. Additionally, the compositions may include active agents in addition to the compounds of the present invention. These additional active agents may include additional compounds according to the invention, and/or one or more other pharmaceutically active agents.

The compositions may be in gaseous, liquid, semi-liquid or solid form, formulated in a manner suitable for the route of administration to be used. For oral administration, capsules and tablets are typically used. For parenteral administration, reconstitution of a lyophilized powder, prepared as described herein, is typically used.

Compositions comprising compounds of the present invention may be administered or coadministered orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery (for example by catheter or stent), subcutaneously, intraadiposally, intraarticularly, or intrathecally. The compounds and/or compositions according to the invention may also be administered or coadministered in slow release dosage forms.

The renin inhibitors and compositions comprising them may be administered or coadministered in any conventional dosage form. Co-administration in the context of this invention is intended to mean the administration of more than one therapeutic agent, one of which includes a renin inhibitor, in the course of a coordinated treatment to achieve an improved clinical outcome. Such co-administration may also be coextensive, that is, occurring during overlapping periods of time.

Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application may optionally include one or more of the following components: a sterile diluent, such as water for injection, saline solution, fixed oil, polyethylene glycol, glycerin, propylene glycol or other synthetic solvent; antimicrobial agents, such as benzyl alcohol and methyl parabens; antioxidants, such as ascorbic acid and sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid (EDTA); buffers, such as acetates, citrates and phosphates; agents for the adjustment of tonicity such as sodium chloride or dextrose, and agents for adjusting the acidity or alkalinity of the composition, such as alkaline or acidifying agents or buffers like carbonates, bicarbonates, phosphates, hydrochloric acid, and organic acids like acetic and citric acid. Parenteral preparations may optionally be enclosed in ampules, disposable syringes or single or multiple dose vials made of glass, plastic or other suitable material.

When compounds according to the present invention exhibit insufficient solubility, methods for solubilizing the compounds may be used. Such methods are known to those of skill in this art, and include, but are not limited to, using cosolvents, such as dimethylsulfoxide (DMSO), using surfactants, such as TWEEN, or dissolution in aqueous sodium bicarbonate. Derivatives of the compounds, such as prodrugs of the compounds may also be used in formulating effective pharmaceutical compositions.

Upon mixing or adding compounds according to the present invention to a composition, a solution, suspension, emulsion or the like may be formed. The form of the resulting composition will depend upon a number of factors, including the intended mode of administration, and the solubility of the compound in the selected carrier or vehicle. The effective concentration needed to ameliorate the disease being treated may be empirically determined.

Compositions according to the present invention are optionally provided for administration to humans and animals in unit dosage forms, such as tablets, capsules, pills, powders, dry powders for inhalers, granules, sterile parenteral solutions or suspensions, and oral solutions or suspensions, and oil-water emulsions containing suitable quantities of the compounds, particularly the pharmaceutically acceptable salts, preferably the sodium salts, thereof. The pharmaceutically therapeutically active compounds and derivatives thereof are typically formulated and administered in unit-dosage forms or multiple-dosage forms. Unit-dose forms, as used herein, refers to physically discrete units suitable for human and animal subjects and packaged individually as is known in the art. Each unit-dose contains a predetermined quantity of the therapeutically active compound sufficient to produce the desired therapeutic effect, in association with the required pharmaceutical carrier, vehicle or diluent. Examples of unit-dose forms include ampoules and syringes individually packaged tablet or capsule. Unit-dose forms may be administered in fractions or multiples thereof. A multiple-dose form is a plurality of identical unit-dosage forms packaged in a single container to be administered in segregated unit-dose form. Examples of multiple-dose forms include vials, bottles of tablets or capsules or bottles of pint or gallons. Hence, multiple dose form is a multiple of unit-doses that are not segregated in packaging.

In addition to one or more compounds according to the present invention, the composition may comprise: a diluent such as lactose, sucrose, dicalcium phosphate, or carboxymethylcellulose; a lubricant, such as magnesium stearate, calcium stearate and talc; and a binder such as starch, natural gums, such as gum acacia gelatin, glucose, molasses, polyvinylpyrrolidine, celluloses and derivatives thereof, povidone, crospovidones and other such binders known to those of skill in the art. Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, or otherwise mixing an active compound as defined above and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, glycols, ethanol, and the like, to form a solution or suspension. If desired, the pharmaceutical composition to be administered may also contain minor amounts of auxiliary substances such as wetting agents, emulsifying agents, or solubilizing agents, pH buffering agents and the like, for example, acetate, sodium citrate, cyclodextrine derivatives, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, and other such agents. Actual methods of preparing such dosage forms are known in the art, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 15th Edition, 1975. The composition or formulation to be administered will, in any event, contain a sufficient quantity of an inhibitor of the present invention to reduce renin activity in vivo, thereby treating the disease state of the subject.

Dosage forms or compositions may optionally comprise one or more compounds according to the present invention in the range of 0.005% to 100% (weight/weight) with the balance comprising additional substances such as those described herein. For oral administration, a pharmaceutically acceptable composition may optionally comprise any one or more commonly employed excipients, such as, for example pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, talcum, cellulose derivatives, sodium crosscarmellose, glucose, sucrose, magnesium carbonate, sodium saccharin, talcum. Such compositions include solutions, suspensions, tablets, capsules, powders, dry powders for inhalers and sustained release formulations, such as, but not limited to, implants and microencapsulated delivery systems, and biodegradable, biocompatible polymers, such as collagen, ethylene vinyl acetate, polyanhydrides, polyglycolic acid, polyorthoesters, polylactic acid and others. Methods for preparing these formulations are known to those skilled in the art. The compositions may optionally contain 0.01%-100% (weight/weight) of one or more renin inhibitors, optionally 0.1-95%, and optionally 1-95%.

Salts, preferably sodium salts, of the inhibitors may be prepared with carriers that protect the compound against rapid elimination from the body, such as time release formulations or coatings. The formulations may further include other active compounds to obtain desired combinations of properties.

A. Formulations for Oral Administration

Oral pharmaceutical dosage forms may be as a solid, gel or liquid. Examples of solid dosage forms include, but are not limited to tablets, capsules, granules, and bulk powders. More specific examples of oral tablets include compressed, chewable lozenges and tablets that may be enteric-coated, sugar-coated or film-coated. Examples of capsules include hard or soft gelatin capsules. Granules and powders may be provided in non-effervescent or effervescent forms. Each may be combined with other ingredients known to those skilled in the art.

In certain variation of the above embodiments and variations, compounds according to the present invention are provided as solid dosage forms, preferably capsules or tablets. The tablets, pills, capsules, troches and the like may optionally contain one or more of the following ingredients, or compounds of a similar nature: a binder; a diluent; a disintegrating agent; a lubricant; a glidant; a sweetening agent; and a flavoring agent.

Examples of binders that may be used include, but are not limited to, microcrystalline cellulose, gum tragacanth, glucose solution, acacia mucilage, gelatin solution, sucrose and starch paste.

Examples of lubricants that may be used include, but are not limited to, talc, starch, magnesium or calcium stearate, lycopodium and stearic acid.

Examples of diluents that may be used include, but are not limited to, lactose, sucrose, starch, kaolin, salt, mannitol and dicalcium phosphate.

Examples of glidants that may be used include, but are not limited to, colloidal silicon dioxide.

Examples of disintegrating agents that may be used include, but are not limited to, crosscarmellose sodium, sodium starch glycolate, alginic acid, corn starch, potato starch, bentonite, methylcellulose, agar and carboxymethylcellulose.

Examples of coloring agents that may be used include, but are not limited to, any of the approved certified water-soluble FD and C dyes, mixtures thereof; and water insoluble FD and C dyes suspended on alumina hydrate.

Examples of sweetening agents that may be used include, but are not limited to, sucrose, lactose, mannitol and artificial sweetening agents such as sodium cyclamate and saccharin, and any number of spray-dried flavors.

Examples of flavoring agents that may be used include, but are not limited to, natural flavors extracted from plants such as fruits and synthetic blends of compounds that produce a pleasant sensation, such as, but not limited to peppermint and methyl salicylate.

Examples of wetting agents that may be used include, but are not limited to, propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate and polyoxyethylene lauryl ether.

Examples of anti-emetic coatings that may be used include, but are not limited to, fatty acids, fats, waxes, shellac, ammoniated shellac and cellulose acetate phthalates.

Examples of film coatings that may be used include, but are not limited to, hydroxyethylcellulose, sodium carboxymethylcellulose, polyethylene glycol 4000 and cellulose acetate phthalate.

If oral administration is desired, the salt of the compound may optionally be provided in a composition that protects it from the acidic environment of the stomach. For example, the composition can be formulated in an enteric coating that maintains its integrity in the stomach and releases the active compound in the intestine. The composition may also be formulated in combination with an antacid or other such ingredient.

When the dosage unit form is a capsule, it may optionally additionally comprise a liquid carrier such as a fatty oil. In addition, dosage unit forms may optionally additionally comprise various other materials that modify the physical form of the dosage unit, for example, coatings of sugar and other enteric agents.

Compounds according to the present invention may also be administered as a component of an elixir, suspension, syrup, wafer, sprinkle, chewing gum or the like. A syrup may optionally comprise, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.

The compounds of the present invention may also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as antacids, H2 blockers, and diuretics. For example, if a compound is used for treating asthma or hypertension, it may be used with other bronchodilators and antihypertensive agents, respectively.

Examples of pharmaceutically acceptable carriers that may be included in tablets comprising compounds of the present invention include, but are not limited to binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, and wetting agents. Enteric-coated tablets, because of the enteric-coating, resist the action of stomach acid and dissolve or disintegrate in the neutral or alkaline intestines. Sugar-coated tablets may be compressed tablets to which different layers of pharmaceutically acceptable substances are applied. Film-coated tablets may be compressed tablets that have been coated with polymers or other suitable coating. Multiple compressed tablets may be compressed tablets made by more than one compression cycle utilizing the pharmaceutically acceptable substances previously mentioned. Coloring agents may also be used in tablets. Flavoring and sweetening agents may be used in tablets, and are especially useful in the formation of chewable tablets and lozenges.

Examples of liquid oral dosage forms that may be used include, but are not limited to, aqueous solutions, emulsions, suspensions, solutions and/or suspensions reconstituted from non-effervescent granules and effervescent preparations reconstituted from effervescent granules.

Examples of aqueous solutions that may be used include, but are not limited to, elixirs and syrups. As used herein, elixirs refer to clear, sweetened, hydroalcoholic preparations. Examples of pharmaceutically acceptable carriers that may be used in elixirs include, but are not limited to solvents. Particular examples of solvents that may be used include glycerin, sorbitol, ethyl alcohol and syrup. As used herein, syrups refer to concentrated aqueous solutions of a sugar, for example, sucrose. Syrups may optionally further comprise a preservative.

Emulsions refer to two-phase systems in which one liquid is dispersed in the form of small globules throughout another liquid. Emulsions may optionally be oil-in-water or water-in-oil emulsions. Examples of pharmaceutically acceptable carriers that may be used in emulsions include, but are not limited to non-aqueous liquids, emulsifying agents and preservatives.

Examples of pharmaceutically acceptable substances that may be used in non-effervescent granules, to be reconstituted into a liquid oral dosage form, include diluents, sweeteners and wetting agents.

Examples of pharmaceutically acceptable substances that may be used in effervescent granules, to be reconstituted into a liquid oral dosage form, include organic acids and a source of carbon dioxide.

Coloring and flavoring agents may optionally be used in all of the above dosage forms.

Particular examples of preservatives that may be used include glycerin, methyl and propylparaben, benzoic add, sodium benzoate and alcohol.

Particular examples of non-aqueous liquids that may be used in emulsions include mineral oil and cottonseed oil.

Particular examples of emulsifying agents that may be used include gelatin, acacia, tragacanth, bentonite, and surfactants such as polyoxyethylene sorbitan monooleate.

Particular examples of suspending agents that may be used include sodium carboxymethylcellulose, pectin, tragacanth, Veegum and acacia. Diluents include lactose and sucrose. Sweetening agents include sucrose, syrups, glycerin and artificial sweetening agents such as sodium cyclamate and saccharin.

Particular examples of wetting agents that may be used include propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate and polyoxyethylene lauryl ether.

Particular examples of organic acids that may be used include citric and tartaric acid.

Sources of carbon dioxide that may be used in effervescent compositions include sodium bicarbonate and sodium carbonate. Coloring agents include any of the approved certified water soluble FD and C dyes, and mixtures thereof.

Particular examples of flavoring agents that may be used include natural flavors extracted from plants such fruits, and synthetic blends of compounds that produce a pleasant taste sensation.

For a solid dosage form, the solution or suspension, in for example propylene carbonate, vegetable oils or triglycerides, is preferably encapsulated in a gelatin capsule. Such solutions, and the preparation and encapsulation thereof, are disclosed in U.S. Pat. Nos. 4,328,245; 4,409,239; and 4,410,545. For a liquid dosage form, the solution, e.g., in a polyethylene glycol, may be diluted with a sufficient quantity of a pharmaceutically acceptable liquid carrier, e.g., water, to be easily measured for administration.

Alternatively, liquid or semi-solid oral formulations may be prepared by dissolving or dispersing the active compound or salt in vegetable oils, glycols, triglycerides, propylene glycol esters (e.g., propylene carbonate) and other such carriers, and encapsulating these solutions or suspensions in hard or soft gelatin capsule shells. Other useful formulations include those set forth in U.S. Pat. Nos. Re 28,819 and 4,358,603.

B. Injectables, Solutions, and Emulsions

The present invention is also directed to compositions designed to administer the compounds of the present invention by parenteral administration, generally characterized by subcutaneous, intramuscular or intravenous injection. Injectables may be prepared in any conventional form, for example as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.

Examples of excipients that may be used in conjunction with injectables according to the present invention include, but are not limited to water, saline, dextrose, glycerol or ethanol. The injectable compositions may also optionally comprise minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents, stabilizers, solubility enhancers, and other such agents, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate and cyclodextrins. Implantation of a slow-release or sustained-release system, such that a constant level of dosage is maintained (see, e.g., U.S. Pat. No. 3,710,795) is also contemplated herein. The percentage of active compound contained in such parenteral compositions is highly dependent on the specific nature thereof, as well as the activity of the compound and the needs of the subject.

Parenteral administration of the formulations includes intravenous, subcutaneous and intramuscular administrations. Preparations for parenteral administration include sterile solutions ready for injection, sterile dry soluble products, such as the lyophilized powders described herein, ready to be combined with a solvent just prior to use, including hypodermic tablets, sterile suspensions ready for injection, sterile dry insoluble products ready to be combined with a vehicle just prior to use and sterile emulsions. The solutions may be either aqueous or nonaqueous.

When administered intravenously, examples of suitable carriers include, but are not limited to physiological saline or phosphate buffered saline (PBS), and solutions containing thickening and solubilizing agents, such as glucose, polyethylene glycol, and polypropylene glycol and mixtures thereof.

Examples of pharmaceutically acceptable carriers that may optionally be used in parenteral preparations include, but are not limited to aqueous vehicles, nonaqueous vehicles, antimicrobial agents, isotonic agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, emulsifying agents, sequestering or chelating agents and other pharmaceutically acceptable substances.

Examples of aqueous vehicles that may optionally be used include Sodium Chloride Injection, Ringers Injection, Isotonic Dextrose Injection, Sterile Water Injection, Dextrose and Lactated Ringers Injection.

Examples of nonaqueous parenteral vehicles that may optionally be used include fixed oils of vegetable origin, cottonseed oil, corn oil, sesame oil and peanut oil.

Antimicrobial agents in bacteriostatic or fungistatic concentrations may be added to parenteral preparations, particularly when the preparations are packaged in multiple-dose containers and thus designed to be stored and multiple aliquots to be removed. Examples of antimicrobial agents that may be used include phenols or cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoic acid esters, thimerosal, benzalkonium chloride and benzethonium chloride.

Examples of isotonic agents that may be used include sodium chloride and dextrose. Examples of buffers that may be used include phosphate and citrate. Examples of antioxidants that may be used include sodium bisulfate. Examples of local anesthetics that may be used include procaine hydrochloride. Examples of suspending and dispersing agents that may be used include sodium carboxymethylcellulose, hydroxypropyl methylcellulose and polyvinylpyrrolidone. Examples of emulsifying agents that may be used include Polysorbate 80 (TWEEN 80). A sequestering or chelating agent of metal ions includes EDTA.

Pharmaceutical carriers may also optionally include ethyl alcohol, polyethylene glycol and propylene glycol for water miscible vehicles and sodium hydroxide, hydrochloric acid, citric acid or lactic acid for pH adjustment.

The concentration of an inhibitor in the parenteral formulation may be adjusted so that an injection administers a pharmaceutically effective amount sufficient to produce the desired pharmacological effect. The exact concentration of an inhibitor and/or dosage to be used will ultimately depend on the age, weight and condition of the patient or animal as is known in the art.

Unit-dose parenteral preparations may be packaged in an ampoule, a vial or a syringe with a needle. All preparations for parenteral administration should be sterile, as is known and practiced in the art.

Injectables may be designed for local and systemic administration. Typically a therapeutically effective dosage is formulated to contain a concentration of at least about 0.1% w/w up to about 90% w/w or more, preferably more than 1% w/w of the renin inhibitor to the treated tissue(s). The inhibitor may be administered at once, or may be divided into a number of smaller doses to be administered at intervals of time. It is understood that the precise dosage and duration of treatment will be a function of the location of where the composition is parenterally administered, the carrier and other variables that may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test data. It is to be noted that concentrations and dosage values may also vary with the age of the individual treated. It is to be further understood that for any particular subject, specific dosage regimens may need to be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the formulations. Hence, the concentration ranges set forth herein are intended to be exemplary and are not intended to limit the scope or practice of the claimed formulations.

The renin inhibitor may optionally be suspended in micronized or other suitable form or may be derivatized to produce a more soluble active product or to produce a prodrug. The form of the resulting mixture depends upon a number of factors, including the intended mode of administration and the solubility of the compound in the selected carrier or vehicle. The effective concentration is sufficient for ameliorating the symptoms of the disease state and may be empirically determined.

C. Lyophilized Powders

The compounds of the present invention may also be prepared as lyophilized powders, which can be reconstituted for administration as solutions, emulsions and other mixtures. The lyophilized powders may also be formulated as solids or gels.

Sterile, lyophilized powder may be prepared by dissolving the compound in a sodium phosphate buffer solution containing dextrose or other suitable excipient. Subsequent sterile filtration of the solution followed by lyophilization under standard conditions known to those of skill in the art provides the desired formulation. Briefly, the lyophilized powder may optionally be prepared by dissolving dextrose, sorbitol, fructose, corn syrup, xylitol, glycerin, glucose, sucrose or other suitable agent, about 1-20%, preferably about 5 to 15%, in a suitable buffer, such as citrate, sodium or potassium phosphate or other such buffer known to those of skill in the art at, typically, about neutral Ph. Then, a renin inhibitor is added to the resulting mixture, preferably above room temperature, more preferably at about 30-35 Oc, and stirred until it dissolves. The resulting mixture is diluted by adding more buffer to a desired concentration. The resulting mixture is sterile filtered or treated to remove particulates and to insure sterility, and apportioned into vials for lyophilization. Each vial may contain a single dosage or multiple dosages of the inhibitor.

D. Topical Administration

The compounds of the present invention may also be administered as topical mixtures. Topical mixtures may be used for local and systemic administration. The resulting mixture may be a solution, suspension, emulsions or the like and are formulated as creams, gels, ointments, emulsions, solutions, elixirs, lotions, suspensions, tinctures, pastes, foams, aerosols, irrigations, sprays, suppositories, bandages, dermal patches or any other formulations suitable for topical administration.

The renin inhibitors may be formulated as aerosols for topical application, such as by inhalation (see, U.S. Pat. Nos. 4,044,126, 4,414,209, and 4,364,923, which describe aerosols for delivery of a steroid useful for treatment of inflammatory diseases, particularly asthma). These formulations for administration to the respiratory tract can be in the form of an aerosol or solution for a nebulizer, or as a Lnicrofine powder for insufflation, alone or in combination with an inert carrier such as lactose. In such a case, the particles of the formulation will typically have diameters of less than 50 microns, preferably less than 10 microns.

The inhibitors may also be formulated for local or topical application, such as for topical application to the skin and mucous membranes, such as in the eye, in the form of gels, creams, and lotions and for application to the eye or for intracisternal or intraspinal application. Topical administration is contemplated for transdermal delivery and also for administration to the eyes or mucosa, or for inhalation therapies. Nasal solutions of the renin inhibitor alone or in combination with other pharmaceutically acceptable excipients can also be administered.

E. Formulations for Other Routes of Administrations

Depending upon the disease state being treated, other routes of administration, such as topical application, transdermal patches, and rectal administration, may also be used. For example, pharmaceutical dosage forms for rectal administration are rectal suppositories, capsules and tablets for systemic effect. Rectal suppositories are used herein mean solid bodies for insertion into the rectum that melt or soften at body temperature releasing one or more pharmacologically or therapeutically active ingredients. Pharmaceutically acceptable substances utilized in rectal suppositories are bases or vehicles and agents to raise the melting point. Examples of bases include cocoa butter (theobroma oil), glycerin-gelatin, carbowax, (polyoxyethylene glycol) and appropriate mixtures of mono-, di- and triglycerides of fatty acids. Combinations of the various bases may be used. Agents to raise the melting point of suppositories include spermaceti and wax. Rectal suppositories may be prepared either by the compressed method or by molding. The typical weight of a rectal suppository is about 2 to 3 gm. Tablets and capsules for rectal administration may be manufactured using the same pharmaceutically acceptable substance and by the same methods as for formulations for oral administration.

F. Examples of Formulations

The following are particular examples of oral, intravenous and tablet formulations that may optionally be used with compounds of the present invention. It is noted that these formulations may be varied depending on the particular compound being used and the indication for which the formulation is going to be used.

ORAL FORMULATION

Compound of the Present Invention
10-100
mg

Citric Acid Monohydrate
105
mg

Sodium Hydroxide
18
mg

Flavoring

Water
q.s. to 100 mL

INTRAVENOUS FORMULATION

Compound of the Present Invention
0.1-10
mg

Dextrose Monohydrate
q.s. to make isotonic

Citric Acid Monohydrate
1.05
mg

Sodium Hydroxide
0.18
mg

Water for Injection
q.s. to 1.0 mL

TABLET FORMULATION

Compound of the Present Invention
1%

Microcrystalline Cellulose
73%

Stearic Acid
25%

Colloidal Silica
1%.

Kits Comprising Renin Inhibitors

The invention is also directed to kits and other articles of manufacture for treating diseases associated with renin. It is noted that diseases are intended to cover all conditions for which the renin possess activity that contributes to the pathology and/or symptomology of the condition.

In one variation of the above embodiments and variations, a kit is provided that comprises a composition comprising at least one inhibitor of the present invention in combination with instructions. The instructions may indicate the disease state for which the composition is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition. The kit may also comprise packaging materials. The packaging material may comprise a container for housing the composition. The kit may also optionally comprise additional components, such as syringes for administration of the composition. The kit may comprise the composition in single or multiple dose forms.

In another variation of the above embodiments and variations, an article of manufacture is provided that comprises a composition comprising at least one inhibitor of the present invention in combination with packaging materials. The packaging material may comprise a container for housing the composition. The container may optionally comprise a label indicating the disease state for which the composition is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition. The kit may also optionally comprise additional components, such as syringes for administration of the composition. The kit may comprise the composition in single or multiple dose forms.

It is noted that the packaging material used in kits and articles of manufacture according to the present invention may form a plurality of divided containers such as a divided bottle or a divided foil packet. The container can be in any conventional shape or form as known in the art which is made of a pharmaceutically acceptable material, for example a paper or cardboard box, a glass or plastic bottle or jar, a re-sealable bag (for example, to hold a “refill” of tablets for placement into a different container), or a blister pack with individual doses for pressing out of the pack according to a therapeutic schedule. The container that is employed will depend on the exact dosage form involved, for example a conventional cardboard box would not generally be used to hold a liquid suspension. It is feasible that more than one container can be used together in a single package to market a single dosage form. For example, tablets may be contained in a bottle that is in turn contained within a box. Typically the kit includes directions for the administration of the separate components. The kit form is particularly advantageous when the separate components are preferably administered in different dosage forms (e.g., oral, topical, transdermal and parenteral), are administered at different dosage intervals, or when titration of the individual components of the combination is desired by the prescribing physician.

One particular example of a kit according to the present invention is a so-called blister pack. Blister packs are well known in the packaging industry and are being widely used for the packaging of pharmaceutical unit dosage forms (tablets, capsules, and the like). Blister packs generally consist of a sheet of relatively stiff material covered with a foil of a preferably transparent plastic material. During the packaging process recesses are formed in the plastic foil. The recesses have the size and shape of individual tablets or capsules to be packed or may have the size and shape to accommodate multiple tablets and/or capsules to be packed. Next, the tablets or capsules are placed in the recesses accordingly and the sheet of relatively stiff material is sealed against the plastic foil at the face of the foil which is opposite from the direction in which the recesses were formed. As a result, the tablets or capsules are individually sealed or collectively sealed, as desired, in the recesses between the plastic foil and the sheet. Preferably the strength of the sheet is such that the tablets or capsules can be removed from the blister pack by manually applying pressure on the recesses whereby an opening is formed in the sheet at the place of the recess. The tablet or capsule can then be removed via said opening.

Another specific variation of the above embodiments and variations of a kit is a dispenser designed to dispense the daily doses one at a time in the order of their intended use. Preferably, the dispenser is equipped with a memory-aid, so as to further facilitate compliance with the regimen. An example of such a memory-aid is a mechanical counter that indicates the number of daily doses that has been dispensed. Another example of such a memory-aid is a battery-powered micro-chip memory coupled with a liquid crystal readout, or audible reminder signal which, for example, reads out the date that the last daily dose has been taken and/or reminds one when the next dose is to be taken.

Preparation and Assaying of Renin Inhibitors

Various methods may be developed for synthesizing compounds according to the present invention. Representative methods for synthesizing these compounds are provided in the Examples. It is noted, however, that the compounds of the present invention may also be synthesized by other synthetic routes that others may devise.

It will be readily recognized that certain compounds according to the present invention have atoms with linkages to other atoms that confer a particular stereochemistry to the compound (e.g., chiral centers). It is recognized that synthesis of compounds according to the present invention may result in the creation of mixtures of different stereoisomers (i.e., enantiomers and diastereomers). Unless a particular stereochemistry is specified, recitation of a compound is intended to encompass all of the different possible stereoisomers.

Various methods for separating mixtures of different stereoisomers are known in the art. For example, a racemic mixture of a compound may be reacted with an optically active resolving agent to form a pair of diastereoisomeric compounds. The diastereomers may then be separated in order to recover the optically pure enantiomers. Dissociable complexes may also be used to resolve enantiomers (e.g., crystalline diastereoisomeric salts). Diastereomers typically have sufficiently distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and can be readily separated by taking advantage of these dissimilarities. For example, diastereomers can typically be separated by chromatography or by separation/resolution techniques based upon differences in solubility. A more detailed description of techniques that can be used to resolve stereoisomers of compounds from their racemic mixture can be found in Jean Jacques Andre Collet and Samuel H. Wilen, Enantiomers, Racemates and Resolutions, John Wiley & Sons, Inc. (1981).

Compounds according to the present invention can also be prepared as a pharmaceutically acceptable acid addition salt by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid. Alternatively, a pharmaceutically acceptable base addition salt of a compound can be prepared by reacting the free acid form of the compound with a pharmaceutically acceptable inorganic or organic base. Inorganic and organic acids and bases suitable for the preparation of the pharmaceutically acceptable salts of compounds are set forth in the definitions section of this Application. Alternatively, the salt forms of the compounds can be prepared using salts of the starting materials or intermediates.

The free acid or free base forms of the compounds can be prepared from the corresponding base addition salt or acid addition salt form. For example, a compound in an acid addition salt form can be converted to the corresponding free base by treating with a suitable base (e.g., ammonium hydroxide solution, sodium hydroxide, and the like). A compound in a base addition salt form can be converted to the corresponding free acid by treating with a suitable acid (e.g., hydrochloric acid, etc).

The N-oxides of compounds according to the present invention can be prepared by methods known to those of ordinary skill in the art. For example, N-oxides can be prepared by treating an unoxidized form of the compound with an oxidizing agent (e.g., trifluoroperacetic acid, permaleic acid, perbenzoic acid, peracetic acid, meta-chloroperoxybenzoic acid, or the like) in a suitable inert organic solvent (e.g., a halogenated hydrocarbon such as dichloromethane) at approximately 0° C. Alternatively, the N-oxides of the compounds can be prepared from the N-oxide of an appropriate starting material.

Compounds in an unoxidized form can be prepared from N-oxides of compounds by treating with a reducing agent (e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like) in an suitable inert organic solvent (e.g., acetonitrile, ethanol, aqueous dioxane, or the like) at 0 to 80° C.

Prodrug derivatives of the compounds can be prepared by methods known to those of ordinary skill in the art. For example, appropriate prodrugs can be prepared by reacting a non-derivatized compound with a suitable carbamylating agent (e.g., 1,1-acyloxyalkylcarbonochloridate, para-nitrophenyl carbonate, or the like) or an acylating agent. Further examples of methods of making prodrugs are described in Saulnier et al. Bioorganic and Medicinal Chemistry Letters, 1994, Vol. 4, p. 1985. Those of ordinary skill in the art have the knowledge and means to accomplish this without undue experimentation.

Protected derivatives of the compounds can be made by methods known to those of ordinary skill in the art. A detailed description of the techniques applicable to the creation of protecting groups and their removal can be found in T. W. Greene, Protecting Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, Inc. 1999.

Compounds according to the present invention may be conveniently prepared or formed during the process of the invention, as solvates (e.g., hydrates). Hydrates of compounds of the present invention may be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents such as dioxin, tetrahydrofuran or methanol.

Compounds according to the present invention can also be prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomer. While resolution of enantiomers can be carried out using covalent diastereomeric derivatives of compounds, dissociable complexes are preferred (e.g., crystalline diastereoisomeric salts). Diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and can be readily separated by taking advantage of these dissimilarities. The diastereomers can be separated by chromatography or, preferably, by separation/resolution techniques based upon differences in solubility. The optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that would not result in racemization. A more detailed description of the techniques applicable to the resolution of stereoisomers of compounds from their racemic mixture can be found in Jean Jacques Andre Collet and Samuel H. Wilen, Enantiomers, Racemates and Resolutions, John Wiley & Sons, Inc. (1981).

As used herein the symbols and conventions used in these processes, schemes and examples are consistent with those used in the contemporary scientific literature, for example, the Journal of the American Chemical Society or the Journal of Biological Chemistry. Standard single-letter or thee-letter abbreviations are generally used to designate amino acid residues, which are assumed to be in the L-configuration unless otherwise noted. Unless otherwise noted, all starting materials were obtained from commercial suppliers and used without further purification. Specifically, the following abbreviations may be used in the examples and throughout the specification:

Ac (acetyl)

atm (atmosphere)

ATP (adenosine triphphatase)

Boc (tert-butyloxycarbonyl)

BOP (bis(2-oxo-3-oxazolidinyl)phosphinic chloride)

Brij35 (polyoxyethyleneglycol dodecyl ether)

BSA (bovine serum albumin)

CBZ (benzyloxycarbonyl)

CDI (1,1-carbonyldiimidazole)

DCC (dicyclohexylcarbodiimide)

DCE (dichloroethane)

DCM (dichloromethane)

DIEA (di-isopropylethylamine)

DMAP (4-dimethylaminopyridine)

DME (1,2-dimethoxyethane)

DMF (N,N-dimethylformamide)

DMPU (N,N′-dimethylpropyleneurea)

DMSO (dimethylsulfoxide)

DTT (dithiothreitol)

EDCI (ethylcarbodiimide hydrochloride)

EDTA (ethylenediaminetetraacetic acid)

Et (ethyl)

Et₂O (diethyl ether)

EtOAc (ethyl acetate)

FMOC (9-fluorenylmethoxycarbonyl)

g (grams)

hrs (hours)

HATU (2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-

tetramethyluronium hexafluorophosphate)

HOAc or AcOH (acetic acid)

HOBT (1-hydroxybenzotriazole)

HOSu (N-hydroxysuccinimide)

HPLC (high performance liquid chromatography)

Hz (hertz)

IBCF (isobutyl chloroformate)

i.v. (intravenous)

i-PrOH (isopropanol)

L (liters)

LAH (lithium aluminium hydride)

M (molar)

mCPBA (meta-chloroperbenzoic acid)

Me (methyl)

MeOH (methanol)

mg (milligrams)

MHz (megahertz)

μL (microliters)

mL (milliliters)

mM (millimolar)

min (minutes)

mmol (millimoles)

mol (moles)

MOMCl (methoxymethyl chloride)

MOPS (morpholinepropanesulfonic acid)

mp (melting point)

NaOAc (sodium acetate)

NEt₃(triethylamine)

OMe (methoxy)

OTf (O-triflate)

OMs (O-mesylate)

Pd(dppf)Cl₂(bis(diphenyl phosphino)ferrocene dichloro

palladium (II)

psi (pounds per square inch)

RP (reverse phase)

rt (ambient temperature)

SPA (scintillation proximity assay)

TBAF (tetra-n-butylammonium fluoride)

TBDMS (tert-butyldimethylsilyl)

TBS (t-butyldimethylsilyl)

tBu (tert-butyl)

TEA (triethylamine)

TFA (trifluoroacetic acid)

TFAA (trifluoroacetic anhydride)

THF (tetrahydrofuran)

TIPS (triisopropylsilyl)

TLC (thin layer chromatography)

TMS (trimethylsilyl)

TMSE (2-(trimethylsilyl)ethyl)

TMSI (trimethylsilyliodide)

RT (retention time)

All references to ether or Et₂O are to diethyl ether; and brine refers to a saturated aqueous solution of NaCl. Unless otherwise indicated, all temperatures are expressed in ° C. (degrees Centigrade). All reactions are conducted under an inert atmosphere at rt unless otherwise noted.

¹H NMR spectra were recorded on a Bruker Avance 400. Chemical shifts are expressed in parts per million (ppm). Coupling constants are in units of Hertz (Hz). Splitting patterns describe apparent multiplicities and are designated as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br (broad). When two rotomers are observed, the combined NMR spectra are presented.

Low-resolution mass spectra (MS) and compound purity data were acquired on a Waters ZQ LC/MS single quadrupole system equipped with electrospray ionization (ESI) source, UV detector (220 and 254 nm), and evaporative light scattering detector (ELSD). Thin-layer chromatography was performed on 0.25 mm E. Merck silica gel plates (60° F.-254), visualized with UV light, 5% ethanolic phosphomolybdic acid, Ninhydrin or p-anisaldehyde solution. Flash column chromatography was performed on silica gel (230-400 mesh, Merck).

The starting materials and reagents used in preparing these compounds are either available from commercial suppliers such as the Aldrich Chemical Company (Milwaukee, Wis.), Bachem (Torrance, Calif.), Sigma (St. Louis, Mo.), or may be prepared by methods well known to a person of ordinary skill in the art, following procedures described in such standard references as Fieser and Fieser's Reagents for Organic Synthesis, vols. 1-17, John Wiley and Sons, New York, N.Y., 1991; Rodd's Chemistry of Carbon Compounds, vols. 1-5 and supps., Elsevier Science Publishers, 1989; Organic Reactions, vols. 1-40, John Wiley and Sons, New York, N.Y., 1991; March J.: Advanced Organic Chemistry, 4th ed., John Wiley and Sons, New York, N.Y.; and Larock: Comprehensive Organic Transformations, VCH Publishers, New York, 1989.

The entire disclosures of all documents cited throughout this application are incorporated herein by reference.

Synthetic Schemes for Compounds of the Present Invention

Compounds according to the present invention may be synthesized according to the reaction schemes shown below. Other reaction schemes could be readily devised by those skilled in the art. It should also be appreciated that a variety of different solvents, temperatures and other reaction conditions can be varied to optimize the yields of the reactions.

In the reactions described hereinafter it may be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice, for examples see T. W. Greene and P. G. M. Wuts in Protective Groups in Organic Chemistry, John Wiley and Sons, 1991.

General synthetic routes for producing compounds of the present invention are shown in the schemes below. The various substituents may be selected from among the various substituents otherwise taught herein.

In each of the above reaction procedures or schemes, the various substituents may be selected from among the various substituents otherwise taught herein.

A. General Synthetic Route I

The imidazol-2-ylpiperidine analogs can be synthesized according to Scheme 1. Condensation of the piperidine-3-carboxylate (1a) with diamine compounds 1b (e.g., aromatic diamines and heterocyclic diamines, such as o-phenylenediamine) in acidic medium, e.g., aqueous HCl, at elevated temperature gives intermediate 1c. Protection of the free amine group of 1c with Boc anhydride (1d) yields the imidazole intermediate 1e, which can be alkylated with alkyl halide compound 1f in the presence of a base such as NaH to give 1g. Removal of N-Boc group in acid conditions such as TFA in DCM or HCl in dioxane affords key piperidine intermediate 1h. Deravitization of the amine group of 1 h with reagent such as isocyanate 1n to give renin inhibitor 1r, or with acid or protected amino acid 1i to give, after proper deprotection if needed, the renin inhibitor 1m.

embedded image

B. General Synthetic Route II

Imidazol-2-ylpiperidine analogs 2m can also be synthesized according to the synthetic route shown in Scheme 2. Coupling of piperidine-3-carboxylic acid (2a) with diamine compounds 2b such as benzene-1,2-diamine with peptide coupling reagent such as EDCI in DCM or DMF gives intermediate 2c. Cyclization of 2c in the presence of acid such as acetic acid with heating (generally 40 to 120° C.) produces 2d, which can be alkylated with 2e in the presence of a base such as NaH to give 2f. Removal of N-Boc group in acid conditions such as TFA in DCM affords key piperidine intermediate 2h; Deravitization of the amine group of 2h with reagent such as isocyanate 2n to give renin inhibitor 2r, or with acid or protected amino acid 2i, after proper deprotection if needed, gives the final renin inhibitor 2m.

embedded image

C. General Synthetic Route III

Alternatively, the renin inhibitors 3m may be synthesized as shown in Scheme 3. Amine 3a may be reacted with ortho-halo-nitro compound 3b (such as 2-F or 2-Cl nitrobenzenes) via SNAr reaction to give intermediate 3c. Reduction of nitro to amine by palladium catalysized hydrogenation or metal reduction (such as by Tin(II) chloride), followed by amide coupling with 3d yields 3e. Upon heating 3e in the presence dehydrating agent such as acetic acid gives key intermediate 3f. Deprotection and then derivatization of the amine with the appropriate reagents such as isocyanate 3n, acid or protected amino acids 31 according to Scheme 1 yield product 3r or 3m, respectively.

embedded image

D. General Synthetic Route IV

The inhibitors of the invention may be prepared in a synthetic route shown in Scheme 4. The N-protected piperidine-3-aldehyde (4a) may be prepared from its corresponding ester 4a⁰through direct reduction with MAL in THF at low temperature (e.g. −78° C.). Alternately, 4a may be pprepared from the oxidation of alcohol 4a¹in pyridine sulfur trioxide. Reaction of aldehyde 4a with diamine 4b, in the presence of an oxidizing agent such as Oxone® 14 or air, gives 4c, which upon deprotection gives the piperidine intermediate 4d. Deprotection and then derivatization of the amine with the appropriate reagent 4i and 4n according to Scheme 1, Steps 4-7, yield products 4m and 4r, respectively.

embedded image

E. General Synthetic Route V

Renin inhibitors having an imidazole ring fused to a saturated or unsaturated cyclic or heterocyclic ring may be synthesized via Scheme 5. Coupling of the N-protected piperidine-3-carboxylic acid (5a) with a saturated or unsaturated cyclic or heterocyclic diamine 5b using EDCI or other amide/peptide coupling reagents gives 5c, which upon heating with acetic acid or other acids to give the dihydro-imidazole intermediate 5d. Alkylation with 5e followed with oxidation with oxygen (air) or other oxidation agents such Oxone®14, DDQ, etc. gives the aromatized N—R₂cyclic imidazole 5f. Deprotection and then derivatization of the amine with 51 or 5n according to Scheme 1, Steps 4-7 yield products 5m or 5r, respectively, in good yields.

embedded image

F. General Synthetic Route VI

Alpha-hydroxy imidazol-2-ylpiperidine analogs 61 may be synthesized according to Scheme 6. The n-alkylated imidazole 6c (a benzimidazole is shown) is deprotonated with a base such as BuLi in THF at low temperature (−78° C. to RT), and further reaction with N-protected piperidin-3-one (6d) affords the hydroxyl intermediate 6e. Deprotection of the N-Boc group in acid conditions such as TFA in DCM affords the piperidine intermediate 6f. The hydroxyl group may be protected with protecting groups such as trimethylsilyl; then the amine group may be derivatized with 6g and deprotected according to Scheme 1, Steps 5-6 to afford hydroxyl renin inhibitor 6i.

embedded image

G. General Synthetic Route VII

Alpha carboxylate and alpha-hydroxymethyl renin inhibitors 7m and 7n respectively, can be synthesized according to Scheme 7. Palladium mediated reaction of N-protected piperidine-3-carboxylate (7a) with 2-halo or sulfonate analog 7b gives 7c. Reduction of carboxylate with LAH or DIBAL in THF at temperature ranging from −78° C. to 70° C. and protection with groups such as diphenylmethylsilyl chloride affords the hydroxymethyl analog 7d, 7c and 7d can be easily converted to final renin inhibitors 7m and 7n respectively, following procedures described in Scheme 1, Steps 4-6.

embedded image

H. General Synthetic Route VIII

Renin inhibitors where the N—R, of the imidazole is an acylaminoalkyl group can be synthesized according to Scheme 8. N-alkylation of 8a with N-phthalimide alkylhalo 8b (bromide or iodide) gives Sc. Removal of the N-Boc group in acid conditions such as TFA in DCM affords the piperidine intermediate 8d, which is then coupled with acid 8e to afford 8f. The phthalyl protecting group is removed by reacting with hydrazine to the free amino derivative 8g. Acylation with acid chloride or acid 8h, e.g. acetyl chloride, followed Bac deprotection gives renin inhibitor 8j with acylaminoaklyl side chain. It is noted that alkylation could also occur at the other nitrogen.

embedded image

I. General Synthetic Route IX

Renin inhibitors where the N—R, side chain of the imidazole is an acylaminoalkyl group may also be made according Scheme 9. N-alkylation of 9a with co-azido-alkyl iodide 9b gives 9c. Removal of the N-Boc group yields 9d, which is then coupled with acid 9e to afford 9f. The azido group is converted to the free amino derivative 9g by hydrogenation in the presence palladium carbon or by reaction with Ph₃P/water in THF. Acylation with acid chloride (such as acetyl chloride) or acid 9h, followed Boc deprotection, gives renin inhibitor 9j with an acylaminoalkyl side chain. It is noted that alkylation could also occur at the other nitrogen.

embedded image

Alternatively, renin inhibitors with an acylaminoalkyl side chaim may be prepared according Scheme 10. N-alkylation of 10a with chloro or bromo acetonitrile (10b) gives 10c¹(and the regioisomer 10c²). Reduction of the nitrile group to the amino group by hydrogenation in the presence a metal catalyst such as Raney nickel, amino protection with acetyl chloride (or other protecting group) and Boc-deprtoection with TFA yields 10d, which is then coupled with acid 10e to afford 10f. Finally, Boc deprotection gives renin inhibitor 10g with an acylaminoalkly side chain.

embedded image

J. General Synthetic Route X

N-linked benzimidazole piperidine renin inhibitor 11j can be made according to the method shown in Scheme 11. Displacement of 2-halophenyl or pyridyl nitro compound 10a with 3-amino-1-Cbz(or Boc) piperidine (11b) gives the adduct 11c, reduction of nitro to amine yields 11d, which is cyclized to form the imidazole analog 11f by reacting with an acid, ester or aldehyde 11e under appropriate conditions such as heating in acetic acid to give 11f. The Cbz protecting group (or Boc) is then removed under standard conditions gives the free piperidine 11g, which can be coupled to 11h and deprotected, according to Scheme 1, Steps 5-6, to give renin inhibitor 11j.

embedded image

K. General Synthetic Route XI

Renin inhibitors of the invention may be synthesized according to Scheme 12. The imidazole analog 12a (where R₃and R₄may be taken together to form a ring) is N-alkylated with R₂X 12b in the presence of a base to give 12c, which is treated with base such as BuLi or a Grignard reagent (such as isopropyl magnesium bromide) and reacted with n-protected piperidin-3-one (12d) following a similar reaction sequence shown in Scheme 6 to afford the hydroxyl analog 12e. The hydroxyl group can be reductively removed by platinum catalyst hydrogenation, Pd—C/hydrogen or other methods such as trialkylsilane/SF₃or trialkylsilane/TFA (TiCl₃/LiAlH₄, Breslow, Ronald; Hunt, John T.; Smiley, Richard; Tarnowski, Thomas; JACSAT; J. Am. Chem. Soc.; EN; 105; 16; 1983; 5337-5342.) (NaBH₄fITA: Nutaitis, Charles F.; Obaza-Nutaitis, Judy; OPPIAK; Org. Prep. Proceed. Int.; EN; 29; 3; 1997; 315-321); (HI/glacial acetic acid: Gilman; Meals; JOCEAH; J. Org. Chem.; 8; 1943; 126, 139.).

Intermediates 12e and 12f can be transformed into the final renin inhibitors 12i by similar reactions as shown in Scheme 1, Steps 4-6.

embedded image

L. Synthesis of 3,4-Diaminobutyric Acid Analogs

Renin inhibitors that are 3,4-diaminobutyric acid analogs may be prepared by further derivatizing the amino group on the piperidine as shown in Scheme 13. Protected piperidine intermediate 13a may be coupled to protected 3,4-diaminobutanoic acid 13b. After removing 4-N-Boc group under acidic conditions, the free amine 13c is obtained. Reaction with an acid/acid chloride, sulfonyl chloride, isocyanate or chloroformate 13d following typical amine coupling conditions gives, after removing Fmoc protecting group with base (piperidine/DMF), renin inhibitors 13e.

embedded image

M. Synthesis of 3-Amino-4-diaminobutyric Acid Analogs

3-amino-4-diaminobutyric acid analogs of the renin inhibitors of the invention may be prepared according to Scheme 14. The piperidine intermediate 14a may be coupled to protected 3-amino-4-hydroxybutanoic (14b). After removing 4-O-benzyl group under hydrogenation conditions, the free alcohol 14c is obtained. Reaction with 14d (phenols, heteroaryl, hydroxyl, or NH group of certain amide and cyclic amide (e.g., 14g)) by following typical Mitsunobu conditions gives, after removing Fmoc protecting group with base (piperidine/DMF), the aryl ether renin inhibitors 14e or the “amide” analog 14f.

embedded image

N. Synthesis of Pyrrolidine Amino Acid Analogs Pyrrolidine amino acid analogs of renin inhibitors of the invention may be prepared by the route shown in Scheme 13. The piperidine intermediate 15a is coupled to a protected N-Boc-3-N-Fmoc pyrrolidine-4-carboxylic acid 15b (made from 15f). After removing 4-N-Boc group under acidic conditions, the free amine 15c is obtained. The free amine 15c may be further derivatized with acid/acid chloride, sulfonyl chloride, isocyanate or chloroformate, and after removing Fmoc protecting group with base (piperidine/DMF), to obtain an amide sulfonamide, urea, or carbamate analog, respectively, of the renin inhibitors 15d.

embedded image

O. Synthesis of Imidazole Reagents

Imidazoles used in the synthesis of the renin inhibitors of the invention are purchased or may be synthesized through many known synthetic methods, e.g., the route shown in Scheme 16.

Aldehyde 16a may react with amine 16b in the presence of acid catalyst and/or dehydrating agent (such as molecular sieves, TiCl₄etc.) to yields the imine 16c. The imine 16c may reacts with toluene p-sulfonylmethyl isocyanide (TOSMIC) (16d) in basic conditions (such as NaH in DME or IC₂CO₃in MeOH) to give imidazole 16e. Deprotonation of 2-H of 16e with a strong base such as BuLi or a Grignard reagent followed by reaction with N-protected 3-piperidone (16f) and subsequent reduction of alpha-hydroxy group with Pt(OH)₂hydrogentation or other reagents described earlier (e.g., Scheme 12), gives piperidine imidazole ananlog 16g, which is converted to the final renin inhibitor 16h using procedures shown in Scheme 1, Steps 5 and 6.

embedded image

P. General Synthetic Route for O-Amino Acids

The beta-amino acids can be easily obtained from readily available α-amino acid acids through Arndt-Eistert Synthesis. N-protected amino acid 17a is transformed to alpha-diazoketone 17b by reaction with isobutyl chloroformate at low temperature and then with diazomethane. Intermediate 17b undergoes Wolff rearrangement catalyzed by silver salt, e.g., benzoic acid salt to give a reactive carbene which is reacted with MeOH to afford the methyl ester. After hydrolysis with base such as LiOH, the beta-amino acid 17c is obtained. Other methods such as Schollkopf method (Synthesis 1981, page 969) are also known to be useful in obtaining non-commercial beta amino acids.

embedded image

Q. General Synthetic Route for α-hydroxy-β-Amino Acids

Alpha-hydroxy-beta-amino acids can be synthesized using the corresponding alpha-amino acids according to Scheme 18. N-protected α-amino acid 18a is first converted to its Weinreb amide 18c through coupling with N,O-dimethylhydroxyamine (18b). Reduction with LAH in THF gives aldehyde 18d, which reacts with potassium or sodium cyanide to afford, after hydrolysis with aqueous HCl, the 1-hydroxy-2-amino acid 18e. Fisher esterification followed by N,O-protection with CDI then ester hydrolysis gives the protected alpha-hydroxy-beta-amino acids 18g, which are ready for further coupling reactions.

embedded image

R. General Synthetic Route for Alpha-Alkyl-Beta-Amino Acid

Alpha-alkyl-beta-amino acids can also be synthesized using the corresponding amino acid esters according to Scheme 19. N-protected amino acid ester 19a is treated with base such as NaH or a Phosphazene base such as P₄-t-Bu and alkyl halide 19b to give 19c and/or 19e depending on the amount of base and halide used. Ester hydrolysis with hydroxide gives the protected alpha-hydroxy-beta-amino acids 19d¹and/or 19d². The amino group of 19a may need to be double protected with groups such as bis-Boc. If an ω-dihalide 19e is used, cyclic alkyl amino acid 19h may be obtained.

embedded image

S. General Synthetic Route for Methylamino-Beta-Amino Acid

Beta-amino acid 19e may be synthesized according Scheme 20. Aldehyde 20a condenses with ethyl 2-cycnoacetate 20b to yield α,β-unsaturated ester 20c. Hydrogenolysis with palladium on carbon and hydrogen reduces both the cyano and the unsaturated bonds to produce 20d after Boc-N protection. Hydrolysis with hydroxide in a mixture of water and dioxane (or THF or EtOH) yields 20e.

embedded image

T. General Synthetic Route for Beta-Amino Acid

Renin inhibitors of the invention having further substituents, e.g., biaryl or heterobiaryls, may be prepared from amino acids which have a reactive handle, such as OH (phenol) or halide, that can be further functionalized. Referring to Scheme 21, biaryl or heterobiaryl 21c can be obtained by coupling the bromide 21a to a halide 21b applying Suzuki conditions. Aryl ether 21e may be formed from coupling 21a to R_aOH 21d employing palladium catalyst or Cu catalyst (Ullman reaction or similar conditions). This reaction is normally carried out at high temperature and may use base such as NaOtBu. Adduct 21g may be formed by coupling amines or anilines 21f to 21a under Buchwald or Hartwig conditions (palladium catalyst and base). Adduct 21g may also form by coupling certain amide and cyclic amide nitrogen to 21a in the presence of a copper salt (normally copper I salt such as CO) and base such as K₃PO₄and diamino-ligand such as N,N′-dimethylethlyenediamine or N,N′-dimethylcyclhexyl-1,2-diamine at elevated temperature (such as refluxing dioxane or toluene). The halide 20a can also be converted to the corresponding pinacol borate 21i via the reaction with bis(pinacolato)diboron 21b in the presence of a palladium catalyst such as Pddpff. The borate 21i can undergo further Suzuki couplings with halide 21j to form the adduct 21k, which otherwise is hard to obtain from 21a.

embedded image

U. General Synthetic Route for Biaryls

Biaryls may be prepared from many halides such as aryl and hereroaryl bromides and iodides by the Suzuki and Buchwald reactions. A few examples that these routes are applicable are shown in Scheme 22. Substrate 22a, which can be made according to Scheme 13 from the coupling of free amine 13c and the corresponding heteroaryl acids 22c/22d/22e, may react with boronic acid (Suzuki) or nitrogen compounds (Buchwald) to give the desired bi-aryl analogs 22b after de-protection. These routes are also suitable for aryl or heteroaryl acids such as 22d and 22e.

embedded image

More examples for Suzuki and Buchwald reactions are shown in Scheme 23. The biaryls, 23b and 23d, where R=aryl or heteroaryl (Suzuki conditions) or where R=nitrogen containing analogs (Buchwald conditions) or R=ether type (Ullman conditions) compounds can be obtained as described previously.

embedded image

Scheme 24, 25 and 26 further show examples for the synthesis of heteroaryl β-amino acids. In Scheme 24, the aldehyde 24a or 24g is reacted with glycine Wittig reagent 24b in the presence of a base to give N-Boc imine 24c or 24h respectively. Reduction of the double with NaBH₄/NiCl, produces alpha-aminoester 24d or 24i. Ester hydrolysis followed by procedures shown in Scheme 17, converts the alpha-aminoacid to beta-aminoacid 24e or 24j. The chiral aminoacid 24f may be synthesized from asymmetric hydrogenation of 24c, using catalysts such as (R,R)—Pr-DuPHOS-Rh as described by Burk et. al. (J. Am. Soc. 1994, 116:10847-10848).

embedded image

Alternatively, these beta-aminoacids can be made through the synthetic routes depicted in Scheme 25 and 26. Referring to Scheme 25, alkylation of arylmethyl halide 25a with diethyl acetamidomalonate 25h in basic conditions gives 25c. Hydrolysis of both esters and amide and N-Boc protection gives amino acid 25d, which is transformed to the beta amino acid 25e following similar procedures described in Scheme 17. Compound 25f can be made by this method.

embedded image

Referring to Scheme 26, condensation of an aldehyde 26a with N-acetylglycine 26b in the presence of sodium acetate and acetic anhydride yields the oxazolone 26c. Treatment of 26c with base and then acid, gives the unsaturated amino acid 26d. Double bond reduction with zinc in HCl, followed by removal of N-acetyl group and protection with Boc anhydride, gives N-Boc amino acid 26f, which is converted to beta-aminoacid using procedures shown in Scheme 17. Specifically, the furan analog 26h may be further reacted with bromine and then converted according to Scheme 17, to 5-bromofuran beta amino acid 26j.

embedded image

Scheme 27 shows the Buchwald amination reaction of the bromide 27a or other halides with imidazol-2-ones 27b to give products N-aryls, 27c, 27d or 27e. The reaction is normally carried at high temperature in dioxane or toluene in the presence of diamine ligand such as N,N′-dimethylethylenediamine and a cupper catalyst such as Cu(I) I.

embedded image

In some cases, the imidazolone analogs 27c can also be made by the route shown in Scheme 28. Reaction of aniline 28a with ortho-halo aryl nitro compound 28b gives 28c after reduction of the nitro group with reagent such as Pd/H₂, NaHS, Ti(II) Cl₂etc. If Boc group was removed under some reaction conditions (acidic), it can be easily added on again with Boc₂O. 28c is converted to 28d using carbonyl reagent such as CDI, COCl₂. (See Scheme 29).

embedded image

V. Synthesis of Reagents

The imidazol-2-ones 27b substrates for Buchwald amination reaction can be easily synthesized from 1,2-diamines 29a and a carbonyl sources such as CDI or 29b.

embedded image

One way to synthesize substituted piperidines 30c is shown in Scheme 30. Hydrogenation of substituted pyridines 30a catalyzed by platinum hydroxide gives piperidine 30b. N-protection with Bac group followed by hydrolysis of the methyl ester yields the desired 30c.

embedded image

ω-azidoalkyl iodide reagent can be synthesized according to Scheme 31. Azide displacement of 1-chloro-ω-bromo(or iodo)alkane 31a gives the azido intermediate 31b. Conversion of the chloride 31b¹to iodide 31c¹is effected by Finkelstein reaction, i.e., heating with NaI in acetone.

embedded image

W. General Synthetic Route for Pyridine Analogs

Pyridine analogs of structure 32j, 32h and 32i can be made by the synthetic routes shown in Scheme 32. 32g is synthesized by similar procedures described earlier in General Synthetic Route V (Scheme 5), deprotection of 32g gives 32h. Displacement of 32h with alkoxide or hydroxide gives 32j, after deprotection

embedded image

Alternatively, the pyridine analogs can also be made through the route shown in Scheme 33. Amine 33b displacement of dichloropyridine 33a gives 33c which is treated with sodium methoxide (or other alkoxide) produces 33d. Following procedures shown earlier in General Synthetic Route IV (Scheme 4), compound 33j is obtained. De-methylation in pyridine-HCl at 150° C. gives the tautomers 33k¹and 33k².

embedded image

X. Synthetic Route for Benzothiazole and Benzoxazole Amino Acid Analogs.

Benzothiazole and benzoxazole amino acid analogs 34f can be synthesized by the route shown in Scheme 34. Protected amino acid nitro compound 34a is reduced to the aniline analog 34b by acid/metal or hydrogenation procedure. 34b is then reacted with bromine, followed by potassium thiocyanate (KSCN), normally in acetic acid or ethanol, to give Benzothiazole 34d (A=S) or cynogen bromide (BrCN) to give the benzoxazole analog 34d (A=O). 34c may or may not be isolated. If the free amino acid is used (X═H), the amino group of 34d is first protected with Boc group before the next reaction. The NW of the triazole/oxazole 34d can be derivatized with, for example, acid chloride, isocyanate or alkyl group (reductive amination). 34d is coupled with piperidine 34e to give 34f after deprotection.

embedded image

Y. Synthetic Route for Selected Pyrrolidine Renin Inhibitors.

Pyrrolidine renin inhibitors with direct N—C bond can be synthesized according to Scheme 35. N-protected pyrrolidine 35a (eg, PG=Boc or Fmoc) reacts with aryl halide or heteroaryl halide 35b under appreciate conditions such as Buchwald conditions (e.g. Cs₂CO₃, Cu₂O and Compound 35c in CH₃CN reflusing) to give the N-aryl/heteroaryl pyrrolidine renin inhibitor 35d after removal the protection group PG. One example of 35d is 35d¹which is derived from 15c (Scheme 15). The aryl/heteroaryl can be further manipulated if a pendant group is present such as ester or NO₁groups.

embedded image

The pyrrolidine analog can be synthesized according Scheme 36, using procedures similar to literature reference. Treating the unsaturated acid with 36b in the presence catalytic TFA gives the pyrrolidine acid 36c. The acid is then converted to the acyl azide by reacting with DPPA, and rearrangement via Curtius reaction to give the N-Boc pyrrolydine acid 36d after hydrolysis of the ester. Acid-amine coupling followed by de-benzylation gives the required pyrrolidine intermediate 36f.

embedded image

Z. Chiral Separation.

Chiral components can be separated and purified using any of a variety of techniques known to those skilled in the art. For example, chiral components can be purified using supercritical fluid chromatography (SFC). In one particular variation, chiral analytical SFC/MS analyses are conducted using a Berger analytical SFC system (AutoChem, Newark, Del.) which consists of a Berger SFC dual pump fluid control module with a Berger FCM 1100/1200 supercritical fluid pump and FCM 1200 modifier fluid pump, a Berger TCM 2000 oven, and an Alcott 718 autosampler. The integrated system can be controlled by BI-SFC Chemstation software version 3.4. Detection can be accomplished with a Waters ZQ 2000 detector operated in positive mode with an ESI interface and a scan range from 200-800 Da with 0.5 second per scan. Chromatographic separations can be performed on a ChiralPak AD-H, ChiralPak AS-H, ChiralCel OD-H, or ChiralCel OJ-H column (5μ, 4.6×250 mm; Chiral Technologies, Inc. West Chester, Pa.) with 10 to 40% methanol as the modifier and with or without ammonium acetate (10 mM). Any of a variety of flow rates can be utilized including, for example, 1.5 or 3.5 mL/min with an inlet pressure set at 100 bar. Additionally, a variety of sample injection conditions can be used including, for example, sample injections of either 5 or 10 μL in methanol at 0.1 mg/mL in concentration.

In another variation, preparative chiral separations are performed using a Berger MultiGram II SFC purification system. For example, samples can be loaded onto a ChiralPak AD column (21×250 mm, 10μ). In particular variations, the flow rate for separation can be 70 mL/min, the injection volume up to 2 mL, and the inlet pressure set at 130 bar. Stacked injections can be applied to increase the efficiency.

AA. General HPLC conditions:

Agilent LC/MSD System Configuration

1. Agilent 1100 HPLC system

Quaternary Pump

Well-plate Sampler

Multiple Wavelength Detectors

Column Heater

2. MSD mass detector

3. Alltech ELSD 2000 detector

4. Columns

FSTTFA (F)
Phenomenex Gemini 3u C18 4.6 × 30 mm

STDTFA (S)
Phenomenex Luna 5u C18 4.6 × 50 mm

5. Gradient

Solvent A
0.05% TFA in H₂O

Solvent B
0.035% TFA in Acetonitrile

Flow Rate
F-1
F-2
F-3
F-4
F-5
F-6
F-7
F-8
F-9

Time (min)
(mL/min)
(B %)
(B %)
(B %)
(B %)
(B %)
(B %)
(B %)
(B %)
(B %)

0.00
3.5
1
5
10
25
45
75
1
5
10

1.50
3.5
95
95
95
95
95
95
10
25
45

1.60
3.5
95
95
95
95
95
95
95
95
95

1.70
3.5
95
95
95
95
95
95
95
95
95

1.80
3.5
1
5
10
25
45
75
1
5
10

2.00
3.5
1
5
10
25
45
75
1
5
10

Flow Rate
S-1
S-2
S-3
S-4
S-5
S-6
S-7
S-8
S-9

Time (min)
(mL/min)
(B %)
(B %)
(B %)
(B %)
(B %)
(B %)
(B %)
(B %)
(B %)

0.00
3.5
1
5
10
25
45
75
1
5
10

3.00
3.5
95
95
95
95
95
95
10
25
45

3.10
3.5
95
95
95
95
95
95
95
95
95

3.20
3.5
95
95
95
95
95
95
95
95
95

3.30
3.5
1
5
10
25
45
75
1
5
10

3.50
3.5
1
5
10
25
45
75
1
5
10

AB. Biological Testing

The activity of compounds as renin inhibitors may be assayed in vitro, in vivo or in a cell line. Example D below provides an in vitro enzymatic activity assay for activity against renin.

Test compounds in varying concentrations may be reacted with recombinant human renin in the presence of substrate, e.g., QXL520-γ-Abu-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Thr-Lys (HiLyteFluo488)-Arg-OH (Anaspec, San Jose, Calif.). The reaction can be followed kinetically using fluorescence (excitation λ=485 nm; emission λ=538 nm). Inhibition constants (IC₅₀) may be calculated by non-linear curve fitting of the compound concentrations and fluorescence intensities to the standard IC₅₀equation. IC₅₀values for selected compounds of the present invention are given in Table XII.

Description of the syntheses of particular compounds according to the present invention based on the above reaction schemes as set forth herein.

The present invention is further exemplified, but not limited, by examples provided below that describe the synthesis of particular compounds according to the invention.

It will be apparent to those skilled in the art that various modifications and variations can be made in the compounds, compositions, kits, and methods of the present invention without departing from the spirit or scope of the invention. Thus, it is intended that the present invention cover the modifications and variations of this invention provided they come within the scope of the appended claims and their equivalents.

EXAMPLE
Example 1
Synthesis of 3-(1H-Benzo[d]imidazol-2-yl)-N-(3-chloro-4-methylphenyl)piperidine-1-carboxamide (1)

embedded image

2-(piperidin-3-yl)-1H-benzo[d]imidazole (100.0 mg, 0.497 mmol) was dissolved in dichloromethane (3.0 mL). To the stirred suspension was added 2-chloro-4-isocyanato-1-methylbenzene (84.1 mg, 0.502 mmol). The reaction was stirred at ambient temperature for one hour. The crude mixture was then concentrated in vacuo and the residue was dissolved in minimal amounts of dimethylformamide and purified via preparative HPLC (10%-50% acetonitrile in water). The pure fractions were combines and lyophilized to yield the title compound 1 as a fluffy white solid (147.5 mg, 63.7%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.55-1.65 (m, 1H), 1.83 (d, J=13.73 Hz, 1H), 1.97 (q, 0.1=18.28 Hz, 1H), 2.25 (s, 3H), 2.30 (s, 1H), 2.99 (t, J=11.44 Hz, 1H), 3.23 (t, J=13.34 Hz, 1H), 3.34-3.38 (m, 1H), 4.11 (d, J=13.35 Hz, 1H), 4.48 (d, J=13.35 Hz, 1H), 7.20 (d, J=8.4 Hz, 1H), 7.32 (d, J=8.5 Hz, 1H), 7.51-7.34 (m, 1H), 7.63 (s, 1H), 7.78-7.80 (m, 1H), 8.76 (s, 1H), ESI-MS: m/z 369.2 (M+H)⁺.

Example 2
Synthesis of N-(3-chloro-4-methylphenyl)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxamide (2)

embedded image

N-(3-chloro-4-methylphenyl)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxamide may be prepared according to Example 1 by using the corresponding N-alkylated piperidinyl benzoimidazole.

Other compounds that were prepared according to the procedure outlined in Example 1-A using the corresponding isocyanato starting reagents are listed in Table I. As described in Example 2, N-alkylated analogs of these compounds may be prepared by using the corresponding N-alkylated piperidinyl benzoimidazole starting reagents.

TABLE I

Compound

ESI-MS:

No.
Structure/Name
m/z (M + H⁺)

3

embedded image

335.4

3-(1H-benzo[d]imidazol-2-yl)-N-benzoylpiperidine-1-

carboxamide

4

embedded image

371.4

3-(1H-benzo[d]imidazol-2-yl)-N-(naphthalen-2-

yl)piperidine-1-carboxamide

5

embedded image

349.3

3-(1H-benzo[d]imidazol-2-yl)-N-benzoylpiperidine-1-

carboxamide

6

embedded image

349.4

3-(1H-benzo[d]imidazol-2-yl)-N-(3,5-

dimethylphenyl)piperidine-1-carboxamide

7

embedded image

423.3

3-(1H-benzo[d]imidazol-2-yl)-N-(4-chloro-3-

(trifluoromethyl)phenyl)piperidine-1-carboxamide

8

embedded image

321.3

3-(1H-benzo[d]imidazol-2-yl)-N-phenylpiperidine-1-

carboxamide

9

embedded image

361.4

3-(1H-benzo[d]imidazol-2-yl)-N-(2,3-dihydro-1H-inden-

5-yl)piperidine-1-carboxamide

10

embedded image

327.4

3-(1H-benzo[d]imidazol-2-yl)-N-cyclohexylpiperidine-1-

carboxamide

11

embedded image

365.3

N-(benzo[d][1,3]dioxol-5-yl)-3-(1H-benzo[d]imidazol-2-

yl)piperidine-1-carboxamide

12

embedded image

407.4

(2S)-methyl 2-(3-(1H-benzo[d]imidazol-2-yl)piperidine-

1-carboxamido)-3-phenylpropanoate

13

embedded image

407.4

(2R)-methyl 2-(3-(1H-benzo[d]imidazol-2-yl)piperidine-

1-carboxamido)-3-phenylpropanoate

14

embedded image

345.4

ethyl 3-(3-(1H-benzo[d]imidazol-2-yl)piperidine-1-

carboxamido)propanoate

15

embedded image

379.3

3-(1H-benzo[d]imidazol-2-yl)-N-(2,3-

dihydrobenzo[b][1,4]dioxin-6-yl)piperidine-1-

carboxamide

16

embedded image

397.4

3-(1H-benzo[d]imidazol-2-yl)-N-(biphenyl-2-

yl)piperidine-1-carboxamide

17

embedded image

287.4

3-(1H-benzo[d]imidazol-2-yl)-N-propylpiperidine-1-

carboxamide

18

embedded image

395.3

N-(benzo[c][1,2,5]thiadiazol-4-yl)-3-(1H-

benzo[d]imidazol-2-yl)piperidine-1-carboxthioamide

19

embedded image

373.4

(2S)-methyl 2-(3-(1H-benzo[d]imidazol-2-yl)piperidine-

1-carboxamido)-4-methylpentanoate

20

embedded image

322.3

3-(1H-benzo[d]imidazol-2-yl)-N-(pyridin-3-

yl)piperidine-1-carboxamide

21

embedded image

325.3

3-(1H-benzo[d]imidazol-2-yl)-N-(furan-2-

ylmethyl)piperidine-1-carboxamide

22

embedded image

Not tested

3-(1H-benzo[d]imidazol-2-yl)-N-(3,4,5-

trimethoxybenzyl)piperidine-1-carboxamide

Example 3
Synthesis of (3R)-1-(3-(1H-Benzo[d]imidazol-2-yl)piperidin-1-yl)-3-amino-4-(4-chlorophenyl)butan-1-one (23)

embedded image

To a flask containing 2-(piperidin-3-yl)-1H-benzo[d]imidazole hydrochloride (200.0 mg, 0.841 mmol) and (R)-3-(tert-butoxycarbonylamino)-4-(4-chlorophenyl) butanoic acid (282.5 mg, 0.900 mmol) was added dichloromethane (5 mL) and triethylamine (0.23 mL, 1.683 mmol); the reaction mixture was stirred at room temperature until all the components dissolved. To the solution was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (193.5 mg, 1.010 mmol) followed by N-hydroxybenzotriazole (142.1 mg, 1.052 mmol). The solution was stirred at ambient temperature for 12 hrs and diluted with excess DCM (5 mL). The solution was washed with water (2×8 mL) and brine (lx 5 mL), and then the organic layer was collected, dried with Na₂SO₄, and concentrated to yield tert-butyl (2R)-4-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(4-chlorophenyl)-4-oxobutan-2-ylcarbamate (3A) as an amorphous solid (415.9 mg, 99.5% yield). ESI-MS: m/z 497.4 (M+H)⁺.

embedded image

Compound 3A from Step A (60.0 mg, 0.121 mmol) was dissolved in dichloromethane (2 mL) and trifluoroacetic acid (1 mL) was added to the vigorously stirred solution at ambient temperature. The reaction was stirred for 2 hrs and then concentrated to an oil. The crude oil was purified via preparative HPLC to yield the title compound (3R)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-amino-4-(4-chlorophenyl)butan-1-one (22) as the TFA salt (30.0 mg, 50.1%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.42-1.49 (m, 1H), 1.72-1.99 (m, 2H), 2.60-3.29 (m, 7H), 3.40-3.56 (m, 1H), 3.65-3.84 (m, 2H), 4.07-4.17 (m, 1H), 4.35 (d, J=17.04 Hz, 0.5H), 4.73 (d, J=12.17 Hz, 0.5H), 7.29-7.43 (m, 6H), 7.66 (d, J=25.88 Hz, 2H), 7.87 (d, J=16.47 Hz, 3H). ESI-MS: m/z 397.2 (M+H)⁺.

Example 4
Synthesis of (3R)-3-amino-4-(4-chlorophenyl)-1-(3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (24)

embedded image

tert-Butyl (2R)-4-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(4-chlorophenyl)-4-oxobutan-2-ylcarbamate (3A) (100.0 mg, 0.201 mmol), as prepared in Example 3, Step A, was dissolved in acetonitrile (1.2 mL) followed by the addition of 1-bromo-3-methoxypropane (307.9 mg, 20.1 mmol) and potassium carbonate (60 mg, 0.434 mmol). The reaction was stirred for 16 hrs at 65° C. The mixture was then cooled to ambient temperature and filtered through Celite. The filtrate was concentrated to tert-butyl (2R)-1-(4-chlorophenyl)-4-(3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (4A) an amorphous solid and used without further purification. ESI-MS: m/z 569.4 (M+H)⁺.

embedded image

Deprotection of Compound 4A as described in Example 3, Step B yielded the title compound (3R)-3-Amino-4-(4-chlorophenyl)-1-(3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (24). ESI-MS: m/z 469.3 (M+H)⁺.

Other compounds that were prepared according to the procedure outlined in Example 3 using the corresponding butanoic acid starting reagents are listed in Table II. N-Alkylated analogs of these compounds may be prepared by the procedure outlined in Example 4, Step A, followed by deprotection according to the procedure in Example 3, Step B.

TABLE II

Compound

ESI-MS:

No.
Structure/Name
m/z (M + H⁺)

25

embedded image

417.1

(3S)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-

amino-3-(4-(trifluoromethyl)phenyl)propan-1-one

26

embedded image

394.1

(3S)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-

amino-3-(2-nitrophenyl)propan-1-one

27

embedded image

397.1

(3R)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-

amino-4-(2-chlorophenyl)butan-1-one

28

embedded image

409.1

(3S)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-

amino-3-(2,3-dimethoxyphenyl)propan-1-one

29

embedded image

419.1

(3R)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-

amino-4-(benzo[b]thiophen-3-yl)butan-1-one

30

embedded image

383.2

(3S)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-

amino-3-(3-chlorophenyl)propan-1-one

31

embedded image

409.2

(3S)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-

amino-3-(3,5-dimethoxyphenyl)propan-1-one

32

embedded image

377.2

(3R)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-

amino-5-phenylpentan-1-one

33

embedded image

394.2

(3S)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-

amino-3-(4-nitrophenyl)propan-1-one

34

embedded image

441.2

(3R)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-

amino-4-(4-bromophenyl)butan-1-one

35

embedded image

417.1

(3S)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-

amino-3-(2,4-dichlorophenyl)propan-1-one

36

embedded image

431.1

(3R)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-

amino-4-(3,4-dichlorophenyl)butan-1-one

37

embedded image

417.1

(3S)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-

amino-3-(2,3-dichlorophenyl)propan-1-one

38

embedded image

413.2

(3R)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-

amino-4-(naphthalen-1-yl)butan-1-one

39

embedded image

408.2

(3R)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-

amino-4-(4-nitrophenyl)butan-1-one

40

embedded image

394.2

(3S)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-

amino-3-(3-nitrophenyl)propan-1-one

41

embedded image

427.1

(3S)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-

amino-3-(3-bromophenyl)propan-1-one

42

embedded image

377.2

(3R)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-

amino-4-o-tolylbutan-1-one

43

embedded image

377.2

(3R)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-

amino-4-m-tolylbutan-1-one

44

embedded image

413.2

(3R)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-

amino-4-(naphthalen-2-yl)butan-1-one

45

embedded image

299.2

(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)(pyrrolidin-2-

yl)methanone

46

embedded image

315.2

(2S)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-

amino-4-methylpentan-1-one

47

embedded image

301.2

(2S)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-

amino-3-methylbutan-1-one

48

embedded image

315.2

(2S,3S)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-

amino-3-methylpentan-1-one

49

embedded image

382.2

(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)((S)-1-

(piperidin-4-yl)pyrrolidin-2-yl)methanone

50

embedded image

273.2

(2R)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-

aminopropan-1-one

51

embedded image

287.2

(2R)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-

aminobutan-1-one

52

embedded image

313.2

(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)(piperidin-3-

yl)methanone

53

embedded image

273.2

(2S)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-

aminopropan-1-one

54

embedded image

299.2

(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)((R)-

pyrrolidin-2-yl)methanone

55

embedded image

285.2

(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)(azetidin-3-

yl)methanone

56

embedded image

315.2

(2S)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-

amino-3,3-dimethylbutan-1-one

57

embedded image

313.2

(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)((1S,2S)-2-

aminocyclopentyl)methanone

58

embedded image

349.2

(2R)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-

amino-3-phenylpropan-1-one

59

embedded image

299.2

(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)(1-

aminocyclobutyl)methanone

60

embedded image

307.1

(2R)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-

amino-3-chloropropan-1-one

61

embedded image

341.2

(2S)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-

amino-2-cyclohexylethanone

62

embedded image

350.2

(2S)-1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-

amino-3-(pyridin-2-yl)propan-1-one

63

embedded image

285.2

(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)(1-

aminocyclopropyl)methanone

64

embedded image

363.2

1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-

(methylamino)-3-phenylpropan-1-one

65

embedded image

421.4

(3R)-3-amino-1-(3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-3-phenylpropan-1-one

66

embedded image

421.2

(3S)-3-amino-1-(3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-3-phenylpropan-1-one

67

embedded image

469.3

(3S)-3-amino-4-(4-chlorophenyl)-1-(3-(1-(3-

methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one

68

embedded image

469.3

(R)-3-amino-4-(4-chlorophenyl)-1-((S)-3-(1-(3-

methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one

69

embedded image

469.3

(S)-3-amino-4-(4-chlorophenyl)-1-((R)-3-(1-(3-

methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one

70

embedded image

469.3

(S)-3-amino-4-(4-chlorophenyl)-1-((S)-3-(1-(3-

methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one

Example 5
Synthesis of (R)-1((R)-3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-amino-4-(biphenyl-4-yl)butan-1-one (71)

embedded image

(R)-tert-butyl 3-(1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (0.29 mmol, 88 mg) in CH₂Cl₂(10 mL) was added TFA (1 mL). The reaction solution was stirred at rt for 1 h and then concentrated in vacuo. The residue containing (R)-2-(piperidin-3-yl)-1H-benzo[d]imidazole (5A) was carried directly on to the next step without further purification. ESI-MS: m/z 202.4 (M+H)⁺.

embedded image

(R)-2-(Piperidin-3-yl)-1H-benzo[d]imidazole (5A) (0.29 mmol, 58 mg) in DMF (15 mL) was added (R)-4-(4-bromophenyl)-3-(tert-butoxycarbonylamino)butanoic acid (0.32 mmol, 115 mg) and N-methylmorphine (1.16 mmol, 0.13 mL). The reaction mixture was stirred at rtfor 5 min and then added HATU (0.32 mmol, 122 mg) and kept stirring at rt overnight. The reaction mixture was poured into H₂O, extracted with EtOAc. The extract was washed with H₂O, brine, dried over MgSO₄and filtered. The filtrate was concentrated in vacuo and purified by preparative LC/MS (35-60% CH₃CN in H₂O) to afford tert-butyl (R)-4-((R)-3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(4-bromophenyl)-4-oxobutan-2-ylcarbamate (5B) (0.22 mmol, 120 mg, two-step yield: 75.9%). ESI-MS: m/z 542.3 (M+H)⁺.

embedded image

tert-Butyl (R)-4-((R)-3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(4-bromophenyl)-4-oxobutan-2-ylcarbamate (5B) (0.22 mmol, 120 mg) in dioxane (2 mL) was added phenylboronic acid (0.29 mmol, 35 mg), 1,1′-bis(diphenylphosphino)ferrocene (0.011 mmol, 8 mg) and sat'd NaHCO₃(1 mL). The reaction mixture was heated to 110° C. in microwave for 15 min and then poured into H₂O, extracted with EtOAc. The extract was washed with brine, dried over MgSO₄and filtered. The filtrate was concentrated in vacuo. The residue containing tert-butyl (R)-4-((R)-3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(biphenyl-4-yl)-4-oxobutan-2-ylcarbamate (5C) was carried directly on to the next step without further purification. ESI-MS: m/z 539.5 (M+H)⁺.

embedded image

tert-Butyl (R)-4-((R)-3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(biphenyl-4-yl)-4-oxobutan-2-ylcarbamate (5C) (0.22 mmol, 120 mg) in DCM (5 mL) was added TEA (1 mL). The reaction solution was stirred at rt for 1 h and then concentrated in vacuo. The residue was purified by preparative LC/MS (20-50% CH₃CN in H₂O) to afford the title compound (R)-1-((R)-3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-amino-4-(biphenyl-4-yl)butan-1-one (71) (0.14 mmol, 63 mg, two-step yield: 63.6%). ESI-MS: m/z 439.4 (M+H)⁺. 1H NMR (400 MHz, MeOD) δ ppm 1.56-1.75 (m, 1H) 1.92 (ddd, J=13.77, 7.29, 3.51Hz, 1H) 2.06 (dd, J=13.01, 3.66 Hz, 1H) 2.38 (dd, J=9.09, 3.73 Hz, 1H) 2.69-2.89 (m, 2H) 3.00-3.16 (m, 2H) 3.16-3.26 (m, 1H) 3.39-3.49 (m, 1H) 3.88 (ddd, J=10.80, 7.33, 3.79 Hz, 1H) 4.32 (d, J=9.54 Hz, 1H) 4.64 (d, J=13.14 Hz, 1H) 4.83 (dd, J=12.92, 3.44 Hz, 1H) 7.29-7.46 (m, 5H) 7.54-7.66 (m, 6H) 7.77 (dd, J=6.16, 3.13 Hz, 2H).

Example 6
Synthesis of (R)-3-Amino-4-(biphenyl-4-yl)-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (72) and (R)-4-(biphenyl-4-yl)-3-hydroxy-1-(3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (73)

embedded image

(R)-1-(3-Methoxypropyl)-2-(piperidin-3-yl)-1H-benzo[d]imidazole (0.29 mmol, 79 mg) in DMF (15 mL) was added to (R)-4-(4-bromophenyl)-3-(tert-butoxycarbonylamino)butanoic acid (0.32 mmol, 115 mg) and N-methylmorphine (1.16 mmol, 0.13 mL). The reaction mixture was stirred at rt for 5 min and then added HATU (0.32 mmol, 122 mg) and kept stifling at rt overnight. The reaction mixture was poured into H₂O, extracted with EtOAc. The extract was washed with H₂O, brine, dried over MgSO₄and filtered. The filtrate was concentrated in vacuo and purified by preparative LC/MS (35-60% CH₃CN in H₂O) to afford tert-butyl (R)-1-(4-bromophenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (6A) (0.26 mmol, 160 mg, yield: 89.7%). ESI-MS: m/z 614.4 (M+H)⁺.

embedded image

6A (0.26 mmol, 160 mg) in dioxane (2 mL) was added phenylboronic acid (0.34 mmol, 41 mg), 1,1′-bis(diphenylphosphino)ferrocene (0.013 mmol, 10 mg) and sat'd NaHCO₃(1 mL). The reaction mixture was heated to 110° C. in microwave for 15 min and then poured into H₂O, extracted with EtOAc. The extract was washed with brine, dried over MgSO₄and filtered. The filtrate was concentrated in vacuo. The residue containing tert-Butyl (R)-1-(biphenyl-4-yl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (6B) was carried directly on to the next step without further purification. ESI-MS: m/z 611.5 (M+H)⁺.

embedded image

6B (0.26 mmol, 160 mg) in DCM (5 mL) was added TEA (1 mL). The reaction solution was stirred at rt for 1 h and then concentrated in vacuo. The residue was purified by preparative LC/MS (20-50% CH₃CN in H₂O) to afford (R)-3-Amino-4-(biphenyl-4-yl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (72) (0.26 mmol, 132 mg, two-step yield: 99.4%). ESI-MS: m/z 511.5 (M+H)⁺.

embedded image

(R)-3-Amino-4-(biphenyl-4-yl)-1-((R)-3-(1-(3-methoxypropyl)-1,1-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (0.26 mmol, 132 mg) in MeOH (1 mL) was added HCl (0.5 M, 2 mL) and NaNO₂(179 mg in 9 mL H₂O). The reaction solution was stirred at rt overnight and then adjusted to pH9, extracted with EtOAc. The extract was washed with brine, dried over MgSO₄, and concentrated in vacuo. The residue was purified by preparative LC/MS (30-50% CH₃CN in H₂O) to afford (R)-4-(Biphenyl-4-yl)-3-hydroxy-1-(3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (73) (0.012 mmol, 6 mg, yield: 4.6%). ESI-MS: m/z 512.5 (M+H)⁺. 1H NMR (400 MHz, MeOD) δ ppm 1.53-1.87 (m, 1H) 1.88-2.40 (m, 4H) 2.53-2.83 (m, 2H) 2.85-3.20 (m, 2H) 3.28 (m, 3H) 3.34-3.46 (m, 3H) 3.47-3.59 (m, 1H) 3.62-3.72 (m, 1H) 4.12 (t, 1H) 4.29-4.39 (m, 1H) 4.55 (t, J=7.17 Hz, 1H) 4.58-4.66 (m, 1H) 4.66-4.77 (m, 1H) 4.80 (br.s, 1H) 7.28-7.45 (m, 5H) 7.50-7.65 (m, 6H) 7.73-7.92 (m, 2H).

Example 7
Synthesis of (R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (74)

embedded image

(R)-1-(tert-Butoxycarbonyl)piperidine-3-carboxylic acid (17.45 mmol, 4.0 g) and benzene-1,2-diamine (17.45 mmol, 1.87 g) were added to a 100 mL round-bottomed flask equipped for stirring under nitrogen. DMF (30 mL) and 4-methylmorpholine (52.35 mmol, 5.76 mL) were added and the resultant solution was allowed to stir for 5 min at room temperature. N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine hydrochloride (20.94 mmol, 4.01 g) and 1H-benzo[d][1,2,3]triazol-1-ol (20.94 mmol, 2.83 g) were then added and the reaction was allowed to stir at room temperature for 16 hr. The reaction solution was poured into water and extracted with ethyl acetate. The organic layer was washed three times with water, two times with saturated aqueous sodium bicarbonate, and once with saturated aqueous sodium chloride. The organic layer was collected and dried with Na₂SO₄. This mixture was then filtered, the filtrate was collected and concentrated and dried in-vacuo affording (R)-tert-Butyl 3-(2-aminophenylcarbamoyl)piperidine-1-carboxylate (7A) as a brownish foam that was carried directly on to the next step without further purification. ESI-MS: m/z 320.4 (M+H)⁺.

embedded image

(R)-tert-Butyl 3-(2-aminophenylcarbamoyl)piperidine-1-carboxylate (7A) (2.80 g, 8.77 mmol) was added to a 100 mL round-bottomed flask equipped for stirring under nitrogen. Glacial acetic acid (20 mL) was then added and the resultant solution was stirred at 65° C. under nitrogen for 2 hr. Analysis of the reaction mixture at this time by LC/MS indicated that the reaction was complete. The reaction solution was then concentrated in-vacuo to give a brownish oil. Toluene (30 mL) was added and the subsequent solution was concentrated in vacuo. This was repeated three times to remove any trace quantities of acetic acid affording (R)-tert-Butyl 3-(1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (7B) as a tannish-white solid. (13.94 mmol, 4.2 g, 80% over 2-steps). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.34-1.52 (m, 10H) 1.73-1.83 (m, 2H) 2.10-2.17 (br. s. 1H) 2.79-2.96 (m, 2H) 3.89-3.96 (br. s., 1H) 4.08-4.33 (br.s., 1H) 4.33-4.43 (br.s, 1H) 7.09-7.18 (dd, 2H, 8.97 Hz, 6.19 Hz) 7.39-7.48 (d, 1H, 6.82 Hz) 7.49-7.57 (d, 1H, 7.07 Hz) 12.27 (s, 1H) ESI-MS: adz 302.4 (M+H)⁺.

embedded image

(R)-tert-Butyl 3-(1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (7B) (9.95 mmol, 3.0 g) was added to a 200 mL round-bottomed flask equipped for stirring under nitrogen. DMF (50 mL) was added and the resultant solution was cooled to 0° C. with an ice bath. NaH (60% in mineral oil, 11.95 mmol, 0.478 g) was then added and the subsequent solution was allowed to stir under nitrogen for 0.5 hr. At this time 1-bromo-3-methoxypropane (12.44 mmol, 1.90 g) was added, the ice bath was removed and the reaction solution was allowed to warm to room temperature and stir fort hr. The reaction solution was then poured into ice-water, extracted with ethyl acetate, and washed once with saturated aqueous sodium chloride. The organic layer was collected and subsequently dried with anhydrous Na₂SO₄and filtered. This filtrate was collected, concentrated, and dried in-vacuo affording a brown oil. This material was then purified by chromatography on silica gel (3-10% CH₃OH in CH₂Cl₂) to afford (R)-tert-butyl 3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (7C) as a brown oil (9.63 mmol, 3.6 g, 96% yield). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.55-1.71 (br.s., 1H) 1.79-1.88 (br.s., 1H) 2.04-2.13 (m, 4H) 2.74-2.88 (br.s., 1H) 2.98-3.38 (m, 7H) 4.21-4.39 (m, 3H) 7.22-7.28 (m, 2H) 7.34-7.40 (dd, 1H, 6.57 Hz, 2.02 Hz) 7.72-7.77 (dd, 1H, 6.57 Hz, 2.02 Hz). ESI-MS: m/z 374.4 (M+H)⁺.

embedded image

(R)-tert-Butyl 3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (4.82 mmol; 1.8 g) was added to a 100 mL round-bottomed flask equipped with a reflux condenser and stirring under nitrogen. EtOH (15 mL) and HCl (8 M in H₂O; 4 mL) were then added and the solution was heated to reflux for 10 min. Analysis of the reaction mixture by LC/MS indicated that the reaction was complete. The solvent was then removed in-vacuo. The resultant oil was then extracted with EtOAc and a 10% aqueous K₂CO₃solution. The organic layer was collected and dried with Na₂SO₄, and was then filtered. The filtrate was concentrated and dried in-vacuo affording (R)-1-(3-methoxypropyl)-2-(piperidin-3-yl)-1H-benzo[d]imidazole (7D) as a brown oil (4.76 mmol, 1.3 g, 99% yield). ESI-MS: m/z 274.4 (M+H)⁺.

embedded image

(R)-1-(3-methoxypropyl)-2-(piperidin-3-yl)-1H-benzo[d]imidazole (7D) (0.387 mmol, 0.120 g) was added to a 10 mL round-bottomed flask equipped for stirring under nitrogen. DMF (3 mL), (R)-3-(tert-butoxycarbonylamino)-4-(naphthalen-2-yl)butanoic acid (0.387 mmol, 0.127 g) and N-methylmorpholine (1.55 mmol, 0.170 mL) were then added and the solution was allowed to stir at rt for 5 min. HATU (0.426 mmol, 0.162 g) was added and the resultant solution was stirred at room temperature for 3 hr. The reaction solution was then directly purified by preparative LC/MS (25-95% CH₃CN in H₂O). The resultant fractions were collected and the solvent was removed in-vacuo affording tert-butyl (R)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (7E) as a clear oil (0.359 mmol, 0.210 g, 93% yield). ESI-MS: m/z 585.5 (M+Hr.

embedded image

tert-Butyl (R)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (7E) (0.257 mmol, 0.150 g) was added to a 10 mL round-bottomed flask equipped for stirring under nitrogen and dissolved in CH₂Cl₂(2 mL). Trifluoroacetic acid (2 mL) was then added and the solution was stirred at room temperature for 2 hr. The solvent was removed in-vacuo affording a clear colored oil. This oil was re-dissolved in methanol (3 mL), filtered, and then purified by preparative CH₃CN in H₂O (25-95%). The resultant fractions were collected and the solvent was removed in-vacuo affording a clear colored oil. This oil was re-dissolved in CH₃CN (1 mL) and water (2 mL). The resultant solution was frozen and lyophilized to afford (R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (74) as its trifluoroacetic acid salt and as a white flocculent solid (0.152 mmol, 0.091 g, yield 59%) ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.42-1.56 (m, 1H) 1.75-2.00 (m, 3H) 2.03-2.18 (m, 2H) 2.62-2.75 (m, 3H) 2.90-3.00 (m, 1H) 3.03-3.29 (m, 8H) 3.34-3.45 (m, 2H) 3.77-3.87 (m, 2H) 4.09-4.68 (m, 3H) 7.42-7.55 (m, 5H) 7.72-8.02 (m, 6H) ESI-MS: 485.5 m/z (M+H)⁺.

Example 8
Synthesis of (R)-3-amino-4-(4-chlorophenyl)-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (75)

embedded image

The title compound was prepared according to the procedure outlined in Example 7, Steps A-F, using reagent (R)-3-(tert-butoxycarbonylamino)-4-(4-chlorophenyl)butanoic acid in Step E. ESI-MS: m/z 470.4 (M+H)⁺. 1H NMR (400 MHz, DMSO-d₆, 65° C.) δ ppm 1.50-1.62 (m, 1H) 1.83-2.16 (m, 5H) 2.64-2.77 (m, 2H) 2.85-3.06 (m, 3H) 3.10-3.27 (m, 5H) 3.32-3.41 (m, 2H) 3.70-3.87 (br. s., 1H) 4.26-4.59 (m, 2H) 5.01-5.36 (m, 4H) 7.27-7.42 (m, 6H) 7.59-7.66 (m, 2H).

Example 9
Synthesis of (R)-3-amino-4-(3,4-difluorophenyl)-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (76)

embedded image

The title compound was prepared according to the procedure outlined in Example 7, Steps A-F, using reagent (R)-3-(tert-butoxycarbonylamino)-4-(3,4-difluorophenyl)butanoic acid in Step E. ESI-MS: m/z 471.1 (M+H)⁺. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.45-2.14 (m, 6H) 2.52-2.79 (m, 3H) 2.85-3.01 (m, 3H) 3.16-3.20 (m, 4H) 3.28-3.48 (m, 3H) 3.67-4.12 (m, 2H) 4.33-4.64 (m, 4H) 7.11-7.16 (br. s, 1H) 7.37-7.47 (m, 4H) 7.71-7.80 (m, 2H).

Example 10
Synthesis of (R)-3-amino-4-(3,4-dichlorophenyl)-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (77)

embedded image

The title compound was prepared according to the procedure outlined in Example 7, Steps A-F, using reagent (R)-3-(tert-butoxycarbonylamino)-4-(3,4-dichlorophenyl)butanoic acid in Step E. ESI-MS: m/z 504.3 (M+H)⁺. 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.45-1.62 (m, 1H) 1.76-2.20 (m, 5H) 2.59-2.82 (m, 3H) 2.91-3.09 (m, 2H) 3.09-3.21 (m, 5H) 3.26-3.54 (m, 4H) 3.67-4.21 (m, 2H) 4.35-4.70 (m, 3H) 7.30 (ddd, J=8.21, 5.94, 2.02 Hz, 1H) 7.43-7.56 (m, 2H) 7.56-7.66 (m, 2H) 7.73-7.88 (m, 2H).

Example 11
Synthesis of (R)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(pyridin-4-yl)butan-1-one (78)

embedded image

The title compound was prepared according to the procedure outlined in Example 7, Steps A-F, using starting material (R)-3-(tert-butoxycarbonylamino)-4-(pyridin-4-yl)butanoic acid in Step E. ESI-MS: 436.5 m/z (M+H)⁺. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.45-1.55 (m, 1H) 1.78-2.19 (m, 4H) 2.64-2.76 (m, 3H) 2.92-3.21 (m, 7H) 3.28-3.44 (m, 4H) 3.79-3.89 (m, 2H) 4.08-4.65 (m, 4H) 7.41-7.49 (m, 2H) 7.66-7.81 (m, 4H) 8.72-8.77 (m, 2H).

Example 12
Synthesis of (R)-3-amino-4-(3-chlorophenyl)-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (79)

embedded image

The title compound was prepared according to the procedure outlined in Example D1, Steps A-F, using reagent (R)-3-(tert-butoxycarbonylamino)-4-(3-chlorophenyl)butanoic acid in Step E. ESI-MS: m/z 470.1 (M+H)*. 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.46-1.59 (m, 1H) 1.79-2.22 (m, 5H) 2.52-2.80 (m, 2H) 2.87-3.21 (m, 5H) 3.27-3.55 (m, 3H) 3.66-4.20 (m, 2H) 4.34-4.71 (m, 3H) 7.23-7.41 (m, 4H) 7.48-7.57 (m, 2H) 7.77-7.88 (m, 2H).

Example 13
Synthesis of (S)-3-amino-3-(3-bromophenyl)-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)propan-1-one (80)

embedded image

The title compound was prepared according to the procedure outlined in Example 7, Steps A-F, using starting material (S)-3-(3-bromophenyl)-3-(tert-butoxycarbonylamino)propanoic acid in Step E. ESI-MS: m/z 501.3 (M+H)⁺. 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.45-1.57 (m, 1H) 1.82-2.18 (m, 5H) 2.65-3.22 (m, 7H) 3.26-3.48 (m, 3H) 3.92-4.71 (m, 5H) 7.36-7.62 (m, 5H) 7.73-7.83 (m, 3H).

Example 14
Synthesis of (R)-3-amino-1((R)-3-(5,6-dichloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (81)

embedded image

The title compound was prepared according to the procedure outlined in Example DI, Steps A-F, using reagents (R)-3-(tert-butoxycarbonylamino)-4-(naphthalen-2-yl)butanoic acid and (R)-5,6-dichloro-1-(3-methoxypropyl)-2-(piperidin-3-yl)-1H-benzo[d]imidazole in Step E. ESI-MS: m/z 553.4 (M+H)⁺. 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.35-1.52 (m, 1H) 1.65-1.89 (m, 3H) 1.91-2.10 (m, 2H) 2.60-2.82 (m, 2H) 2.89-3.18 (m, 7H) 3.18-3.44 (m, 3H) 3.69-3.99 (m, 2H) 4.07-4.21 (m, 1H) 4.23-4.53 (m, 2H) 7.40-7.57 (m, 3H) 7.75-8.00 (m, 6H).

Example 15
Synthesis of (R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(pyridin-3-yl)butan-1-one (82)

embedded image

The title compound was prepared according to the procedure outlined in Example 7, Steps A-F, using starting material (R)-3-(tert-butoxycarbonylamino)-4-(pyridin-3-yl)butanoic acid in Step E. ESI-MS: m/z 436.4 (M+H)⁺. 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.41-1.65 (m, 1H) 1.75-2.23 (m, 5H) 2.57-2.85 (m, 3H) 3.18 (d, J=7.33 Hz, 6H) 3.23-3.50 (m, 4H) 3.72-4.22 (m, 2H) 4.30-4.70 (m, 3H) 7.43-7.57 (m, 2H) 7.70-7.88 (m, 3H) 8.16 (d, J=7.83 Hz, 1H) 8.21 (d, J=8.08 Hz, 1H) 8.67-8.77 (m, 2H).

Example 16
Synthesis of (S)-3-amino-3-(3-chlorophenyl)-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)propan-1-one (83)

embedded image

The title compound was prepared according to the procedure outlined in Example 7, Steps A-F, using starting material (S)-3-(tert-butoxycarbonylamino)-3-(3-chlorophenyl)propanoic acid in Step E. ESI-MS: m/z 455.1 (M+H)⁺. 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.41-1.65 (m, 1H) 1.76-2.22 (m, 5H) 2.62-3.55 (m, 10H) 3.90-4.75 (m, 5H) 7.41-7.54 (m, 5H) 7.63 (d, J=15.16 Hz, 1H) 7.71-7.86 (m, 2H).

Example 17
Synthesis of (S)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-(3-(trifluoromethyl)phenyl)propan-1-one (84)

embedded image

The title compound was prepared according to the procedure outlined in Example 7, Steps A-F, using starting material (S)-3-(tert-butoxyamino)-3-(3-(trifluoromethyl)phenyl)propanoic acid in Step E. ESI-MS: m/z 489.1 (M+H)⁺. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.41-1.67 (m, 1H) 1.77-2.23 (m, 5H) 2.62-3.20 (m, 6H) 3.21-3.59 (m, 4H) 3.89-4.27 (m, 1H) 4.33-4.87 (m, 4H) 7.41-7.56 (m, 2H) 7.62-7.72 (m, 1H) 7.72-7.88 (m, 4H) 7.94 (d, J=11.37 Hz, 1H).

Example 18
Synthesis of 3-((S)-1-amino-3-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-oxopropyl)benzonitrile (85)

embedded image

The title compound was prepared according to the procedure outlined in Example 7, Steps A-F, using starting material (S)-3-(tert-butoxyamino)-3-(3-cyanophenyl)propanoic acid in Step E. ESI-MS: m/z 446.2 (M+H)⁺. 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.45-1.66 (m, 1 H) 1.79-2.22 (m, 5H) 2.62-3.21 (m, 6H) 3.22-3.54 (m, 4H) 3.92-4.26 (m, 1H) 4.33-4.68 (m, 3H) 4.75 (br. s., 1H) 7.40-7.54 (m, 2H) 7.60-7.70 (m, 1H) 7.73-7.90 (m, 4H) 8.02 (d, J=19.45 Hz, 1H).

Example 19
Synthesis of (R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(2,4,5-trifluorophenyl)butan-1-one (86)

embedded image

The title compound was prepared according to the procedure outlined in Example 7, Steps A-F, using starting material (R)-3-(tert-butoxycarbonylamino)-4-(2,4,5-trifluorophenyl)butanoic acid in Step E. ESI-MS: m/z 489.4 (M+H)⁺. 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.41-1.61 (m, 1H) 1.74-2.18 (m, 5H) 2.57-2.85 (m, 3H) 2.85-3.22 (m, 6 H) 3.25-3.46 (m, 3H) 3.70 (br. s., 1H) 3.79-4.07 (m, 1H) 4.22-4.65 (m, 3H) 7.28-7.45 (m, 2H) 7.46-7.64 (m, 2H) 7.64-7.75 (m, 2H).

Example 20
Synthesis of (R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-yl)-4-phenylbutan-1-one (87)

embedded image

The title compound was prepared according to the procedure outlined in Example 7, Steps A-F, using starting material (R)-3-(tert-butoxycarbonylamino)-4-phenylbutanoic acid in Step E. ESI-MS: m/z 435.1 (M+H)⁺. 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.40-1.60 (m, 1 H) 1.72-2.22 (m, 5H) 2.56-2.79 (m, 3H) 2.82-3.22 (m, 5H) 3.23-3.53 (m, 4H) 3.70 (br. s., 1H) 3.77-4.19 (m, 1H) 4.29-4.71 (m, 3H) 7.23-7.41 (m, 5H) 7.45-7.57 (m, 2H) 7.74-7.90 (m, 2H).

Example 21
Synthesis of (S)-3-amino-4-(benzyloxy)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (88)

embedded image

The title compound was prepared according to the procedure outlined in Example 7, Steps A-F, using starting material (S)-4-(benzyloxy)-3-(tert-butoxycarbonylamino)butanoic acid in Step E. ESI-MS: m/z 465.2 (M+H)⁺. 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.44-1.70 (m, 1H) 1.76-2.23 (m, 5H) 2.63-2.89 (m, 3H) 2.95-3.20 (m, 4H) 3.28-3.39 (m, 3H) 3.42-3.75 (m, 4H) 3.88-4.22 (m, 1H) 4.41-4.76 (m, 6H) 7.24-7.44 (m, 5H) 7.48-7.59 (m, 2H) 7.80 (d, J=8.08 Hz, 1H) 7.88 (t, 0.7=7.33 Hz, 1H).

Example 22
Synthesis of (S)-3-amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-phenylpropan-1-one (89)

embedded image

The title compound was prepared according to the procedure outlined in Example 7, Steps A-F, using starting material (S)-3-(tert-butoxycarbonylamino)-3-phenylpropanoic acid in Step E. ESI-MS: m/z 421.2 (M+H)⁺. 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.43-1.64 (m, 1H) 1.78-2.19 (m, 5H) 2.64-3.25 (m, 8H) 3.25-3.55 (m, 3H) 3.88-4.71 (m, 6H) 7.33-7.57 (m, 7H) 7.70-7.82 (m, 2H).

Example 23
Synthesis of (R)-3-amino-4-(4-tert-butylphenyl)-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (90)

embedded image

The title compound was prepared according to the procedure outlined in Example 7, Steps A-F, using starting material (R)-3-(tert-butoxycarbonylamino)-4-(4-tert-butylphenyl)butanoic acid in Step E. ESI-MS: m/z 491.2 (M+H)⁺. 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.27 (d, J=4.04 Hz, 9H) 1.39-1.58 (m, 1H) 1.74-2.21 (m, 5H) 2.56-2.78 (m, 3H) 2.80-3.23 (m, 6H) 3.23-3.49 (m, 4H) 3.68 (br. s., 1H) 3.78-4.18 (m, 1H) 4.32-4.69 (m, 4H) 7.20 (dd, J=9.85, 8.34 Hz, 2H) 7.37 (dd, J=13.26, 8.21Hz, 2H) 7.41-7.52 (m, J=13.86, 6.85, 6.69, 6.69 Hz, 2H) 7.70-7.84 (m, 2H).

Example 24
Synthesis of (R)-3-amino-4-(4-bromophenyl)-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (91)

embedded image

The title compound was prepared according to the procedure outlined in Example 7, Steps A-F, using starting material (R)-4-(4-bromophenyl)-3-(Cert-butoxycarbonylamino)butanoic acid in Step E. ESI-MS: m/z 514.1 (M+H)⁺. 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.40-1.62 (m, 1H) 1.71-2.21 (m, 5H) 2.57-2.80 (m, 3H) 2.83-3.14 (m, 3H) 3.19 (d, J=13.64 Hz, 3H) 3.26-3.47 (m, 3H) 3.68 (br. s., 1H) 3.78-4.13 (m, 1H) 4.21-4.67 (m, 5H) 7.25 (dd, J=8.34, 6.82 Hz, 2H) 7.33-7.49 (m, 2H) 7.55 (dd, J=12.13, 8.34 Hz, 2H) 7.66-7.80 (m, 2H).

Example 25
Synthesis of (2R,3R)-3-amino-2-hydroxy-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-phenylpropan-1-one (92)

embedded image

The title compound was prepared according to the procedure outlined in Example D1, Steps A-F, using starting material (2R,3R)-3-(tert-butoxycarbonylamino)-2-hydroxy-4-phenylbutanoic acid in Step E. ESI-MS: m/z 437.2 (M+H)⁺. 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.45-1.62 (m, 1H) 1.74-2.21 (m, 5H) 2.63-3.09 (m, 2H) 3.18 (d, J=2.27 Hz, 3H) 3.23-3.58 (m, 4H) 4.00-4.59 (m, 7H) 4.74-4.94 (m, 1H) 7.31-7.54 (m, 7H) 7.67-7.82 (m, 2H).

Example 26
Synthesis of 4-amino-3-(4-chlorophenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (93)

embedded image

The title compound was prepared according to the procedure outlined in Example 7, Steps A-F, using starting material (2R)-4-(tert-butoxycarbonylamino)-3-(4-chlorobenzyl)-2-hydroxybutanoic acid in Step E. ESI-MS: m/z 470.1 (M+H)⁺. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.28-1.65 (m, 1H) 1.72-2.17 (m, 5H) 2.55-3.51 (m, 13H) 3.91-4.20 (m, 1H) 4.31-4.64 (m, 4H) 7.26-7.49 (m, 5H) 7.64-7.82 (m, 3H).

Example 27
Synthesis of Intermediates: (R)-tert-butyl 3-(4-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (27D¹) and (R)-tert-butyl 3-(7-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (27D²)

embedded image

3-Chloro-2-nitroaniline (27.35 mmole, 4.72 g) in MeOH (120 mL) in HOAc (Glacial, 12 mL) was cooled in ice-water bath and added Zn (dust, 162.5 mmole, 8.95 g) in 3 portions. The ice-water bath was removed and let slowly warm up to RT. The reaction mixture was stirred at rt overnight, filtered over Celite 500 and then concentrated in vacuo. The residue was dissolved in EtOAc (100 mL) and H₂O (50 mL). The aqueous layer was adjusted to pH 8-9 by using sat'd NaHCO₃, washed with brine, dried over MgSO₄and filtered. The organic layers containing 3-chlorobenzene-1,2-diamine (27A) were combined, concentrated in vacuo and carried directly on to the next step without further purification. ESI-MS: m/z 143.3 (M₊H)⁺.

embedded image

3-Chlorobenzene-1,2-diamine (27A) (27.35 mmole, 3.90 g) in DMF (60 mL) was added (R)-(−)-N-Boc-Nipecotic acid (32.82 mmole, 7.52 g) and N-methylmorpholine (82.05 mmole, 9.02 mL). The reaction mixture was stirred at rt for 5 min and then added EDC.HCl (35.56 mmole, 6.82 g) and HOBt (35.56 mmole, 4.81 g). The reaction mixture was kept stirring at rt overnight and then poured into H₂O, extracted with EtOAc. The extract was washed with H₂O, brine, dried over MgSO₄and filtered. The filtrate was concentrated in vacuo and purified by flash chromatography (Silica gel EtOAc-hexane: 1:3) to afford a mixture of (R)-tert-Butyl 3-(2-amino-6-chlorophenylcarbamoyl)piperidine-1-carboxylate (27B¹) and (R)-tert-butyl 3-(2-amino-3-chlorophenylcarbamoyl)piperidine-1-carboxylate (27B²) (26.90 mmole, 9.52 g, two-step yield: 98.4%). ESI-MS: m/z 354.3 (M+H)⁺.

embedded image

A mixture of (R)-tert-butyl 3-(2-amino-6-chlorophenylcarbamoyl)piperidine-1-carboxylate (27B¹) and (R)-tert-butyl 3-(2-amino-3-chlorophenylcarbamoyl)piperidine-1-carboxylate (27B¹) (26.90 mmole, 9.52 g) was added HOAc (Glacial, 20 mL). The reaction mixture was heated to 80° C. and stirred for 3 hr. HOAc was removed by evaporation and the residue was purified by flash chromatography (Silica gel EtOAc-hexane: 1:1) to afford a mixture of (R)-tert-Butyl 3-(4-chloro-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (27C¹) and (R)-tert-butyl 3-(7-chloro-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (27C²) (23.67 mmole, 8.02 g, yield: 88.0%). ESI-MS: m/z 336.4 (M+H)⁺.

embedded image

A mixture of (R)-tert-butyl 3-(4-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (27C¹) and (R)-tert-butyl 3-(7-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (27C²) (23.82 mmole, 8.00 g) in DMF (150 mL) was cooled in ice-water bath and NaH (28.58 mmole, 1.14 g) in 3 portions. The reaction solution was stirred at 0° C. for 30 min and then added 1-bromo-3-methoxypropane. The cooling bath was removed and the reaction solution was heated to 80° C. for 3 hr. The reaction solution was poured into H₂O, extracted with EtOAc. The extract was washed with brine, dried over MgSO₄and filtered. bThe filtrate was concentrated in vacuo and purified by flash chromatography (Silica gel, EtOAc-hexane: 1:3) to afford a mixture of (R)-tert-butyl 3-(4-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (27D¹) and (R)-tert-butyl 3-(7-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (27D²) (18.39 mmole, 7.50 g, yield: 77.2%). ESI-MS: m/z 408.4 (M+H)⁺.

Example 28
Synthesis of 3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-(piperidin-4-yl)propan-1-one (94)

embedded image

(R)-1-(3-Methoxypropyl)-2-(piperidin-3-yl)-1H-benzo[d]imidazole (0.293 mmol, 0.080 g) was added to a 10 mL round-bottomed flask equipped for stirring under nitrogen. DMF (3 mL), 34(9H-fluoren-9-yl)methoxy)carbonylamino)-3-(1-(tert-butoxycarbonyl)piperidin-4-yl)propanoic acid (0.293 mmol, 0.145 g) and N-methylmorpholine (0.879 mmol, 0.097 mL) were then added and the solution was allowed to stir at rt for 5 min. HATU (0.322 mmol, 0.122 g) was added and the resultant solution was stirred at room temperature for 3 hr. The reaction solution was then directly purified by preparative LC/MS (35-95% CH₃CN in H₂O). The resultant fractions were collected and the solvent was removed in-vacuo affording tert-butyl 4-(1-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-oxopropyl)piperidine-1-carboxylate (28A) as a clear oil which was used without further purification. ESI-MS: m/z 750.6 (M+H)⁺.

embedded image

Compound 28A (0.293 mmol max, crude oil) was added to a 10 mL round-bottomed flask equipped for stirring under nitrogen and dissolved in CH₂Cl₂(2 mL). Trifluoroacetic acid (2 mL) was then added and the solution was stirred at room temperature for 2 hr. The solvent was removed in-vacuo affording a clear colored oil. This oil was re-dissolved in DMF (3 mL) and piperidine (0.500 mL) and allowed to stir at room temperature for 3 hr. This reaction solution was then directly purified by preparative LC/MS (5-50% CH₃CN in H₂O). The resultant fractions were collected and the solvent was removed in-vacuo affording a clear colored oil. This oil was re-dissolved in CH₃CN (1 mL) and water (2 mL). The resultant solution was frozen and lyophilized to afford 3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-(piperidin-4-yl)propan-1-one (94) as its bis-trifluoroacetic acid salt and as a clear oil (0.176 mmol, 0.118 g, 60% yield over 3-steps). ESI-MS: m/z 428.5 (M+H)⁺.

Example 29
Synthesis of (R)-3-amino-1((R)-3-(6-fluoro-1-(3-methoxypropyl)-1,1-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (95) and (R)-3-amino-1((R)-3-(5-fluoro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (96)

embedded image

(R)-1-(tert-Butoxycarbonyl)piperidine-3-carboxylic acid (8.72 mmol, 2.0 g) and 4-fluorobenzene-1,2-diamine (8.72 mmol, 1.1 g) were added to a 50 mL round-bottomed flask equipped for stirring under nitrogen. DMF (10 mL) and 4-methylmorpholine (26.2 mmol, 2.9 mL) were added and the resultant solution was allowed to stir for 5 min at room temperature. N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine hydrochloride (10.5 mmol, 2.0 g) and 1H-benzo[d][1,2,3]triazol-1-ol (10.5 mmol, 1.42 g) were then added and the reaction was allowed to stir at room temperature for 16 hr. The reaction solution was poured into water and extracted with ethyl acetate. The organic layer was washed three times with water, two times with saturated aqueous sodium bicarbonate, and once with saturated aqueous sodium chloride. The organic layer was collected and NaiSO₄was added to remove residual water. The mixture was then filtered; the filtrate was collected, concentrated, and dried in-vacuo affording a mixture of (R)-tert-Butyl 3-(2-amino-4-fluorophenylcarbamoyl)piperidine-1-carboxylate (29A¹) and (R)-tert-butyl 3-(2-amino-5-fluorophenylcarbamoyl)piperidine-1-carboxylate (29A²) as a brownish foam that was carried directly on to the next step without further purification. ESI-MS: m/z 338.3 (M+H)⁺.

embedded image

Mixture of 29A¹and 29A²(8.72 mmol, crude oil) were added to a 100 mL round-bottomed flask equipped for stirring under nitrogen. Glacial acetic acid (20 mL) was then added and the resultant solution was stirred at 65° C. under nitrogen for 2 hrs and at 75° C. for 2 hr. Analysis of the reaction mixture by LC/MS indicated that the reaction was complete. The reaction solution was then concentrated in-vacuo and gave a brownish oil. Toluene (30 mL) was added and the subsequent solution was concentrated in vacuo. The dissolution in toluene and re-concentration were repeated three times to remove any trace quantities of acetic acid affording (R)-tert-Butyl 3-(6-fluoro-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (29B) as a brown oil which was used without further purification. ESI-MS: m/z 320.4 (M+H)⁺.

embedded image

29B (1.85 mmol max, 0.590 g of crude oil) was added to a 100 mL round-bottomed flask equipped for stirring under nitrogen. DMF (10 mL) was added and the resultant solution was cooled to 0° C. with an ice bath. NaH (60% in mineral oil, 2.04 mmol, 0.081 g) was then added and the subsequent solution was allowed to stir under nitrogen for 0.5 hr. At this time 1-bromo-3-methoxypropane (2.13 mmol, 0.326 g) was added, the ice bath was removed and the reaction solution was allowed to warm to room temperature and stir for 1 hr. The reaction solution was then poured into ice-water, extracted with ethyl acetate, and washed once with saturated aqueous sodium chloride. The organic layer was collected and anhydrous Na₂SO₄was added to remove water. The suspension was then filtered. This filtrate was collected, concentrated, and dried in-vacuo affording a brown oil. This material was then purified by chromatography on silica gel (5-10% CH₃OH/CH₂Cl₂) to afford a mixture of (R)-tert-Butyl 3-(6-fluoro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (290 and (R)-tert-butyl 3-(5-fluoro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (29C²) as a clear oil which was carried on without further purification. ESI-MS: m/z 392.4 (M+H)⁺.

embedded image

A mixture of 290¹and 29C²(0.38 mmol, 0.150 g) was added to a 10 mL round-bottomed flask equipped for stirring under nitrogen. Dichloromethane (1 mL) and trifluoroacetic acid (1 mL) were then added and the resultant solution was allowed to stir under nitrogen for 4 hr. The reaction was then concentrated and dried in-vacuo affording a mixture of (R)-6-fluoro-1-(3-methoxypropyl)-2-(piperidin-3-yl)-1H-benzo[d]imidazole (29D¹) and (R)-5-fluoro-1-(3-methoxypropyl)-2-(piperidin-3-yl)-1H-benzo[d]imidazole (29D²) as a brown oil that was used without further purification. ESI-MS: m/z 292.4 (M+H)⁺,

embedded image

A mixture of 29D¹and 29D²(0.380 mmol max, crude oil) were added to a 10 mL round-bottomed flask equipped for stirring under nitrogen. DMF (2 mL), (R)-3-(tert-butoxycarbonylamino)-4-(naphthalen-2-yl)butanoic acid (0.400 mmol, 0.108 g) and N-methylmorpholine (1.52 mmol, 0.167 mL) were then added and the solution was allowed to stir at rt for 5 min. HATU (0.410 mmol, 0.156 g) was added and the resultant solution was stirred at room temperature for 3 hR. The reaction solution was then directly purified by preparative LC/MS (35-95% CH₃CN in H₂O). The resultant fractions were collected and the solvent was removed in-vacuo affording tert-Butyl (R)-4-((R)-3-(6-fluoro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (29E¹) and tert-butyl (R)-4-((R)-3-(5-fluoro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (29E²) as a clear oil (0.153 mmol, 0.093 g, 40% yield over 4-steps). ESI-MS: m/z 603.5 (M+H)⁺.

embedded image

A mixture of 29E¹and 29E²(0.153 mmol, 0.093 g)) was added to a 10 mL round-bottomed flask equipped for stirring under nitrogen and dissolved in CH₂Cl₂(2 mL). Trifluoroacetic acid (2 mL) was then added and the solution was stirred at room temperature for 2 hr. The solvent was removed in-vacuo affording a clear colored oil. The enantiomers were further separated by Berger Prep/SFC under the following conditions: column: ChiralPak AD-H (5 um, 21.2×250 mm); mobile phase:A: liquid CO₂, B: 10 mM NH₄OAc in EtOH, flow rate: 50 mL/min, gradient: 17% B, run time: 52 min (half-stack-injection method applied), prep injection volume: 500 uL, yielding separated positional isomers (total 83% yield):

Compound 95. (R)-3-amino-1((R)-3-(6-fluoro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (0.066 mmol, 0.033 g). ESI-MS: m/z 503.4 (M+H)⁺.

Compound 96. (R)-3-amino-1((R)-3-(5-fluoro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (0.062 mmol, 0.031 g). ESI-MS: m/z 503.4 (M+H)⁺.

Example 30
Synthesis of (R)-3-Amino-1((R)-3-(7-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (97)

embedded image

1-Chloro-2-fluoro-3-nitrobenzene (2.85 mmol, 0.500 g) was added to an oven dried 50 mL round-bottomed flask equipped for stifling under nitrogen. Dichlormethane (10 mL) and triethylamine (3.13 mmol, 0.437 mL) were added and the resultant solution was cooled to 0° C. with an ice-bath. 3-Methoxypropan-1-amine (2.85 mmol, 0.292 mL) was then added drop-wise via syringe and the resultant solution was stirred at 0° C. for 1 hr. The ice-bath was removed and the reaction was allowed to warm to room temperature and stirred for 16 hr. The reaction solution was poured into water and extracted twice with dichloromethane (50 mL). The organic layer was collected and water was subsequently removed with anhydrous Na₂SO₄and the suspension was filtered. The filtrate was collected, concentrated, and dried in-vacuo affording an orange oil, which was then purified by chromatography on slica gel (10-70% ethyl aetate/hexanes) to afford 2-chloro-N-(3-methoxypropyl)-6-nitroaniline (30A) as a yellow solid (2.23 mmol, 0.542 g, 78% yield). ESI-MS: m/z 245.3 (M+H)⁺.

embedded image

2-Chloro-N-(3-methoxypropyl)-6-nitroaniline (30A) (2.23 mmol, 0.542 g) was added to an oven dried 50 mL round-bottomed flask equipped for stirring under nitrogen. Methanol (10 mL) and acetic acid (1 mL, glacial) were then added. Zinc (11.17 mmol, 0.730 g, 20-30 mesh) was then added and the resultant mixture was allowed to stir at room temperature for 16 hr. Analysis of the reaction by LC/MS indicated a complete conversion to product at this time. This resultant mixture was then filtered over Celite®, concentrated in-vacuo, and transferred to a 250 mL seperatory funnel with ethyl acetate (2×20 mL) and water (2×10 mL). The layers were separated and the organic layer was washed once with saturated aqueous sodium chloride (40 mL). The organic layer was collected and water was subsequently removed with anhydrous Na₂SO₄, and the suspension filtered. This filtrate was collected, concentrated, and dried in-vacuo affording 6-Chloro-N-1-(3-methoxypropyl)benzene-1,2-diamine (30B) a brown oil which was used without further purification. ESI-MS: m/z 215.3 (M+H)⁺.

embedded image

(R)-1-(tert-Butoxycarbonyl)piperidine-3-carboxylic acid (30B) (2.23 mmol, 0.511 g) and 6-chloro-N-1-(3-methoxypropyl)benzene-1,2-diamine (2.23 mmol, crude oil) were added to a 25 mL round-bottomed flask equipped for stirring under nitrogen. DMF (5 mL) and diisopropylethylamine (6.69 mmol, 1.2 mL) were added and the resultant solution was allowed to stir for 5 min at room temperature. N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine hydrochloride (2.45 mmol, 0.470 g) and 1H-benzo[d][1,2,3]triazol-1-ol (2.45 mmol, 0.331 g) were then added and the reaction was allowed to stir at room temperature for 16 hr. Analysis of the reaction solution by LC/MS indicated multiple products along with a small quantity of the desired title compound. The reaction solution was poured into water and extracted with ethyl acetate. The organic layer was washed three times with water, two times with saturated aqueous sodium bicarbonate, and once with saturated aqueous sodium chloride. The organic layer was collected and Na₂SO4 was added to remove residual water. This mixture was then filtered; the filtrate was collected, concentrated, and dried in-vacuo affording (R)-tert-Butyl 3-(3-chloro-2-(3-methoxypropylamino)phen ylcarbamoyl)piperidine-1-carboxylate (30C) a brownish foam that was carried directly on to the next step without further purification. ESI-MS: m/z 426.4 (M+H)⁺.

embedded image

(R)-tert-Butyl 3-(3-chloro-2-(3-methoxypropylamino)phenylcarbamoyl)piperidine-1-carboxylate (30C) (crude material, 2.23 mmol max) was added to a 50 mL round-bottomed flask equipped for stirring under nitrogen. Glacial acetic acid (10 mL) was then added and the resultant solution was stirred at 70° C. under nitrogen for 16 hr. Analysis of the reaction mixture at this time by LC/MS indicated that the reaction was complete. The reaction solution was then concentrated in-vacuo to give a brownish oil. Toluene (30 mL) was added and the subsequent solution was concentrated in vacuo. This dissolution in toluene and re-concentration was repeated three times to remove any trace quantities of acetic acid affording (R)-tert-butyl 3-(7-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (30D) as a brown oil. This oil was then purified by preparative LC/MS (25-85% CH₃CN in H₂O) to afford the title compound 30D as a tan oil (0.233 mmol, 0.095 g, 10% yield over 3-steps). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.39 (s, 9H) 1.46-1.60 (m, 1H) 1.72-1.96 (m, 2H) 1.97-2.12 (m, 3H) 2.77-2.92 (m, 1H) 3.02-3.15 (m, 2H) 3.24 (s, 3H) 3.29-3.40 (m, 2H) 3.93-4.02 (m, 1H) 4.12 (br. s., 1H) 4.51-4.59 (m, 2H) 7.20 (t, J=7.83 Hz, 1H) 7.28 (d, J=7.83 Hz, 1H) 7.58 (d, J=7.83 Hz, 1H) ESI-MS: m/z 408.2 (M+H)⁺.

embedded image

(R)-tert-Butyl 3-(7-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (0.222 mmol, 0.090 g) was added to a 10 mL round-bottomed flask equipped for stirring under nitrogen. Dichloromethane (1 mL) and trifluoroacetic acid (1 mL) were then added and the resultant solution was allowed to stir under nitrogen for 4 hr. The reaction was then concentrated and dried in-vacuo affording (R)-7-Chloro-1-(3-methoxypropyl)-2-(piperidin-3-yl)-1H-benzo[d]imidazole (30E) a brown oil and used without further purification. ESI-MS: m/z 308.2 (M+H)⁺.

embedded image

((R)-7-chloro-1-(3-methoxypropyl)-2-(piperidin-3-yl)-1H-benzo[d]imidazole (0.111 mmol max, about half of crude oil from Step E) was added to a 15 mL round-bottomed flask equipped for stirring under nitrogen. DMF (2 mL), (R)-3-(tert-butoxycarbonylamino)-4-(naphthalen-2-yl)butanoic acid (0.122 mmol, 0.040 g) and N-methylmorpholine (0.555 mmol, 0.061 mL) were then added and the solution was allowed to stir at rt for 5 min. HATU (0.122 mmol, 0.046 g) was added and the resultant solution was stirred at room temperature for 3 hr. The reaction solution was then directly purified by preparative LC/MS (20-85% CH₃CN in H₂O). The resultant fractions were collected and the solvent was removed in-vacuo affording tert-butyl (R)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (30F) as a clear oil that was used directly onto the next step. ESI-ESI-MS: m/z 619.5 (M+H)⁺.

embedded image

tert-Butyl (R)-4-((R)-3-(7-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (0.111 mmol max, crude oil from Step F) was added to a 10 mL round-bottomed flask equipped for stirring under nitrogen. Dichloromethane (1 mL) and trifluoroacetic acid (1 mL) were then added and the resultant solution was allowed to stir under nitrogen for 4 HR. The solvent was removed in-vacuo affording a clear colored oil. This oil was re-dissolved in methanol (3 mL), filtered, and then purified by preparative LC/MS (25-65% CH₃CN in H₂O). The resultant fractions were collected and the solvent was removed in-vacuo affording a clear colored oil. This oil was re-dissolved in CH₃CN (1 mL) and water (2 mL). The resultant solution was frozen and lyophilized to afford (R)-3-amino-1-((R)-3-(7-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (97) as its trifluoroacetic acid salt as a white flocculent solid (0.052 mmol, 0.033 g, 47% over 3-steps) ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.35-1.56 (m, 1H) 1.63-2.14 (m, 5H) 2.60-2.78 (m, 2H) 2.88-3.42 (m, 9H) 3.69-4.01 (m, 3H) 4.00-4.61 (m, 5H) 7.10-7.30 (m, 2H) 7.42-7.60 (m, 4H) 7.73-7.99 (m, 4H) ESI-MS: m/z 519.2 (M+H)⁺.

Example 31
Synthesis of (R)-3-amino-4-(biphenyl-4-yl)-1((R)-3-(7-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (98)

embedded image

((R)-7-Chloro-1-(3-methoxypropyl)-2-(piperidin-3-yl)-1H-benzo[d]imidazole (30E) (0.111 mmol, crude oil) prepared according to the procedure described in Example 30, Steps A-E was added to a 15 mL round-bottomed flask equipped for stirring under nitrogen. DMF (2 mL), (R)-4-(4-bromophenyl)-3-(tert-butoxycarbonylamino)butanoic acid (0.122 mmol, 0.032 g) and N-methylmorpholine (0.555 mmol, 0.061 mL) were then added and the solution was allowed to stir at rt for 5 min. HATU (0.122 mmol, 0.046 g) was added and the resultant solution was stirred at room temperature for 3 hrs. The reaction solution was then directly purified by preparative LC/MS (20-85% CH₃CN in H₂O). The resultant fractions were collected and the solvent was removed in-vacuo affording tert-butyl (R)-1-(4-bromophenyl)-4-((R)-3-(7-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (31A) as a clear oil that was used directly onto the next step. EST-MS: m/z 647.3 (M+H)⁺.

embedded image

tert-Butyl (R)-1-(4-bromophenyl)-4-((R)-3-(7-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (31A) (0.111 mmol max, crude oil) and phenylboronic acid (0.144 mmol, 0.018 g) were added to a 5 mL microwave vessel equipped with a magnetic stir bar. Dioxane (2 mL) and Na₂CO₃(1 mL of a 2 M in aqueous solution) were then added and the reaction vessel was flushed with nitrogen gas. PdCl₂(dppf) (0.006 mmol, 0.004 g) was added, the reaction vessel was sealed and placed in a microwave reactor and heated to 120° C. for 15 minutes. The reaction solution was then poured into water, extracted with ethyl acetate, and washed once with saturated aqueous sodium chloride. The organic layer was collected and subsequently dried with anhydrous Na₂SO₄and filtered. This filtrate was collected, concentrated, and dried in-vacuo. This crude material was directly purified by preparative LC/MS (gradient 25-85% CH₃CN in H₂O). The resultant fractions were collected and the solvent was removed in-vacuo affording tert-butyl (R)-1-(biphenyl-4-yl)-4-((R)-3-(7-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (31B) as a clear oil. ESI-MS: m/z 645.5 (M+H)⁺.

embedded image

tert-Butyl (R)-1-(biphenyl-4-yl)-4-((R)-3-(7-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (31B) (0.111 mmol max, crude oil) was added to a 10 mL round-bottomed flask equipped for stirring under nitrogen. Dichloromethane (1 mL) and trifluoroacetic acid (1 mL) were then added and the resultant solution was allowed to stir under nitrogen for 4 hr. The solvent was removed in-vacuo affording a clear colored oil. This oil was re-dissolved in methanol (3 mL), filtered, and then purified by preparative LC/MS (20-45% CH₃CN in H₂O). The resultant fractions were collected and the solvent was removed in-vacuo affording a clear colored oil. This oil was re-dissolved in CH₃CN (1 mL) and water (2 mL). The resultant solution was frozen and lyophilized to afford(R)-3-amino-4-(biphenyl-4-yl)-1-((R)-3-(7-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (98) as its trifluoroacetic acid salt as a white flocculent solid (0.067 mmol, 0.044 g, 60% over 4-steps). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.40-1.59 (m, 1H) 1.71-2.16 (m, 5H) 2.58-3.49 (m, 12H) 3.67-4.04 (m, 2H) 4.37-4.62 (m, 3H) 7.13-7.23 (m, 1H) 7.23-7.30 (m, 1H) 7.30-7.41 (m, 3H) 7.47 (td, J=7.58, 3.54 Hz, 2H) 7.50-7.71 (m, 5H) ESI-MS: m/z 545.2 (M+H)⁺.

Example 32
Synthesis of (R)-3-amino-1((R)-3-(6-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (99)

embedded image

4-Chloro-2-fluoro-1-nitrobenzene (2.85 mmol, 0.500 g) was added to an oven dried 25 mL round-bottomed flask equipped for stirring under nitrogen. DMF (5 mL) was added and the resultant solution was cooled to 0° C. with an ice-bath. 3-Methoxypropan-1-amine (2.99 mmol, 0.306 mL) was then added drop-wise via syringe and the resultant solution was stirred at 0° C. for 1 hr. The ice-bath was removed and the reaction was allowed to warm to room temperature and stir for 16 hr. The reaction solution was then poured into water, extracted with ethyl acetate, and washed once with saturated aqueous sodium chloride. The organic layer was collected and subsequently dried with anhydrous Na₂SO₄and filtered; filtrate was collected, concentrated, and dried in-vacuo affording 5-chloro-N-(3-methoxypropyl)-2-nitroaniline (32A) as an orange oil. This material was used directly in the next step without further purification. ESI-MS: m/z 245.3 (M+H)⁺.

embedded image

5-Chloro-N-(3-methoxypropyl)-2-nitroaniline (32A) (2.85 mmol max, crude oil) was added to an oven dried 100 mL round-bottomed flask equipped for stirring under nitrogen. Methanol (20 mL) and acetic acid (1.5 mL, glacial) were then added. Zinc (15.29 mmol, 1.0 g, 20-30 mesh) was then added and the resultant mixture was allowed to stir at room temperature for 16 hr. Analysis of the reaction by LC/MS indicated a complete conversion to product at this time. This resultant mixture was then filtered over Celite®, concentrated in-vacuo, and transferred to a 250 mL seperatory funnel with ethyl acetate (2×30 mL) and water (2×20 mL). The layers were separated and the organic layer was washed once with saturated aqueous sodium chloride (40 mL). The organic layer was collected and subsequently dried with anhydrous Na₂SO₄and filtered. This filtrate was collected, concentrated, and dried in-vacuo affording 5-chloro-N-1-(3-methoxypropyl)benzene-1,2-diamine (32B) a brown oil which was used directly in the next step without further purification. ESI-MS: m/z 215.3 (M+H)⁺.

embedded image

5-Chloro-N-1-(3-methoxypropyl)benzene-1,2-diamine (32B) (0.932 mmol; 0.200 g) and (R)-1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid (0.932 mmol; 0.214 g) were added to a 5 mL microwave vessel equipped with a magnetic stir bar. Pyridine (2 mL) and triisopropylphosphite (1.03 mmol; 0.270 mL) were then added and the reaction vessel was flushed with nitrogen gas. The reaction vessel was sealed and placed in a microwave reactor and heated to 220° C. for 15 minutes. The reaction solution was then poured into water, extracted with ethyl acetate, and washed once with saturated aqueous sodium chloride. The organic layer was collected and subsequently dried with anhydrous Na₂SO₄and filtered. This filtrate was collected, concentrated, and dried in-vacuo. This crude material was purified by silica gel chromatography (20% CH₃CN/CH₂Cl₂). The resultant fractions were collected and the solvent was removed in-vacuo affording (R)-tert-butyl 3-(6-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (32C) as a tan oil (0.135 mmol, 0.055 g, 14% yield over 3-steps). ESI-MS: m/z 408.4 (M+H)⁺.

embedded image

((R)-tert-Butyl 3-(6-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (32C) (0.135 mmol, 0.055 g) was added to a 10 mL round-bottomed flask equipped for stirring under nitrogen. Dichloromethane (1 mL) and trifluoroacetic acid (1 mL) were then added and the resultant solution was allowed to stir under nitrogen for 4 hr. The reaction was then concentrated and dried in-vacuo affording (R)-6-chloro-1-(3-methoxypropyl)-2-(piperidin-3-yl)-1H-benzo[d]imidazole (32D) as a tan oil that was used directly in the next step without further purification. ESI-MS: m/z 308.3 (M+H)⁺.

embedded image

(R)-6-Chloro-1-(3-methoxypropyl)-2-(piperidin-3-yl)-1H-benzo[d]imidazole (32D) (0.135 mmol, 0.055 g) was added to a 15 mL round-bottomed flask equipped for stirring under nitrogen. DMF (2 mL), (R)-3-(tert-butoxycarbonylamino)-4-(naphthalen-2-yl)butanoic acid (0.197 mmol, 0.053 g) and N-methylmorpholine (0.706 mmol, 0.079 mL) were then added and the solution was allowed to stir at rt for 5 min. HATU (0.197 mmol, 0.075 g) was added and the resultant solution was stirred at room temperature for 3 hr. The reaction solution was then directly purified by preparative LC/MS (25-85% CH₃CN in H₂O). The resultant fractions were collected and the solvent was removed in-vacuo affording tert-Butyl (R)-4-((R)-3-(6-chloro-1-(3-methoxypropyl)-1H-benz o[d]imidazol-2-yl)piperidine-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (32E) as a clear oil that was used directly onto the next step. ESI-MS: m/z 619.5 (M+H)⁺,

embedded image

tert-Butyl (R)-4-((R)-3-(6-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (32E) (0.135 mmol max, crude oil) was added to a 10 mL round-bottomed flask equipped for stirring under nitrogen. Dichloromethane (1 mL) and trifluoroacetic acid (1 mL) were then added and the resultant solution was allowed to stir under nitrogen for 4 hr. The solvent was removed in-vacuo affording a clear colored oil. This oil was re-dissolved in methanol (3 mL), filtered, and then purified by preparative LC/MS (15-55% CH₃CN in H₂O). The resultant fractions were collected and the solvent was removed in-vacuo affording a clear colored oil. This oil was re-dissolved in CH₃CN (1 mL) and water (2 mL). The resultant solution was frozen and lyophilized to afford (R)-3-amino-1-((R)-3-(6-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (99) as its trifluoroacetic acid salt and as a white flocculent solid (0.074 mmol, 0.047 g, 55% yield over 3-steps). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.33-1.54 (m, 1H) 1.68-2.11 (m, 5H) 2.61-2.77 (m, 3H) 2.88-3.44 (m, 9H) 3.71-4.04 (m, 2H) 4.07-4.23 (m, 1H) 4.25-4.39 (m, 1H) 4.49 (dd, J=36.51, 13.26 Hz, 1H) 7.21-7.31 (m, 1H) 7.44 (ddd, J=8.40, 4.61, 1.64 Hz, 1H) 7.47-7.56 (m, 2H) 7.61 (dd, J=17.43, 8.59 Hz, 1H) 7.71-8.06 (m, 5H). ESI-MS: m/z 519.4 (M+H)⁺,

Example 33
Synthesis of (R)-3-amino-1-(3-(5-methoxy-3-(3-methoxypropyl)-3H-imidazo[4,5-b]pyridin-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (100)

embedded image

2,6-Dichloro-3-nitropyridine (3.29 mmol, 0.635 g) was added to an oven dried 50 mL round-bottomed flask equipped for stirring under nitrogen. Dichlormethane (12 mL) and triethylamine (3.62 mmol, 0.504 mL) were added and the resultant solution was cooled to −15° C. with an acetone/ice bath. 3-methoxypropan-1-amine (3.29 mmol, 0.337 mL) was then added drop-wise via syringe and the resultant solution was stirred at −15° C. for 0.5 hr. The acetone/ice bath was removed and the reaction was allowed to warm to room temperature and stir for 0.5 hr. The reaction solution was poured into water and extracted twice with dichloromethane (50 mL). The organic layer was collected and subsequently dried with anhydrous Na₂SO₄and filtered. This filtrate was collected, concentrated, and dried in-vacuo affording an orange oil. This material was then purified by chromatography on silica gel (20% ethyl acetate/hexanes) to afford 6-chloro-N-(3-methoxypropyl)-3-nitropyridin-2-amine (33A) as a yellow solid (3.01 mmol, 0.740 g, 92% yield). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.79-1.89 (m, 2H) 3.00 (s, 3H) 3.43 (t, J=6.06 Hz, 2H) 3.53-3.61 (m, 2H) 6.77 (d, J=8.59 Hz, 1H) 8.42 (d, J=8.08 Hz, 1H). ESI-MS: m/z 246.2 (M+H)⁺.

embedded image

6-Chloro-N-(3-methoxypropyl)-3-nitropyridin-2-amine (33A) (1.56 mmol, 0.383 g)) was added to an oven dried 50 mL round-bottomed flask equipped for stirring under nitrogen. Methanol (10 mL) was then added and the solution was cooled to 0° C. with an ice-bath. Sodium methoxide (6.93 mmol, 1.3 mL of a 30 wt % soln. in CH₃OH) was then added dropwise via syringe at 0° C. The ice bath was removed and the solution was allowed to warm to room temperature and stir for 2 hr. The reaction solution was then poured into water (150 mL) and the pH was adjusted to pH=7 with 1N HCl. The resultant solution was extracted with ethyl acetate, and washed once with saturated aqueous sodium chloride. The organic layer was collected and subsequently dried with anhydrous Na₂SO₄and filtered. This filtrate was collected, concentrated, and dried in-vacuo affording 6-methoxy-N-(3-methoxypropyl)-3-nitropyridin-2-amine (33B) as a brown oil. This crude material was used directly in the next step without further purification. ESI-MS: m/z 242.3 (M+H)⁺.

embedded image

6-Methoxy-N-(3-methoxypropyl)-3-nitropyridin-2-amine (33B) (1.56 mmol max, crude oil) and (R)-tert-butyl 3-formylpiperidine-1-carboxylate (1.56 mmol, 0.332 g) were added to an oven dried 50 mL round-bottomed flask equipped with a reflux condenser and for stirring under nitrogen. Ethanol (4 mL) and dimethyl sulfoxide (2 mL) were added and the solution was allowed to stir at room temperature for 5 min. Sodium hydrosulfite (4.68 mmol; 0.959 g of 85%) was then added and the resultant mixture was heated to reflux and allowed to stir for 16 hr. The reaction solution was then concentrated in-vacuo, poured into water (100 mL), extracted with ethyl acetate, and washed once with saturated aqueous sodium chloride. The organic layer was collected and subsequently dried with anhydrous Na₂SO₄and filtered. This filtrate was collected, concentrated, and dried in-vacuo affording a brown oil that was further purified by silica gel chromatography (20% CH₃CN/CH₂Cl₂) to afford tert-butyl 3-(5-methoxy-3-(3-methoxypropyl)-3H-imidazo[4,5-b]pyridin-2-yl)piperidine-1-carboxylate (33C) as a clear oil (1.19 mmol, 0.481 g, 76% yield over 2-steps). ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.48 (s, 9H) 1.54-1.70 (m, 1H) 1.84 (dt, J=13.83, 2.81Hz, 1H) 2.02-2.21 (m, 4H) 2.73-2.88 (m, 1H) 2.96-3.18 (m, 2H) 3.29-3.41 (m, 5H) 3.98 (s, 3H) 4.08-4.44 (m, 4H) 6.65 (d, J=8.59 Hz, 1H) 7.86 (d, J=8.59 Hz, 1H). ESI-MS: m/z 405.5 (M+H)⁺.

embedded image

tert-Butyl 3-(5-methoxy-3-(3-methoxypropyl)-3H-imidazo[4, 5-13]pyridin-2-yl)piperidine-1-carboxylate (33C) (1.19 mmol; 0.481 g) was added to a 100 mL round-bottomed flask equipped with a reflux condenser and stirring under nitrogen. EtOH (15 mL) and HCl (8M in H₂O; 4 mL) were then added and the solution was heated to reflux for 15 min. Analysis of the reaction mixture by LC/MS indicated that the reaction was complete at this time. The ethanol was then removed in-vacuo. The resultant solution was extracted with EtOAc and a 10% aqueous K₂CO₃solution. The organic layer was collected and dried with Na₂SO₄. This was then filtered and concentrated and dried in-vacuo affording 5-Methoxy-3-(3-methoxypropyl)-2-(piperidin-3-yl)-3H-imidazo[4,5-b]pyridine (330) as a brown oil. (1.15 mmol, 0.351 g, 97% yield). ESI-MS: m/z 305.1 (M+H)⁺.

embedded image

5-Methoxy-3-(3-methoxypropyl)-2-(piperidin-3-yl)-3H-imidazo[4,5-b]pyridine (33D) (0.600 mmol, 0.182 g) was added to a 15 mL round-bottomed flask equipped for stirring under nitrogen. DMF (2 mL), (R)-3-(tert-butoxycarbonylamino)-4-(naphthalen-2-yl)butanoic acid (0.455 mmol, 0.150 g) and N-methylmorpholine (1.8 mmol, 0.198 mL) were then added and the solution was allowed to stir at rt for 5 min. HATU (0.660 mmol, 0.251 g) was added and the resultant solution was stirred at room temperature for 3 hr. The reaction solution was then directly purified by preparative LC/MS (35-80% CH₃CN in H₂O). The resultant fractions were collected and the solvent was removed in-vacuo affording (R)-tert-butyl 4-(3-(5-methoxy-3-(3-methoxypropyl)-3H-imidazo[4,5-b]pyridin-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (33E) as a clear oil. (0.333 mmol, 0.205 g, 73% yield). ESI-MS: m/z 616.5 (M+H)⁺.

embedded image

(R)-tert-Butyl 4-(3-(5-methoxy-3-(3-methoxypropyl)-3H-imidazo[4,5-b]pyridin-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (33E) (0.069 mmol, 0.042 g) was added to a 10 mL round-bottomed flask equipped for stirring under nitrogen. Dichloromethane (1 mL) and trifluoroacetic acid (1 mL) were then added and the resultant solution was allowed to stir under nitrogen for 4 hr. The solvent was removed in-vacuo affording a clear colored oil. This oil was re-dissolved in methanol (3 mL), filtered, and then purified by preparative LC/MS (5-55% CH₃CN in H₂O). The resultant fractions were collected and the solvent was removed in-vacuo affording a clear colored oil. This oil was re-dissolved in CH₃CN (1 mL) and water (2 mL). The resultant solution was frozen and lyophilized to afford (R)-3-amino-1-(3-(5-methoxy-3-(3-methoxypropyl)-3H-imidazo[4,5-b]pyridin-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (100) as its trifluoroacetic acid salt and as a white flocculent solid (0.067 mmol, 0.035 g, 98% yield) ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.37-1.58 (m, 1 H) 1.68-2.14 (m, 5H) 2.57-2.89 (m, 2H) 2.89-3.23 (m, 8H) 3.24-3.48 (m, 2H) 3.92 (d, J=2.53 Hz, 5H) 4.02-4.35 (m, 2H) 4.36-4.62 (m, 1H) 6.63-6.76 (m, 1 FI) 7.35-7.59 (m, 3 H) 7.72-8.02 (m, 5H). ESI-MS: m/z 516.2 (M+H)⁺.

Example 34
Synthesis of (R)-2-(1-(3-amino-4-(naphthalen-2-yl)butanoyl)piperidin-3-yl)-3-(3-methoxypropyl)-3H-imidazo[4,5-b]pyridin-5(4H)-one (101)

embedded image

(R)-tert-Butyl 4-(3-(5-methoxy-3-(3-methoxypropyl)-3H-imidazo[4,5-b]pyridin-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (33E) (0.114 mmol, 0.070 g) prepared according to Example 33, Steps A-E and pyridine hydrochloride (8.65 mmol, 1.00 g) were added to a 15 mL round bottomed flask equipped for stirring under nitrogen. The reaction was subsequently heated to 150° C. and stirred for 15 min. The reaction was cooled to room temperature and water (2 mL) was added. The solution was stirred for 30 minutes at room temperature to allow the solid to completely dissolve. This solution was then filtered and directly purified by preparative LC/MS (10-50% CH₃CN in H₂O). The resultant fractions were collected and the solvent was removed in-vacuo affording the title compound as a clear colored oil (0.004 mmol, 0.002 g, 3% yield). ESI-MS: m/z 502.2 (M+H)⁺.

Example 35
Synthesis of (R)-3-amino-1-(3-(5-chloro-3-(3-methoxypropyl)-3H-imidazo[4,5-b]pyridin-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (102)

embedded image

6-Chloro-N-(3-methoxypropyl)-3-nitropyridin-2-amine (2.84 mmol, 0.698 g) was added to an oven dried 50 mL round-bottomed flask equipped for stirring under nitrogen. Methanol (15 mL) and acetic acid (1.5 mL, glacial) were then added. Zinc (15.29 mmol, 1.0 g, 20-30 mesh) was then added and the resultant mixture was allowed to stir at room temperature for 16 hr. Analysis of the reaction by LC/MS indicated a complete conversion to product at this time. This resultant mixture was then filtered over Celite®, concentrated in-vacuo, and transferred to a 250 mL seperatory funnel with ethyl acetate (2×30 mL) and water (2×20 mL). The layers were separated and the organic layer was washed once with saturated aqueous sodium chloride (40 mL). The organic layer was collected and subsequently dried with anhydrous Na₂SO₄and filtered. This filtrate was collected, concentrated, and dried in-vacuo affording 6-chloro-N2-(3-methoxypropyl)pyridine-2,3-diamine (35A) as a brown oil which was used directly in the next step without further purification. ESI-MS: mix 216.3 (M+H)⁺.

embedded image

(R)-1-(cert-Butoxycaxbonyl)piperidine-3-carboxylic acid (2.84 mmol, 0.651 g) and 6-chloro-N2-(3-methoxypropyl)pyridine-2,3-diamine (35A) (2.84 mmol, crude oil) was added to a 50 mL round-bottomed flask equipped for stirring under nitrogen. DMF (10 mL) and N-methylmorpholine (11.36 mmol, 1.25 mL) were added and the resultant solution was allowed to stir for 5 min at room temperature. N1-((ethylimino)methylene)-N3,N³-dimethylpropane-1,3-diamine hydrochloride (3.12 mmol, 0.598 g) and 1H-benzo[d][1,2,3]triazol-1-ol (3.12 mmol, 0.422 g) were then added and the reaction was allowed to stir at room temperature for 16 hr. Analysis of the reaction solution by LC/MS indicated multiple products along with a small quantity of the desired title compound. The reaction solution was poured into water and extracted with ethyl acetate. The organic layer was washed three times with water, two times with saturated aqueous sodium bicarbonate, and once with saturated aqueous sodium chloride. The organic layer was collected and dried with Na₂SO₄and then filtered. The filtrate was collected, concentrated, and dried in-vacuo affording (R)-tert-butyl 3-(6-chloro-2-(3-methoxypropylamino)pyridin-3-ylcarbamoyl)piperidine-1-carboxylate (35B) as a brownish foam that was carried directly on to the next step without further purification. ESI-MS: m/z 427.4 (M+H)⁺.

embedded image

Compound 35B (crude material, 2.84 mmol max) prepared in Step 13 was added to a 50 trLL round-bottomed flask equipped for stirring under nitrogen. Glacial acetic acid (10 mL) was then added and the resultant solution was stirred at reflux under nitrogen for 16 hr. The reaction solution was concentrated in-vacuo to give a brownish oil. Toluene (30 mL) was added and the subsequent solution was concentrated in vacuo; this was repeated three times to remove any trace quantities of acetic acid affording the title compound as a brown oil. This oil was then purified by preparative LC/MS (5-50% CH₃CN in H₂O) to afford 5-chloro-3-(3-methoxypropyl)-2-(piperidin-3-yl)-3H-imidazo[4,5-b]pyridine (35C) as a tan oil. (088 mmol, 0.122 g, 10% yield over 3-steps). Subsequent analysis of a later derivative of this compound revealed that the chiral center had been epimerized during this reaction sequence. ESI-MS: m/z 309.4 (M+H)⁺.

embedded image

Compound 35C (0.288 mmol, 0.122 g) was added to a 10 mL round-bottomed flask equipped for stirring under nitrogen. DMF (2 mL), (R)-3-(tert-butoxycarbonylamino)-4-(naphthalen-2-yl)butanoic acid (0.455 mmol, 0.150 g) and N-methylmorpholine (1.15 mmol, 0.127 mL) were then added and the solution was allowed to stir at it for 5 min. HATU (0.317 mmol, 0.120 g) was added and the resultant solution was stirred at room temperature for 3 hr. The reaction solution was then directly purified by preparative LC/MS (40-95% CH₃CN in H₂O). The resultant fractions were collected and the solvent was removed in-vacuo affording (R)-tert-Butyl 4-(3-(5-chloro-3-(3-methoxypropyl)-3H-imidazo[4,5-b]pyridin-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (35D) as a clear oil (0.177 mmol, 0.110 g, 62% yield). ESI-MS: m/z 620.4 (M+H)⁺.

embedded image

(R)-4-(4-brornobenzyl)-2-oxooxazolidine-5-carboxylic acid-(R)-tert-Butyl 4-(3-(5-chloro-3-(3-methoxypropyl)-3H-imidazo[4,5-b]pyridin-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (35D) (0.045 mmol, 0.028 g) was added to a 10 mL round-bottomed flask equipped for stirring under nitrogen. Acetic acid (3 mL) was added and the resultant solution was allowed to stir at reflux under nitrogen for 4 hr. The solvent was removed in-vacuo affording a clear colored oil. This oil was re-dissolved in methanol (3 mL), filtered, and then purified by preparative LC/MS (25-50% CH₃CN in H₂O). The resultant fractions were collected and the solvent was removed in-vacuo affording a clear oil. This oil was re-dissolved in CH₃CN (1 mL) and water (2 mL). The resultant solution was frozen and lyophilized to afford (R)-3-amino-1-(3-(5-chloro-3-(3-methoxypropyl)-3H-imidazo[4,5-b]pyridin-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (102) as its trifluoroacetic acid salt and as a white flocculent solid. (0.008 mmol, 0.0043 g, 18% yield) ESI-MS: m/z 520.4 (M+H)⁺.

Example 36
Synthesis of (R)-3-amino-4-(biphenyl-4-yl)-1((R)-3-(3-(3-methoxypropyl)-3H-imidazo[4,5-c]pyridin-2-yl)piperidin-1-yl)butan-1-one (103)

embedded image

3-Bromo-4-nitropyridine 1-oxide (4.57 mmol, 1.0 g) was added to an oven dried 200 mL round-bottomed flask equipped for stirring under nitrogen. Acetonitrile (30 mL) and K₂CO₃(11.42 mmol, 1.60 g) were added and the resultant solution was cooled to 0° C. with an ice bath.

3-Methoxypropan-1-amine (5.02 mmol, 0.514 mL) was then added drop-wise via syringe and the resultant solution was stirred at 0° C. for 0.5 hr. The ice bath was removed and the reaction was allowed to warm to room temperature and stir for 16 hr. The reaction solution was filtered over Celite®. The filtrate was collected, concentrated, and dried in-vacuo affording 3-(3-methoxypropylamino)-4-nitropyridine 1-oxide (36A) as dark brown oil which was used without further purification. ESI-MS: mh 228.3 (M+H)⁺.

embedded image

3-(3-Methoxypropylamino)-4-nitropyridine 1-oxide (3.69 mmol, 0.842 g) was added to an oven dried 50 mL round-bottomed flask equipped for stirring. Methanol (15 mL) was then added and the solution was vacuum degassed with nitrogen three times. Ranay nickel (0.5 mL of a 50% slurry in H₂O) was then added and the solution was degassed an additional three times with nitrogen. The reaction was then evacuoted under vacuum and hydrogen gas was added via balloon pressure and the reaction was stirred under hydrogen for 16 hr. At this time, the hydrogen balloon was removed and the solution was vacuum de-gassed with nitrogen twice. The reaction solution was then filtered over Celite®. The filtrate was collected, concentrated, and dried in-vacuo affording N3-(3-Methoxypropyl)pyridine-3,4-diamine (36B) as dark brown oil which was used without further purification. ESI-MS: m/z 182.3 (M+H)⁺.

embedded image

(R)-1-(tert-Butoxycarbonyl)piperidine-3-carboxylic acid (2.15 mmol, 0.493 g) and N3-(3-methoxypropyl)pyridine-3,4-diamine (36B) (2.15 mmol, 0.493 g) were added to a 25 mL round-bottomed flask equipped for stirring under nitrogen. DMF (7 mL) and 4-methylmorpholine (6.45 mmol, 0.709 mL) were added and the resultant solution was allowed to stir for 5 min at room temperature. N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine hydrochloride (2.37 mmol, 0.453 g) and 1H-benzo[d][1,2,3]triazol-1-ol (2.37 mmol, 0.320 g) were then added and the reaction was allowed to stir at room temperature for 16 hr. Analysis of the reaction solution by LC/MS indicated multiple products along with a small quantity of the desired title compound. The reaction solution was poured into water and extracted with ethyl acetate. The organic layer was washed three times with water, two times with saturated aqueous sodium bicarbonate, and once with saturated aqueous sodium chloride. The organic layer was collected and dried with Na₂SO₄. This mixture was then filtered, the filtrate was collected and concentrated and dried in-vacuo affording a brown oil. This oil was directly purified by preparative LC/MS (10-80% CH₃CN in H₂O) to afford (R)-tert-butyl 3-(3-(3-methoxypropylamino)pyridin-4-ylcarbamoyl)piperidine-1-carboxylate (36C) as a clear oil (0.614 mmol, 0.241 g, 29% yield over 3-steps). ESI-MS: m/z 393.3 (M+H)+.

embedded image

(R)-tert-Butyl 3-(3-(3-methoxypropylamino)pyridin-4-ylcarbamoyl)piperidine-1-carboxylate (36C) (0.614 mmol, 0.241 g) was added to a 5 mL microwave reactor. Glacial acetic acid (2 mL) was then added and the resultant solution heated at 85° C. in the microwave for 1.5 hr. The reaction solution was then transferred to a 50 mL round bottomed flask and concentrated in-vacuo to give a brownish oil. Toluene (30 mL) was added and the subsequent solution was concentrated in vacuo. This was repeated three times to remove any trace quantities of acetic acid affording the title compound as a brown oil. This oil was then purified by silica gel chromatography (5-15% CH₃OH/CH₂Cl₂) to afford (R)-tert-butyl 3-(3-(3-methoxypropyl)-3,1-imidazo[4,5-c]pyridin-2-yl)piperidine-1-carboxylate (36D) as a clear oil (0.279 mmol, 0.105 g, 45% yield). ESI-MS: m/z 375.3 (M+H)+.

embedded image

(R)-tert-Butyl 3-(3-(3-methoxypropyl)-3H-imidazo[4,5-c]pyridin-2-yl)piperidine-1-carboxylate (36D) (0.279 mmol, 0.105 g) was added to a 10 mL round-bottomed flask equipped for stirring under nitrogen. Dichloromethane (1 mL) and trifluoroacetic acid (1 mL) were then added and the resultant solution was allowed to stir under nitrogen for 4 hr. The reaction was then concentrated and dried in-vacuo affording (R)-3-(3-Methoxypropyl)-2-(piperidin-3-yl)-3H-imidazo[4,5-c]pyridine (35E) as a clear oil that was used without further purification. ESI-MS: m/z 275.1 (M+H)+.

embedded image

(R)-3-(3-Methoxypropyl)-2-(piperidin-3-yl)-3H-imidazo[4,5-c]pyridine (35E) (0.279 mmol, crude oil) was added to a 15 mL round-bottomed flask equipped for stirring under nitrogen. DMF (2 mL), (R)-4-(4-bromophenyl)-3-(tert-butoxycarbonylamino)butanoic acid (0.335 mmol, 0.086 g) and N-methylmorpholine (1.95 mmol, 0.214 mL) were then added and the solution was allowed to stir at rt for 5 min. HATU (0.335 mmol, 0.127 g) was added and the resultant solution was stirred at room temperature for 3 hr. The reaction solution was then directly purified by preparative LC/MS (25-85% CH₃CN in H₂O). The resultant fractions were collected and the solvent was removed in-vacuo affording tert-butyl (R)-1-(4-bromophenyl)-4-((R)-3-(3-(3-methoxypropyl)-3H-imidazo[4,5-c]pyridin-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (35F) as a clear oil (0.238 mmol, 0.146 g, 85% yield). ESI-ESI-MS: adz 614.3 (M+H)⁺.

embedded image

tert-Butyl (R)-1-(4-bromophenyl)-4-((R)-3-(3-(3-methoxypropyl)-3H-imidazo[4,5-c]pyridin-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (35F) (0.229 mmol, 0.141 g) and phenylboronic acid (0.298 mmol, 0.036 g) were added to a 5 mL microwave vessel equipped with a magnetic stir bar. Dioxane (2 mL) and Na₂CO₃(1 mL of a 2M in H₂O soln.) were then added and the reaction vessel was flushed with nitrogen gas. PdCl₂(dppf) (0.011 mmol, 0.008 g) was added, the reaction vessel was sealed and placed in a microwave reactor and heated to 120° C. for 25 minutes. The reaction solution was then poured into water, extracted with ethyl acetate, and washed once with saturated aqueous sodium chloride. The organic layer was collected and subsequently dried with anhydrous Na₂SO₄and filtered. This filtrate was collected, concentrated, and dried in-vacuo. This crude material was directly purified by preparative LC/MS (25-85% CH₃CN in H₂O). The resultant fractions were collected and the solvent was removed in-vacuo.

tert-Butyl (R)-1-(biphenyl-4-yl)-4-((R)-3-(3-(3-methoxypropyl)-3H-imidazo[4,5-c]pyridin-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (39G) was recovered as a clear oil (0.09 mmol, 0.055 g, 39% yield). (ESI-MS: m/z 612.4 (M+H)⁺. (R)-3-amino-4-(biphenyl-4-yl)-1((R)-3-(3-(3-methoxypropyl)-3H-imidazo[4,5-c]pyridin-2-yl)piperidin-1-yl)butan-1-one (103) was isolated as a clear oil (0.035 mmol, 0.022 g, 15% yield). This oil was re-dissolved in CH₃CN (1 mL) and water (2 mL). The resultant solution was frozen and lyophilized to afford Compound 103 as its trifluoroacetic acid salt and as a white flocculent solid. 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.41-1.61 (m, 1H) 1.70-2.20 (m, 5H) 2.60-2.86 (m, 3H) 2.88-3.38 (m, 10H) 3.76-4.09 (m, 2H) 4.34-4.65 (m, 2H) 7.29-7.41 (m, 3H) 7.42-7.51 (m, 2H) 7.56-7.71 (m, 4H) 8.09 (t, J=6.06 Hz, 1H) 8.57 (t, J=6.19 Hz, 1H) 9.38 (d, J=10.61Hz, 1H). ESI-MS: m/z 512.3 (M+H)⁺.

Example 37
Synthesis of (R)-3-amino-1((R)-3-(4-methoxy-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl-4-(naphthalen-2-yl)butan-1-one (104)

embedded image

Into a 25 mL round bottomed was added 1-fluoro-3-methoxy-2-nitrobenzene (500 mg, 2.92 mmol) and N,N-dimethylforamide (5.8 mL). The flask was cooled to −15° C. and 3-methoxypropylamine (313 mg, 3.5 mmol) in N,N-dimethylforamide (2.2 mL) was slowly added. The reaction was allowed to warm to room temperature overnight. Solvent was removed under vacuum and the residue was purified by column chromatography (20% ethylacetate:hexanes) to give 3-methoxy-N-(3-methoxypropyl)-2-nitroaniline (37A) as a yellow oil (560 mg, 80% yield). ESI-MS:m/z 241.3 (M+H)⁺.

embedded image

Into a 100 mL round bottomed flask was added 3-methoxy-N-(3-methoxypropyl)-2-nitroaniline (36A) (560 mg, 2.33 mmol) and methanol (46 mL). Zinc metal (2.11 g, 32.4 mmol) and acetic acid (2.0 mL) was added and the mixture was stirred at room temperature for 5 hr. The mixture was filtered through a fritted Buchner funnel and the solvent was removed under vacuum. Ethyl acetate (100 mL) was added and the precipitate was filtered through a Buchner funnel with a pad of Celite. The filtrate was concentrated under vacuum to leave 3-methoxy-N¹-(3-methoxypropyl)benzene-1,2-diamine (37B) as a yellow oil which was used without further purification. ESI-MS:mlz 211.4 (M-F1-1)⁺.

embedded image

The residue 37B was dissolved in N,N-dimethylforamide (12 mL). HOSt (241 mg, 1.78 mmol), EDC (341 mg, 1.78 mmol), and (R)-1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid (409 mg, 1.78 mmol) were added and stirred overnight at room temperature. The solvent was removed under vacuum and the residue was partitioned between water (25 mL) and ethyl acetate (25 mL). The organic layer was separated and the aqueous was extracted with ethyl acetate (2×25 mL). The organics were combined and washed with 1N NaOH (25 mL). The organics were dried over sodium sulfate and filtered. Solvent was removed under vacuum and the residue (R)-tert-butyl 3-(2-methoxy-6-(3-methoxypropylamino)phenylcarbamoyl)piperidine-1-carboxylate (37C) was taken into the next step without further purification. ESI-MS:mlz 422.5 (M+H)⁺.

embedded image

The residue (37C) was dissolved with acetic acid (15 mL) and heated to 80° C. for 4 hr. Solvent was removed under vacuum. The residue containing (R)-ter(R)-tert-butyl 3-(4-methoxy-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (37D) was used in the next step with out further purification. ESI-MS:m/z 404.5 (M+H)⁺.

embedded image

Into a 10 mL round bottomed was added (R)-ter(R)-tert-butyl 3-(4-methoxy-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (36D), 25% trifluoroacetic acid in dichloromethane (5 mL) was added and stirred at room temperature for 3 hrs. The solvent was removed under vacuum. The residue containing (R)-4-methoxy-1-(3-methoxypropyl)-2-(piperidin-3-yl)-1H-benzo[d]imidazole (37E) was used in the next step without purification. ESI-MS:m/z 303.2 (M+H)⁺.

embedded image

(R)-4-methoxy-1-(3-methoxypropyl)-2-(piperidin-3-yl)-1H-benzo[d]imidazole (37E) (133 mg, 438 μmol) was dissolved with 2:1 acetonitrile:dichloromethane (2.2 mL). (R)-3-(tert-butoxycarbonylamino)-4-(naphthalen-2-yl)butanoic acid (159 mg, 482 μmol) in 2:1 acetonitrile:dichloromethane (2.3 mL) was added. HOBt (65 mg, 482 μmol) in DMF (2.3 mL) was added. Into a fritted syringe was added PS-carbodiimide resin (1.31 mmol/g, 669 mg). The amine, acid and HOBt solutions were taken up in the syringe and capped. The mixture was shaken overnight at room temperature. The solution was expelled into a round bottomed and the solvent was removed under vacuum. The residue containing tert-butyl (R)-4-((R)-3-(4-methoxy-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate. (37F) was taken into the next step without further purification. ESI-MS:m/z 615.5 (M+H)⁺.

embedded image

tert-Butyl (R)-4-((R)-3-(4-methoxy-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (37F) was dissolved in 25% trifluoroacetic acid and stirred at room temperature for 3 hr. Solvent was removed under vacuum and purified by preparatory LC/MS (25-30% CH₃CN in H₂O) to give (R)-3-amino-1((R)-3-(4-methoxy-1-(3-methoxypropyl)-1H-benzokflimidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butari-1-one (104) as a TFA salt (35 mg, 13%). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.45 (br. s., 1H) 1.78 (m, 2H) 1.88-2.18 (m, 3H) 2.53-2.79 (m, 3H) 2.86-3.50 (m, 9H) 3.82 (br. s., 2H) 4.00 (m, 3H) 4.05-4.70 (m, 3H) 7.07 (m, 1H) 7.34-7.58 (m, 5H) 7.76-7.95 (m, 4 H). ESI-MS:m/z 515.4 (M+H)⁺.

Example 38
Synthesis of (R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-5-methyl-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (105)

embedded image

N-(3-Methoxypropyl)-4-methyl-2-nitroaniline (38A) was prepared as described in Example 37, Step A. ESI-MS:m/z 225.4 (M+H)⁺.

embedded image

N1-(3-Methoxypropyl)-4-methylbenzene-1,2-diamine (38B) was prepared as described in Example 37, Step B. ESI-MS:m/z 195.4 (M+H)⁺.

embedded image

(R)-tert-Butyl 3-(2-(3-methoxypropylamino)-5-methylphenylcarbamoyl)piperidine-1-carboxylate (38C) was prepared as described in Example 37, Step C. ESI-MS:m/z 406.5 (M+H)⁺.

embedded image

(R)-tert-Butyl 3-(1-(3-methoxypropyl)-5-methyl-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (38D) was prepared as described in Example 37, Step D. ESI-MS:m/z 288.4 (M+H)⁺.

embedded image

(R)-1-(3-Methoxypropyl)-5-methyl-2-(piperidin-3-yl)-1H-benzo[d]imidazole (38E) was prepared as described in Example 37, Step E. ESI-MS:mlz 288.4 (M+H)⁺.

embedded image

tert-Butyl (R)-4-((R)-3-(1-(3-met h ox ypropyl)-5-methyl-1H-benzoldlimidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (38F) was prepared as described in Example 37, Step F. ESI-MS:mlz 599.5 (M+H)⁺.

embedded image

Compound 105 was prepared as described in Example 37, Step G. Purified by preparatory LC/MS (25-25% CH₃CN in H₂O) gave (R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-5-methyl-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (105) as a TFA salt (131 mg, 36% yield). 111 NMR (400 MHz, DMSO-d₆) δ ppm 1.38-1.62 (m, 1H) 1.71-2.22 (m, 5H) 2.47-2.49 (m, 2H) 2.57-2.77 (m, 2H) 2.87-3.47 (m, 9H) 3.78 (m, 2H) 3.97 (s, 2H) 4.08-4.69 (m, 3H) 7.30-7.59 (m, 5H) 7.69-7.95 (m, 5H). ESI-MS:m/z 499.5 (M+H)⁺.

Example 39
Synthesis of (R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-4-methyl-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (106) and (R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-7-methyl-1H-benzoicljimidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (107)

embedded image

Into a microwave vial was added 3-methylbenzene-1,2-diamine (150 mg, 1.23 mmol) and (R)-1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid (281 mg, 1.23 mmol). The mixture was dissolved with pyridine (6.2 mL). Triphenylphosphite (469 mg, 1.51 mmol) was added and the vial was capped. The reaction was microwaved at 220° C. for 10 minutes. Solvent was removed under vacuum and the residue was purified by preparatory LC/MS (20-30% CH₃CN in H₂O) to give (R)-tert-butyl 3-(4-methyl-1H-benzo[d]imidazol-2-yl)piperidine-1-carb oxylate (39A) (80 mg, 21% yield). ESI-MS:m/z 316.4 (M+H)⁺.

embedded image

Into a 10 mL round bottomed was added (R)-tert-butyl 3-(4-methyl-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (39A). 25% trifluoroacetic acid in dichloromethane (5 mL) was added and stirred at room temperature for 3 hr. The solvent was removed under vacuum and the residue containing (R)-4-methyl-2-(piperidin-3-yl)-1H-benzo[d]imidazole (39B) was used in the next step without purification. ESI-MS:m/z 215.1 (M+H)⁺.

embedded image

(R)-4-Methyl-2-(piperidin-3-yl)-1H-benzo[d]imidazole (80 mg, 372 μmol) was dissolved in 2:1 acetonitrile:dichloromethane (1.9 mL). (R)-3-(tert-butoxycarbonylamino)-4-(naphthalen-2-yl)butanoic acid (135 mg, 409 μmol) in 2:1 acetonitrile:dichloromethane (2.0 mL) was added. HOBt (55 mg, 409 μmol in DMF (4.1 mL) was added. Into a fritted syringe was added PS-carbodiimide resin (975 mg, 1.34 mmol. The amine, acid and HOBt solutions were taken up in the syringe and capped. The mixture was shaken overnight at room temperature. The solution was expelled into a round bottomed and the solvent was removed under vacuum. The residue containing tert-butyl (R)-4-((R)-3-(4-methyl-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (39C) was taken into the next step without further purification. ESI-MS:mlz 527.5 (M+H)⁺.

embedded image

Into a 10 mL round bottomed flask was added tert-butyl (R)-4-((R)-3-(4-methyl-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (39C) (68 mg, 129 μmol) and N,N-dimethylforamide (0.5 mL). NaI (25 mg, 168 μmol) and NaH (7 mg, 168 μmol, 60% disp.) were added in sequence. The mixture was stirred for 30 minutes at room temperature. 3-Methoxypropyl bromide (26 mg, 168 μmol) was added at once and stirred overnight at room temperature. Solvent was removed under vacuum and the residue containing tert-butyl (R)-4-((R)-3-(1-(3-methoxypropyl)-4-methyl-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (39D¹) and tert-butyl (R)-4-((R)-3-(1-(3-methoxypropyl)-7-methyl-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (39D²) used without further purification. ESI-MS:m/z 599.5 (M+H)⁺.

embedded image

The residue from Step D above was dissolved in 25% trifluoroacetic acid and stirred at room temperature for 3 hrs. The solvent was removed in-vacuo affording a clear colored oil that the regioisomers were further separated by Berger Prep/SFC under the conditions: column: ChiralPak AD-H (5 μm, 21.2×250 mm); mobile phases: A is liquid CO₂, B is 10 mM NH₄OAc in EtOH; flow rate: 50 mL/min; gradient: 17% B; run time: 52 min (half-stack-injection method applied); and Prep injection volume: 500 μL. The resultant regioisomers:

Compound 106: (R)-3-Amino-1-((R)-3-(1-(3-methoxypropyl)-4-methyl-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (15 mg, 23% yield). ESI-MS: m/z 498.3 (M+H)⁺.

Compound 107: (R)-3-Amino-1-((R)-3-(1-(3-methoxypropyl)-7-methyl-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (8 mg, 13% yield). ESI-MS:mlz 498.3 (M+H)⁺.

Example 40
Synthesis of (R)-3-amino-1((R)-3-(4-methoxy-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (104) and (R)-3-amino-1-((R)-3-(7-methoxy-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (108)

embedded image

3-Methoxybenzene-1,2-diamine (920 mg, 6.66 mmol) was dissolved in N,N-dimethylforamide (6.7 mL). HOBt (1.08 g, 7.99 mmol), EDC (1.53 g, 7.99 mmol), and ®-1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid (1.83 g, 7.99 mmol) were added and stirred overnight at room temperature. The solvent was removed under vacuum and the residue was partitioned between water (25 mL) and ethyl acetate (25 mL). The organic layer was separated and the aqueous was extracted with ethyl acetate (2×25 mL). The organics were combined and washed with 1N NaOH (25 mL). The organics were dried over sodium sulfate and filtered. Solvent was removed under vacuum and the residue containing ®-tert-butyl 3-(2-Amino-3-methoxyphenylcarbamoyl)piperidine-1-carboxylate (40A) was taken into the next step without further purification. ESI-MS:m/z 350.4 (M+H)⁺.

embedded image

The residue from Step A was dissolved with acetic acid (15 mL) and heated to 80° C. for 4 hr. Solvent was removed under vacuum. The residue containing (R)-tert-butyl 3-(4-methoxy-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (40B) was used in the next step without further purification. ESI-MS:m/z 332.5 (M+H)⁺.

embedded image

Into a 10 mL round bottomed was added (R)-tert-butyl 3-(4-methoxy-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (40B). 25% trifluoroacetic acid in dichloromethane (5 mL) was added and stirred at room temperature for 3 hr. The solvent was removed under vacuum. The residue containing (R)-4-Methoxy-2-(piperidin-3-yl)-1H-benzo[d]imidazole (40B) was used in the next step without purification. ESI-MS:m/z 232.4 (M+H)⁺.

embedded image

(R)-4-Methoxy-2-(piperidin-3-yl)-1H-benzo[d]imidazole (140 mg, 603 vmol) was dissolved with 2:1 acetonitrile:dichloromethane (3.0 mL). (R)-3-(tert-butoxycarbonylamino)-4-(naphthalen-2-yl)butanoic acid (218 mg, 663 μmol) in 2:1 acetonitrile:dichloromethane (3.3 mL) was added. HOBt (90 mg, 663 μmol) in DMF (3.3 mL) was added. Into a fritted syringe was added PS-carbodiimide resin (1.31 mmol/g, 921 mg). The amine, acid and HOBt solutions were taken up in the syringe and capped. The mixture was shaken overnight at room temperature. The solution was expelled into a round bottomed and the solvent was removed under vacuum. The residue containing tert-butyl (R)-4-((R)-3-(4-methoxy-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (40D) was taken into the next step without further purification. ESI-MS:mlz 542.3 (M+H)⁺.

embedded image

Into a 10 mL round bottomed was added the residue containing 40D from Step D (180 mg, 332 μmol) and N,N-dimethylforamide (1.7 mL). NaI (75 mg, 497 μmol) and NaH (20 mg, 497 μmol, 60% disp.) were added in sequence. The mixture was stirred for 30 minutes at room temperature. 3-Methoxy propyl bromide (76 mg, 497 μmol) was added at once and stirred overnight at room temperature. Solvent was removed under vacuum and the residue containing the mixture of tert-butyl (R)-4-((R)-3-(4-methoxy-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (40E¹) and tert-butyl (R)-4-((R)-3-(7-methoxy-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (40E²) used without further purification. ESI-MS:m/z 615.5 (M+H)⁺.

embedded image

Residue from Step E was dissolved in 25% trifluoroacetic acid and stirred at room temperature for 3 hr. Solvent was removed under vacuum and purified by preparatory LC/MS (25-30% CH₃CN in H₂O) to give (R)-3-amino-1((R)-3-(4-methoxy-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (104) and (R)-3-amino-1-((R)-3-(7-methoxy-1-(3-methoxypropyl)-1H-benzo[c]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (108) as a mixture of TFA salts (11 mg, 5% yield). ESI-MS:m/z 515.4 (M+H)⁺.

Example 41
Synthesis of 24(R)-1((R)-3-amino-4-(naphthalen-2-yl)butanoyl)piperidin-3-yl)-1-(3-methoxypropyl)-1H-benzo[d]imidazole-6-carbonitrile (109)

embedded image

3-Fluoro-4-nitrobenzonitrile (3.50 mmol, 581 mg) in CH₂Cl₂(12 mL) was added Et₃N (3.85 mmol, 0.54 mL) at −15° C. The reaction solution was stirred at −15° C. for 30 min. To the reaction solution was added 3-methoxypropan-1-amine (3.50 mmole, 0.36 mL) and stirred at −15° C. for 30 min. The cooling bath was removed to let the reaction solution warm to rt and kept stirring at rt for 30 min. The reaction solution containing 3-(3-methoxypropylamino)-4-nitrobenzonitrile (41A) was concentrated in vacuo and carried directly on to the next step without further purification. ESI-MS: m/z 236.3 (M+H)⁺.

embedded image

3-(3-Methoxypropylamino)-4-nitrobenzonitrile (41A) (3.50 mmol, 823 mg) in MeOH (15 mL) was added HOAc (glacial, 1.5 mL) and Zn (dust, 17.50 mmol, 1.14 g). The reaction mixture was stirred at rt overnight. The reaction mixture was filtered over Celite 500 and then concentrated in vacuo. The residue was dissolved in EtOAc, washed with H₂O, NaOH (1N) and brine, dried over MgSO₄and filtered. The filtrate containing 4-amino-3-(3-methoxypropylamino)benzonitrile (41B) was concentrated in vacuo and carried directly on to the next step without further purification. ESI-MS: m/z 206.4 (M+H)⁺.

embedded image

4-Amino-3-(3-methoxypropylamino)benzonitrile (41B) (3.50 mmol, 718 mg) in DMF (25 mL) was added (R)-(−)—N-Boc-Nipecotic acid (4.55 mmol, 1.04 g) and N-methylmotpholine (10.50 mmol, 1.15 mL). The reaction mixture was stirred at rt for 5 min and then added HATU (5.25 mmol, 2.00 g) and kept stirring at rt overnight. The reaction mixture was poured into H₂O, extracted with EtOAc. The extract was washed with H₂O, NaHCO₃, brine, dried over MgSO₄and filtered. The filtrate was concentrated in vacuo and purified by flash chromatography (silica gel EtOAc-hexane: 1:2) to afford (R)-tert-butyl 3-(4-cyano-2-(3-methoxypropylamino)phenylcarbamoyl)piperidine-1-carboxylate (41C) (2.40 mmol, 1.01 g, three-step yield: 68.6%). ESI-MS: m/z 417.5 (M+H)⁺.

embedded image

(R)-tert-Butyl 3-(4-cyano-2-(3-methoxypropylamino)phenylcarbamoyl)piperidine-1-carboxylate (41C) (2.40 mmol, 1.00 g) was added HOAc (glacial, 3 mL). The reaction mixture was heated to 80° C. and stirred for 7 hr. HOAc was removed by evaporation and the residue was purified by flash chromatography (silica gel EtOAc-hexane: 1:4) to afford (R)-tert-butyl 3-(6-cyano-1-(3-methoxypropyl)-1H-benzo[d]iimidazol-2-yl)piperidine-1-carboxylate (41D) (0.20 mmol, 80 mg, yield: 8.3%). ESI-MS: m/z 399.4 (M+H)⁺.

embedded image

(R)-tert-Butyl 3-(6-cyano-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (41D) (0.20 mmol, 80 mg) in DCM (10 mL) was added TFA (2 mL). The reaction solution was stirred at rt for 1 hr and then concentrated in vacuo. The residue containing (R)-1-(3-Methoxypropyl)-2-(piperidin-3-yl)-1H-benzo[d]imidazole-6-carbonitrile (41E) was carried directly on to the next step without further purification. ESI-MS: m/z 236.3 (M+H)⁺.

embedded image

(R)-1-(3-Methoxypropyl)-2-(piperidin-3-yl)-1H-benzo[d]imidazole-6-carbonitrile (41E) (0.20 mmol, 80 mg) in DMF (6 mL) was added (R)-3-(tert-butoxycarbonylamino)-4-(naphthalen-2-yl)butanoic acid (0.22 mmol, 72 mg) and N-methylmorpholine (0.80 mmol, 0.09 mL). The reaction mixture was stirred at it for 5 min and then added HATU (0.22 mmol, 84 mg) and kept stirring at it overnight. The reaction mixture was poured into H₂O, extracted with EtOAc. The extract was washed with H₂O, NaHCO₃, brine, dried over MgSO₄and filtered. The filtrate was concentrated in vacuo and purified by preparative LC/MS (40-90% CH₃CN in H₂O) to afford tert-Butyl (R)-4-((R)-3-(6-cyano-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (41F) (0.16 mmol, 100 mg, yield: 80%). ESI-MS: m/z 610.5 (M+H)⁺.

embedded image

tert-Butyl(R)-4-((R)-3-(6-cyano-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (41F) (0.16 mmol, 98 mg) in DCM (2 mL) was added TEA (2 mL). The reaction solution was stirred at rt for 1 hr and then concentrated in vacuo. The residue was purified by preparative LC/MS (20-50% CH₃CN in H₂O) to afford 2-((R)-1-((R)-3-amino-4-(naphthalen-2-yl)butanoyl)piperidin-3-yl)-1-(3-methoxypropyl)-1H-benzo[d]imidazole-6-carbonitrite (109) (0.14 mmol, 71 mg, yield: 87.5%). ESI-MS: m/z 510.5 (M+H)⁺. 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.28 (none, 1H) 1.68-2.05 (m, 3H) 2.33 (m, 2H) 2.64-2.77 (m, 2H) 2.89-3.23 (m, 7H) 3.29 (t, J=5.81Hz, 1H) 3.42 (dd, J=14.15, 11.18 Hz, 3H) 3.71-3.98 (m, 2H) 4.14-4.24 (m, 2H) 4.31-4.53 (m, 2H) 7.41-7.47 (m, 1H) 7.49-7.55 (m, 2H) 7.55-7.61 (m, 1H) 7.67-7.77 (m, 1H) 7.80 (d, J=4.67 Hz, 1 H) 7.82-7.96 (m, 3H) 8.17 (d, J=5.75 Hz, 1H).

Example 42
Synthesis of (R)-3-amino-1((R)-3-(6-methoxy-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (110)

embedded image

3-Fluoro-4-nitroanisole (3.50 mmol, 599 mg) in CH₂Cl₂(12 mL) was added Et₃N (3.85 mmol, 0.54 mL) at −15° C. The reaction solution was stirred at −15° C. for 30 min. To the reaction solution was added 3-methoxypropan-1-amine (3.50 mmole, 0.36 mL) and stirred at −15° C. for 30 min. The cooling bath was removed to let the reaction solution warm to it and kept stirring at it for 30 min. The reaction solution containing 5-methoxy-N-(3-methoxypropyl)-2-nitroaniline (42A) was concentrated in vacuo and carried directly on to the next step without further purification. ESI-MS: m/z 241.3 (M+H)⁺.

embedded image

5-Methoxy-N-(3-methoxypropyl)-2-nitroaniline (42A) (3.50 mmol, 841 mg) in MeOH (15 mL) was added HOAc (glacial, 1.5 mL) and Zn (dust, 17.50 mmol, 1.14 g). The reaction mixture was stirred at it overnight. The reaction mixture was filtered over Celite 500 and then concentrated in vacuo. The residue was dissolved in EtOAc, washed with HAD, NaOH (1N) and brine, dried over MgSO₄and filtered. The filtrate containing 5-methoxy-N^t-(3-methoxypropyl)benzene-1,2-diamine (41B) was concentrated in vacuo and carried directly on to the next step without further purification. ESI-MS: m/z 211.4 (M+H)⁺.

embedded image

5-Methoxy-N¹-(3-methoxypropyl)benzene-1,2-diamine (42B) (1.81 mmol, 380 mg) in DMF (20 mL) was added (R)-(−)-N-Boc-nipecotic acid (2.35 mmol, 541 mg) and N-methylmorpholine (5.43 mmol, 0.60 mL). The reaction mixture was stirred at rt for 5 min and then added HATU (2.72 mmol, 1.03 g) and kept stirring at rt overnight. The reaction mixture was poured into H₂O, extracted with EtOAc. The extract was washed with H₂O, NaHCO₃, brine, dried over MgSO₄and filtered. The filtrate was concentrated in vacuo and purified by flash chromatography (silica gel, EtOAc-hexane: 1:2) to afford (R)-tert-butyl 3-(4-methoxy-2-(3-methoxypropylamino)phenylcarbarnoyl)piperidine-1-carboxylate (42C) (2.82 mmol, 1.19 g, three-step yield: 80.6%). ESI-MS: m/z 422.5 (M+H)⁺.

embedded image

(R)-tert-Butyl 3-(4-methoxy-2-(3-methoxypropylamino)phenylcarbamoyl)piperidine-1-carboxylate (42C) (2.82 mmol, 1.19 g) was added HOAc (glacial, 4.0 mL). The reaction mixture was heated to 80° C. and stirred for 7 hr. The reaction solution containing (R)-tert-butyl 3-(6-methoxy-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (420) was concentrated in vacuo and carried directly on to the next step without further purification. ESI-MS: m/z 404.5 (M+H)⁺.

embedded image

(R)-tert-Butyl 3-(6-methoxy-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (42D) (2.82 mmol, 1.14 g) in DCM (10 mL) was added TFA (3 mL). The reaction solution was stirred at rt for 1 hr and then concentrated in vacuo. The residue containing (R)-6-methoxy-1-(3-methoxypropyl)-2-(piperidin-3-yl)-1H-benzo[d]imidazole (42E) was carried directly on to the next step without further purification. ESI-MS: m/z 304.4 (M+H)⁺.

embedded image

(R)-6-Methoxy-1-(3-methoxypropyl)-2-(piperidin-3-yl)-1H-benzo[d]imidazole (41E) (2.82 mmol, 0.86 g) in DMF (16 mL) was added (R)-3-(tert-butoxycarbonylamino)-4-(naphthalen-2-yl)butanoic acid (3.10 mmol, 1.02 g) and N-methylmorpholine (11.28 mmol, 1.24 mL). The reaction mixture was stirred at rt for 5 min and then added HATU (3.10 mmol, 1.18 g) and kept stirring at rt overnight. The reaction mixture was poured into H₂O, extracted with EtOAc. The extract was washed with H₂O, NaHCO₃, brine, dried over MgSO₄and filtered. The filtrate was concentrated in vacuo and purified by preparative LC/MS (40-90% CH₃CN in H₂O) to afford tert-butyl (R)-4-((R)-3-(6-methoxy-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (42F) (0.63 mmol, 0.387 g, three-step yield: 22.3%). ESI-MS: m/z 616.5 (M+H)⁺.

embedded image

tert-Butyl (R)-4-((R)-3-(6-methoxy-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (42F) (0.63 mmol, 387 mg) in DCM (15 mL) was added TEA (3 mL). The reaction solution was stirred at rt for 1 hr and then concentrated in vacuo. The residue was purified by preparative LC/MS (20-50% CH₃CN in H₂O) to afford (R)-3-amino-1((R)-3-(6-methoxy-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (110) (0.05 mmol, 27 mg, yield: 7.9%). ESI-MS: m/z 515.5 (M+H)⁺. 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.38-1.56 (m, 1H) 1.72-1.99 (m, 4H) 2.01-2.21 (m, 2H) 2.58-2.77 (m, 3H) 2.87-2.98 (m, 1H) 3.01-3.25 (m, 7H) 3.37 (t, J=5.75 Hz, 2H) 3.82 (d, 0.1=10.23 Hz, 2H) 3.88 (d, J=7.07 Hz, 3H) 4.05-4.69 (m, 3H) 7.04-7.12 (m, 1H) 7.35 (d, J=13.07 Hz, 1H) 7.45 (dd, J=8.46, 2.72 Hz, 1H) 7.48-7.55 (m, 2H) 7.64 (t, J=9.69 Hz, 1H) 7.80 (d, J=6.06 Hz, 1H) 7.83-8.03 (m, 3H).

Example 43
Synthesis of methyl 2-(1-((R)-3-amino-4-(naphthalen-2-yl)butanoyl)piperidin-3-yl)-1-(3-methoxypropyl)-1H-benzo[d]imidazole-6-carboxylate (111)

embedded image

Methyl 3-fluoro-4-nitrobenzoate (10.14 mmol, 2.02 g) in CH₂Cl₂(12 mL) was added Et₃N (11.15 mmol, 1.57 mL) at −15° C. The reaction solution was stirred at −15° C. for 30 min, To the reaction solution was added 3-methoxypropan-1-amine (11.2 mmole, 1.15 mL) and stirred at −15° C. for 30 min. The cooling bath was removed to let the reaction solution warm to rt and kept stirring at rt for 30 min. The reaction solution containing methyl 3-(3-methoxypropylamino)-4-nitrobenzoate (43B) was concentrated in vacuo and carried directly on to the next step without further purification. ESI-MS: m/z 269.3 (M+H)⁺.

embedded image

Methyl 3-(3-methoxypropylamino)-4-nitrobenzoate (43A) (4.00 mmol, 1.07 g) in EtOH (30 mL) was added tert-butyl 3-formylpiperidine-1-carboxylate (4.00 mmol, 0.85 g) and Na₂S₂O₄solution (12.0 mmol, 2.09 g in 12 mL H₂O). The reaction mixture was heated at 80° C. for 5 hrs and then poured into H₂O, extracted with EtOAc. The extract was washed with H₂O, brine, dried over MgSO₄and filtered. The filtrate containing methyl 2-(1-(tert-butoxycarbonyl)piperidin-3-yl)-1-(3-methoxypropyl)-1H-benzo[d]imidazole-6-carboxylate (43B) was concentrated in vacuo and carried directly on to the next step without further purification. ESI-MS: m/z 432.4 (M+H)⁺.

embedded image

Methyl 2-(1-(tert-bu toxycarbonyl)piperidin-3-yl)-1-(3-methoxypropyl)-1H-benzo[d]imidazole-6-carboxylate (43B) (3.10 mmol, 1.25 g) in DCM (10 mL) was added TFA (2 mL). The reaction solution was stirred at rt for 1 hr and then concentrated in vacuo. The residue was purified by preparative LC/MS (15-40% CH₃CN in H₂O) to afford methyl 1-(3-methoxypropyl)-2-(piperidin-3-yl)-1H-benzo[d]imidazole-6-carboxylate (43C) (1.48 mmol, 490 mg, yield: 47.7%). ESI-MS: m/z 332.4 (M+H)⁺.

embedded image

Methyl 1-(3-methoxypropyl)-2-(pi peridin-3-yl)-1H-benzo[d]imidazole-6-carboxylate (43C) (1.45 mmol, 0.480 g) in DMF (20 mL) was added (R)-3-(tert-butoxycarbonylamino)-4-(naphthalene-2-yl)butanoic acid (1.60 mmol, 0.527 g) and N-methylmorpholine (5.80 mmol, 0.64 mL). The reaction mixture was stirred at rt for 5 min and then added HATU (1.60 mmol, 0.608 g) and kept stirring at rt overnight. The reaction mixture was poured into H₂O, extracted with EtOAc. The extract was washed with H₂O, NaHCO₃, brine, dried over Mg80₄and filtered. The filtrate was concentrated in vacuo and purified by preparative LC/MS (50-80% CH₃CN in H₂O) to afford methyl 2-(1-((R)-3-(tert-butoxycarbonylamino)-4-(naphthalene-2-yl)butan oyl)butano yl)piperi dine-3-yl)-1-(3-methoxypropyl)-1H-benzo[d]imidazole-6-carboxylate (43D) (1.09 mmol, 0.70 g, yield: 75.2%). ESI-MS: m/z 643.5 (M+H)⁺.

embedded image

Methyl 2-(1-((R)-3-(tert-butoxycarbonylamino)-4-(naphthalen-2-yl)butanoyl)piperidin-3-yl)-1-(3-methoxypropyl)-1H-benzo[d]imidazole-6-carboxylate (43D) (0.22 mmol, 140 mg) in DCM (10 mL) was added TEA (2 mL). The reaction solution was stirred at rt for 1 hr and then concentrated in vacuo. The residue was purified by preparative LC/MS (20-50% CH₃CN in H₂O) to afford methyl 2-(14(R)-3-amino-4-(naphthalen-2-yl)butanoyl)piperidin-3-yl)-1-(3-methoxypropyl)-1H-benzo[d]imidazole-6-carboxylate (111) (0.05 mmol, 26 mg, yield: 22.7%). ESI-MS: m/z 543.5 (M+H)⁺. 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.70-2.12 (m, 6H) 2.70 (d, J=6.51Hz, 3H) 2.87-3.06 (m, 2H) 3.06-3.19 (m, 4H) 3.19-3.25 (m, 2H) 3.30 (t, J=5.62 Hz, 1H) 3.27-3.32 (m, 1H) 3.74-3.85 (m, 2H) 3.89 (d, J=6.88 Hz, 3H) 3.96 (s, 1H) 4.18-4.60 (m, 3H) 7.44 (dd, J=9.03, 6.13 Hz, 1H) 7.48-7.56 (m, 2H) 7.63-7.72 (m, 1H) 7.80 (d, J=7.39 Hz, 1H) 7.84 (dd, J=8.91, 2.08 Hz, 2H) 7.87-7.95 (m, 3H).

Example 44
Synthesis of methyl 2-(1-((R)-3-amino-4-(naphthalen-2-yl)butanoyl)piperidin-3-yl)-1-(3-methoxypropyl)-1H-benzo[d]imidazole-7-carboxylate (112)

embedded image

Methyl 2-amino-3-nitrobenzoate (3.82 mmol, 0.75 g) in DMF (20 mL) was added NaI (8.40 mmol, 1.26 g). The reaction solution was stirred at 0° C. for 5 min and then added NaH (5.00 mmol, 0.20 g) at 0° C. The reaction solution was stirred at 0° C. for 30 min and then added 1-bromo-3-methoxypropane (5.00 mmol, 0.77 g). The reaction solution was heated to 80° C. and kept stirring at 80° C. for 6 hr. After cooling down the reaction solution was poured into H₂O, extracted with EtOAc. The extract was washed with H₂O, brine dried over MgSO₄and filtered. The filtrate was concentrated in vacuo and purified by flash chromatography (silica gel, EtOAc-hexane: 5:95) to afford methyl 2-(3-methoxypropylamino)-3-nitrobenzoate (44A) (1.49 mmol, 800 mg, yield: 78.1%). ESI-MS: m/z 269.3 (M+H)⁺.

embedded image

Methyl 2-(3-methoxypropylamino)-3-nitrobenzoate (3.82 mmol, 1.02 g) (44A) in EtOH (30 mL) was added tert-butyl 3-formylpiperidine-1-carboxylate (3.82 mmol, 0.82 g) and Na₂S₂O₄solution (11.46 mmol, 2.00 g in 12 mL H₂O). The reaction mixture was heated at 80° C. for 5 hrs and then poured into H₂O, extracted with EtOAc. The extract was washed with H₂O, brine, dried over MgSO₄and filtered. The filtrate containing methyl 2-(1-(tert-butoxycarbonyl)piperidin-3-yl)-1-(3-methoxypropyl)-1H-benzo[d]imidazole-7-carboxylate (44B) was concentrated in vacuo and carried directly on to the next step without further purification. ESI-MS: m/z 432.4 (M+H)⁺.

embedded image

Methyl 2-(1-(tert-butoxycarbonyl)piperidin-3-yl)-1-(3-methoxypropyl)-1H-benzo[d]imidazole-7-carboxylate (44B) (1.91 mmol, 400 mg) in DCM (10 mL) was added TFA (2 mL). The reaction solution was stirred at rt for 1 hr and then concentrated in vacuo. The residue was purified by preparative LC/MS (15-40% CH₃CN in H₂O) to afford methyl 1-(3-methoxypropyl)-2-(piperidin-3-yl)-1H-benzo[d]imidazole-7-carboxylate (44C) (0.36 mmol, 120 mg, yield: 18.8%). EST-MS: m/z 332.4 (M+H)⁺.

embedded image

Methyl 1-(3-methoxypropyl)-2-(piperidin-3-yl)-1H-benzo[d]imidazole-7-carboxylate (42C) (0.36 mmol, 120 mg) in DMF (10 mL) was added (R)-3-(tert-butoxycarbonylamino)-4-(naphthalen-2-yl)butanoic acid (0.40 mmol, 132 mg) and N-methylmorpholine (1.44 mmol, 0.16 mL). The reaction mixture was stirred at rt for 5 min and then added HATU (0.40 mmol, 152 mg) and kept stirring at rt overnight. The reaction mixture was poured into H₂O, extracted with EtOAc. The extract was washed with H₂O, NaHCO₃, brine, dried over MgSO₄and filtered. The filtrate was concentrated in vacuo and purified by preparative LC/MS (40-70% CH₃CN in H₂O) to afford methyl 2-(1-((R)-3-(tert-butoxycarbonylamino)-4-(naphthalen-2-yl)butanoyl)piperidin-3-yl)-1-(3-methoxypropyl)-1H-benzo[d]imidazole-7-carboxylate (44D) (0.06 mmol, 40 mg, yield: 16.7%). ESI-MS: m/z 643.5 (M+H)⁺.

embedded image

Methyl 2-(1-((R)-3-(tert-butoxycarbonylamino)-4-(naphthalen-2-yl)butanoyl)piperidin-3-yl)-1-(3-methoxypropyl)-1H-benzo[d]imidazole-7-carboxylate (440) (0.04 mmol, 25 mg) in DCM (5 mL) was added TEA (1 mL). The reaction solution was stirred at rt for 1 hr and then concentrated in vacuo. The residue was purified by preparative LC/MS (20-50% a CH₃CN in H₂O) to afford methyl 2-(1-((R)-3-amino-4-(naphthalen-2-yl)butanoyl)piperidin-3-yl)-1-(3-methoxypropyl)-1H-benzo[d]imidazole-7-carboxylate (112) (0.018 mmol, 10 mg, yield: 45.0%). ESI-MS: 543.5 m/z (M+H)⁺. ¹H NMR (400 MHz, MeOD) δ ppm 1.52-1.74 (m, 2H) 1.85-2.11 (m, 4H) 2.15-2.32 (m, 2H) 2.65 (s, 2H) 2.69-2.89 (m, 4H) 2.90-3.09 (m, 4H) 3.23 (s, 1H) 3.35 (t, J=5.53 Hz, 1H) 3.40-3.50 (m, 1H) 3.89 (d, J=13.83 Hz, 1H) 4.34-4.44 (m, 2H) 4.57 (dd, 2H) 4.66 (d, 0.1=13.07 Hz, 2H) 7.43 (t, J=8.12 Hz, 1H) 7.47-7.53 (m, 2H) 7.56 (t, J=8.72 Hz, 1H) 7.76-7.93 (m, 4H) 7.93-7.98 (m, 2H).

Example 45
Synthesis of (3R)-3-amino-1-(3-(6-(hydroxymethyl)-1-(3-methoxypropyl)-1,1-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (113)

embedded image

Methyl 2-(1-((R)-3-(tert-butoxycarbonylamino)-4-(naphthalen-2-yl)butanoyl)piperidin-3-yl)-1-(3-methoxypropyl)-1H-benzo[d]imidazole-6-carboxylate (0.12 mmol, 75 mg) in THF (10 mL) was added LiAlH₄(0.13 mmol, 4.9 mg) at 0° C. The reaction mixture was stirred at 0° C. for 30 min and then poured into sat. NaHCO₃, extracted with EtOAc. The extract was washed with brine, dried over MgSO₄and filtered. The filtrate containing tert-butyl (2R)-4-(3-(6-(hydroxymethyl)-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (45A) was concentrated in vacuo and carried directly on to the next step without further purification. ESI-MS: m/z 615.5 (M+H)⁺.

embedded image

tert-Butyl (2R)-4-(3-(6-(hydrox ymethyl)-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (45A) (0.20 mmol, 120 mg) in DCM (10 mL) was added TEA (2 mL). The reaction solution was stirred at rt for 1 hr and then concentrated in vacuo. The residue was purified by preparative LC/MS (5-45% CH₃CN in H₂O) to afford (3R)-3-amino-1-(3-(6-(hydroxymethyl)-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (113) (0.016 mmol, 8 mg, two-step yield: 13.3%). ESI-MS: m/z 515.5 (M+H)⁺. 1H NMR (400 MHz, MeOD) δ ppm 1.56-1.70 (m, 1H) 1.77-2.09 (m, 2H) 1.85-1.86 (m, 3H) 2.12-2.34 (m, 3H) 2.63-3.02 (m, 4H) 3.03-3.11 (m, 2H) 3.13 (d, J=7.26 Hz, 2H) 3.15-3.27 (m, 3H) 3.29 (s, 1H) 3.36-3.51 (m, 3H) 3.67-4.29 (m, 4H) 4.50-4.72 (m, 1H) 7.39-7.44 (m, 2H) 7.49 (ddd, J=9.32, 6.06, 2.81Hz, 3H) 7.56 (d, 0.7=8.65 Hz, 1H) 7.69-7.74 (m, 1H) 7.79-7.94 (m, 3H).

Example 46
Synthesis of (R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-6-nitro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (114) and (R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-7-nitro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (115)

embedded image

(R)-1((R)-3-(tert-Butoxycarbonylamino)-4-(naphthalen-2-yl)butanoyl)piperidine-3-carboxylic acid (0.454 mmol, 200 mg) in DMF (15 mL) was added 4-nitrobenzene-1,2-diamine (0.454 mmol, 77 mg) and N-methylmorpholine (1.36 mmol, 0.15 mL). The reaction mixture was stirred at rt for 5 min and then added HATU (0.50 mmol, 190 mg) and kept stirred at rt overnight. The reaction mixture was poured into H₂O, extracted with EtOAc. The extract was washed with H₂O, NaHCO₃, brine, dried over MgSO₄and filtered. The filtrate containing tert-Butyl (R)-4-((R)-3-(2-amino-4-nitrophenylcarbamoyl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (46A) was concentrated in vacuo and carried directly on to the next step without further purification. ESI-MS: m/z 576.4 (M+H)⁺.

embedded image

tert-Butyl (R)-4-((R)-3-(2-amino-4-nitrophenylcarbamoyl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylearbamate (0.045 mmol, 261 mg) was added HOAc (glacial, 4 mL). The reaction mixture was heated to 80° C. and stirred for 6 hr. HOAc was removed by evaporation and the residue was purified by preparative LC/MS (30-90% CH₃CN in H₂O) to afford a mixture of tert-butyl (R)-1-(naphthalen-2-yl)-4-((R)-3-(6-nitro-1H-benzokflimidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (46B¹) and ten-butyl (R)-1-(naphthalen-2-yl)-4-((R)-3-(5-n it ro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (46B²) (0.197 mmol, 110 mg, two-step yield: 43.4%). ESI-MS: m/z 558.5 (M+H)⁺.

embedded image

The mixture of tert-butyl (R)-1-(naphthalen-2-yl)-4-((R)-3-(6-nitro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (46B¹) and tert-butyl (R)-1-(naphthalen-2-yl)-4-((R)-3-(5-nitro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (46B²) (0.20 mmol, 110 mg) in DMF (15 mL) was added NaT (0.22 mmol, 33 mg). The reaction solution was stirred at 0° C. for 5 min and then added NaH (0.26 mmol, 10 mg) at 0° C. The reaction solution was stirred at 0° C. for 30 min and then added 1-bromo-3-methoxypropane (0.26 mmol, 39 mg). The reaction solution was heated to 80° C. and kept stirring at 80° C. for 4 hrs. After cooling down the reaction solution was poured into 1120, extracted with EtOAc. The extract was washed with H₂O, brine dried over MgSO₄and filtered. The filtrate containing tert-butyl (R)-4-((R)-3-(1-(3-methoxypropyl)-6-nitro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (46C¹) and tart-butyl (R)-4-((R)-3-(1-(3-methoxypropyl)-5-nitro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (46C²) was concentrated in vacuo and carried directly on to the next step without further purification. EST-MS: m/z 630.5 (M+H)⁺.

embedded image

A mixture of tert-butyl (R)-4-((R)-3-(1-(3-methoxypropyl)-6-nitro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (460 and tert-butyl (R)-4-((R)-3-(1-(3-methoxypropyl)-5-nitro-1H-benzoicijimidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (46C²) (0.20 mmol, 124 mg) in DCM (10 mL) was added TEA (2 mL). The reaction solution was stirred at rt for 1 hr and then concentrated in vacuo.

The residue was separated by preparative LC/MS (35-60% CH₃CN in H₂O) to afford the two regioisomers:

Compound 114: (R)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-6-nitro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (0.028 mmol, 15 mg, yield: 14.0%). ESI-MS: m/z 530.5 (M+H)⁺. 1H NMR (400 MHz, MeOD) δ ppm 1.35-1.70 (m, 1H) 1.71-1.90 (m, 1H) 1.91-2.08 (m, 4H) 2.19-2.32 (m, 2H) 2.66-3.08 (m, 4H) 3.08-3.20 (m, 4H) 3.20-3.28 (m, 4H) 3.33-3.46-3.51 (m, 3H) 3.62-4.07 (m, 2H) 4.11-4.36 (m, 1H) 7.34-7.45 (m, 2H) 7.46-7.56 (m, 1H) 7.64-7.74 (m, 1H) 7.78 (t, J=6.51Hz, 2H) 7.83-7.93 (m, 2H) 8.08-8.25 (m, 1H) 8.33-8.53 (m, 1H).

Compound 115: (R)-3-arni no-1-((R)-3-(1-(3-methoxypropyl)-5-nitro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (115) (0.043 mmol, 23 mg, yield: 21.5%). ESI-MS: m/z 530.5 (M+H)⁺. 1H NMR (400 MHz, MeOD) δ ppm 1.50-1.69 (m, 1H) 1.72-2.29 (m, 4H) 2.55-2.95 (m, 4H) 2.95-3.13 (m, 4H) 3.14-3.27 (m, 4H) 3.34-3.67 (m, 3H) 3.77-4.07 (m, 2H) 4.09-4.32 (m, 1H) 4.36-4.76 (m, 2H) 7.30-7.60 (m, 2H) 7.63-7.82 (m, 3H) 7.82-7.94 (m, 3H) 7.95-8.33 (m, 1H) 8.42-8.62 (m, 1H).

Example 47
Synthesis of (R)-3-amino-1((R)-3-(6-isopropyl-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-yl)-4-(naphthalen-2-yl)butan-1-one (116) and (R)-3-amino-1((R)-3-(5-isopropyl-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (117)

embedded image

(R)-1((R)-3-(tert-butoxycarbonylamino)-4-(naphthalen-2-yl)butanoyl)piperidine-3-carboxylic acid (0.454 mmol, 200 mg) in DMF (15 mL) was added 4-isopropylbenzene-1,2-diamine (0.454 mmol, 68 mg) and N-methylmorpholine (1.36 mmol, 0.15 mL). The reaction mixture was stirred at rt for 5 min and then added HATU (0.50 mmol, 190 mg) and kept stirring at rt overnight. The reaction mixture was poured into H₂O, extracted with EtOAc. The extract was washed with H₂O, NaHCO₃, brine, dried over MgSO₄and filtered. The filtrate containing Cert-butyl (R)-4-((R)-3-(2-amino-4-isopropylphenylcarbamoyl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (47A)was concentrated in vacuo and carried directly on to the next step without further purification. ESI-MS: m/z 573.5 (M+H)⁺.

embedded image

47A (0.454 mmol, 260 mg) was added HOAc (glacial, 4 mL). The reaction mixture was heated to 80° C. and stirred for 6 hr. HOAc was removed by evaporation and the residue was purified by preparative LC/MS (40-90% CH₃CN in H₂O) to afford a mixture of tert-butyl (R)-4-((R)-3-(6-isopropyl-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (47B¹) and tert-butyl (R)-4-((R)-3-(5-isopropyl-1H-benzo[d]imidazol-2-yl)piperidin-1-yl-1-(naphthalen-2-yl-4-oxobutan-2-ylcarbamate (47B²) (0.09 mmol, 50 mg, two-step yield: 19.8%). EST-MS: nilz 555.5 (M+H)⁺.

embedded image

To a mixture of 478¹and 47B²(0.09 mmol, 50 mg) in DMF (10 mL) was added NaI (0.10 mmol, 15 mg). The reaction solution was stirred at 0° C. for 5 min and then added NaH (0.12 mmol, 3 mg) at 0° C. The reaction solution was stirred at 0° C. for 30 min and then added 1-bromo-3-methoxypropane (0.12 mmol, 18 mg). The reaction solution was heated to 80° C. and kept stirring at 80° C. for 4 hrs. After cooling down the reaction solution was poured into H₂O, extracted with EtOAc. The extract was washed with H₂O, brine dried over MgSO₄and filtered. The filtrate containing Step C. tert-butyl (R)-4-((R)-3-(6-isopropyl-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (47C¹) and tert-butyl (R)-4-((R)-3-(5-isopropyl-1-(3-methoxypropyl)-1,1-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (47C²) was concentrated in vacuo and carried directly on to the next step without further purification. ESI-MS: m/z 627.6 (M+H)⁺.

embedded image

A mixture of 47C¹and 47C²(0.09 mmol, 56 mg) in DCM (10 mL) was added TEA (2 mL). The reaction solution was stirred at rt for 1 hr and then concentrated in vacuo. The residue was purified by preparative LC/MS (35-60% CH₃CN in H₂O) to afford a mixture of (R)-3-amino-1-((R)-3-(6-isopropyl-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (116) and (R)-3-amino-1-((R)-3-(5-isopropyl-1-(3-methoxypropyl)-1H-benz olagimidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (117) (0.059 mmol, 31 mg, two-step: 65.6%). ESI-MS: m/z 527.6 (M+H)⁺.

Example 48
Synthesis of (R)-3-amino-4-(biphenyl-4-yl)-1-((R)-3-(4-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (118)

embedded image

(R)-tert-Butyl3-(4-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (0.245 mmol, 0.100 g) was added to a 10 mL round-bottomed flask equipped for stirring under nitrogen. Dichloromethane (1 mL) and trifluoroacetic acid (1 mL) were then added and the resultant solution was allowed to stir under nitrogen for 4 hr. The reaction was then concentrated and dried in-vacuo affording (R)-4-chloro-1-(3-methoxypropyl)-2-(piperidin-3-yl)-1H-benzo[d]imidazole (48A) as a light brown oil that was used without further purification. ESI-MS: m/z 308.2 (M+H)⁺.

embedded image

(R)-4-chloro-1-(3-methoxypropyl)-2-(piperidin-3-yl)-1H-benzo[d]imidazole (0.245 mmol, crude oil) (48A) was added to a 15 mL round-bottomed flask equipped for stirring under nitrogen. DMF (2 mL), (R)-4-(4-bromophenyl)-3-(tert-butoxycarbonylamino)butanoic acid (0.319 mmol, 0.082 g) and N-methylmorpholine (1.47 mmol, 0.162 mL) were then added and the solution was allowed to stir at rt for 5 min. HATU (0.319 mmol, 0.121 g) was added and the resultant solution was stirred at room temperature for 3 hr. The reaction solution was then directly purified by preparative LC/MS (25-85% CH₃CN in H₂O). The resultant fractions were collected and the solvent was removed in-vacuo affording tert-Butyl (R)-1-(4-bromophenyl)-4-((R)-3-(4-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (48B) as a clear oil which was used without further quantification. ESI-ESI-MS: m/z 647.3 (M+H)⁺.

embedded image

tert-Butyl (R)-1-(4-bromophenyl)-4-((R)-3-(4-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (48B) (0.245 mmol, crude oil) and phenylboronic acid (0.294 mmol, 0.036 g) were added to a 5 mL microwave vessel equipped with a magnetic stir bar. Dioxane (2 mL) and Na₂CO₃(1 mL of a 2M in aq. soln.) were then added and the reaction vessel was flushed with nitrogen gas. PdCl₂(dppf) (0.025 mmol, 0.018 g) was added, the reaction vessel was sealed and placed in a microwave reactor and heated to 110° C. for 15 minutes. The reaction solution was then poured into water, extracted with ethyl acetate, and washed once with saturated aqueous sodium chloride. The organic layer was collected and subsequently dried with anhydrous Na₂SO₄and filtered. This filtrate was collected, concentrated, and dried in-vacuo. This crude material was directly purified by preparative LC/MS (25-85% CH₃CN in H₂O). The resultant fractions were collected and the solvent was removed in-vacuo affording tert-butyl (R)-1-(biphenyl-4-yl)-4-((R)-3-(4-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (48C) as a clear oil. ESI-MS: m/z 645.3 (M+H)⁺.

embedded image

tert-Butyl (R)-1-(biphenyl-4-yl)-4-((R)-3-(4-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (48C) (0.245 mmol, crude oil) was added to a 10 mL round-bottomed flask equipped for stirring under nitrogen. Dichloromethane (2 mL) and trifluoroacetic acid (2 mL) were then added and the solution was stirred at room temperature for 2 hr. The solvent was removed in-vacuo affording a clear colored oil. This oil was re-dissolved in methanol (3 mL), filtered, and then purified by preparative LC/MS (15-65% CH₃CN in H₂O). The resultant fractions were collected and the solvent was removed in-vacuo affording a clear colored oil. This oil was re-dissolved in CH₃CN (1 mL) and water (2 mL). The resultant solution was frozen and lyophilized to afford (R)-3-amino-4-(biphenyl-4-yl)-1((R)-3-(4-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (118) as its trifluoroacetic acid salt and as a white flocculent solid (0.134 mmol, 0.088 g, 55% yield over 4-steps). ESI-MS: 545.2 m/z (M+H)⁺. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.40-1.55 (m, 1H) 1.70-2.14 (m, 5H) 2.61-2.87 (m, 3H) 2.87-3.09 (m, 4H) 3.09-3.31 (m, 5H) 3.40-3.85 (m, 2H) 3.95-4.62 (m, 5H) 7.17-7.30 (m, 2H) 7.33-7.42 (m, 3H) 7.42-7.56 (m, 3H) 7.58-7.72 (m, 4H).

Example 49
Synthesis of (S)-3-amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-(pyridin-3-yppropan-1-one (119)

embedded image

Into a 10 mL round bottomed flask was added (S)-3-(tert-butoxycarbonylamino)-3-(pyridin-3-yl)propanoic acid (63 mg, 238 μmol) and (R)-1-(3-methoxypropyl)-2-(piperidin-3-yl)-1H-benzo[d]imidazole (65 mg, 238 μmol). The mixture was dissolved with dichloromethane (2.5 mL) and N-methylmorpholine (96 mg, 952 μmol) and HATU (160 mg, 262 μmol) were added. The mixture was stirred overnight at room temperature. Solvent was removed under vacuum. The residue containing tert-Butyl(S)-34(R)-3-(1-(3-methoxypropyl)-1,1-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-oxo-1-(pyridin-3-yl)propylcarbamate (49A) was used in the next step without further purification. ESI-MS:mlz 522.5 (M+H)⁺.

embedded image

tert-Butyl(S)-3-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-oxo-1-(pyridin-3-yepropylcarbamate (49A) was dissolved in 25% trifluoroacetic acid and stirred at room temperature for 3 hr. Solvent was removed under vacuum and purified by preparatory LC/MS (5-25% CH₃CN in H₂O) to give (S)-3-amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-(pyridin-3-yl)propan-1-one (119) as a TFA salt (119 mg, 94% yield). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.39-1.67 (m, 1 H) 1.77-2.22 (m, 5H) 2.69 (s, 1H) 2.87-3.57 (m, 8H) 3.96 (s, 1H) 4.16-4.67 (m, 4H) 4.77 (br. s., 1H) 7.43-7.65 (m, 3H) 7.74-7.89 (m, 2H) 7.97-8.12 (m, 1H) 8.56-8.91 (m, 2H). ESI-MS:m/z 422.4 (M+H)⁺.

Example 50
Synthesis of (S)-3-amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-(4-methoxypyridin-3-yppropan-1-one (120)

embedded image

tert-Butyl(S)-3-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(4-methoxypyridin-3-yl)-3-oxopropylcarbamate (50A) was prepared as described for Example 49, Step A. ESI-MS:m/z 552.5 (M+H)⁺.

embedded image

(S)-3-Amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-(4-methoxypyridin-3-yl)propan-1-one (120) was prepared as described for Example 49, Step B and was purified by preparatory LC/MS (10-25% CH₃CN in H₂O) to give the product as a TFA salt (108 mg, 80% yield). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.42-1.67 (m, 1H) 1.78-2.23 (m, 5H) 2.62-3.20 (m, 7H) 3.22-3.38 (m, 2H) 3.48 (m, 1H) 3.84 (m, 3H) 3.96 (s, 1H) 4.19-4.73 (m, 4H) 6.88 (m, 1H) 7.49 (m, 2H) 7.74-7.92 (m, 3H) 8.28-8.32 (m, 1H). ESI-MS:m/z 452.4 (M+H)⁺.

Example 51
Synthesis of (S)-3-amino-3-(3-methoxyphenyl)-1-(R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-yppropan-1-one (121)

embedded image

tert-Butyl(S)-1-(3-methoxyphenyl)-3-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-3-oxopropylcarbamate (51A) was prepared as described for Example 49, Step A. ESI-MS:m/z 551.5 (M+H)⁺.

embedded image

(S)-3-Amino-3-(3-methoxyphenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yppropan-1-one (121) was prepared as described for Example 49, Step B and was purified by preparatory LC/MS (15-25% CH₃CN in H₂O) to give the product as a TFA salt (111 mg, 83% yield). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.42-1.64 (m, 1 H) 1.79-2.20 (m, 5H) 2.62-3.25 (m, 7H) 3.25-3.37 (m, 2H) 3.49 (m, 1H) 3.72-3.80 (m, 3H) 3.89-4.25 (m, 1H) 4.34-4.69 (m, 4H) 6.95 (m, 1H) 7.02-7.16 (m, 2H) 7.28-7.37 (m, 1H) 7.42-7.52 (m, 2H) 7.73-7.84 (m, 2H). ESI-MS:mlz 451.4 (M+H)⁺.

Example 52
Synthesis of (R)-3-amino-4-(biphenyl-3-yl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (122)

embedded image

tert-Butyl (R)-1-(3-chlorophenyl)-4-((R)-3-(1-(3-methoxypropyl)-1,1-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (0.105 mmol, 0.060 g), phenylboronic acid (0.158 mmol, 0.019 g), cesium fluoride (0.315 mmol, 0.048 g), 2′-(dicyclohexylphosphino)-N,N-dimethylbiphenyl-2-amine (0.016 mmol, 0.006 g), and dioxane (3 mL) were added to an oven-dried 25 mL Schlenk flask equipped for stirring under nitrogen and under vacuum. Vacuum degassed the solution three times with nitrogen. Added diacetoxypalladium (0.010 mmol, 0.002 g) and vacuum degassed the reaction solution three times with nitrogen and allowed to stir at room temperature under nitrogen for 16 hrs. Heated the reaction to 100° C. and allowed to heat under nitrogen for 72 hrs. The reaction solution was then poured into water, extracted with ethyl acetate, and washed once with saturated aqueous sodium chloride. The organic layer was collected and subsequently dried with anhydrous Na₂SO₄and filtered. This filtrate was collected, concentrated, and dried in-vacuo. This crude material was directly purified by preparative LC/MS (30-80% CH₃CN in H₂O). The resultant fractions were collected and the solvent was removed in-vacuo affording tert-butyl (R)-1-(biphenyl-3-yl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (52A) as a clear oil. (0.05 mmol, 0.030 g, 47% yield). ESI-MS: m/z 611.3 (M+H)⁺.

embedded image

tert-Butyl(R)-1-(biphenyl-3-yl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (52A) (0.05 mmol, 0.030 g) was weighed into a 20 mL round-bottomed flask equipped for stirring under nitrogen. CH₂Cl₂(1 mL) and trifluoroacetic acid (1 mL) were then added and the solution was stirred at room temperature for 2 hrs. The solvent was removed in-vacuo affording a clear colored oil. This oil was re-dissolved in methanol (3 mL), filtered, and then purified by preparative LC/MS (20-55% CH₃CN in H₂O). The resultant fractions were collected and the solvent was removed in-vacuo affording a clear colored oil. This oil was re-dissolved in CH₃CN (1 mL) and water (2 mL). The resultant solution was frozen and lyophilized to afford (R)-3-amino-4-(biphenyl-3-yl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (122) as its trifluoroacetic acid salt and as a white flocculent solid (0.021 mmol, 0.013 g, 42% yield). ¹H NMR (400 MHz, DMSO-d₅) δ ppm 1.39-1.58 (m, 1H) 1.73-2.15 (m, 5H) 2.60-2.88 (m, 4H) 2.90-3.13 (m, 4H) 3.15-3.25 (m, 3H) 3.30-3.51 (m, 3H) 4.07-4.32 (m, 2H) 4.34-4.68 (m, 3H) 7.23-7.32 (m, 1H) 7.33-7.52 (m, 6H) 7.54-7.61 (m, 2H) 7.62-7.80 (m, 4H). ESI-MS: m/z 511.2 (M+H)⁺.

Example 53
Synthesis of Methyl 4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl-4-oxobutyl)biphenyl-4-carboxylate (123)

embedded image

tert-Butyl (R)-1-(4-bromophenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (6A) (as prepared in Example 6, Step A) (0.114 mmol, 0.070 g) and 4-(methoxycarbonyl)phenylboronic acid (0.148 mmol, 0.027 g) were added to a 5 mL microwave vessel equipped with a magnetic stir bar. Dioxane (2 mL) and Na₂CO₃(1 mL of a 2 M aq. soln.) were then added and the reaction vessel was flushed with nitrogen gas. PdCl₂(dppf) (0.006 mmol, 0.004 g) was added, the reaction vessel was sealed and placed in a microwave reactor and heated to 120° C. for 15 minutes. The reaction solution was then poured into water, extracted with ethyl acetate, and washed once with saturated aqueous sodium chloride. The organic layer was collected and subsequently dried with anhydrous Na₂SO₄and filtered. This filtrate was collected, concentrated, and dried in-vacuo. This crude material was directly purified by preparative LC/MS (25-85% CH₃CN in H₂O). The resultant fractions were collected and the solvent was removed in-vacuo affording methyl 4′-((R)-2-(tert-butoxycarbonylamino)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-carboxylate (53A) as a clear oil. (0.08 mmol, 0.054 g, 70% yield). ESI-MS: m/z 669.4 (M+H)⁺.

embedded image

Methyl 4′-((R)-2-(tert-butoxycarbonylamino)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-carboxylate (53A) (0.08 mmol, 0.054 g) was weighed into a 20 mL scintillation vial and dissolved in CH₂Cl₂(2 mL). Trifluoroacetic acid (2 mL) was then added and the solution was stirred at room temperature for 2 hrs. The solvent was removed in-vacuo affording a clear colored oil. This oil was re-dissolved in methanol (3 mL), filtered, and then purified by preparative LC/MS (20-55% CH₃CN in H₂O). The resultant fractions were collected and the solvent was removed in-vacuo affording a clear colored oil. This oil was re-dissolved in CH₃CN (1 mL) and water (2 mL). The resultant solution was frozen and lyophilized to afford methyl 4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-carboxylate (123) as its trifluoroacetic acid salt and as a white flocculent solid. (0.07 mmol, 0.040 g, 88% yield). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.40-1.63 (m, 1H) 1.73-2.21 (m, 5H) 2.56-2.87 (m, 3H) 2.91-3.15 (m, 3H) 3.16-3.52 (m, 5H) 3.68-3.92 (m, 4H) 4.05-4.70 (m, 5H) 7.37-7.53 (m, 4H) 7.68-7.87 (m, 6H) 8.02-8.07 (m, 2H). ESI-MS: 569.3 m/z (M+H)⁺.

Other compounds that were prepared according to the general procedure described for Examples 52 or 53 are listed in Table III.

TABLE III

Com-

pound

No.
Structure/Name
Physical Property

124

embedded image

ESI-MS: m/z 511.4 (M + H)⁺. 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.41-1.59 (m, 1 H) 1.72- 2.17 (m, 6 H) 2.62-2.86 (m, 3 H) 2.90-3.54 (m, 10 H) 3.66-4.09 (m, 2 H) 4.21-4.63 (m, 3 H) 7.26- 7.42 (m, 5 H) 7.42-7.51 (m, 2 H) 7.57-7.71 (m, 6 H)

(R)-3-amino-4-(biphenyl-4-yl)-1-((R)-3-(1-(3-

methoxypropyl)-1H-benzo[d]imidazol-2-

yl)piperidin-1-yl)butan-1-one

125

embedded image

ESI-MS: m/z 512.2 (M + H)⁺. 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.42-1.62 (m, 1 H) 1.73- 2.22 (m, 5 H) 2.59-2.88 (m, 3 H) 2.92-3.16 (m, 4 H) 3.16-3.48 (m, 5 H) 3.76 (br. s., 1 H) 3.82-4.70 (m, 4 H) 7.40-7.53 (m, 4 H) 7.66 (dt, J = 7.83, 5.56 Hz, 1 H) 7.72- 7.84 (m, 4 H) 8.27 (ddd, J = 16.74, 9.92, 1.64 Hz, 1 H) 8.67 (d, J = 5.05 Hz, 1 H) 9.00 (dd, J = 6.19, 2.15 Hz, 1 H).

(R)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4-

(pyridin-3-yl)phenyl)butan-1-one.

126

embedded image

ESI-MS: m/z 512.2 (M + H)⁺. 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.41-1.63 (m, 1 H) 1.74- 2.22 (m, 5 H) 2.61-2.76 (m, 2 H) 2.81-3.47 (m, 9 H) 3.83-4.69 (m, 6 H) 7.42-7.55 (m, 4 H) 7.72- 7.84 (m, 2 H) 7.95 (dd, J = 13.26, 8.21 Hz, 2 H) 8.12 (dd, J = 15.66, 6.32 Hz, 2 H) 8.84 (d, J = 5.56 Hz, 2 H)

(R)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4-

(pyridin-4-yl)phenyl)butan-1-one

127

embedded image

ESI-MS: m/z 624.3 (M + H)⁺. 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.41-1.64 (m, 1 H) 1.73-2.24 (m, 5 H) 2.57-2.85 (m, 3 H) 2.88-3.15 (m, 4 H) 3.16-3.91 (m, 16 H) 4.10-4.72 (m, 4 H) 7.36- 7.44 (m, 2 H) 7.45-7.57 (m, 4 H) 7.65-7.88 (m, 6 H)

(R)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4′-

(morpholine-4-carbonyl)biphenyl-4-yl)butan-1-one

128

embedded image

ESI-MS: m/z 596.3 (M + H)⁺. 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.40-1.62 (m, 1 H) 1.72- 2.21 (m, 5 H) 2.58-2.81 (m, 4 H) 2.86-3.10 (m, 4 H) 3.10-3.51 (m, 10 H) 3.63-4.18 (m, 6 H) 4.27- 4.70 (m, 3 H) 6.99-7.06 (m, 2 H) 7.27-7.37 (m, 2 H) 7.40-7.52 (m, 2 H) 7.52-7.64 (m, 4 H) 7.70- 7.85 (m, 2 H)

(R)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4′-

morpholinobiphenyl-4-yl)butan-1-one

129

embedded image

ESI-MS: m/z 568.2 (M + H)⁺. 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.42-1.63 (m, 1 H) 1.74- 2.24 (m, 8 H) 2.57-2.82 (m, 3 H) 2.87-3.14 (m, 4 H) 3.16-3.56 (m, 5 H) 3.65-3.80 (m, 1 H) 3.81- 4.73 (m, 4 H) 7.35 (t, J = 8.84 Hz, 2 H) 7.45-7.72 (m, 8 H) 7.75-7.89 (m, 2 H) 10.07 (s, 1 H)

N-(4′-((R)-2-amino-4-((R)-3-(1-(3-

methoxypropyl)-1H-benzo[d]imidazol-2-

yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-yl)acetamide

130

embedded image

ESI-MS: 555.25 m/z (M + H)⁺.

(R)-3-amino-4-(2′-(methoxymethyl)biphenyl-4-

yl)-1-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one

131

embedded image

ESI-MS: 546.21 m/z (M + H)⁺.

(R)-3-amino-4-(4-(3-chloropyridin-4-yl)phenyl)-

1-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one

132

embedded image

ESI-MS: 572.27 m/z (M + H)⁺.

(R)-3-amino-4-(4-(2,6-dimethoxypyridin-3-

yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one

133

embedded image

ESI-MS: 546.21 m/z (M + H)⁺.

(R)-3-amino-4-(4-(2-chloropyridin-4-yl)phenyl)-

1-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one

134

embedded image

ESI-MS: 594.27 m/z (M + H)⁺. 1H NMR (400 MHz, DMSO-d₆) δ ppm 0.59 (d, J = 3.28 Hz, 2 H) 0.66-0.74 (m, 2 H) 1.51 (br. s., 1 H) 1.74-2.18 (m, 5 H) 2.63-3.49 (m, 13 H) 3.75 (br. s., 1 H) 4.06-4.67 (m, 4 H) 7.40 (t, J = 8.72 Hz, 4 H) 7.73 (dd, J = 17.56, 8.21 Hz, 6 H) 7.88-7.94 (m, 2 H) 8.46 (br. s., 1 H).

4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-

1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-

oxobutyl)-N-cyclopropylbiphenyl-4-carboxamide

135

embedded image

ESI-MS: 597.3 m/z (M + H)⁺.

(R)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4-(6-

morpholinopyridin-3-yl)phenyl)butan-1-one

136

embedded image

ESI-MS: 527.22 m/z (M + H)⁺. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.40-1.62 (m, 1 H) 1.73- 2.20 (m, 5 H) 2.61-2.85 (m, 3H) 2.87-3.48 (m, 11 H) 3.66-4.09 (m, 2 H) 4.23-4.64 (m, 3 H) 7.08 (d, J = 9.85 Hz, 1 H) 7.33-7.46 (m, 4 H) 7.59-7.76 (m, 4 H) 8.03- 8.32 (m, 4 H).

(R)-3-amino-4-(4-(6-aminopyridin-3-yl)phenyl)-

1-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one

137

embedded image

ESI-MS: 529.25 m/z (M + H)⁺.

(R)-3-amino-4-(4-(3,5-dimethyl-1H-pyrazol-4-

yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one

138

embedded image

ESI-MS: 556.24 m/z (M + H)⁺. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.34 (t, J = 7.07 Hz, 3 H) 1.40- 1.62 (m, 1 H) 1.71-2.22 (m, 5 H) 2.59-2.85 (m, 3 H) 2.88-3.13 (m, 4 H) 3.15-3.48 (m, 6 H) 3.74 (br. s., 1 H) 3.80-4.68 (m, 7 H) 6.89 (dd, J = 8.72, 1.89 Hz, 1 H) 7.31-7.52 (m, 4 H) 7.65 (dd, J = 11.37, 8.08 Hz, 2 H) 7.70-7.82 (m, 2 H) 7.97- 8.04 (m, 1 H) 8.47 (d, J = 2.02 Hz, 1 H).

(R)-3-amino-4-(4-(6-ethoxypyridin-3-

yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-

1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one

139

embedded image

ESI-MS: 551.23 m/z (M + H)⁺. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.43-1.65 (m, 1 H) 1.72- 2.22 (m, 5 H) 2.6-2.76 (m, 3 H) 2.81-3.52 (m, 11 H) 3.73-4.12 (m, 2 H) 4.26-4.65 (m, 3 H) 7.31- 7.56 (m, 4 H) 7.67-7.85 (m, 4 H) 8.07 (d, J = 9.60 Hz, 1 H) 8.19-8.35 (m, 3 H) 9.28 (d, J = 6.57 Hz, 1 H).

(R)-3-amino-4-(4-(imidazo[1,2-a]pyridin-6-

yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one

140

embedded image

ESI-MS: 553.2 m/z (M + H)⁺. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.40-1.63 (m, 1 H) 1.73- 2.20 (m, 5 H) 2.63-2.90 (m, 3 H) 2.93-3.48 (m, 9 H) 3.72-4.12 (m, 2 H) 4.21- 4.68 (m, 3 H) 7.33- 7.52 (m, 4 H) 7.64-7.76 (m, 2 H) 7.84-8.05 (m, 3 H) 8.13-8.21 (m, 1 H) 8.31 (d, J = 6.06 Hz, 1 H).

(R)-3-amino-4-(4-(benzo[c][1,2,5]oxadiazol-5-

yl)phenyl)-1-((R)-3-(1-(3-metboxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one

141

embedded image

ESI-MS: 501.2 m/z (M + H)⁺.

(R)-4-(4-(1H-pyrazol-5-yl)phenyl)-3-amino-1-

((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one

142

embedded image

ESI-MS: 570.3 m/z (M + H)⁺. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.32 (dd, J = 6.19, 1.39 Hz, 6 H) 1.44-1.61 (m, 1 H) 1.73-2.21 (m, 5 H) 2.58-2.85 (m, 3 H) 2.86- 3.48 (m, 9 H) 3.67-4.15 (m, 2 H) 4.25-4.69 (m, 3 H) 5.29 (dq, J = 12.35, 6.09, 5.94, 1.64 Hz, 1 H) 7.32-7.51 (m, 4 H) 7.65 (dd, J = 11.49, 8.21 Hz, 2 H) 7.69-7.81 (m, 2 H) 7.95-8.01 (m, 2 H) 8.47 (d, J = 2.53 Hz, 1 H).

(R)-3-amino-4-(4-(6-isopropoxypyridin-3-

yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one

143

embedded image

ESI-MS: 582.26 m/z (M + H)⁺. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.28-0.38 (m, 2 H) 0.50- 0.62 (m, 2 H) 1.17-1.34 (m, 1 H) 1.41-1.62 (m, 1 H) 1.73-2.22 (m, 5 H) 2.58-2.84 (m, 3 H) 2.88- 3.48 (m, 9 H) 3.73 (br. s., 1 H) 3.80-4.17 (m, 3 H) 4.25-4.68 (m, 3 H) 6.91 (dd, J = 8.59, 1.52 Hz, 1 H) 7.32-7.51 (m, 4 H) 7.59-7.80 (m, 4 H) 7.99 (ddd, J = 8.72, 6.57,

(R)-3-amino-4-(4-(6-
2.65 Hz, 1 H) 8.41-8.50 (m, 1 H).

(cyclopropylmethoxy)pyridin-3-yl)phenyl)-1-

((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one

144

embedded image

ESI-MS: 542.25 m/z (M + H)⁺.

(R)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4-(3-

methoxypyridin-4-yl)phenyl)butan-1-one

Example 54
Synthesis of (R)-3-amino-4-(4-(furan-3-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (145)

embedded image

tert-Butyl(R)-1-(4-(furan-3-yl)phenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (54A) was prepared from 6A (Example 6, Step A) as described for Example 53, Step A. ESI-MS:m/z 601.5 (M+H)⁺.

embedded image

tert-Butyl(R)-1-(4-(furan-3-yl)phenyl)-4-((R)-3-(1-(3-methoxypropyl)-1,1-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (54A) was dissolved in 25% trifluoroacetic acid and stirred at room temperature for 3 hrs. Solvent was removed under vacuum and purified by preparatory LC/MS (20-50% CH₃CN in H₂O) to give product (R)-3-amino-4-(4-(furan-3-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (145) as a TFA salt (32 mg, 64% yield). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.51 (br. s., 1H) 1.72-2.22 (m, 5H) 2.57-3.51 (m, 1H) 3.71 (br. s., 1H) 3.77-4.73 (m, 5H) 6.96 (br. s., 1H) 7.30 (m, 2H) 7.37-7.50 (m, 2H) 7.59 (m, 2H) 7.75 (br. s., 3H) 8.17 (s, 1H). ESI-MS:mlz 501.2 (M+H)⁺.

Example 55
Synthesis of (R)-3-amino-4-(4-(furan-2-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[c]iimidazol-2-yl)piperidin-1-yl)butan-1-one (146)

embedded image

tert-Butyl(R)-1-(4-(furan-2-yl)phenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (54A) was prepared as described in Example 54, Step A. ESI-MS:mlz 601.5 (M+H)⁺.

embedded image

(R)-3-Amino-4-(4-(furan-2-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (146) was prepared as described above for Example 54, Step B and was purified by preparatory LC/MS (20-50% CH₃CN in H₂O) to give the product 146 as a TFA salt (13 mg, 26% yield). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.53 (br. s., 1H) 1.74-2.18 (m, 5H) 2.72 (br. s., 2H) 2.86-3.50 (m, 6H) 3.65 (m, 3H) 3.73-3.91 (m, 2H) 4.35 (s, 4H) 7.38 (m, 2H) 7.43-7.57 (m, 5H) 7.64-7.76 (m, 4H). ESI-MS:m/z 501.2 (M+H)⁺.

Example 56
Synthesis of (R)-3-amino-4-(4-(6-(dimethylamino)pyridin-3-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (147)

embedded image

tert-Butyl(R)-1-(4-(6-(dimethylamino)pyridin-3-yl)phenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (56A) was prepared as described for Example 54, Step A. ESI-MS:m/z 655.5 (M+H)⁺.

embedded image

(R)-3-amino-4-(4-(6-(dimethylamino)pyridin-3-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (147) was prepared as described above for Example 54, Step B and was purified by preparatory LC/MS (10-40% CH₃CN in H₂O) to give the product 147 as a TFA salt (47 mg, 95% yield). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.51 (br. s., 1H) 1.76-2.21 (m, 5H) 2.59-3.49 (m, 1H) 3.74 (br. s., 2H) 4.06-4.70 (m, 4H) 7.10 (m, 1H) 7.38 (m, 2H) 7.48 (m, 2H) 7.66 (m, 2H) 7.79 (m, 2H) 8.09-8.19 (m, 1H) 8.34 (m, 1H). ESI-MS:m/z 555.3 (M+H)⁺.

Example 57
Synthesis of (R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4-(2-methoxypyridin-4-yl)phenyl)butan-1-one (148)

embedded image

(tert-Butyl(R)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(4-(2-methoxypyridin-4-yl)phenyl)-4-oxobutan-2-ylcarbamate (57A) was prepared as described for Example 54, Step A. ESI-MS:m/z 642.5 (M+H)⁺.

embedded image

(R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]inaidazol-2-yl)piperidin-1-yl)-4-(4-(6-methoxypyridin-3-yl)phenyl)butan-1-one (148) was prepared as described above for Example 54, Step B and was purified by preparatory LC/MS (20-55% CH₃CN in H₂O) to give product as a TFA salt (39 mg, 92% yield). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.51 (br. s., 1H) 1.75-2.22 (m, 5H) 2.60-2.85 (m, 3H) 2.88-3.50 (m, 9H) 3.67-3.88 (m, 1H) 3.90 (m, 3H) 4.10-4.72 (m, 4H) 6.92 (m, 1H) 7.38 (m, 2H) 7.42-7.52 (m, 2H) 7.65 (m, 2H) 7.80 (m, 2H) 8.01 (m, 1H) 8.49 (m, 1H). ESI-MS:m/z 542.2 (M+H)⁺.

Example 58
Synthesis of (R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4-(pyrimidin-5-yl)phenyl)butan-1-one (149)

embedded image

tert-Butyl(R)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxo-1-(4-(pyrimidin-5-yl)phenyl)butan-2-ylcarbamate (58A) was prepared as described in Example 54, Step A. ESI-MS:mlz 613.5 (M+H)⁺.

embedded image

(R)-3-Amino-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4-(pyrimidin-5-yl)phenyl)butan-1-one (149) was prepared as described above for Example 54, Step B and was purified by preparatory LC/MS (15-50% CH₃CN in H₂O) to give the product as a TFA salt (35 mg, 83% yield). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.51 (br. s., 1H) 1.90 (m, 5H) 2.61-3.50 (m, 12H) 3.77 (br. s., 1H) 4.06-4.70 (m, 4H) 7.46 (m, 4H) 7.69-7.79 (m, 2H) 7.82 (m, 2H) 9.15 (m, 3H). ESI-MS:m/z 513.2 (M+H)⁺.

Example 59
Synthesis of (R)-3-amino-4-(4-(2-fluoropyridin-4-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (150)

embedded image

tert-Butyl(R)-1-(4-(2-fluoropyridin-4-yl)phe n yl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (59A) was prepared as described for Example 54, Step A. ESI-MS:m/z 630.5 (M+H)⁺.

embedded image

(R)-3-amino-4-(4-(2-fluoropyridin-4-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (150) was prepared as described above for Example 53, Step B and was purified by preparatory LC/MS (20-40% CH₃CN in H₂O) to give the product as a TFA salt (37 mg, 86% yield). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.50 (br. s., 1H) 1.74-2.20 (m, 5H) 2.63-3.02 (m, 4H) 3.03-3.25 (m, 6H) 3.34 (m, 2H) 3.70-3.90 (m, 1H) 4.04-4.68 (m, 4H) 7.46 (m, 4H) 7.53 (m, 1H) 7.71 (m, 3H) 7.87 (m, 2H) 8.31 (m, 1 H). ESI-MS:m/z 530.2 (M+H)⁺.

Example 60
Synthesis of (R)-3-amino-4-(4-(2-fluoropyridin-3-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (151)

embedded image

tert-Butyl(R)-1-(4-(2-fluoropyridin-3-yl)phenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (60A) was prepared as described in Example 54, Step A. ESI-MS:m/z 630.5 (M+H)⁺.

embedded image

(R)-3-Amino-4-(4-(2-fluoropyridin-3-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (151) was prepared as described above for Example 54, Step B and was purified by preparatory LC/MS (20-40% CH₃CN in H₂O) to give the product as a TFA salt (40 mg, 93% yield). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.52 (br. s., 1H) 1.76-2.21 (m, 5H) 2.62-3.02 (m, 4H) 3.03-3.49 (m, 8H) 3.78 (m, 1H) 4.11-4.69 (m, 4H) 7.40-7.51 (m, 5H) 7.62 (m, 2H) 7.78 (m, 2H) 8.06-8.14 (m, 1H) 8.25 (m, 1H). ESI-MS:m/z 530.2 (M+H)⁺.

Example 61
Synthesis of (R)-4-(4-(1H-pyrrol-3-yl)phenyl)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (152)

embedded image

tert-Butyl(R)-4-((R)-3-(1-(3-methoxypropyl)-1H-b enz ofdlimidazol-2-yl)piperidin-1-yl)-4-oxo-1-(4-(1-(triisopropylsilyl)-1H-pyrrol-3-yl)phenyl)butan-2-ylcarbamate (61A) was prepared as described in Example 54, Step A. ESI-MS:m/z 756.6 (M+H)⁺.

embedded image

(R)-4-(4-(1H-Pyrrol-3-yl)phenyl)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (152) was prepared as described above for Example 54, Step B and was purified by preparatory LC/MS (20-30% CH₃CN in H₂O) to give product as a TFA salt (12 mg, 24% yield). ESI-MS:m/z 500.2 (M+H)⁺.

Example 62
Synthesis of (R)-4-(4-(1H-pyrrol-2-yl)phenyl)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (153)

embedded image

tert-Butyl 2-(4-((R)-2-(tert-butoxycarbonylamino)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-1H-pyrrole-1-carboxylate (62A) was prepared as described in Example 54, Step A. ESI-MS:mh 600.5 (M+H)⁺.

embedded image

(R)-4-(4-(1H-pyrrol-2-yl)phenyl)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (153) was prepared as described above for Example 54, Step B and was purified by preparatory LC/MS (20-30% CH₃CN in H₂O) to give product as a TFA salt (11 mg, 22% yield). ESI-MS:m/z 500.2 (M+H)⁺.

Example 63
Synthesis of (R)-3-amino-4-(4-(2-aminopyrimidin-5-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-ypbuthn-1-one (154)

embedded image

tert-Butyl(R)-1-(4-(2-aminopyrimidin-5-yl)phenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-ylpiperidin-1-yl)-4-oxobutan-2-ylcarbamate (63A) was prepared as described in Example 54, Step A. ESI-MS:m/z 628.5 (M+H)⁺.

embedded image

(R)-3-amino-4-(4-(2-aminopyrimidin-5-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (154) was prepared as described above for Example 54, Step B and was purified by preparatory LC/MS (10-35% CH₃CN in H₂O) to give product as a TFA salt (42 mg, 81% yield). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.51 (br. s., 1H) 1.75-2.22 (m, 5H) 2.58-2.81 (m, 3H) 2.88-3.52 (m, 9H) 3.71 (br. s., 1H) 4.11-4.72 (m, 4H) 7.35 (m, 2H) 7.45-7.55 (m, 2H) 7.63 (m, 2H) 7.78 (m, 1H) 7.83 (m, 1H) 8.65 (m, 2H). ESI-MS:m/z 528.2 (M+H)⁺.

Example 64
Synthesis of (R)-3-amino-4-(2′-chlorobiphenyl-4-yl)-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (155)

embedded image

Into a microwave reaction vessel was added 2-chlorophenylboronic acid (22 mg, 137 μmol) and tert-butyl (R)-1-(4-bromophenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (56 mg, 92 μmol). (dppf)PdCl₂(3 mg, 45 μmol) was added and the mixture was dissolved with dioxane (0.6 mL) and saturated sodium bicarbonate (0.3 mL). The vessel was capped and microwaved for 10 minutes at 110° C. The mixture was filtered and the solvent removed under vacuum. The residue containing tert-butyl(R)-1-(2′-chlorobiphenyl-4-yl)-4-((R)-3-(1-(3-methoxypropyl-1H-benzo[d]imidazal-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (64A) was carried to the next step without further purification. ESI-MS:m/z 644.3 (M+H)⁺.

embedded image

The solvent was removed and the residue containing (R)-3-amino-4-(2′-chlorobiphenyl-4-yl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (155) was purified by preparatory LC/MS (20-40% CH₃CN in H₂O) to give the product as a TFA salt (53 mg, 86% yield over two steps). ESI-MS:m/z 545.2 (M+H)⁺.

Example 65
Synthesis of (R)-3-amino-4-(4′-methoxybiphenyl-4-yl)-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (156)

embedded image

tert-Butyl(R)-1-(4′-rnethoxybiphenyl-4-yl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (65A) was prepared as described for Example 64, Step A. ESI-MS:m/z 640.4 (M+H)⁺.

embedded image

(R)-3-Amino-4-(4′-methoxybiphenyl-4-yl)-1-((R)-3-(1-(3-methoxypropyl)-1,1-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (156) was prepared as described for Example 64, Step B and was purified by preparatory LC/MS (20-40% CH₃CN in H₂O) to give the product as a TFA salt (46 mg, 76% yield over two steps). ESI-MS:m/z 541.3 (M+H)⁺.

Example 66
Synthesis of (R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl-4-(2′-methylbiphenyl-4-yl)butan-1-one (157)

embedded image

tert-Butyl(R)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)ppiperidin-1-yl)-1-(2′-methylbiphenyl-4-yl)-4-oxobutan-2-ylcarbamate (66A) was prepared as described for Example 64, Step A. ESI-MS:m/z 624.4 (M+H)⁺.

embedded image

(R)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(2′-methylbiphenyl-4-yl)butan-1-one (66A) was prepared as described for Example 64, Step B and was purified by preparatory LC/MS (20-40% CH₃CN in H₂O) to give the product as a TFA salt (44 mg, 74% yield over two steps). ESI-MS:m/z 525.2 (M+H)⁺.

Example 67
Synthesis of (R)-3-amino-4-(3′-methoxybiphenyl-4-yl-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (158)

embedded image

tert-Butyl(R)-1-(3′-methoxybiphenyl-4-yl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (67A) was prepared as described for Example 64, Step A. ESI-MS:m/z 640.4 (M+H)⁺.

embedded image

(R)-3-Amino-4-(3′-methoxybiphenyl-4-yl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (158) prepared as described for Example 64, Step B and was purified by preparatory LC/MS (20-40% CH₃CN in H₂O) to give the product as a TFA salt (40 mg, 66% yield over two steps). ESI-MS:m/z 541.3 (M+H)⁺.

Example 68
Synthesis of (R)-3-amino-4-(2′-methoxybiphenyl-4-yl-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (159)

embedded image

tert-Butyl(R)-1-(2′-methoxybiphen yl-4-yl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (68A) was prepared as described for Example 64, Step A. ESI-MS:m/z 640.4 (M+H)⁺.

embedded image

(R)-3-amino-4-(T-methoxybiphenyl-4-yl)-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (159) was prepared as described for Example 64, Step 13 and was purified by preparatory LC/MS (20-40% CH₃CN in H₂O) to give the product as a TFA salt (39 mg, 65% yield over two steps). ESI-MS:m/z 541.3 (M+H)⁺.

Example 69
Synthesis of (R)-3-amino-4-(2′-fluorobiphenyl-4-yl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (160)

embedded image

tert-Butyl(R)-1-(2′-fluorobiphenyl-4-yl)-4-((R)-3-(1-(3-methoxypropyl)-1,1-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-yl carbamate (69A) was prepared as described for Example 64, Step A. ESI-MS:m/z 628.3 (M+H)⁺.

embedded image

(R)-3-amino-4-(2′-fluorobiphenyl-4-yl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (160) was prepared as described for Example 64, Step B and was purified by preparatory LC/MS (20-40% CH₃CN in H₂O) to give the product as a TFA salt (37 mg, 61% yield over two steps). ESI-MS:m/z 529.2 (M+H)⁺.

Example 70
Synthesis of (R)-3-amino-4-(4′-(dimethylamino)biphenyl-4-yl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (161)

embedded image

tert-Butyl(R)-1-(4′-(dimethylamino)biphenyl-4-yl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (70A) was prepared as described for Example 64, Step A. ESI-MS:m/z 653.4 (M+H)⁺.

embedded image

(R)-3-Amino-4-(4′-(dimethylamino)biphenyl-4-yl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (161) was prepared as described for Example 64, Step B and was purified by preparatory LC/MS (20-40% CH₃CN in H₂O) to give the product as a TFA salt (41 mg, 66% yield over two steps). ESI-MS:m/z 554.3 (M+H)⁺.

Example 71
Synthesis of (R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl-4-(4-(4-methoxypyridin-3-yl)phenyl)butan-1-one (162)

embedded image

tert-Butyl(R)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-ylpperidin-1-yl)-1-(4-(4-methoxypyridin-3-yl)phenyl)-4-oxobutan-2-ylcarbamate (71A) was prepared as described for Example 64, Step A. ESI-MS:mh 641.4 (M+H)⁺.

embedded image

(R)-3-Amino-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4-(4-methoxypyridin-3-yl)phenyl)butan-1-one (162) was prepared as described for Example 64, Step B and was purified by preparatory LC/MS (20-40% CH₃CN in H₂O) to give the product 162 as a TFA salt (31 mg, 50% yield over two steps). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.54 (br. s., 1H) 1.76-2.20 (m, 5H) 2.65-3.50 (m, 3H) 3.77 (br. s., 1H) 4.06 (m, 3H) 4.31-4.67 (m, 4H) 7.43 (m, 4H) 7.59 (m, 2H) 7.69 (m, 3H) 8.67 (m, 1H) 8.81 (m, 1H). ESI-MS:m/z 542.3 (M+H)⁺.

Example 72
Synthesis of (R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4-(2-methoxypyridin-3-yl)phenyl)butan-1-one (163)

embedded image

tert-Butyl(R)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(4-(2-methoxypyridin-3-yl)phenyl)-4-oxobutan-2-ylcarbamate (72A) was prepared as described for Example 64, Step A. ESI-MS:m/z 641.4 (M+H)⁺.

embedded image

(R)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4-(2-methoxypyridin-3-yl)phenyl)butan-1-one (163) was prepared as described for Example 63, Step B and was purified by preparatory LC/MS (20-40% CH₃CN in H₂O) to give the product 163 as a TFA salt (41 mg, 67% yield over two steps). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.52 (br. s., 1H) 2.06 (m, 4H) 2.64-3.48 (m, 12H) 3.75 (br. s., 1H) 3.88 (m, 3H) 4.07-4.67 (m, 4H) 7.10 (m, 1H) 7.35 (m, 4H) 7.56 (m, 2H) 7.72 (m, 3H) 8.18 (m, 1H). ESI-MS:m/z 542.3 (M+H)⁺.

Example 73
Synthesis of 4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyphiphenyl-4-carbonitrile (164)

embedded image

tert-Butyl(R)-1-(4′-cyanobiphenyl-4-yl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (73A) was prepared as described for Example 64, Step A. ESI-MS:m/z 635.4 (M+H)⁺.

embedded image

4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-carbonitrile (164) was prepared as described for Example 64, Step B and was purified by preparatory LC/MS (20-40% CH₃CN in H₂O) to give the product 164 as a TFA salt (44 mg, 72% yield over two steps). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.50 (br. s., 1H) 1.73-2.18 (m, 5H) 2.64-3.48 (m, 12H) 3.76 (br. s., 1H) 4.03-4.66 (m, 4H) 7.43 (m, 4H) 7.67-7.80 (m, 5H) 7.86-7.95 (m, 3H). ESI-MS:m/z 536.2 (M+H)⁺.

Example 74
Synthesis of (R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4′-(methylsulfonyl)biphenyl-4-yl)butan-1-one (165)

embedded image

tert-Butyl(R)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(4′-(methylsulfonyl)biphenyl-4-yl)-4-oxobutan-2-ylcarbamate (74A) was prepared as described for Example 64, Step A. ESI-MS:m/z 688.3 (M+H)⁺.

embedded image

(R)-3-Amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4′-(methylsulfonyebiphenyl-4-yl)butan-1-one (165) was prepared as described for Example 64, Step B and was purified by preparatory LC/MS (20-40% CH₃CN in H₂O) to give the product 165 as a TFA salt (41 mg, 63% yield over two steps). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.51 (br. s., 1H) 1.75-2.19 (m, 5H) 2.63-3.48 (m, 15H) 3.76 (br. s., 1H) 4.06-4.67 (m, 4H) 7.44 (m, 4H) 7.69-7.80 (m, 4H) 7.94 (m, 4H). ESI-MS:m/z 589.2 (M+H)⁺.

Example 75
Synthesis of (R)-3-amino-4-(4-(3,5-dimethylisoxazol-4-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (166)

embedded image

tert-Butyl(R)-1-(4-(3,5-dimethylisoxazol-4-yl)phenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (75A) was prepared as described for Example 64, Step A. ESI-MS:m/z 629.4 (M+H)⁺.

embedded image

(R)-3-Amino-4-(4-(3,5-dimethylisoxazol-4-yl)phenyl)-1-aR)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (166) was prepared as described for Example 64, Step B and was purified by preparatory LC/MS (20-40% CH₃CN in H₂O) to give the product 166 as a TFA salt (35 mg, 58% yield over two steps). ESI-MS:m/z 530.2 (M+H)⁺.

Example 76
Synthesis of (R)-3-amino-4-(4-(2-chloropyridin-3-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (167)

embedded image

tert-Butyl(R)-1-(4-(2-chloropyridin-3-yl)phenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (76A) was prepared as described for Example 64, Step A. ESI-MS:m/z 645.3 (M+H)⁺.

embedded image

(R)-3-Amino-4-(4-(2-chloropyridin-3-yl)phenyl)-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (167) was prepared as described for Example 64, Step B and was purified 167 by preparatory LC/MS (20-40% CH₃CN in H₂O) to give the product as a TFA salt (34 mg, 56% yield over two steps). ESI-MS:m/z 546.2 (M+H)⁺.

Example 77
Synthesis of 4% ((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-carboxamide (168)

embedded image

tert-Butyl(R)-1-(4′-carbamoylbiphenyl-4-yl)-4-((R)-3-(1-(3-mettioxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (77A) was prepared as described for Example 64, Step A. ESI-MS:m/z 653.4 (M+H)⁺.

embedded image

4′-((R)-2-Amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-carboxamide (168) was prepared as described for Example 64, Step B and was purified by preparatory LC/MS (20-40% CH₃CN in H₂O) to give the product 168 as a TFA salt (37 mg, 60% yield over two steps). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.51 (br. s., 1H) 1.75-2.19 (m, 5H) 2.61-3.47 (m, 12H) 3.75 (br. s., 1H) 4.07-4.67 (m, 4H) 7.34-7.48 (m, 5H) 7.74 (m, 6H) 7.97 (m, 3H). ESI-MS:mh 554.3 (M+H)⁺.

Example 78
Synthesis of 5-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyppyrimidine-2,4(1H,3H)-dione (169)

embedded image

tert-Butyl(R)-1-(4-(2,4-di-tert-butoxypyrimidin-5-yl)phenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (78A) was prepared as described for Example 64, Step A. ESI-MS:m/z 757.7 (M+H)⁺.

embedded image

5-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)pyrimidine-2,4(1H,3H)-dione (169) was prepared as described for Example 64, Step B and was purified by preparatory LC/MS (10-35% CH₃CN in H₂O) to give the product 169 as a TFA salt (36 mg, 68% yield over two steps). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.50 (br. s., 1H) 2.06 (d, J=115.92 Hz, 5H) 2.61-3.45 (m, 12H) 3.70 (br. s., 1H) 4.39 (d, J=15.41Hz, 4H) 7.26 (m, 2H) 7.43 (m, 2H) 7.55 (m, 2H) 7.61 (m, 1H) 7.74 (m, 2H) 11.17-11.23 (m, 1H) 11.28 (m, 1H). ESI-MS:m/z 545.2 (M+H)⁺.

Example 79
Synthesis of (R)-3-amino-4-(4′-aminobiphenyl-4-yl)-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (170)

embedded image

tert-Butyl (R)-1-(4′-aminobiphenyl-4-yl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (79A) was prepared as described for Example 64, Step A. ESI-MS:m/z 626.5 (M+H)⁺.

embedded image

(R)-3-Amino-4-(4′-aminobiphenyl-4-yl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (170) was prepared as described for Example 64, Step B and was purified by preparatory LC/MS (10-40% CH₃CN in H₂O) to give the product 170 as a TFA salt (34 mg, 65% yield over two steps). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.52 (m, 1H) 1.74-2.20 (m, 5H) 2.59-3.47 (m, 12H) 3.72 (br. s., 1H) 4.08-4.68 (m, 4H) 6.96 (m, 2H) 7.32 (m, 2H) 7.40-7.62 (m, 6H) 7.71-7.81 (m, 2H). ESI-MS:m/z 526.2 (M+H)⁺.

Example 80
Synthesis of 1-(4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyphiphenyl-4-yl)-3-cyclopropylurea (171)

embedded image

tert-Butyl(R)-1-(4′-(3-cyclopropylureido)biphenyl-4-yl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (80A) was prepared as described for Example 64, Step A. ESI-MS:m/z 709.6 (M+H)⁺.

embedded image

1-(4′-((R)-2-Amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-yl)-3-cyclopropylurea (171) was prepared as described for Example 64, Step B and was purified by preparatory LC/MS (20-40% CH₃CN in H₂O) to give the product 171 as a TFA salt (29 mg, 49% yield over two steps). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.37-0.44 (m, 2H) 0.60-0.68 (m, 2H) 1.50 (br. s., 1H) 1.74-2.18 (m, 5H) 2.52-3.47 (m, 12H) 3.72 (br. s., 1H) 4.06-4.66 (m, 5H) 6.56 (br. s., 1H) 7.33 (m, 2H) 7.37 7.47 (m, 2H) 7.48-7.57 (m, 4H) 7.61 (m, 2H) 7.70 (m, 2H) 8.54 (m, 1H). ESI-MS:m/z 609.3 (M+H)⁺.

Example 81
Synthesis of 1-(4% ((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyphiphenyl-4-yl)urea (172)

embedded image

tert-Butyl(R)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxo-1-(4′-ureidobiphenyl-4-yl)butan-2-ylcarbamate (81A) was prepared as described for Example 64, Step A. ESI-MS:m/z 669.6 (M+H)⁺.

embedded image

1-(4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-yl)urea (172) was prepared as described for Example 64, Step B and was purified by preparatory LC/MS (15-35% CH₃CN in H₂O) to give the product 172 as a TFA salt (27 mg, 49% yield over two steps). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.52 (m, 1H) 1.74-2.19 (m, 5H) 2.59-3.46 (m, 10H) 3.66-3.88 (m, 1H) 4.36 (m, 6H) 5.92 (br. s., 2H) 7.33 (t, J=8.84 Hz, 2H) 7.44 (d,1=8.84 Hz, 2H) 7.47-7.56 (m, 4H) 7.60 (m, 2H) 7.73 (m, 2H) 8.71 (m, 1H). ESI-MS:m/z 569.2 (M+H)⁺.

Example 82
Synthesis of 1-(4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-yl)-3-ethylurea (173)

embedded image

tert-Butyl(R)-1-(4′-(3-ethylureido)biphenyl-4-yl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (82A) was prepared as described for Example 64, Step A. ESI-MS:m/z 697.6 (M+H)⁺.

embedded image

(1-(4′-((R)-2-Amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-yl)-3-ethylurea (173) was prepared as described for Example 64, Step B and was purified by preparatory LC/MS (20-35% CH₃CN in H₂O) to give the product 173 as a TFA salt (30 mg, 52% yield over two steps). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.06 (m, 3H) 1.50 (br. s., 1H) 1.73-2.21 (m, 5H) 2.60-3.47 (m, 12H) 3.72 (br. s., 1H) 4.05-4.68 (m, 6H) 6.24 (br. s., 1H) 7.33 (m, 2H) 7.37-7.46 (m, 2H) 7.47-7.56 (m, 4H) 7.60 (m, 2H) 7.72 (m, 2H) 8.62 (m, 1H). ESI-MS:m/z 597.3 (M+H)⁺.

Example 83
Synthesis of 3-(4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-yl)-1,1-dimethylurea (174)

embedded image

tert-Butyl(R)-1-(4′-(3,3-dimethylureido)biphenyl-4-yl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]hnidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (83A) was prepared as described for Example 64, Step A. ESI-MS:m/z 697.6 (M+H)⁺.

embedded image

3-(4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyphiphenyl-4-yl)-1,1-dimethylurea (174) was prepared as described for Example 64, Step B and was purified by preparatory LC/MS (20-40% CH₃CN in H₂O) to give the product 174 as a TFA salt (26 mg, 45% yield over two steps). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.50 (br. s., 1H) 1.74-2.19 (m, 5H) 2.61-3.48 (m, 16H) 3.71 (br. s., 1H) 4.06-4.69 (m, 6H) 7.33 (m, 4H) 7.52-7.66 (m, 6H) 7.72 (m, 2H) 8.39 (s, 1H). ESI-MS:m/z 597.3 (M+H)⁺.

Example 84
Synthesis of 1-(4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-yl)-3-methylurea (175)

embedded image

tert-Butyl(R)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(4′-(3-methylureido)biphenyl-4-yl)-4-oxobutan-2-ylcarbamate (84A) was prepared as described for Example 64, Step A. ESI-MS:m/z 683.5 (M+H)⁺.

embedded image

1-(4′-((R)-2-Amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-yl)-3-methylurea (175) was prepared as described for Example 64, Step B and was purified by preparatory LC/MS (20-30% CH₃CN in H₂O) to give the product 175 as a TFA salt (29 mg, 52% yield over two steps). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.42-1.59 (m, 1H) 1.73-2.20 (m, 5H) 2.58-3.48 (m, 14H) 3.65-3.89 (m, 1H) 4.07-4.68 (m, 5H) 6.12-6.21 (m, 1H) 7.33 (m, 2H) 7.36-7.56 (m, 6H) 7.59 (m, 2H) 7.69-7.80 (m, 2H) 8.72 (s, 1H). ESI-MS:m/z 583.2 (M+H)⁺.

Example 85
Synthesis of methyl 4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-ylcarbamate (176)

embedded image

[4′-((R)-2-tert-Butoxylcarbonylamino-4-{(R)-3-[1-(3-methoxy-propyl)-1H-benzoimidazol-2-yl]-piperidin-1-yl}-4-oxo-butyl)-biphenyl-4-yl]-carbamic acid methyl ester (85A) was prepared as described for Example 64, Step A. ESI-MS:m/z 684.6 (M+H)⁺.

embedded image

Methyl 4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-ylcarbamate (176) was prepared as described for Example 64, Step B and was purified by preparatory LC/MS (20-35% CH₃CN in H₂O) to give the product 176 as a TFA salt (41 mg, 72% yield over two steps). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.50 (br. s., 1H) 1.90 (m, 5H) 2.59-3.47 (m, 11H) 3.68 (s, 4H) 4.34 (m, 5H) 7.34 (m, 2H) 7.38-7.48 (m, 2H) 7.53-7.66 (m, 6H) 7.73 (dm, 2H) 9.77 (s, 1H). ESI-MS:m/z 584.2 (M+H)⁺.

Example 86
Synthesis of 4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-N-(2-methoxyethypbiphenyl-4-carboxamide (177)

embedded image

Methyl 4′-((R)-2-(tert-butoxycarbonylamino)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-carboxylate (53A) (prepared by the procedure for Example 53, Step A) (0.815 mmoles, 0.545 g) was added to a 25 mL round-bottomed flask equipped for stirring under nitrogen. Tetrahydrofuran (2 mL), methanol (1 mL), and LiOH (2.0 mmoles, 1.0 mL of 2N in H₂O) were then added and the resultant solution was allowed to stir at room temperature for 16 hrs. Citric acid (2.09 mmoles, 0.403 g) in H₂O (1 mL) was then added and the resultant solution was concentrated in-vacuo, filtered, and then purified by preparative LC/MS. The resultant fractions were collected and the solvent was removed in-vacuo affording a brown colored oil. This oil was re-dissolved in CH₃CN (1 mL) and water (2 mL). The resultant solution was frozen and lyophilized to afford 4′-((R)-2-(tert-butoxycarbonylamino)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-carboxylic acid (86A) as a tan flocculent solid (0.637 mmoles, 0.417 g, 78% yield). ESI-MS: m/z 655.5 (M+H)⁺.

embedded image

4′-((R)-2-(tert-butoxycarbonylamino)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-carboxylic acid (86A) (0.061 mmoles, 0.040 g) was added to a 5 mL round-bottomed flask equipped for stirring under nitrogen. DMF (1.0 mL), 2-methoxyethanamine (0.079 mmoles, 0.007 mL) and N-methylmorpholine (0.183 mmoles, 0.020 mL) were then added and the solution was allowed to stir at it for 5 min. HATU (0.079 mmoles, 0.030 g) was added and the resultant solution was stirred at room temperature for 3 hrs. The reaction solution was then directly purified by preparative LC/MS (20-65% CH₃CN in H₂O). The resultant fractions were collected and the solvent was removed in-vacuo affording tert-butyl (R)-1-(4′-(2-methoxyethylcarbamoyl)biphenyl-4-yl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-34)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (86B) as a clear oil. (0.053 mmoles, 0.038 g, 86% yield). ESI-MS: m/z 712.4 (M+H)⁺.

embedded image

tert-butyl (R)-1-(4′-(2-methoxyethylcarbamoyl)biphenyl-4-yl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (86B) (0.053 mmoles, 0.038 g) was added to a 10 mL round-bottomed flask equipped for stirring under nitrogen. Dichloromethane (1 mL) and trifluoroacetic acid (1 mL) were then added and the resultant solution was allowed to stir under nitrogen for 4 hrs. The solvent was removed in-vacuo affording a clear colored oil. This oil was re-dissolved in Methanol (3 mL), filtered, and then purified by preparative LC/MS (0.5-50% CH₃CN in H₂O). The resultant fractions were collected and the solvent was removed in-vacuo affording a clear colored oil. This oil was re-dissolved in CH₃CN (1 mL) and water (2 mL). The resultant solution was frozen and lyophilized to afford 4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-N-(2-methoxyethyl)biphenyl-4-carboxamide (177) as its trifluoroacetic acid salt and as a white flocculent solid (0.033 mmoles, 0.024 g, 62% yield). ESI-MS: m/z 612.3 (M+H)⁺. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.40-1.62 (m, 1H) 1.74-2.21 (m, 5H) 2.58-2.86 (m, 3H) 2.90-3.16 (m, 4H) 3.16-3.25 (m, 3H) 3.28 (s, 3H) 3.30-3.51 (m, 7H) 3.64-4.19 (m, 2H) 4.27-4.70 (m, 4H) 7.36-7.50 (m, 4H) 7.68-7.82 (m, 6H) 7.95 (dd, J=8.46, 2.40 Hz, 2H) 8.54-8.63 (m, 1H).

Other compounds that were prepared by the procedure of Example 86 are listed in Table IV.

TABLE IV

Com-

pound

No.
Structure/Name
Physical Properties

178

embedded image

ESI-MS: m/z 626.3 (M + H)⁺¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.12 (t, J = 6.95 Hz, 3 H) 1.40-1.60 (m, 1 H) 1.72-2.18 (m, 5 H) 2.61-2.86 (m, 3 H) 2.89-3.23 (m, 8 H) 3.23- 3.90 (m, 11 H) 4.01-4.65 (m, 3 H) 7.27- 7.46 (m, 4 H) 7.62-7.81 (m, 6 H) 7.92-8.00 (m, 2 H) 8.59 (t, J = 5.68 Hz, 1 H)

4′-((R)-2-amino-4-((R)-3-(1-(3-

methoxypropyl)-1H-benzo[d]imidazol-2-

yl)piperidin-1-yl)-4-oxobutyl)-N-(2-

ethoxyethyl)biphenyl-4-carboxamide

179

embedded image

ESI-MS: m/z 640.4 (M + H)⁺. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.09 (d, J = 6.06 Hz, 6 H) 1.41-1.61 (m, 1 H) 1.73-2.19 (m, 6 H) 2.60-2.85 (m, 3H) 2.90-3.15 (m, 4 H) 3.15- 3.27 (m, 3 H) 3.29-3.46 (m, 4 H) 3.47- 3.62 (m, 4 H) 3.69-4.14 (m, 2 H) 4.25-4.68 (m, 3 H) 7.35-7.49 (m, 4 H) 7.68-7.81 (m, 6 H) 7.92-8.00 (m, 2 H) 8.53-8.60 (m, 1 H)

4′-((R)-2-amino-4-((R)-3-(1-(3-

methoxypropyl)-1H-benzo[d]imidazol-2-

yl)piperidin-1-yl)-4-oxobutyl)-N-(2-

isopropoxyethyl)biphenyl-4-carboxamide

180

embedded image

ESI-MS: m/z 626.4 (M + H)⁺. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.37-1.63 (m, 1 H) 1.70-2.23 (m, 7 H) 2.59-2.86 (m, 3 H) 2.89-3.16 (m, 4 H) 3.16-3.27 (m, 6 H) 3.27-3.47 (m, 7 H) 3.67-4.15 (m, 2 H) 4.26- 4.70 (m, 4 H) 7.33-7.52 (m, 4 H) 7.64- 7.81 (m, 6 H) 7.86-7.97 (m, 2 H) 8.48-8.57 (m, 1 H)

4′-((R)-2-amino-4-((R)-3-(1-(3-

methoxypropyl)-1H-benzo[d]imidazol-2-

yl)piperidin-1-yl)-4-oxobutyl)-N-(3-

methoxypropyl)biphenyl-4-carboxamide

181

embedded image

ESI-MS: m/z 628.3 (M + H)⁺.

4′-((R)-2-amino-4-((R)-3-(1-(3-

methoxypropyl)-1H-benzo[d]imidazol-2-

yl)piperidin-1-yl)-4-oxobutyl)-N-(2,3-

dihydroxypropyl)biphenyl-4-carboxamide

182

embedded image

ESI-MS: m/z 598.3 (M + H)⁺.

4′-((R)-2-amino-4-((R)-3-(1-(3-

methoxypropyl)-1H-benzo[d]imidazol-2-

yl)piperidin-1-yl)-4-oxobutyl)-N-(2-

hydroxyethyl)biphenyl-4-carboxamide

183

embedded image

ESI-MS: 626.3 m/z (M + H)⁺. 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.33 (s, 6 H) 1.38-1.60 (m, 1 H) 1.71-2.18 (m, 5 H) 2.61-2.86 (m, 4 H) 2.87-3.23 (m, 7 H) 3.24-3.47 (m, 4 H) 3.65-4.08 (m, 2 H) 4.22-4.63 (m, 3 H) 7.27-7.46 (m, 4 H) 7.58 (s, 1 H) 7.63-7.80 (m, 6 H) 7.87-7.92 (m, 2 H)

4′-((R)-2-amino-4-((R)-3-(1-(3-

methoxypropyl)-1H-benzo[d]imidazol-2-

yl)piperidin-1-yl)-4-oxobutyl)-N-(1-hydroxy-

2-methylpropan-2-yl)biphenyl-4-carboxamide

184

embedded image

ESI-MS: 626.3 m/z (M + H)⁺. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.40-1.58 (m, 1 H) 1.72-2.17 (m, 5 H) 2.61-2.86 (m, 3 H) 2.89-3.24 (m, 7 H) 3.24-3.47 (m, 3 H) 3.50-3.55 (m, 4 H) 3.67-4.08 (m, 4 H) 4.22- 4.63 (m, 5 H) 7.26-7.47 (m, 4 H) 7.60- 7.80 (m, 6 H) 7.94-8.04 (m, 3 H)

4′-((R)-2-amino-4-((R)-3-(1-(3-

methoxypropyl)-1H-benzo[d]imidazol-2-

yl)piperidin-1-yl)-4-oxobutyl)-N-(1,3-

dihydroxypropan-2-yl)biphenyl-4-carboxamide

185

embedded image

ESI-MS: 624.3 m/z (M + H)⁺. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.40-1.60 (m, 1 H) 1.73-2.21 (m, 7 H) 2.58-2.85 (m, 3 H) 2.89-3.28 (m, 8 H) 3.28-3.68 (m, 8 H) 3.74 (br. s., 1 H) 3.80-4.66 (m, 5 H) 7.32-7.49 (m, 4H) 7.57-7.64 (m, 2 H) 7.66-7.77 (m, 6 H).

(R)-3-amino-4-(4′-((R)-3-hydroxypyrrolidine-

1-carbonyl)biphenyl-4-yl)-1-((R)-3-(1-(3-

methoxypropyl)-1H-benzo[d]imidazol-2-

yl)piperidin-1-yl)butan-1-one

186

embedded image

ESI-MS: 612.3 m/z (M + H)⁺. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.14 (d , J = 6.82 Hz, 3 H) 1.37-1.63 (m, 1 H) 1.72-2.21 (m, 5 H) 2.62-2.86 (m, 3 H) 2.90-3.25 (m, 7 H) 3.29- 3.52 (m, 4 H) 3.74 (br. s., 1 H) 3.80- 4.14 (m, 3 H) 4.25-4.66 (m, 5 H) 7.33- 7.48 (m, 4 H) 7.65-7.83 (m, 6 H) 7.93-7.98 (m, 2 H) 8.10-8.19 (m, 1 H).

4′-((R)-2-amino-4-((R)-3-(1-(3-

methoxypropyl)-1H-benzo[d]imidazol-2-

yl)piperidin-1-yl)-4-oxobutyl)-N-((R)-1-

hydroxypropan-2-yl)biphenyl-4-carboxamide

187

embedded image

ESI-MS: 612.3 m/z (M + H)⁺. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.15 (d, J = 6.82 Hz, 3 H) 1.40-1.60 (m, 1 H) 1.72-2.21 (m, 5 H) 2.59-2.86 (m, 3 H) 2.90-3.25 (m, 7 H) 3.29- 3.51 (m, 4 H) 3.74 (br. s., 1 H) 3.81- 4.15 (m, 3 H) 4.27-4.68 (m, 5 H) 7.36- 7.51 (m, 4 H) 7.67-7.81 (m, 6 H) 7.93-7.98 (m, 2 H) 8.16 (d, J = 8.08 Hz, 1 H).

4′-((R)-2-amino-4-((R)-3-(1-(3-

methoxypropyl)-1H-benzo[d]imidazol-2-

yl)piperidin-1-yl)-4-oxobutyl)-N-((S)-1-

hydroxypropan-2-yl)biphenyl-4-carboxamide

188

embedded image

ESI-MS: 612.3 m/z (M + H)⁺. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.14 (d, J = 6.82 Hz, 3 H) 1.37-1.63 (m, 1 H) 1.72-2.21 (m, 5 H) 2.62-2.86 (m, 3 H) 2.90-3.25 (m, 7 H) 3.29- 3.52 (m, 4 H) 3.74 (br. s., 1 H) 3.80- 4.14 (m, 3 H) 4.25-4.66 (m, 5 H) 7.33- 7.48 (m, 4 H) 7.65-7.83 (m, 6 H) 7.93-7.98 (m, 2 H) 8.10-8.19 (m, 1 H).

4′-((R)-2-amino-4-((R)-3-(1-(3-

methoxypropyl)-1H-benzo[d]imidazol-2-

yl)piperidin-1-yl)-4-oxobutyl)-N-(2-hydroxy-

2-methylpropyl)biphenyl-4-carboxamide

189

embedded image

ESI-MS: 637.4 m/z (M + H)⁺. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.39-1.61 (m, 1 H) 1.71-2.18 (m, 5 H) 2.60-2.86 (m, 3 H) 2.90-3.11 (m, 4 H) 3.12-3.47 (m, 8 H) 3.67-4.15 (m, 6 H) 4.23-4.66 (m, 4 H) 7.06- 7.14 (m, 1 H) 7.30-7.58 (m, 6 H) 7.64- 7.80 (m, 5 H) 8.16 (br. s., 1 H).

4-(4′-((R)-2-amino-4-((R)-3-(1-(3-

methoxypropyl)-1H-benzo[d]imidazol-2-

yl)piperidin-1-yl)-4-

oxobutyl)biphenylcarbonyl)piperazin-2-one

Example 87
Synthesis of 4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-fluoro-N-(2-hydroxyethyl) biphenyl-4-carboxamide (190)

embedded image

Ethyl 4′-((R)-2-(tert-butoxycarbonylamino)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-fluorobiphenyl-4-carboxylate (87A) was prepared by the procedure of Example 53, Step A. ESI-MS:m/z 700.5 (M+H)⁺.

embedded image

4′-((R)-2-(tert-Butoxycarbonylamino)-4-((R)-3-(1-(3-methoxypropyl)-1,1-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-fluorobiphenyl-4-carboxylic acid (87B) was prepared according to Example 86, Step A. The solvent was removed and the residue was purified by preparatory LC/MS (35-55% CH₃CN in H₂O) to give the product 87B (130 mg, 79% yield over two steps). ESI-MS:m/z 672.3 (M+H)⁺.

embedded image

tert-Butyl (R)-1-(3′-fluoro-4′-(2-hydroxyethylcarbamoyl)biphenyl-4-yl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (87C) was prepared according to Example 86, Step B. The solvent was removed and the residue was purified by preparatory LC/MS (25-50% CH₃CN in H₂O). ESI-MS:m/z 716.3 (M+H)⁺.

embedded image

4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-fluoro-N-(2-hydroxyethyl)biphenyl-4-carboxamide (190) was prepared according to Example 86, Step C. The solvent was removed and the residue was purified by preparatory LC/MS (20-30% CH₃CN in H₂O) to give the product 190 as a TFA salt (15 mg, 21% yield over two steps). ESI-MS:m/z 616.3 (M+H)⁺.

Example 88
Synthesis of 4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-fluoro-N-(2-methoxyethyphiphenyl-4-carboxamide (191)

embedded image

tert-Butyl (R)-1-(3′-fluoro-4′-(2-methoxyethylcarbamoyl)biphenyl-4-yl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (88A) was prepared from 87B (Example 87) according to the procedure of Example 87, Step C. The solvent was removed and the residue was purified by preparatory LC/MS (35-55% CH₃CN in H₂O). ESI-MS:m/z 730.5 (M+H)⁺.

embedded image

4′-((R)-2-Amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzoldlimidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-fluoro-N-(2-methoxyethyl)biphenyl-4-carboxamide (191) was prepared from 88A according to the procedure of Example 87, Step D. The solvent was removed and the residue was purified by preparatory LC/MS (20-40% CH₃CN in H₂O) to give the product 191 as a TFA salt (33 mg, 46% yield over two steps). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.41-1.62 (m, 1H) 1.74-2.20 (m, 5H) 2.61-3.50 (m, 19H) 3.70-3.90 (m, 1H) 4.09-4.68 (m, 4H) 7.41 (m, 4H) 7.62 (m, 2H) 7.68-7.81 (m, 5H) 8.29-8.35 (m, 1H). ESI-MS:m/z 630.3 (M+H)⁺.

Example 89
Synthesis of 4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-2-chloro-N-(2-hydroxyethyl)biphenyl-4-carboxamide (192)

embedded image

Methyl 4′-((R)-2-(tert-butoxycarbonylamino)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-2-chlorobiphenyl-4-carboxylate (89A) was prepared according to the procedure of Example 87, Step A. ESI-MS:m/z 702.3 (M+H)⁺.

embedded image

4′-((R)-2-(tert-Butoxycarbonylamino)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-2-chlorobiphenyl-4-carboxylic acid (89B) was prepared from 89A according to the procedure described in Example 87, Step B. The solvent was removed and the residue was purified by preparatory LC/MS (35-45% CH₃CN in H₂O) to give the product (116 mg, 69% yield over two steps). ESI-MS:m/z 688.3 (M+H)⁺.

embedded image

tert-Butyl(R)-1-(2′-chloro-4′-(2-hydroxyethylcarbamoyl)biphenyl-4-yl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (89C) was prepared from 89B according to the procedure described in Example 87, Step C. The solvent was removed and the residue was purified by preparatory LC/MS (25-45% CH₃CN in H₂O). ESI-MS:m/z 732.3 (M+H)⁺.

embedded image

4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]iimidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-2-chloro-N-(2-hydroxyethyl)biphenyl-4-carboxamide (192) was prepared from 89C according to the procedure of Example 87, Step D. The solvent was removed and the residue was purified by preparatory LC/MS (20-35% CH₃CN in H₂O) to give the product 192 as a TFA salt (24 mg, 38% yield over two steps). ESI-MS:m/z 632.3 (M+H)⁺.

Example 90
4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-2-chloro-N-(2-methoxyethyl)biphenyl-4-carboxamide (193)

embedded image

tert-Butyl(R)-1-(2′-chloro-4′-(2-methoxyethylcarbamoyl)biphenyl-4-yl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (90A) was prepared from 89B (Example 89) according to the procedure described in Example 87, Step C. The solvent was removed and the residue was purified by preparatory LC/MS (35-50% CH₃CN in H₂O). ESI-MS:m/z 746.5 (M+H)⁺.

embedded image

4′-((R)-2-Amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-2-chloro-N-(2-methoxyethyl)biphenyl-4-carboxamide (193) was prepared from 90A according to the procedure of Example 87, Step D. The solvent was removed and the residue was purified by preparatory LC/MS (20-35% CH₃CN in H₂O) to give the product 193 as a TFA salt (29 mg, 45% yield over two steps). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.50 (br. s., 1H) 1.93 (br. s., 5H) 2.63-3.51 (m, 19H) 3.77 (br. s., 1H) 4.07-4.66 (m, 4H) 7.36-7.52 (m, 7H) 7.72 (m, 2H) 7.92 (m, 1H) 8.04 (s, 1H) 8.74 (br. s., 1H). ESI-MS:m/z 646.3 (M+H)⁺.

Example 91
Synthesis of 5-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-N-(2-hydroxyethyppieolinamide (194)

embedded image

Methyl 5-(4-((R)-2-(tert-butoxycarbonylamino)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)picolinate (91A) was prepared according to the procedure of Example 87, Step A. ESI-MS:m/z 670.5 (M+H)⁺.

embedded image

5-(4-((R)-2-(tert-Butox ylcarbonylamino)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)picolinic acid (91B) was prepared from 91A according to the procedure described in Example 87, Step B. The solvent was removed and the residue was purified by preparatory LC/MS (25-45% CH₃CN in H₂O) to give the product (150 mg, 94% yield over two steps). ESI-MS:m/z 656.3 (M+H)⁺.

embedded image

tert-Butyl (R)-1-(4-(6-(2-hydroxyethylcarbamoyl)pyridin-3-yl)phenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcaxbamate (91C) was prepared from 91B according to the procedure of Example 87, Step C. The solvent was removed and the residue was purified by preparatory LC/MS (25-45% CH₃CN in H₂O). ESI-MS:m/z 699.6 (M+H)⁺.

embedded image

5-(4-((R)-2-Amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-N-(2-hydroxyethyl)picolinamide (194) was prepared according to the procedure of Example 87, Step D. The solvent was removed and the residue was purified by preparatory LC/MS (15-30% CH₃CN in H₂O) to give the product 194 as a TFA salt (25 mg, 31% yield over two steps). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.50 (br. s., 1H) 2.07 (m, 5H) 2.60-3.57 (m, 15H) 3.76 (br. s., 2H) 4.08-4.68 (m, 5H) 7.46 (m, 4H) 7.82 (m, 4H) 8.12 (m, 1H) 8.28 (m, 1H) 8.69 (m, 1H) 8.94-8.97 (m, 1H). ESI-MS:m/z 599.3 (M+H)⁺.

Example 92
Synthesis of 5-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-yl)-4-oxobutyl)phenyl)-N-(2-methoxyethyl)picolinamide (195)

embedded image

tert-Butyl (R)-1-(4-(6-(2-methoxyethylearbamoyppyridin-3-yl)phenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (92A) was prepared from 91B (prepared in Example 91) according to the procedure described for Example 87, Steps A-C. The solvent was removed and the residue was purified by preparatory LC/MS (35-45% CH₃CN in H₂O). ESI-MS:m/z 713.6 (M+H)⁺.

embedded image

Compound 195 was prepared from 92A according to the procedure of Example 87, Step D. The solvent was removed and the residue was purified by preparatory LC/MS (15-40% CH₃CN in H₂O) to give the product 195 as a TFA salt (24 mg, 29% yield over two steps). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.74 (br. s., 1H) 1.92-2.36 (m, 5H) 2.69-3.28 (m, 9H) 3.39-3.67 (m, 10H) 3.98 (s, 2H) 4.65 (m, 3H) 7.44-7.52 (m, 2H) 7.63 (m, 2H) 7.78 (m, 3H) 7.85-7.95 (m, 1H) 8.14-8.24 (m, 2H) 8.91 (br. s., 1H). ESI-MS:m/z 613.3 (M+H)⁺.

Example 93
Synthesis of 5-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutypphenye-N-(1-hydroxy-2-methylpropan-2-yl)thiophene-2-carboxamide (196)

embedded image

5-(4-((R)-2-(tert-Butoxycarbonylamino)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)thiophene-2-carboxylic acid (93A) was prepared according to the procedure of Example 87, Step B.

embedded image

tert-Butyl (R)-1-(4-(5-(1-hydroxy-2-methylpropan-2-ylcarbamoyl)thiophen-2-yl)phenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (93B) was prepared from 93A according to the procedure of Example 87, Step C. The solvent was removed and the residue was purified by preparatory LC/MS (30-50% CH₃CN in H₂O). ESI-MS:m/z 732.4 (M+H)⁺.

embedded image

5-(4-((R)-2-Amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-N-(1-hydroxy-2-methylpropan-2-yOthiophene-2-carboxamide (196) was prepared according to the procedure of Example 87, Step D. The solvent was removed and the residue was purified by preparatory LC/MS (15-35% CH₃CN in H₂O) to give the product 196 as a TFA salt (18 mg, 26% yield over two steps). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.30 (s, 6H) 1.49 (br. s., 1H) 1.74-2.18 (m, 5H) 2.62-3.53 (m, 12H) 3.67-3.88 (m, 1H) 4.04-4.67 (m, 7H) 7.35 (m, 4H) 7.51 (m, 1H) 7.58 (s, 1H) 7.69 (m, 4H) 7.82 (m, 1H). ESI-MS:m/z 632.3 (M+H)⁺.

Example 94
Synthesis of N-(4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-yl)-2-methoxyacetamide (197)

embedded image

tert-Butyl (R)-1-(4′-(2-methoxyacetamido)biphenyl-4-yl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (94A) was prepared from 79A (Example 79) according to the procedure of Example 86, Step B. The solvent was removed and the residue was purified by preparatory LC/MS (30-50% CH₃CN in H₂O). ESI-MS:m/z 698.4 (M+H)⁺.

embedded image

N-(4′-((R)-2-Amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-yl)-2-methoxyacetamide (197) was prepared according to the procedure of Example 86, Step C. The solvent was removed and the residue was purified by preparatory LC/MS (15-40% CH₃CN in H₂) to give the product 197 as its TFA salt (56 mg, 62% yield over two steps). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.50 (br. s., 1H) 1.73-2.20 (m, 5H) 2.58-3.46 (m, 14H) 3.73 (br. s., 1H) 4.02 (s, 2H) 4.35 (m, 5H) 7.35 (m, 2H) 7.39-7.50 (m, 2H) 7.63 (m, 4H) 7.77 (m, 4H) 9.88 (m, 1H). ESI-MS:m/z 598.3 (M+H)⁺.

Example 95
Synthesis of N-(4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-yl-2-hydroxyacetamide (198)

embedded image

tert-Butyl (R)-1-(4′-(2-hydroxyacetamido)biphenyl-4-yl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (95A) was prepared according to the procedure described in Example 94, Step A. The solvent was removed and the residue was purified by preparatory LC/MS (30-50% CH₃CN in H₂O). ESI-MS:m/z 684.4 (M+H)⁺.

embedded image

N-(4′-((R)-2-Amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-yl)-2-hydroxyacetamide (198) was prepared according to the procedure of Example 94, Step B. The solvent was removed and the residue was purified by preparatory LC/MS (15-30% CH₃CN in H₂O) to give the product 198 as its TFA salt (21 mg, 24% yield over two steps). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.36 (s, 6H) 1.50 (br. s., 1 H) 1.73-2.19 (m, 5H) 2.59-3.46 (m, 13H) 3.73 (br. s., 1H) 4.08-4.68 (m, 4H) 7.35 (m, 2H) 7.44 (m, 2H) 7.64 (m, 4H) 7.74 (m, 2H) 7.84 (m, 2H) 9.67 (m, 1H). ESI-MS:m/z 584.2 (M+H)⁺.

Example 96
Synthesis of N-(4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-yl)-2-hydroxy-2-methylpropanamide (199)

embedded image

tert-Butyl (R)-1-(4′-(2-hydroxy-2-methylpropanamido)biphenyl-4-yl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (96A) was prepared as described in Example 94, Step A. The solvent was removed and the residue was purified by preparatory LC/MS (35-50% CH₃CN in H₂O). ESI-MS:m/z 712.4 (M+H)⁺.

embedded image

N-(4′-((R)-2-Amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-yl)-2-hydroxy-2-methylpropanamide (199) was prepared according to the procedure described in Example 94, Step B. The solvent was removed and the residue was purified by preparatory LC/MS (15-40% CH₃CN in H₂O) to give the product 199 as its TFA salt (36 mg, 39% yield over two steps). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.51 (br. s., 1H) 1.74-2.20 (m, 5H) 2.60-3.47 (m, 12H) 3.73 (br. s., 1H) 4.01 (s, 2H) 4.36 (br. s., 4H) 7.35 (m, 2H) 7.44 (br. s., 2H) 7.63 (m, 4H) 7.81 (m, 4H) 9.78 (s, 1H). ESI-MS:m/z 612.3 (M+H)⁺.

Example 97
Synthesis of (R)-3-amino-4-(4-(2-ethoxythiazol-4-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (200)

embedded image

tert-Butyl(R)-1-(4-bromophenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (6A) (prepared according to Example 6, Step A) (0.815 mmol, 0.500 g), bis(pinacolato)diboron (2.45 mmol, 0.623 g), Pd(dppf)Cl₂, and sodium acetate (2.45 mmol, 0.201 g) were then added to a reaction vessel. The reaction vessel was flushed with nitrogen, sealed, and heated to 80° C. for 48 hrs. The reaction solution was then poured into water, extracted with ethyl acetate, and washed once with saturated aqueous sodium chloride. The organic layer was collected and subsequently dried with anhydrous Na₂SO₄and filtered. This filtrate was collected, concentrated, and dried in-vacuo. This crude material was directly purified by preparative LC/MS (15-85% CH₃CN in H₂O). The resultant fractions were collected and the solvent was removed in-vacuo affording the title compound as a brown oil. This oil was re-dissolved in CH₃CN (1 mL) and water (2 mL). The resultant solution was frozen and lyophilized to afford tert-butyl (R)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxo-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)butan-2-ylcarbamate (97A) as a brown flocculent solid (0.646 mmol, 0.427 g, 79% yield). ESI-MS: m/z 661.6 (M+H)⁺.

embedded image

tert-Butyl (R)-4-((R)-3-O-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxo-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)butan-2-ylcarbamate (97A) (0.091 mmol, 0.060 g) and 4-bromo-2-ethoxythiazole (0.10 mmol, 0.021 g) were added to a 5 mL microwave vessel equipped with a magnetic stir bar. Dioxane (2 mL) and Na₂CO₃(1 mL of a 2 M aqueous solution) were then added and the reaction vessel was flushed with nitrogen gas. PdCl₂(dppf) (0.009 mmol, 0.007 g) was added, the reaction vessel was sealed and placed in a microwave reactor and heated to 110° C. for 15 minutes. The reaction solution was then poured into water, extracted with ethyl acetate, and washed once with saturated aqueous sodium chloride. The organic layer was collected and subsequently dried with anhydrous Na₂SO₄and filtered. This filtrate was collected, concentrated, and dried in-vacuo. This crude material was directly purified by preparative LC/MS (25-85% CH₃CN in H₂O). The resultant fractions were collected and the solvent was removed in-vacuo affording tert-butyl (R)-4-(R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-yl)-1-(4-(2-methoxythiazol-4-yl)phenyl)-4-oxobutan-2-ylcarbamate (97B) as a clear oil which was used directly in the next step without further quantification. ESI-MS: m/z 662.4 (M+H)⁺.

embedded image

tert-Butyl (R)-1-(4-(2-ethoxythiazol-4-yl)phenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (97B) (0.091 mmol max, crude oil) was added to a 10 mL round-bottomed flask equipped for stirring under nitrogen. Dichloromethane (2 mL) and trifluoroacetic acid (2 mL) were then added and the solution was stirred at room temperature for 2 hrs. The solvent was removed in-vacuo affording a clear colored oil. This oil was re-dissolved in methanol (3 mL), filtered, and then purified by preparative LC/MS (10-55% CH₃CN in H₂O). The resultant fractions were collected and the solvent was removed in-vacuo affording a clear colored oil. This oil was re-dissolved in CH₃CN (1 mL) and water (2 mL). The resultant solution was frozen and lyophilized to afford (R)-3-amino-4-(4-(2-ethoxythiazol-4-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (200) as its trifluoroacetic acid salt as a white flocculent solid (0.061 mmol, 0.041 g, 67% yield over 2-steps). ESI-MS: 562.2 m/z (M+H)⁺. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.39-1.66 (m, 1H) 1.67-2.12 (m, 5H) 2.28-2.44 (m, 2H) 2.56-2.95 (m, 4H) 2.94-3.28 (m, 7H) 3.84-4.05 (m, 1H) 4.09 (d, J=1.77 Hz, 5H) 4.44-4.61 (m, 1 H) 7.09-7.60 (m, 7H) 7.70-7.93 (m, 2H).

Other compounds that were prepared by the procedure of Example 97 are listed in Table V.

TABLE V

Com-

pound

No.
Structure/Name
Physical Properties

201

embedded image

ESI-MS: 548.3 m/z (M + H)⁺. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.39- 1.66 (m, 1 H) 1.67-2.12 (m, 5 H) 2.28- 2.44 (m, 2 H) 2.56-2.95 (m, 4 H) 2.94- 3.28 (m, 7 H) 3.84-4.05 (m, 1 H) 4.09 (d, J = 1.77 Hz, 5 H) 4.44-4.61 (m, 1 H) 7.09- 7.60 (m, 7 H) 7.70-7.93 (m, 2 H).

(R)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-

1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-

4-(4-(2-methoxythiazol-4-yl)phenyl)butan-1-one

202

embedded image

ESI-MS: 548.3 m/z (M + H)⁺. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.39- 1.66 (m, 1 H) 1.67-2.12 (m, 5 H) 2.28- 2.44 (m, 2 H) 2.56-2.95 (m, 4 H) 2.94- 3.28 (m, 7 H) 3.84-4.05 (m, 1 H) 4.09 (d, J = 1.77 Hz, 5 H) 4.44-4.61 (m, 1 H) 7.09- 7.60 (m, 7 H) 7.70-7.93 (m, 2 H)

(R)-3-amino-4-(4-(2-isopropylthiazol-4-yl)phenyl)-

1-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one

Example 98
Synthesis of 4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-N-cyclohexylbenzamide (203)

embedded image

tert-Butyl (R)-1-(4-bromophenyl)-4-((R)-3-(1-(3-methoxypropyl)-11⁻¹-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (6A) (as prepared in Example 6, Step A) (0.098 mmol, 0.060 g) was added to a 5 mL microwave vessel equipped for stirring. Cyclohexanamine (0.293 moles, 0.034 mL), palladium(II) acetate (0.01 mmol, 0.002 g), Mo(CO)₆(0.098 mmol, 0.026 g), 1,8 diazabicyclo[5.4.0]undec-7-ene (0.293 mmol, 0.044 mL), imidazole (0.049 mmol, 0.003 g), and THF (2 mL) were then added. The flask was sealed and heated to 150° C. for 15 min in the microwave. The reaction mixture was filtered over celite and the solid rinsed with THF (20 mL). The filtrate was collected and concentrated in-vacuo. This crude oil was re-dissolved in methanol (3 mL), filtered, and then purified by preparative LC/MS (20-80% CH₃CN in H₂O). The resultant fractions were collected and the solvent was removed in-vacuo affording tert-butyl (R)-1-(4-(cyclohexylcarbamoyl)phenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (98A) as a clear colored oil (0.039 mmol, 0.025 g, 39% yield). ESI-MS: 660.4 m/z (M+H)⁺.

embedded image

98A (0.039 mmol, 0.025 g) was added to a 10 mL round-bottomed flask equipped for stirring under nitrogen. Dichloromethane (2 mL) and trifluoroacetic acid (2 mL) were then added and the solution was stirred at room temperature for 2 hrs. The solvent was removed in-vacuo affording a clear colored oil. This oil was re-dissolved in methanol (3 mL), filtered, and then purified by preparative LC/MS (0.5-50% CH₃CN in H₂O). The resultant fractions were collected and the solvent was removed in-vacuo affording a clear colored oil. This oil was re-dissolved in CH₃CN (1 mL) and water (2 mL). The resultant solution was frozen and lyophilized to afford 4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-N-cyclohexylbenzamide (203) as its trifluoroacetic acid salt and as a white flocculent solid. (0.009 mmol, 0.006 g, 24% yield). ESI-MS: 560.3 m/z (M+H)⁺.

Example 99
Synthesis of (R)-3-amino-4-(4-(1,2-dimethyl-1H-imidazol-5-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (204)

embedded image

The mixture of aryl bromide, (R)-3-amino-4-(4-(2-ethoxythiazol-4-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (6A) (as prepared in Example 6, Step A) (614 mg, 1.00 mmol), bis(pinacolato)diboron (305 mg, 1.2 mmol, 1.2 eq), sodium acetate (246 mg, 3.0 mmol, 3 eq), Pd(dppf)Cl₂(36.6 mg, 5% mol) in DMF (4 mL) was heated at 90° C. for 30 min in a microwave reactor. More pinocoldiboron (150 mg) was added, the reaction was heated at 90° C. for 105 min. Solvent was removed in vacuo, the black-brown residue was suspended in DCM and passed through a pad of SiO₂, washed with DCM, then 50% DCM/50% EtOAd2% MeOH. After removing solvents, the crude product tert-butyl (R)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzoldjimidazol-2-yl)piperidin-1-yl)-4-oxo-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)butan-2-ylcarbamate (99A) was obtained as a yellow oil (720 mg, 100% yield). ESI-MS: m/z 661.6 (M+H)⁺. ¹H NMR (400 MHz, MeOH-d₄) δ ppm 3.31 (s, 3H) 3.66-3.70 (m, 2H) 4.21-4.25 (m, 2H) 7.1-7.6 (m, 8H); HPLC rentation time: T. 1.070 min, FSTFA-2 method and T. 1.764 min, STDTFA-2 method.

embedded image

tert-Butyl (R)-1-(4-(1,2-dimethyl-1H-imidazol-5-yl)phenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (99B) was prepared according to the procedure outlined in Example 97, Step B. ESI-MS:m/z 629.6 (M+H)⁺.

embedded image

Crude product (R)-3-amino-4-(4-(1,2-dimethyl-1H-imidazol-5-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (204) was prepared as described above for Example 97, Sep C. Purification by preparatory LC/MS (10-30% CH₃CN in H₂O) gave the product 204 as its TFA salt (25 mg, 47% yield). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.53 (br. s., 1H) 1.95 (m, 5H) 2.66 (s, 5H) 2.84-3.51 (m, 9H) 3.65 (m, 3H) 3.72-3.90 (m, 1H) 4.35 (s, 5H) 7.38 (m, 2H) 7.44-7.56 (m, 4H) 7.65-7.74 (m, 3H). ESI-MS:m/z 529.2 (M+H)⁺.

Example 100
Synthesis of 5-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-1,3-dimethylpyrimidine-2,4(1H,3H)-dione (205)

embedded image

tert-Butyl (R)-1-(4-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)phenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (100A) was prepared according to the procedures outlined in Example 97, Step B. ESI-MS:m/z 673.5 (M+H)⁺.

embedded image

Crude product of 5-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-1,3-dimethylpyrimidine-2,4(1H,3H)-dione (205) was prepared as described above for Example 97, Step C. Purification by preparatory LC/MS (15-30% CH₃CN in H₂O) gave the product (205) as its TFA salt (31 mg, 42% yield). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.52 (br. s., 1H) 1.75-2.22 (m, 5H) 2.59-2.81 (m, 3H) 2.85-3.47 (m, 15H) 3.73 (br. s., 1H) 4.04-4.68 (m, 4H) 7.30 (m, 2H) 7.39-7.51 (m, 2H) 7.58 (t, Ham, 2H) 7.74 (m, 2H) 7.97 (m, 1H). ESI-MS:m/z 573.2 (M+H)⁺.

Example 101
Synthesis of 4-(4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-yl)-3-methyl-1H-1,2,4-triazol-5(4H)-one (206)

embedded image

tert-butyl(R)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(4′-(3-methyl-5-oxo-1H-1,2,4-triazol-4(5H)-yl)biphenyl-4-yl)-4-oxobutan-2-ylcarbamate (101A) was prepared according to the procedures outlined in Example 97, Step B. ESI-MS:m/z 708.6 (M+H)⁺.

embedded image

Crude product of 4-(4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-yl)-3-methyl-1H-1,2,4-triazol-5(4H)-one (206) was prepared as described above for Example 97, Step C. Purification by preparatory LC/MS (20-40% CH₃CN in H₂O) gave the title compound as a TFA salt (20 mg, 14% yield over two steps). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.51 (br. s., 1H) 2.11 (s, 8H) 2.62-3.48 (m, 10H) 3.75 (br. s., 1H) 4.06-4.66 (m, 6H) 7.41 (m, 4H) 7.51 (m, 2H) 7.68-7.76 (m, 4H) 7.81 (m, 2H) 11.66 (s, 1H). ESI-MS:m/z 608.3 (M+H)⁺.

Example 102
Synthesis of 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutypphenyppyridin-2(1H)-one (207)

embedded image

A suspension of bromide, tert-butyl (R)-1-(4-bromophenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (6A) (prepared as described in Example 6, Step A) (45 mg, 0.088 mmol), 2-pyridone (16.7 mg, 2 eq), CuI (3.3 mg, 20% mol), N,N′-dimethylethylenediamine (3.1 mg, 40% mol), potassium phosphate (K₃PO₄) (37.4 mg, 2 eq) in 2 mL dioxane was heated at 110° C. for 19 hrs. The mixture was filtered; the filtrate was washed with EtOAc and concentrated to give a greenish oil which was used without further purification.

embedded image

The residue was dissolved in 4 mL 30% TFA/DCM. After 10 mins, solvents removed in vacuo, the residue was dissolved in MeOH (2 mL) and filtered. The filtrate loaded on prep-HPLC for purification to give the product as a white powder (30.3 mg, 71% yield). ESI-MS: m/z 528.5 (M+H)⁺. ¹H NMR (400 MHz, MeOH-d₄) δ ppm 3.31 (s, 3H) 3.66-3.70 (m, 2H) 4.21-4.25 (m, 2H) 7.1-7.6 (m, 8H); HPLC retention time T=0.855 min, STDTFA-2 method.

Example 103
Synthesis of (R)-4-(4-(1H-imidazol-1-yl)phenyl)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (208)

embedded image

A suspension of bromide, tert-butyl (R)-1-(4-bromophenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (prepared from the procedure of Example 6, Step A) (45 mg, 0.088 mmol), imidazole (11 mg, 2 eq), CuI (3.3 mg, 20% mol), N,N′-dimethylethylenediamine (3.1 mg, 40% mol), potassium phosphate (K₃PO₄) (37.4 mg, 2 eq) in 2 mL dioxane was heated at 110° C. for 27 hrs. The mixture was filtered; the filtrate was washed with EtOAc and concentrated to give a greenish oil.

embedded image

The residue was dissolved in 4 mL 30% TFA/DCM. After 20 mins, solvents removed in vacuo, the grey residue was dissolved in MeOH (2 mL) and filtered. The filtrate loaded on prep-HPLC for purification to give the product as a white sticky solid 8.4 mg (21% yield). ESI-MS: m/z 501.5 (M+H)⁺. ¹H NMR (400 MHz, MeOH-d₄) δ ppm 1.66 (m, 1H) 1.7-2.3 (m, 5H) 4.21-4.25 (m, 2H) 7.1-7.6 (m, 8H). HPLC retention time T=0.781 min, STDTFA-2 method.

Example 104
Synthesis of 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)pyrrolidin-2-one (209)

embedded image

(tert-Butyl (R)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxo-1-(4-(2-oxopyrrolidin-1-yl)phenyl)butan-2-ylcarbamate (104A) was dissolved in 25% trifluoroacetic acid and stirred at room temperature for 3 hrs. Solvent was removed under vacuum and the residue was purified by preparatory LC/MS (15-40% CH₃CN in H₂O) to give the product 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)pyrrolidin-2-one (209) as a TFA salt (8 mg, 17% yield). ESI-MS:m/z 518.2 (M+H)⁺.

Example 105
Synthesis of 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-3-methylpyrimidine-2,4(1H,3H)-dione (210)

embedded image

tert-Butyl(R)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxo-1-(4-(2-oxopyrrolidin-1-yl)phenyl)butan-2-ylcarbamate (105A) was prepared as described in Example 102, Step A. ESI-MS:m/z 659.5 (M+H)⁺.

embedded image

1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-3-methylpyrimidine-2,4(1H,3H)-dione (210) was prepared as described in Example 104, Step B and was purified by preparatory LC/MS (10-40% CH₃CN in H₂O) to give the product (210) as a TFA salt (7 mg, 14% yield). ESI-MS:m/z 559.3 (M+H)⁺.

Example 106
Synthesis of 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl-4-oxobutyl)phenyl)-3-methylpyrimidine-2,4(1H,3H)-dione (211)

embedded image

1-(4-((R)-2-Amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-3-methylpyrimidine-2,4(1H,3H)-dione (106A) was prepared as described in Example 102, Step A. ESI-MS:m/z 667.3 (M+H)⁺.

embedded image

1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-3-methylpyri midine-2,4(1H,3H)-dione (211) was prepared as described in Example 104, Step B and was purified by preparatory LC/MS (25-30% CH₃CN in H₂O) to give the product (211) as a TFA salt (22 mg, 44% yield). ESI-MS:m/z 568.2 (M+H)⁺.

Example 107
Synthesis of 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-3-methylpyrimidine-2,4(1H,3H)-dione (212)

embedded image

1-(4-((R)-2-Amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-3-methylpyrimidine-2,4(1H,3H)-dione (107A) was prepared as described in Example 102, Step A. ESI-MS:m/z 667.5 (M+H)⁺.

embedded image

Crude product of 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-3-methylpyrimidine-2,4(1H,3H)-dione (212) was prepared as described in Example 104, Step B and was purified by preparatory LC/MS (25-30% CH₃CN in WO) to give the product (212) as a TFA salt (26 mg, 52% yield). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.52 (br. s., 1H) 1.74-2.19 (m, 5H) 2.73 (m, 3H) 2.80-3.48 (m, 8H) 3.77 (br. s., 1H) 4.08-4.69 (m, 5H) 6.96-7.10 (m, 4H) 7.35-7.56 (m, 6H) 7.73 (m, 2H). ESI-MS:m/z 567.2 (M+H)⁺.

Example 108
1-(4-((R)-2-Amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-3-methylpyrimidine-2,4(1H,3H)-dione (213)

embedded image

1-(4-((R)-2-Amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-3-methylpyrimidine-2,4(1H,3H)-dione (108A) was prepared as described in Example 102, Step A. ESI-MS:m/z 634.5 (M+H)⁺.

embedded image

1-(4-((R)-2-Amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-3-methylpyrimidine-2,4(1H,3H)-dione (213) was prepared as described in Example 104, Step B and was purified by preparatory LC/MS (10-30% CH₃CN in H₂O) to give the product (213) as a TFA salt (7 mg, 15% yield). ESI-MS:m/z 534.4 (M+H)⁺.

Example 109
Synthesis of 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-3-(2-methoxyethyl)-1H-benzo[d]imidazol-2(3H)-one (214)

embedded image

Into a 25 mL round bottomedwas added 2-fluoronitrobenzene (500 mg, 3.54 mmol) and DMF (7 mL), and 2-methoxyethylamine (346 mg, 4.60 mmol) in DMF (2.39 mL) was added slowly via syringe. The mixture was stirred at room temperature overnight. Solvent was removed under vacuum and the residue containing N-(2-rnethoxyethyl)-2-nitroaniline (109A) was taken to the next step without further purification. ESI-MS:m/z 197.3 (M+H)⁺.

embedded image

The residue 109A was dissolved in methanol (60 mL) and acetic acid (4 mL). Zinc metal (3.24 g, 49.6 mmol) was added and the mixture was stirred overnight at room temperature. The reaction was decanted off from unreacted zinc metal. The solvent was removed under vacuum and resuspended in ethyl acetate (30 mL). The precipitate was removed by filtration on a Buchner funnel with Celite. Solvent was removed from the filtrate and the residue was purified by column chromatography (2% MeOH/DCM) to give the product N1-(2-methoxyethyl)benzene-1,2-diamine (109B) as a red oil (422 mg, 72% yield over two steps). ESI-MS:m/z 167.4 (M+H)⁺.

embedded image

The residue 109B (422 mg, 2.54 mmol) was dissolved in THF (7.5 mL). CDI (494 mg, 3.05 mmol) in THF (7.6 mL) was added slowly via addition funnel. After addition the mixture was stirred overnight at room temperature, solvent was removed under vacuum. The residue was purified by column chromatography (5% MeOH/DCM) to give the product 1-(2-methoxyethyl)-1H-benzo[d]imidazol-2(3H)-one (109C) as an orange solid (449 mg, 92%). ESI-MS:m/z 193.3 (M+H)⁺.

embedded image

tert-Butyl (R)-1-(4-(3-(2-methoxyethyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)phenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (109D) was prepared as described in Example 102, Step A. ESI-MS:m/z 724.4 (M+H)⁺.

embedded image

1-(4-((R)-2-Amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-3-(2-methoxyethyl)-1H-benzo[d]imidazol-2(3H)-one (214) was prepared as described in Example 104, Step B and was purified by preparatory LC/MS (20-45% CH₃CN in H₂O) to give the product as a TFA salt (49 mg, 45% yield over two steps). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.53 (br. s., 1H) 1.93 (m, 5H) 2.63-3.48 (m, 15H) 3.65 (m, 2H) 3.79 (br. s., 1H) 4.08 (m, 2H) 4.38 (m, 4H) 7.04 (m, 2H) 7.13 (m 1H) 7.32 (m, 1H) 7.41-7.57 (m, 6H) 7.72-7.82 (m, 2H). ESI-MS:m/z 625.3 (M+H)⁺.

Example 110
Synthesis of the mixture of 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-5-methyl-1H-benzo[d]imidazol-2(3H)-one (215) and 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-6-methyl-1H-henzo[d]imidazol-2(3H)-one (216)

embedded image

Into a 100 mL round bottomed flask, 3,4-diaminotoluene (1.00 g, 8.2 mmol) was dissolved in THF (8.2 mL). CDT (1.59 g, 9.8 mmol) in THF (25 mL) was added slowly via addition funnel. After addition the mixture was stirred overnight at room temperature. Solvent was removed under vacuum and the residue was purified by column chromatography (5% MeOH/DCM) to give the product 5-methyl-1H-benzo[d]imidazol-2(3H)-one (110A) as a brown-tan solid (990 mg, 82% yield). ESI-MS:m/z 149.4 (M+H)⁺.

embedded image

The mixture of tert-Butyl (R)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(4-(5-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)phenyl-4-oxobutan-2-ylcarbamate (110B¹) and tert-butyl (R)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(4-(6-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)phenyl)-4-oxobutan-2-ylcarbamate (110B²) was prepared as described in Example 102, Step A and was purified by preparatory LC/MS (35-45% CH₃CN in H₂O). ESI-MS:m/z 680.4 (M+H)⁺.

embedded image

The mixture of 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1,1-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-5-methyl-1H-benzo[d]imidazol-2(3H)-one (215) and 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-6-methyl-1H-benzo[d]imidazol-2(3H)-one (216) was prepared as described in Example 104, Step 13 and was purified by preparatory LC/MS (20-45% CH₃CN in H₂O) to give the product as a TFA salt (8 mg, 8% yield over two steps). ESI-MS:m/z 581.3 (M+H)⁺.

Example 111
Synthesis of the mixture of 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-4-fluoro-1H-benzo[d]imidazol-2(3H)-one (217) and 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-7-fluoro-1H-benzo[d]imidazol-2(3H)-one (218)

embedded image

Into a 25 mL round bottomed flask was added 2,3-diaminofluorobenzene (250 mg, 1.98 mmol) and THF (2 mL). CDI (386 mg, 2.38 mmol) in THF (6 mL) was added slowly via addition funnel. The reaction was stirred at room temperature overnight. The resultant precipitate was isolated by filtration on a Buchner funnel and washed with cold THF to give 4-fluoro-1H-benzo[d]imidazol-2(3H)-one (111A) as a white solid (200 mg, 66%). ESI-MS:m/z 153.3 (M+H)⁺.

embedded image

Crude product of the mixture of tert-butyl (R)-1-(4-(4-fluoro-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)phenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (111B¹) and tert-butyl (R)-1-(4-(7-fluoro-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)phenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzoidlimidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (111B²) was prepared as described in Example 102, Step A. The residue was purified by preparatory LC/MS (30-45% CH₃CN in H₂O). ESI-MS:m/z 684.3 (M+H)⁺.

embedded image

The mixture of 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-4-fluoro-1H-benzo[d]imidazol-2(3H)-one (217) and 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-7-fluoro-1H-benzo[d]imidazol-2(3H)-one (218) was prepared as described in Example 104, Step B and was purified by preparatory LC/MS (20-40% CH₃CN in H₂O) to give the product as a TFA salt (18 mg, 17% yield over two steps). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.53 (br. s., 1H) 1.76-2.19 (m, 5H) 2.62-3.46 (m, 12H) 3.78 (br. s., 1H) 4.10-4.68 (m, 4H) 6.82 (m, 1H) 6.99 (m, 2H) 7.37-7.56 (m, 6H) 7.74 (m, 2H) 11.74 (m, 1H). ESI-MS:m/z 585.3 (M+H)⁺.

Example 112
Synthesis of 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzoldjimidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-5,6-dimethyl-1H-benzo[d]imidazol-2(3H)-one (219)

embedded image

Crude product of tert-butyl (R)-1-(4-(5,6-dimethyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)phenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (112A) was prepared as described above for Example 102, Step A. The residue was purified by preparatory LC/MS (35-55% CH₃CN in H₂O). ESI-MS:m/z 695.5 (M+H)⁺.

embedded image

Crude product of 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-5,6-dimethyl-1H-benzo[d]imidazol-2(3H)-one (219) was prepared as described in Example 104, Step B and was purified by preparatory LC/MS (20-45% CH₃CN in H₂O) to give the product as a TFA salt (20 mg, 19% yield over two steps). 1H NMR (400 MHz, DMSO-d₅) δ ppm 1.53 (br. s., 1H) 1.74-2.14 (m, 5H) 2.14-2.24 (m, 6H) 2.62-3.49 (m, 12H) 3.77 (br. s., 1H) 4.08-4.68 (m, 4H) 6.80 (m, 1H) 6.87 (m, 1H) 7.34-7.54 (m, 6H) 7.67-7.77 (m, 2H) 10.96 (m, 1H). ESI-MS:m/z 595.3 (M+H)⁺.

Example 113
Synthesis of 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one (220)

embedded image

Crude product of tert-butyl (R)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(4-(3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)phenyl)-4-oxobutan-2-ylcarbamate (113A) was prepared as dexcribed for Example 102, Step A and was purified by preparatory LC/MS (35-50% CH₃CN in H₂O). ESI-MS:m/z 680.4 (M+H)⁺.

embedded image

Crude product of 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one (220) was prepared as described in Example 104, Step B and was purified by preparatory LC/MS (20-40% CH₃CN in H₂O) to give the product as a TFA salt (20 mg, 19% yield over two steps). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.53 (br. s., 1H) 1.93 (br. s., 5H) 2.61-3.46 (m, 15H) 3.79 (br. s., 1H) 4.10-4.69 (m, 4H) 7.00-7.09 (m, 2H) 7.16 (m, 1H) 7.26 (m, 1H) 7.38-7.57 (m, 6H) 7.70-7.81 (m, 2H). ESI-MS:m/z 581.3 (M+H)⁺.

Example 114
Synthesis of 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-3-propyl-1H-benzo[d]imidazol-2(3H)-one (221)

embedded image

Crude product of tert-butyl (R)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxo-1-(4-(2-oxo-3-propyl-2,3-dihydro-1H-benzo[d]imidazol-1-yl)phenyl)butan-2-ylcarbamate (114A) was prepared as described for Example 102, Step A and was purified by preparatory LC/MS (35-45% CH₃CN in H₂O). ESI-MS:m/z 708.4 (M+H)⁺.

embedded image

Crude product of 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-3-propyl-1H-benzo[d]imidazol-2(3H)-one (221) was prepared as described in Example 104, Step B and was purified by preparatory LC/MS (20-40% CH₃CN in H₂O) to give the product as a TFA salt (46 mg, 43% yield over two steps). 1H NMR (400 MHz, DMSO-d₆) δ ppm 0.92 (m, 3H) 1.53 (br. s., 1H) 1.66-1.76 (m, 2H) 1.93 (m, 5H) 2.63-3.46 (m, 12H) 3.72-3.83 (m, 1H) 3.87 (m, 2H) 4.11-4.68 (m, 4H) 7.01-7.08 (m, 2H) 7.14 (m, 1H) 7.32 (m, 1H) 7.39-7.57 (m, 6H) 7.70-7.80 (m, 2H). ESI-MS:m/z 609.3 (M+H)⁺.

Example 115
Synthesis of 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-3-(2-hydroxyethyl)-1H-benzo[d]imidazol-2(3H)-one (222)

embedded image

Crude product of tert-butyl (R)-1-(4-(3-(2-hydroxyethyl)-2-oxo-2,3-dihydro-1,1-benzotdjimidazol-1-yl)phenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (115A) was prepared as described in Example 102, Step A. The residue was purified by preparatory LC/MS (30-40% CH₃CN in H₂O). ESI-MS:m/z 711.5 (M+H)⁺.

embedded image

Crude product of 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-3-(2-hydroxyethyl)-1H-benzo[d]imidazol-2(3H)-one (222) was prepared as described for Example 104, Step B. The solvent was removed and the residue was purified by preparatory LC/MS (20-30% CH₃CN in H₂O) to give the product as a TFA salt (31 mg, 58% yield over two steps). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.53 (br. s., 1H) 1.93 (d, J=6.32 Hz, 5H) 2.63-3.47 (m, 12H) 3.67-3.73 (m, 2H) 3.82 (br. s., 1H) 3.92-3.99 (m, 2H) 4.10-4.68 (m, 4H) 7.01-7.06 (m, 2H) 7.10-7.17 (m, 1H) 7.31 (m, 1H) 7.38-7.57 (m, 6H) 7.74 (d, J=6.57 Hz, 2H). ESI-MS:m/z 611.3 (M−H)+.

Example 116
Synthesis of the mixture of 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-5-fluoro-1H-benzo[d]imidazol-2(3H)-one (223) and 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-6-fluoro-1H-benzo[d]imidazol-2(3H)-one (224)

embedded image

Into a 8 mL vial was added tert-butyl (R)-1-(4-bromophenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (6A) (as prepared in Example 6, Step A) (90 mg, 147 μmol), 5-fluoro-1H-benzo[d]imidazol-2(3H)-one (110A) (45 mg, 293 μmol), potassium phosphate (62 mg, 293 μmol), copper(I) iodide (6 mg, 29 μmol) and N¹,N²-dimethylethane-1,2-diamine (5 mg, 56 μmol). The mixture was suspended in dioxane (4 mL). The vial was capped with a high temperature Teflon cap and heated at 110° C. for 18 hrs. The reaction was filtered through a Buchner funnel with Celite. The solvent was removed from the filtrate under vacuum. The residue containing a mixture of tert-butyl (R)-1-(4-(5-fluoro-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)phenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (116A′) and tert-butyl (R)-1-(4-(6-fluoro-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)phenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (116A²) was purified by preparatory LC/MS (30-50% CH₃CN in H₂O). ESI-MS:m/z 685.5 (M+H)⁺.

embedded image

The product from the previous step was dissolved in 25% trifluoroacetic acid in dichloromethane (5 mL). The mixture was stirred at room temperature for 3 hrs. The solvent was removed and the residue was purified by preparatory LC/MS (20-40% CH₃CN in H₂O) to give the mixed product of 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin−1-yl)-4-oxobutyl)phenyl)-5-fluoro-1H-benzo[d]imidazol-2(3H)-one (223) and 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-6-fluoro-1H-henzo[d]imidazol-2(3H)-one (224) as a TFA salt (31 mg, 30% yield over two steps). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.53 (br. s., 1H) 1.75-2.19 (m, 5H) 2.62-3.48 (m, 12H) 3.77 (br. s., 1H) 4.07-4.68 (m, 4H) 6.77-7.10 (m, 3 H) 7.36-7.57 (m, 6H) 7.73 (m, 2H) 11.20-11.39 (m, 1H). ESI-MS:m/z 585.2 (M+H)⁺.

Example 117
Synthesis of a mixture of 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-4-methyl-1H-benzo[d]imidazol-2(3H)-one (225) and 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1,1-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-7-methyl-1H-benzo[d]imidazol-2(3H)-one(226)

embedded image

Crude product of the mixture of tert-butyl (R)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(4-(4-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)phenyl)-4-oxobutan-2-ylcarbamate (117A¹) and tert-butyl (R)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(4-(7-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)phenyl)-4-oxobutan-2-ylcarbamate (117A²) was prepared by the procedure dexcribed in Example 102, Step A. The residue was purified by preparatory LC/MS (30-50% CH₃CN in H₂O). ESI-MS:m/z 681.6 (M+H)⁺.

embedded image

Mixture of crude product 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-4-methyl-1H-benzo[d]imidazol-2(3H)-one (225) and 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-7-methyl-1H-benzo[d]imidazol-2(3H)-one (226) was prepared according to the procedure described for Example 104, Step B. The solvent was removed and the residue was purified by preparatory LC/MS (20-40% CH₃CN in H₂O) to give the product as a TFA salt (37 mg, 36% yield over two steps). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.53 (br. s., 1H) 1.75-2.21 (m, 5H) 2.33 (s, 3H) 2.63-3.47 (m, 12H) 3.77 (br. s., 1H) 4.10-4.68 (m, 4H) 6.82 (m, 1H) 6.86-6.93 (m, 2H) 7.38-7.56 (m, 6H) 7.74 (m, 2H) 11.24 (m, 1H). ESI-MS:m/z 581.3 (M+H)⁺.

Example 118
Synthesis of the mixture of 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-5-methoxy-1H-benzo[d]imidazol-2(3H)-one (227) and 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxyp ropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-6-methoxy-1H-benzo[d]imidazol-2(3H)-one (228)

embedded image

Into a 8 mL vial was added tert-butyl-(R)-1-(4-bromophenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (90 mg, 147 μmol), 5-methoxy-1,4-benzo[d]imidazol-2(3H)-one (48 mg, 293 μmol), potassium phosphate (62 mg, 293 μmol), copper(I) iodide (6 mg, 29 μmol) and N¹,N²-dimethylethane-1,2-diamine (5 mg, 56 gmol). The mixture was suspended in dioxane (4 mL). The vial was capped with a high temperature Teflon cap and heated at 110° C. for 18 hrs. The reaction was filtered through a Buchner funnel with Celite. The solvent was removed from the filtrate under vacuum. The residue containing the mixture of tert-butyl (R)-1-(4-(5-methoxy-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yDphenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (118A) and tert-butyl (R)-1-(4-(6-methoxy-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)phenyl)-4-((R)-3-(1-(3-methoxypropyl)-1,1-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (118B) was purified by preparatory LC/MS (30-45% CH₃CN in H₂O). ESI-MS:m/z 697.5 (M+H)⁺.

embedded image

The product from the previous step was dissolved in 25% trifluoroacetic acid in dichloromethane (5 mL). The mixture was stirred at room temperature for 3 hrs. The solvent was removed and the residue containing the mixture of 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-5-methoxy-1H-benzo[d]imidazol-2(3H)-one (227) and 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin−1-yl)-4-oxobutyl)phenyl)-6-methoxy-1H-benzo[d]imidazol-2(3H)-one (228) was purified by preparatory LC/MS (15-35% CH₃CN in H₂O) to give the product as a TFA salt (22 mg, 21% yield over two steps). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.53 (br. s., 1H) 1.74-2.19 (m, 5H) 2.62-3.47 (m, 12H) 3.66-3.91 (m, 4H) 4.10-4.68 (m, 4 H) 6.53-6.70 (m, 2H) 6.98 (m, 1H) 7.38-7.56 (m, 6H) 7.74 (m, 2H) 10.95-11.13 (m, 1H). ESI-MS:m/z 597.3 (M+H)⁺.

Example 119
Synthesis of 2-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)isoquinolin-1(2H)-one (229)

embedded image

Crude product tert-butyl (R)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxo-1-(4-(1-oxoisoquinolin-2(1H)-yl)phenyl)butan-2-ylcarbamate (119A) was prepared according to the procedure described in Example 102, Step A. The residue was purified by preparatory LC/MS (30-60% CH₃CN in H₂O). ESI-MS:m/z 678.4 (M+H)⁺.

embedded image

2-(4-((R)-2-Amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyeisoquinolin-1(2H)-one (229) was prepared as described for Example 104, Step B. The solvent was removed and the residue was purified by preparatory LC/MS (20-45% CH₃CN in H₂O) to give the product as a TFA salt (41 mg, 40% yield over two steps). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.53 (br. s., 1H) 1.75-2.21 (m, 5H) 2.63-3.48 (m, 12H) 3.78 (br. s., 1H) 4.11-4.69 (m, 4H) 6.74 (m, 1H) 7.36-7.51 (m, 7H) 7.52-7.60 (m, 1H) 7.71-7.82 (m, 4H) 8.24 (m, 1H). ESI-MS:m/z 578.3 (M+H)⁺.

Example 120
Synthesis of 2-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)isoquinolin-1(2H)-one (230)

embedded image

tert-Butyl (R)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxo-1-(4-(3-oxoisoquinolin-2(3H)-yl)phenyl)butan-2-ylcarbamate (120A) was prepared as described for Example 102, Step A. ESI-MS:m/z 678.5 (M+H)⁺.

embedded image

2-(4-((R)-2-Amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenypisoquinolin-3(2H)-one (230) was prepared as described for Example 104, Step B.

Example 121
Synthesis of (R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4-(4-phenylpiperazin-1-yl)phenyl)butan-1-one (231)

embedded image

tert-Butyl (R)-1-(4-bromophenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (6A) (prepared as described in Example 6, Step A) (0.29 mmole, 180 mg) in toluene (1 mL) was added bis(dibenzylideneacetone)palladium (0.015 mmole, 9 mg), 1,1′-bis(di-tert-butylphosphino)ferrocene (0.022 mmole, 10 mg), KOtBu (0.35 mmole, 39 mg) and 1-phenylpiperazine (0.32 mmole, 52 mg). The reaction mixture was heated to 80° C. for 6 hrs and then poured into H₂O, extracted with EtOAc. The extract was washed with brine, dried over MgSO₄and filtered. The filtrate was concentrated in vacuo. The residue containing tert-Butyl (R)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin−1-yl)-4-oxo-1-(4-(4-phenylpiperazin-1-yl)phenyl)butan-2-ylcarbamate (121A) was carried directly on to the next step without further purification. ESI-MS: m/z 695.7 (M+H)⁺.

embedded image

Residue from the last step (0.29 mmole, 202 mg) in DCM (10 mL) was added TEA (2 mL). The reaction solution was stirred at rt for 1 hr and then concentrated in vacuo. The residue was purified by preparative LC/MS (20-50% CH₃CN in H₂O) to afford (R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4-(4-phenylpiperazin-1-yl)phenyl)butan-1-one (231) (0.11 mmole, 66 mg, two-step yield: 38.3%). ESI-MS: m/z 595.5 (M+H)⁺. 1H NMR (400 MHz, MeOD) δ ppm 1.59-1.79 (m, 1H) 1.89-2.15 (m, 3H) 2.18-2.27 (m, 2H) 2.28-2.37 (m, 1H) 2.63-2.81 (m, 2H) 2.82-2.94 (m, 1H) 2.94-3.09 (m, 2H) 3.19 (d, J=3.98 Hz, 1H) 3.27 (s, 3H) 3.39 (q, J=5.35 Hz, 1H) 3.43-3.61 (m, 5H) 3.78-3.90 (m, 2H) 3.95 (d, J=13.26 Hz, 1H) 4.15-4.24 (m, 1H) 4.49-4.62 (m, 1H) 4.65 (t, J=6.95 Hz, 2 H) 4.72 (d, J=13.39 Hz, 1H) 4.85 (d, J=12.69 Hz, 1H) 7.11-7.17 (m, 1H) 7.17-7.22 (m, 1H) 7.22-7.27 (m, 1H) 7.28-7.34 (m, 2H) 7.38-7.44 (m, 1H) 7.54 (t, J=8.05 Hz, 2H) 7.60-7.68 (m, 3H) 7.78-7.84 (m, 1H) 7.89-7.96 (m, 1H).

Example 122
Synthesis of (R)-4-(4-(4-acetylpiperazin-1-yl)phenyl)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (232)

embedded image

tert-Butyl (R)-1-(4-bromophenyl)-4-((R)-3(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (6A) (prepared as described in Example 6, Step A) (0.29 mmole, 180 mg) in toluene (1 mL) was added bis(dibenzylideneacetone)palladium (0.015 mmole, 9 mg), 1,1′-bis(di-tert-butylphosphino)ferrocene (0.022 mmole, 10 mg), KOtBu (0.35 mmole, 39 mg) and 1-acetylpiperazine (0.32 mmole, 41 mg). The reaction mixture was heated to 80° C. for 6 hrs and then poured into H₂O, extracted with EtOAc. The extract was washed with brine, dried over MgSO₄and filtered. The filtrate was concentrated in vacuo. The residue containing tert-butyl (R)-1-(4-(4-acetylpiperazin-1-yl)phenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (122A) was carried directly on to the next step without further purification. ESI-MS: m/z 661.6 (M+H)⁺.

embedded image

tert-Butyl (R)-1-(4-(4-acetylpiperazin-1-yl)phenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (122A) (0.29 mmole, 202 mg) in DCM (10 mL) was added TEA (2 mL). The reaction solution was stirred at rt for 1 hr and then concentrated in vacuo. The residue was purified by preparative LC/MS (10-25% CH₃CN in H₂O) to afford (R)-4-(4-(4-Acetylpiperazin-1-yl)phenyl)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (232) (0.0018 mmole, 1.5 mg, two-step yield: 0.9%). ESI-MS: m/z 561.5 (M+H)+. 1H NMR (400 MHz, MeOD) δ ppm 1.90-2.12 (m, 3H) 2.15 (s, 3H) 2.18-2.37 (m, 3H) 2.58-3.04 (m, 2H) 3.11-3.24 (m, 6H) 3.27 (s, 3H) 3.39-3.60 (m, 4H) 3.65-3.76 (m, 4H) 3.79 (dd, J=9.13, 4.58 Hz, 1H) 3.94 (d, J=14.21Hz, 1H) 4.14 (d, J=15.03 Hz, 1H) 4.42-4.60 (m, 1H) 4.64 (t, J=6.92 Hz, 1H) 4.72 (d, J=14.15 Hz, 1H) 6.96-7.05 (m, 2H) 7.14-7.24 (m, 2H) 7.56-7.66 (m, 2H) 7.75-7.82 (m, 1H) 7.86-7.93 (m, 1H).

Example 123
Synthesis of 4-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-1-phenylpiperazin-2-one (233)

embedded image

tert-Butyl (R)-1-(4-bromophenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (6A) (prepared as described in Example 6, Step A) (0.29 mmole, 180 mg) in toluene (1 mL) was added bis(dibenzylideneacetone)palladium (0.015 mmole, 9 mg), 1,1′-bis(di-tert-butylphosphino)ferrocene (0.022 mmole, 10 mg), KOtBu (0.35 mmole, 39 mg) and 1-phenylpiperazin-2-one (1.13 TFA salt form) (0.32 mmole, 98 mg). The reaction mixture was heated to 80° C. for 6 hrs and then poured into H₂O, extracted with EtOAc. The extract was washed with brine, dried over MgSO₄and filtered. The filtrate was concentrated in vacuo. The residue containing tert-butyl (R)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxo-1-(4-(3-oxo-4-phenylpiperazin-1-yl)phenyl)butan-2-ylcarbamate (123A) was carried directly on to the next step without further purification. ESI-MS: m/z 709.5 (M+H)⁺.

embedded image

tert-Butyl (R)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxo-1-(4-(3-oxo-4-phenylpiperazin-1-yl)phenyl)butan-2-ylcarbamate (123A) (0.29 mmole, 206 mg) in DCM (10 mL) was added TEA (2 mL). The reaction solution was stirred at rt for 1 hr and then concentrated in vacuo. The residue was purified by preparative LC/MS (45-55% CH₃CN in H₂O) to afford 4-(4-((R)-2-Amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-1-phenylpiperazin-2-one (233) (0.11 mmole, 14 mg, two-step yield: 7.9%). ESI-MS: m/z 609.5 (M+H)⁺. 1H NMR (400 MHz, MeOD) δ ppm 1.54-1.83 (m, 1H) 1.87-2.15 (m, 3H) 2.18-2.38 (m, 3H) 2.61-2.80 (m, 1H) 2.80-2.91 (m, 1H) 2.93-3.05 (m, 2H) 3.10-3.24 (m, 2H) 3.26 (s, 3H) 3.33-3.59 (m, 4H) 3.68 (t, J=5.43 Hz, 1H) 3.74-4.09 (m, 4H) 4.49-4.78 (m, 3H) 4.84 (br. s., 1H) 6.94-7.08 (m, 1H) 7.15-7.30 (m, 2H) 7.30-7.39 (m, 2H) 7.40-7.55 (m, 3H) 7.55-7.70 (m, 3H) 7.76-7.86 (m, 1H) 7.88-7.99 (m, 1H).

Example 124
Synthesis of (R)-3-amino-4-(4-(4-hydroxypiperidin-1-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (234)

embedded image

tert-Butyl (R)-1-(4-bromophenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (6A) (prepared as described in Example 6, Step A) (0.325 mmole, 199 mg) in toluene (2 mL) was added bis(dibenzylideneacetone)palladium (0.016 mmole, 9 mg), 1,1′-bis(di-tert-butylphosphino)ferrocene (0.049 mmole, 23 mg), KOtBu (0.39 mmole, 44 mg) and 4-hydroxypiperidine (0.39 mmole, 39 mg). The reaction mixture was heated to 80° C. for 6 hrs and then poured into H₂O, extracted with EtOAc. The extract was washed with brine, dried over MgSO₄and filtered. The filtrate was concentrated in vacuo. The residue containing tert-butyl (R)-1-(4-(4-hydroxypiperidin-1-yl)phenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (124A) was carried directly on to the next step without further purification. ESI-MS: mh 634.5 (M+H)⁺.

embedded image

tert-Butyl (R)-1-(4-(4-hydroxypiperidin-1-yl)phenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (0.325 mmole, 206 mg) in DCM (10 mL) was added TEA (2 mL). The reaction solution was stirred at rt for 1 hr and then concentrated in vacuo. The residue was purified by preparative LC/MS (10-15% CH₃CN in H₂O) to afford (R)-3-Amino-4-(4-(4-hydroxypiperidin-1-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (234) (0.024 mmole, 13 mg, two-step yield: 7.5%). ESI-MS: m/z 534.7 (M+H)+. 1H NMR (400 MHz, MeOD) δ ppm 1.20-1.43 (m, 5H) 1.78-2.39 (m, 4H) 2.69-3.11 (m, 4H) 3.10-3.17 (m, 1H) 3.15-3.24 (m, 3H) 3.27 (s, 3H) 3.35-3.55 (m, 2H) 3.66-3.78 (m, 2H) 3.80-3.89 (m, 1H) 3.90-4.00 (m, 2 H) 4.37-4.46 (m, 1H) 4.48-4.58 (m, 1H) 4.59-4.67 (m, 2H) 4.67-4.76 (m, 1H) 7.30-7.35 (m, 1H) 7.38-7.46 (m, 3H) 7.55-7.67 (m, 2H) 7.73-7.82 (m, 1H) 7.83-7.93 (m, 1H).

Example 125
Synthesis of (R)-3-amino-4-(4-(4-(hydroxymethyl)piperidin-1-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (235)

embedded image

tert-Butyl (R)-1-(4-bromophenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (0.325 mmole, 199 mg) in toluene (2 mL) was added bis(dibenzylideneacetone)palladium (0.016 mmole, 9 mg), 1,1′-bis(di-tert-butylphosphino)ferrocene (0.049 mmole, 23 mg), KOtBu (0.39 mmole, 44 mg) and 4-piperidine-methanol (0.39 mmole, 45 mg). The reaction mixture was heated to 80° C. for 6 hrs and then poured into H₂O, extracted with EtOAc. The extract was washed with brine, dried over MgSO₄and filtered. The filtrate was concentrated in vacuo. The residue containing tert-butyl (R)-1-(4-(4-(hydroxymethyl)piperidin-1-yl)phenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (125A) was carried directly on to the next step without further purification. ESI-MS: m/z 648.6 (M+H)⁺.

embedded image

tert-Butyl (R)-1-(4-(4-(hydroxymethyl)piperidin-1-yl)phenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]irriidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (0.325 mmole, 211 mg) in DCM (10 mL) was added TEA (2 mL). The reaction solution was stirred at it for 1 hr and then concentrated in vacuo. The residue was purified by preparative LC/MS (10-15% CH₃CN in H₂O) to afford (R)-3-Amino-4-(4-(4-(hydroxymethyl)piperidin-1-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (235) (0.0055 mmole, 3 mg, two-step yield: 1.7%). ESI-MS: m/z 548.5 (M+H)⁺. 1H NMR (400 MHz, MeOD) δ ppm 1.43-1.54 (m, 2H) 1.62-1.76 (m, 2H) 1.91-2.16 (m, 4H) 2.21 (t, J=5.40 Hz, 2H) 2.25-2.37 (m, 1H) 2.54-3.11 (m, 3H) 3.12-3.15 (m, 1H) 3.16-3.25 (m, 2H) 3.27 (s, 3H) 3.36-3.55 (m, 4H) 3.61-3.77 (m, 3H) 3.83-3.92 (m, 1H) 3.93-4.02 (m, 1H) 4.32-4.42 (m, 1H) 4.50-4.60 (m, 1H) 4.63 (t, J=6.92 Hz, 2H) 4.67-4.84 (m, 1H) 7.20-7.39 (m, 1H) 7.40-7.51 (m, 2H) 7.52-7.57 (m, 1H) 7.58-7.65 (m, 2H) 7.75-7.81 (m, 1H) 7.85-7.92 (m, 1H).

Example 126
Synthesis of (R)-3-amino-4-(4-(4-(hydroxyethyl)piperidin-1-yDphenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (236)

embedded image

tert-Butyl(R)-1-(4-bromophenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (0.325 mmole, 199 mg) in toluene (2 mL) was added bis(dibenzylideneacetone)palladium (0.016 mmole, 9 mg), 1,1′-bis(di-tert-butylphosphino)ferrocene (0.049 mmole, 23 mg), KOtBu (0.39 mmole, 44 mg) and 4-piperidineethanol (0.39 mmole, 50 mg). The reaction mixture was heated to 80° C. for 6 hrs and then poured into H₂O, extracted with EtOAc. The extract was washed with brine, dried over MgSO₄and filtered. The filtrate was concentrated in vacuo. The residue containing tert-butyl (R)-1-(4-(4-(2-hydrox yethyl)piperidin-1-yl)phenyl)-4-((R)-3-(1-(3-methoxypropyl)-1,1-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (126A) was carried directly on to the next step without further purification. ESI-MS: m/z 662.6 (M+H)⁺.

embedded image

Residue 126A from the previous step (0.325 mmole, 215 mg) in DCM (10 mL) was added TEA (2 mL). The reaction solution was stirred at it for 1 hr and then concentrated in vacuo. The residue was purified by preparative LC/MS (10-15% CH₃CN in H₂O) to afford (R)-3-amino-4-(4-(4-(2-hydroxyethyl)piperidin-1-yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (236) (0.007 mmole, 4 mg, two-step yield: 2.2%). ESI-MS: m/z 562.7 (M+H)⁺. 1H NMR (400 MHz, MeOD) δ ppm 1.24-1.35 (m, 1H) 1.54-1.78 (m, 3H) 1.80-1.99 (m, 2H) 1.99-2.16 (m, 3H) 2.16-2.24 (m, J=6.09, 5.87, 5.76, 5.76 Hz, 1H) 2.25-2.34 (m, 1H) 2.65-3.15 (m, 4H) 3.16-3.25 (m, 2H) 3.27 (s, 3H) 3.35-3.59 (m, 4H) 3.60-3.72 (m, 3H) 3.82-3.92 (m, 2H) 3.97 (d, J=15.28 Hz, 2H) 4.18 (d, J=12.19 Hz, 1H) 4.48-4.59 (m, 1H) 4.62 (t, J=7.01Hz, 2H) 4.71 (d, J=14.84 Hz, 1H) 4.81 (br. s., 1H) 7.35-7.52 (m, 2H) 7.52-7.64 (m, 3H) 7.74-7.81 (m, 1H) 7.83-7.90 (m, 1H).

Example 127
Synthesis of methyl 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-henzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxohutyl)phenyl)piperidine-4-carboxylate (237)

embedded image

tert-Butyl (R)-1-(4-bromophenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (0.325 mmole, 199 mg) in toluene (2 mL) was added bis(dibenzylideneacetone)palladium (0.016 mmole, 9 mg), 1,1′-bis(di-tert-butylphosphino)ferrocene (0.049 mmole, 23 mg), KOtBu (0.39 mmole, 44 mg) and methyl isonipecotate (0.39 mmole, 56 mg). The reaction mixture was heated to 80° C. for 6 hrs and then poured into H₂O, extracted with EtOAc. The extract was washed with brine, dried over MgSO₄and filtered. The filtrate was concentrated in vacuo. The residue containing methyl 1-(4-((R)-2-(tert-butoxycarbonylamino)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)piperidine-4-carboxylate (127A) was carried directly on to the next step without further purification. ESI-MS: m/z 676.5 (M+H)⁺.

embedded image

Residue 127A from the previous step (0.325 mmole, 220 mg) in DCM (10 mL) was added TEA (2 mL). The reaction solution was stirred at rt for 1 h and then concentrated in vacuo. The residue was purified by preparative LC/MS (10-15% CH₃CN in H₂O) to afford methyl 1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)ppiperidin-1-yl)-4-oxobutyl)phenyl)piperidine-4-carboxylate (237) (0.010 mmole, 6 mg, two-step yield: 3.2%). ESI-MS: adz 576.5 (M+H)⁺. 1H NMR (400 MHz, MeOD) δ ppm 1.22-1.42 (m, 1H) 1.45-1.57 (m, 1H) 1.61-1.80 (m, 1H) 1.91-2.26 (m, 6H) 2.26-2.37 (m, 1H) 2.64-2.82 (m, 2H) 2.83-3.15 (m, 3H) 3.15-3.25 (m, 2H) 3.27 (s, 3H) 3.34-3.61 (m, 4H) 3.63-3.76 (m, 3H) 3.80-3.91 (m, 1H) 3.96 (d, J=14.65 Hz, 1H) 4.20 (d, J=12.25 Hz, 1H) 4.58 (q, J=7.33 Hz, 1H) 4.64 (t, J=6.95 Hz, 2H) 4.72 (d, J=13.20 Hz, 1H) 4.83 (br. s., 1H) 7.33 (d, J=3.54 Hz, 1H) 7.41 (s, 3H) 7.59-7.67 (m, J=5.84, 5.62, 5.51, 5.51Hz, 2H) 7.76-7.83 (m, 1H) 7.88-7.94 (m, 1H).

Example 128
Synthesis of (R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4-phenoxyphenyl)butan-1-one (238)

embedded image

Into a 15 mL sealed tube vessel was added tert-butyl (R)-1-(4-bromophenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (100 mg, 163 μmol), copper(I) iodide (3 mg, 16 μmol), N,N-dimethylglycine hydrochloride (7 mg, 49 μmol), cesium carbonate (106 mg, 326 μmol) and phenol (23 mg, 245 μmol). Dioxane (400 μL) was added and heated at 90° C. for 20 hrs. The reaction was cooled and filtered through a Buchner funnel with Celite. The solvent was removed from the filtrate and the residue was purified by preparatory LC/MS (40-50% CH₃CN in H₂O) to give tert-butyl (R)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxo-1-(4-phenoxyphenyl)butan-2-ylcarbanlate (128B) as a TFA salt (55 mg, 50% yield). ESI-MS:m/z 627.3 (M+H)⁺.

embedded image

The solvent was removed and the residue was purified by preparatory LC/MS (20-50% CH₃CN in H₂O) to give (R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4-phenoxyphenyl)butan-1-one (239) as TFA salt (47 mg, 45% yield over two steps). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.52 (br. s., 1H) 1.76-2.21 (m, 5H) 2.58-3.48 (m, 12H) 3.62-3.89 (m, 1H) 4.08-4.67 (m, 4H) 6.94-7.04 (m, 4H) 7.14 (m, 1H) 7.29 (m, 2H) 7.34-7.49 (m, 4H) 7.73 (m, 2H). ESI-MS:m/z 527.2 (M+H)⁺.

Example 129
Synthesis of N-(2-(2-((R)-1((R)-3-amino-4-(naphthalen-2-yl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-yl)ethyl)acetamide (239)

embedded image

Tert-butyl 3-(1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (4.36 mmol, 1.3 g) was added to a 50 mL oven-dried round-bottomed flask equipped for stirring under nitrogen. DMF (15 mL) was added and the solution was cooled to 0° C. NaH (4.80 mmol, 192 mg) was then added in one portion and the resultant solution was stirred at 0° C. for 0.5 hr. At this time 2-(2-bromoethyl)isoindoline-1,3-dione (5.01 mmoles, 1.27 g) was added; the ice bath was removed and the reaction solution was allowed to warm to room temperature and stirred for 16 hrs. The reaction was then heated to 100° C. and allowed to stir for an additional 16 hrs. Analysis of the reaction solution by LC/MS indicated about an approx. 10% conversion to the desired title compound (129A). The reaction was cooled to rt and then poured into ice-water, extracted with ethyl acetate, and washed once with saturated aqueous sodium chloride. The organic layer was collected and subsequently dried with anhydrous Na₂SO₄and filtered. This filtrate was collected, concentrated, and dried in-vacuo affording tert-butyl 3-(1-(2-(1,3-dioxoisoindolin-2-yl)ethyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (129A) as a mixture of products that was carried onto the next step without further purification. ESI-MS: m/z 475.3 (M+H)⁺.

embedded image

tert-Butyl 3-(1-(2-(1,3-dioxoisoindolin-2-yl)ethyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (129A) (4.36 mmoles max, crude mixture) was added to a 20 mL scintillation vial equipped for stirring. CH₂Cl₂(3 mL) and trifluoroacetic acid (1 mL) were then added and the resultant solution was allowed to stir at room temperature for 72 hrs. The reaction was concentrated and dried in-vacuo affording 2-(2-(2-(piperidin-3-yl)-1H-benzo[d]imidazol-1-yl)ethyl)isoindoline-1,3-dione (129B) as a mixture that was used without further purification. ESI-MS: m/z 375.3 (M+H)⁺.

embedded image

(R)-2-(2-(2-(piperidin-3-yl)-1H-benzo[d]imidazol-1-yflethypisoindoline-1,3-dione (129B) (500 mg of mixture) from previous step, was weighed into a 25 mL round-bottomed flask equipped for stirring under nitrogen. DMF (3 mL), (R)-3-(tert-butoxycarbonylamino)-4-(naphthalen-2-yl)butanoic acid (2.48 mmoles, 0.817 g) and N-methylmorpholine (7.44 mmoles, 0.818 mL) were then added and the solution was allowed to stir at rt for 5 min. HATU (2.73 mmoles, 1.04 g) was added and the resultant solution was stirred at room temperature for 3 hrs. The reaction solution was then directly purified by preparative LC/MS (35-95% CH₃CN in H₂O). The resultant fractions were collected and the solvent was removed in-vacuo affording tert-butyl (R)-4-((R)-3-(1-(2-(1,3-dioxoisoindolin-2-yl)ethyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (129C) as a clear oil. (0.105 mmoles, 0.072 g, 4% yield over 2-steps). ESI-MS: m/z 686.5 (M+H)⁺.

embedded image

tert-Butyl (R)-4-((R)-3-(1-(2-(1,3-dioxoisoindolin-2-yl)ethyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (0.105 mmoles, 0.072 g) was added to a 25 mL round-bottomed flask equipped with a reflux condenser and for stirring under nitrogen. Ethanol (6 mL), methanol (6 mL), and hydrazine hydrate (0.84 mmoles, 0.041 mL) were then added and the solution was heated to reflux temperature for 2 hrs. The reaction solution was then concentrated and dried in-vacuo to give tert-butyl (R)-4-((R)-3-(1-(2-aminoethyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (129D) as a brownish oil that was used without further purification. ESI-MS: m/z 556.5 (M+H)⁺.

embedded image

tert-Butyl (R)-4-((R)-3-(1-(2-aminoethyl)-1H-benzo[d]imidazoI-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (129D) was added to a 25 mL round-bottomed flask equipped for stirring under nitrogen. Dichloromethane (5 mL) was added and the solution was cooled to 0° C. with an ice/water bath. Acetyl chloride (0.703 mmoles; 0.050 mL) and pyridine (2.47 mmoles, 0.200 mL) were then added and the resultant solution was stirred at 0° C. for 10 min. Solution was allowed to warm to it and stirred for 1 hr. The reaction solution was subsequently concentrated in-vacuo, re-dissolved in methanol (3 mL), and then directly purified by preparative LC/MS (20-90% CH₃CN in H₂O) to afford tert-butyl (R)-4-((R)-3-(1-(2-acetamidoethyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (129E) as a clear oil (0.038 mmoles, 0.023 g, 36% yield over 2-steps). ESI-MS: m/z 598.5 (M+H)⁺.

embedded image

Residue from previous step tert-butyl (R)-4-((R)-3-(1-(2-acetamidoethyl)-1E-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (0.038 mmoles, 0.023 g) was weighed into a 20 mL scintillation vial and dissolved in CH₂Cl₂(2 mL). Trifluoroacetic acid (2 mL) was then added and the solution was stirred at room temperature for 2 hrs. The solvent was removed in-vacuo affording a clear colored oil. This oil was re-dissolved in methanol (3 mL), filtered, and then purified by preparative LC/MS (5-55% CH₃CN in H₂O). The resultant fractions were collected and the solvent was removed in-vacuo affording a clear colored oil. This oil was re-dissolved in CH₃CN (1 mL) and water (2 mL). The resultant solution was frozen and lyophilized to afford N-(2-(2-((R)-1((R)-3-amino-4-(naphthalen-2-yl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-3^,1)ethyl)acetamide (239) as its trifluoroacetic acid salt as a white flocculent solid. (0.029 mmoles, 0.018 g, 77% yield). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.14-1.31 (m, 0H) 1.35-1.73 (m, 4H) 1.73-2.01 (m, 2 H) 2.04-2.24 (m, 1H) 2.59-2.79 (m, 2H) 2.84-3.00 (m, 1H) 3.00-3.25 (m, 2H) 3.25-3.54 (m, 2H) 3.67-4.11 (m, 3H) 4.13-4.76 (m, 4H) 7.34-7.61 (m, 4H) 7.63-7.80 (m, 2H) 7.81-8.15 (m, 5H) EST-MS: m/z 498.4 (M+H)⁺.

Example 130
Synthesis of (R)-4-(4-bromobenzyl)-2-oxooxazolidine-5-carboxylic acid (130F)

embedded image

To a 0° C. solution of 130A (8 g), TEA (3.5 mL) and HATU (9.7 g) in dry CH₂Cl₂(50 mL) was added N,O-dimethylhydroxylamine hydrochloride (2.75 g) and TEA (3.9 mL). The reaction was allowed to warm to RT, and stirred overnight. The reaction was partitioned between CH₁Cl₂and 1N HCl. The organic layer was separate and washed with saturated NaHCO₃and brine, dried over anhydrous Na₂SO₄, filtered and concentrated to give 9 g of (R)-tert-butyl 3-(4-bromophenyl)-1-(methoxy(methyl)amino)-1-oxopropan-2-ylcarbamate (130B). 1H NMR (300 MHz, CDCl₃) δ=7.40-7.29 (q, 2H), 7.04-7.01 (m, 2H), 5.19-5.14 (t, 1H), 4.92 (m, 1H) 3.67 (s, 3H), 3.18 (s, 3H), 3.03-2.98 (m, 1H), 1.39 (s, 9H).

embedded image

LiAlH₄(1 g) was added to 20 mL Et₂O in a round-bottom flask equipped with a pressure-equalizing dropping funnel, placed under N₂. Then a solution of compound 130B (9 g) in 50 mL Et₂O was added to the LiAlH₄suspension at a rate in which the temperature was not allowed to exceed 5° C. After all amide was added, the reaction mixture was stirred for 30 min, then EtOAc was added, and 100 mL. KHSO₄solution was added drop-wise to quench the reaction. The temperature of the mixture was maintained at less than 5° C. Then the mixture was washed with 1N HCl, saturated NaCO₃and brine, and dried over anhydrous Na₂SO₄, concentrated to afford 7 g of crude (R)-tert-butyl 3-(4-bromophenyl)-1-(methoxy(methyl)amino)-1-oxopropan-2-ylcarbamate (130C). 1H NMR (300 MHz, CDCl₃) δ=9.61 (s, 1H), 7.44-7.40 (q, 2H), 7.06-7.01 (m, 2H), 5.01-5.00 (t, 1H), 4.40-4.38 (t, 1H) 3.08-3.04 (m, 2H), 1.49 (s, 9H).

embedded image

130C (7 g) was dissolved in MeOH and chilled to 5° C. NaHSO₃(2.22 g) was dissolved in de-ionized water and chilled to 5° C. before addition. Then the mixture was stirred at 5° C. for 2 hrs; then NaCN (1.25 g) was added and the mixture was stirred at it overnight. The organic layer was collected, dried with Na₂SO₄, filtered, and concentrated to yield a crude product. The crude product was dissolved in 1,4-dioxane, concentrated HCl and anisole. The solution was heated to reflux overnight, then cooled to RT, and concentrated in vacuo. Acetone was added and the suspension was filtered to product 2.9 g of crude (R)-3-amino-4-(4-bromophenyl)-2-hydroxybutanoic acid (130D). 1H NMR (300 MHz, CD₃OD) δ=7.53-7.50 (q, 2H), 7.26-7.23 (m, 2H), 4.09-4.06 (m, 1H), 3.82-3.80 (m, 1H), 3.09-2.98 (m, 2H).

embedded image

A solution of MeOH was cooled to 0° C., SOCli (5.2 g) was added drop-wise, and then compound 130D (2.9 g) in 10 mL MeOH was added to the above solution. The solution was allowed to warm to rt and stirred for 6 hrs. MeOH was removed under reduce pressure to afford 3 g of compound (R)-methyl 3-amino-4-(4-bromophenyl)-2-hydroxybutanoate (130E). 1H NMR (300 MHz, CD₃OD) δ=7.53-7.50 (q, 2H), 7.26-7.23 (m, 2H), 4.12-4.10 (m, 1H), 3.80 (m, 111), 3.74-3.70 (m, 3H), 3.09-2.98 (m, 2H).

embedded image

Compound 130E (2.9 g) was dissolved in 20 mL THF, and cooled to about 0° C. TEA was then added to the mixture and the mixture was stirred for 10 min. A solution of BTC (3 g) in THF was added drop-wise for 4 hrs while the temperature of the solution was maintained at below 5° C. THF was removed under reduce pressure, and the resulting mixture was partitioned between EtOAc and 1N NaHSO₃. The organic layer was dried with NaSO₄, filtered and concentrated, purified by chromatography (ethyl acetate:hexanes, 1:4) to afford the ester product (0.4 g).

To a solution of above ester product (0.4 g) in THF was added a solution of LiOH (0.16 g) in water; the mixture was stirred at rt for 4 hrs. The mixture was adjusted to pH 3 by 10% HCl. EtOAc was added, and the organic layer was washed with brine and dried with NaSO₄, and then concentrated to afford the product, which is pure (R)-4-(4-bromobenzyl)-2-oxooxazolidine-5-carboxylic acid (130F) (0.35 g). 1H NMR (300 MHz, DMSO-d₆) δ=7.49-7.45 (q, 2H), 7.22-7.18 (m, 2H), 4.75-4.70 (m, 1H), 4.16-4.10 (m, 1H), 3.00-2.88 (m, 2H).

Example 131
Synthesis of (R)-3-amino-2-benzyl-4-(4-chlorophenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (ID: SYR147702B:001) (240)

embedded image

(R)-1-(3-Methoxypropyl)-2-(piperidin-3-yl)-1H-benzo[d]imidazole (0.25 mmole, 68 mg) in DMF (10 mL) was added (R)-4-(4-chlorophenyl)-3-(tert-butoxycarbonylamino)butanoic acid (0.28 mmole, 88 mg) and N-methylmorphine (1.00 mmole, 0.11 mL). The reaction mixture was stirred at it for 5 min and then added HATU (0.28 mmole, 107 mg) and kept stirring at it overnight. The reaction mixture was poured into H₂O, extracted with EtOAc. The extract was washed with H₂O, brine, dried over MgSO₄and filtered. The filtrate was concentrated in vacuo. The residue containing tert-Butyl (R)-1-(4-chlorophenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzoldlimidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (131A) was carried directly on to the next step without further purification. ESI-MS: mh 570.5 (M+H)⁺.

embedded image

tert-Butyl (R)-1-(4-chlorophenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (131A) (0.25 mmole, 142 mg) in THF (5 mL) was cooled to −78° C., added butyl lithium (0.375 mmole, 1.6 M in hexane, 0.23 mL) and stirred for 30 min. The reaction solution was added benzyl bromide (1.25 mmole, 0.15 mL) and stirred at rt overnight. The reaction mixture was poured into H₂O, extracted with EtOAc. The extract was washed with brine, dried over MgSO₄and filtered. The filtrate was concentrated in vacuo. The residue containing tert-Butyl (R)-3-benzyl-1-(4-chlorophenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (131B) was carried directly on to the next step without further purification. EST-MS: m/z 659.5 (M+H)⁺.

embedded image

tert-Butyl (R)-3-benzyl-1-(4-chlorophenyl)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (131B) (0.25 mmole, 165 mg) in DCM (10 mL) was added TEA (2 mL). The reaction solution was stirred at rt for 1 hr and then concentrated in vacuo. The residue was purified by preparative LC/MS (25-30% CH₃CN in H₂O) to afford (R)-3-amino-2-benzyl-4-(4-chlorophenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (240) (0.016 mmole, 9 mg, two-step yield: 6.4%). ESI-MS: m/z 560.4 (M+H)⁺. ESI-MS: m/z 560.4 (M+H)⁺. 1H NMR (400 MHz, MeOD) δ ppm 1.49-1.74 (m, 1H) 1.82-1.95 (m, 1H) 2.01-2.33 (m, 3H) 2.50-2.95 (m, 3H) 2.95-3.09 (m, 2H) 3.11-3.23 (m, 1H) 3.24 (s, 3H) 3.44-3.59 (m, 2H) 3.62-3.95 (m, 2H) 4.62-4.86 (m, 4H) 5.88-6.10 (m, 2H) 7.18 (d, 0.1=6.25 Hz, 2H) 7.23-7.32 (m, 2H) 7.38 (d, J=2.40 Hz, 5H) 7.57-7.76 (m, 3H) 7.99-8.07 (m, 1H).

Example 132
Synthesis of (R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-4,5,6,7-tetrahydro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (241)

embedded image

Into a microwave vial was added 1,2-diaminocyclohexane (150 mg, 1.3 mmol) and

(R)-1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid (301 mg, 1.3 mmol). The mixture was dissolved with pyridine (6.6 mL). Triphenylphosphite (500 mg, 1.6 mmol) was added and the vial was capped. The reaction was microwaved at 220° C. for 10 minutes. Solvent was removed under vacuum and the residue was purified by column chromatography (15% MeOH/DCM) to give yellow oil of (3R)-tert-butyl 3-(3a,4,5,6,7,7a-hexahydro-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (132A) (247 mg, 61% yield). ESI-MS:m/z 308.4 (M+H)⁺.

embedded image

Oxalyl chloride (112 mg, 0.89 mmol) was added to a 10 mL round bottomed flask with dichloromethane (0.9 mL) and cooled to −78° C. DMSO (138 mg, 1.77 mmol) was added via syringe over 10 minutes. The reaction was stirred at −78° C. for an additional 10 min. before (132A) (247 mg, 0.81 mmol) in dichloromethane (0.2 mL) was added over 10 min. Triethylamine (407 mg, 4.0 mmol) was added over 10 min. at −78° C. The reaction was allowed to stir and warm to room temperature overnight. Solvent was removed under vacuum. The residue was purified by preparatory LC/MS (35-40% CH₃CN in H₂O) to give (R)-tert-butyl 3-(4,5,6,7-tetrahydro-1H-benzo[d]hnidazol-2-yl)piperidine-1-carboxylate (132B) as an oil (195 mg, 79% yield). ESI-MS:m/z 306.4 (M+H)⁺.

embedded image

Into a 10 mL round bottomed was added (132B) (195 mg, 638 μmol) and N,N-dimethylforamide (2.1 mL). NaI (105 mg, 702 μmol) and NaH (33 mg, 830 μmol, 60% disp.) were added in sequence. The mixture was stirred for 30 minutes at room temperature. 3-methoxy propyl bromide (127 mg, 830 μmol) was added at once and stirred overnight at room temperature. Solvent was removed under vacuum and the residue was purified by preparatory LC/MS (30-35% CH₃CN in H₂O) to give (R)-tert-butyl 3-(1-(3-methoxypropyl)-4,5,6,7-tetrahydro-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (132C) as an oil (40 mg, 17% yield). ESI-MS:m/z 376.4 (M+H)⁺.

embedded image

Into a 10 mL round bottomed flask was added (132C) (40 mg, 106 μmol). 25% trifluoroacetic acid in dichloromethane (5 mL) was added and stirred at room temperature for 3 hrs. The solvent was removed under vacuum. The residue (R)-1-(3-methoxypropyl)-2-(piperidin-3-yl)-4,5,6,7-tetrahydro-1H-benzo[d]imidazole (132D) was used in the next step without purification. ESI-MS:m/z 278.4 (M+H)⁺.

embedded image

The residue (132D) from the previous step was added dichloromethane (1 mL). HATU (44 mg, 117 μmol, N-methyl-morpholine (43 mg, 424 μmol) and (R)-3-(tert-butoxycarbonylamino)-4-(naphthalen-2-yl)butanoic acid (35 mg, 106 μmol). The reaction was stirred overnight at room temperature. Solvent was removed under vacuum and the residue containing tert-butyl (R)-4-((R)-3-(1-(3-methoxypropyl)-4,5,6,7-tetrahydro-1H benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (132E) was carried on to the next step without further purification. ESI-MS:m/z 589.5 (M+H)⁺.

embedded image

The residue 132E from the previous step was treated with 25% trifluoroacetic acid in dichloromethane (5 mL). The mixture was stirred at room temperature for 3 hrs. The solvent was removed under vacuum and the residue was purified by preparatory LC/MS (30-35% CH₃CN in H₂O) to give (R)-3-amino-1((R)-3-(1-(3-methoxypropyl)-4,5,6,7-tetrahydro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (241) as a TFA salt (30 mg, 47% yield from 132C). 1H NMR (400 MHz, DMSO-d₆)δ ppm 1.46 (br. s., 1H) 1.61-2.09 (m, 8H) 2.53-2.63 (m, 4H) 2.63-2.85 (m, 3H) 2.87-3.38 (m, 9H) 3.70-4.22 (m, 4H) 4.51 (br. s., 2H) 7.52 (m, 3H) 7.75-7.94 (m, 4H). ESI-MS:m/z 489.4 (M+H)⁺.

Example 133
Synthesis of methyl 4′-((2R)-2-amino-4-(3-(5-tert-butyl-1-(3-methoxypropyl)-1,1-imidazol-2-yl)-3-hydroxypiperidin-1-yl)-4-oxobutyl)biphenyl-4-carboxylate (242)

embedded image

Into a 50 mL round bottomed flask was added pivaldehyde (500 mg, 5.8 mmol), 3-methoxypropylamine (569 mg, 6.4 mmol) and magnesium sulfate. Dichloromethane (20 mL) was added and the mixture was stirred overnight under nitrogen. The mixture was filtered through a pad of Celite and the solvent was removed form the filtrate under vacuum. The residue was dissolved in methanol (10 mL); 3-methoxypropylamine (466 mg, 5.2 mmol) and TOSMIC (942 mg, 4.8 mmol) was added and the mixture was again stirred overnight. Solvent was removed under vacuum, and the residue was purified by preparatory LC/MS (10-25% CH₃CN in H₂O) to give 5-tert-butyl-1-(3-methoxypropyl)-1H-imidazole (133A) as a yellow oil (376 mg, 40% yield). ESI-MS:m/z 197.4 (M+H)⁺.

embedded image

Into a 50 mL round bottomed flask was added 5-tert-butyl-1-(3-methoxypropyl)-1H-imidazole (133A) (376 mg, 1.9 mmol) and THF (9.6 mL). The solution was cooled to −78° C. and n-BuLi (843 μL, 2.5 M/hexanes, 2.1 mmol) was added slowly via syringe. The mixture was stirred for 20 minutes and slowly warmed to −30° C. The solution was cooled to −78° C. and N-Boc-3-piperidone (418 mg, 2.1 mmol) in THF (5 mL) was added slowly via syringe; the mixture was allowed to warm to room temperature overnight. Solvent was removed under vacuum and the residue was partitioned between water (25 mL) and ethyl acetate (25 mL). The organic layer was separated and discarded. The aqueous layer extracted with ethyl acetate (2×25 mL). The organic portions were combined and washed with brine (50 mL) and dried over sodium sulfate and filtered. The solvent was removed in vacuo and the residue was purified by preparatory LC/MS (10-45% CH₃CN in H₂O) to give tert-butyl 3-(5-tert-butyl-1-(3-methoxypropyl)-1H-imidazol-2-yl)-3-hydroxypiperidine-1-carboxylate (133B) as a yellow oil (160 mg, 21% yield). ESI-MS:m/z 396.5 (M+H)⁺.

embedded image

The residue 133 from the previous step was treated with 25% trifluoroacetic acid in dichloromethane (5 mL). The mixture was stirred at room temperature for 3 hrs. The solvent was removed and the residue containing 3-(5-tert-butyl-1-(3-methoxypropyl)-1H-imidazol-2-yl)piperidin-3-ol (133C) was purified by preparatory LC/MS (10-45% CH₃CN in H₂O). ESI-MS:m/z 296.2 (M+H)⁺.

embedded image

(R)-4-(4-bromophenyl)-3-(tert-butoxycarbonylamino)butanoic acid (45 mg, 81 gmol), EDC (24 mg, 125 μmol), HOBt (17 mg, 125 μmol) and 3-(5-tert-butyl-1-(3-methoxypropyl)-1H-imidazol-2-yl)piperidin-3-ol TFA salt (133C) (34 mg, 83 μmol) were added to a 10 mL round bottomed flask. DMF (420 μL) was added and the reaction was stirred overnight at room temperature. The solvent was removed and the residue was purified by preparatory LC/MS (35-50% CH₃CN in H₂O) to give the product tert-butyl (2R)-1-(4-bromophenyl)-4-(3-(5-tert-butyl-1-(3-methoxypropyl)-1H-imidazol-2-yl)-3-hydroxypiperidin-1-yl)-4-oxobutan-2-ylcarbamate (133D) (29 mg, 55% yield). ESI-MS:m/z 635.4 (M+H)⁺.

embedded image

Crude product of methyl 4′-((2R)-2-(tert-butoxycarbonylamino)-4-(3-(5-tert-butyl-1-(3-me thoxypropyl)-1H-imidazol-2-yl)-3-hydroxypiperidin-1-yl)-4-oxobutyl)biphenyl-4-carboxylate (133E) was prepared according to the procedure described in Example 53, Step A. The solvent was removed and the residue was purified by preparatory LC/MS (25-50% CH₃CN in H₂O). ESI-MS:m/z 691.6 (M+H)⁺.

embedded image

Product 133E from the previous step was treated with 25% trifluoroacetic acid in dichloromethane (5 mL). The mixture was stirred at room temperature for 3 hrs. The solvent was removed and the residue was purified by preparatory LC/MS (20-40% CH₃CN in H₂O) to give the product methyl 4′-((2R)-2-amino-4-(3-(5-tert-butyl-1-(3-methoxypropyl)-1H-imidazol-2-yl)-3-hydroxypiperidin-1-yl)-4-oxobutyl)biphenyl-4-carboxylate (242) (19 mg, 59% yield over two steps). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.38 (m, 9H) 1.51-2.24 (m, 6H) 2.58-3.55 (m, 12H) 3.66-4.01 (m, 5H) 4.43 (br. s., 3H) 7.37-7.45 (m, 2H) 7.74 (m, 2H) 7.84 (m, 2H) 8.02-8.07 (m, 2H). ESI-MS:m/z 591.5 (M+H)⁺.

Example 134
Synthesis of (R)-3-amino-1-((R)-3-(2-(3-methoxypropyl)-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (243)

embedded image

Into a 25 mL round bottomed flask was added 1-fluoro-2-nitrobenzene (638 mg, 4.5 mmol) and N,N-dimethylforamide (9 mL). The flask was cooled to −15° C. and (R)-tert-butyl 3-aminopiperidine-1-carboxylate (950 mg, 4.7 mmol) in N,N-dimethylforamide (3 mL) was slowly added. The reaction was allowed to warm to room temperature overnight. Solvent was removed under vacuum and the residue was purified by column chromatography (15% ethylacetate:hexanes) to give (R)-cert-butyl 3-(2-nitrophenylamino)piperidine-1-carboxylate (134A) as a yellow oil (808 mg, 56% yield). ESI-MS:m/z 344.4 (M+Na)⁺.

embedded image

Into a 100 mL round bottomed flask was added 1334A and methanol (46 mL). Zinc metal (2.28 g, 34.9 mmol) and acetic acid (1.7 mL) was added and the mixture was stirred at room temperature for 5 hr. The mixture was filtered through a fritted Buchner funnel and the solvent was removed under vacuum. Ethyl acetate (100 mL) was added and the precipitate was filtered through a Buchner funnel with a pad of Celite. The filtrate was concentrated under vacuum to leave red oil (R)-tert-butyl 3-(2-aminophenylamino)piperidine-1-carboxylate (134B) which was used without further purification. ESI-MS:m/z 292.4 (M+H)⁺.

embedded image

The residue 134B was dissolved in N,N-dimethylforamide (6.9 mL). HOBt (139 mg, 1.03 mmol), EDC (197 mg, 1.03 mmol), N-methylmorpholine (208 mg, 2.06 mmol) and 3-methoxybutyric acid (122 mg, 1.03 mmol) were added and stirred overnight at room temperature. The solvent was removed under vacuum and the residue was partitioned between water (10 mL) and ethyl acetate (10 mL). The organic layer was discarded, and the aqueous layer was extracted with ethyl acetate (2×10 mL). The organics were combined and washed with 1N NaOH (25 mL), dried over sodium sulfate and filtered. The solvent was removed under vacuum and the residue containing (R)-tert-butyl 3-(2-(4-methoxybutanamido)phenylamino)piperidine-1-carboxylate (134C) was taken into the next step without further purification. ESI-MS:m/z 392.5 (M+H)⁺.

embedded image

The residue 134C was dissolved with acetic acid (15 mL) and heated to 100° C. for 4 hr. Solvent was removed under vacuum. The residue containing (R)-tert-butyl 3-(2-(3-methoxypropyl)-1H-benzo[d]imidazol-1-yl)piperidine-1-carboxylate (134D) was used in the next step with out further purification. ESI-MS:m/z 374.4 (M+H)⁺.

embedded image

134D was dissolved in 25% trifluoroacetic acid and stirred at room temperature for 3 hr. Solvent was removed under vacuum and the residue containing (R)-2-(3-methoxypropyl)-1-(piperidin-3-yl)-1H-benzo[d]imidazole (134E) was used in the next step without further purification. ESI-MS:m/z 274.4 (M+H)⁺.

embedded image

The residue 133E was dissolved in N,N-dimethylforamide (6.9 mL). HOBt (111 mg, 823 μmol), EDC (158 mg, 823 μmol), N-methylmorpholine (278 mg, 2.74 mmol) and (R)-3-(tert-butoxycarbonylamino)-4-(naphthalen-2-yl)butanoic acid (271 mg, 823 μmol) were added and stirred overnight at room temperature. The solvent was removed under vacuum and the residue was partitioned between water (10 mL) and ethyl acetate (10 mL). The organic layer was discarded and the aqueous layer was extracted with ethyl acetate (2×10 mL). The organics were combined, washed with 1N NaOH (25 mL), dried over sodium sulfate, and filtered. Solvent was removed under vacuum and the residue containing tert-butyl (R)-4-((R)-3-(2-(3-methoxypropyl)-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate 134F was taken into the next step without further purification. ESI-MS:m/z 585.5 (M+H)⁺.

embedded image

134F was dissolved in 25% trifluoroacetic acid and stirred at room temperature for 3 hr. Solvent was removed under vacuum and purified by preparatory LC/MS (20-25% CH₃CN in H₂O) to give (R)-3-amino-1((R)-3-(2-(3-methoxypropyl)-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (243) as a TFA salt (97 mg, 24%). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.62 (m, 1H) 1.86 (br. s., 1H) 1.97-2.15 (m, 3H) 2.53-2.91 (m, 3H) 2.94-3.26 (m, 7H) 3.40 (m, 3H) 3.75-4.10 (m, 3H) 4.42-4.71 (m, 2H) 7.50 (m, 5H) 7.72-7.96 (m, 5H) 8.21 (m, 1H). ESI-MS:m/z 485.5 (M+H)⁺.

Example 135
Synthesis of (R)-3-amino-1-((S)-3-(2-methyl-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (244) and (R)-3-amino-1((R)-3-(2-methyl-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (245)

embedded image

(2-methyl-1-(piperidin-3-yl)-1H-benzo[d]imidazole (0.486 mmoles, 0.160 g) was added to a 10 mL round-bottomed flask equipped for stirring under nitrogen. DMF (4 mL), (R)-3-(tert-butoxycarbonylamino)-4-(naphthalen-2-yl)butanoic acid (0.486 mmoles, 0.140 g) and N-methylmorpholine (1.94 mmoles, 0.214 mL) were then added and the solution was allowed to stir at rt for 5 min. HATU (0.534 mmoles, 0.204 g) was added and the resultant solution was stirred at room temperature for 3 hr. The reaction solution was then directly purified by preparative LC/MS (35-95% CH3CN in H2O). The resultant fractions were collected and the solvent was removed in-vacuo affording (R)-tert-butyl 4-(3-(2-methyl-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (1354) as a clear oil. ESI-MS: raiz 527.5 (M+H)⁺.

embedded image

135A (0.486 mmoles max, crude oil) was added to a 10 mL round-bottomed flask equipped for stirring under nitrogen and dissolved in CH₂Cl₂(2 mL). Trifluoroacetic acid (2 mL) was then added and the solution was stirred at room temperature for 2 hr. The solvent was removed in-vacuo affording a clear colored oil which was further separated by Berger PrepSFC Conditions: column: ChiralPak AD-H (5 μm, 21.2×250 mm), mobile phase: A: liquid CO₂, B: 10 mM NH₄OAc in IPOH, flow rate: 50 mL/min, gradient: 30% B, run time: 35 min (stack-injection method applied), prep injection volume: 400 μL, yielding the separated enantiomers:

Eutomer: (R)-3-amino-1-((S)-3-(2-methyl-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (244) (0.077 mmoles, 0.033 g). ESI-MS: m/z 427.4 (M+H)⁺.

Distomer: (R)-3-amino-1((R)-3-(2-methyl-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (245) (0.061 mmoles, 0.026 g). ESI-MS: m/z 427.4 (M+H)⁺.

Example 136
Synthesis of (3R)-3-amino-1-(3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)-5-methylpiperidin-1-yl)-4-(nanhthalen-2-yl)butan-1-one (246)

embedded image

Into a 100 mL round bottomed flask was added methyl-5-methylnicotinate (1.00 g, 6.6 mmol) and methanol (66 mL). The sample was hydrogenated using an H-Cube hydrogenator at 50° C. and 60 bar of hydrogen pressure. Solvent was removed under vacuum and the residue containing methyl 5-methylpiperidine-3-carboxylate (136A) was used in the next step without further purification. ESI-MS:m/z 158.4 (M+H)⁺.

embedded image

136A was dissolved in dioxane (15 mL). Di-tert-butyl dicarbonate (2.16 g, 9.9 mmol) and sodium bicarbonate (1.11 g, 13.2 mmol) was added and the mixture was stirred at room temperature overnight. Solvent was removed under vacuum and the residue was partitioned between water (50 mL) and ethyl acetate (50 mL). The mixture was transferred to a separatory funnel. The organic layer was separated and the aqueous was extracted with ethyl acetate (2×50 mL). The organics were combined and washed with brine (50 mL). The organics were dried over sodium sulfate and filtered. Solvent was removed under vacuum to leave a clear oil of 1-tert-butyl 3-methyl 5-methylpiperidine-1,3-dicarboxylate (136B) which was used in the next step without further purification. ESI-MS:m/z 280.4 (M+Na)⁺.

embedded image

136B was dissolved with dioxane (14 mL) and methanol (7 mL). Sodium hydroxide (1.32 g, 33 mmol) in water (2 mL) was added and the mixture was heated to 80° C. for 5 hrs. Solvent was removed under vacuum and the residue was partitioned between 2N HCl (50 mL) and ethyl acetate (50 mL). The mixture was transferred to a separatory funnel and the organics were separated. The aqueous layer was extracted with ethyl acetate (2×25 mL), and the organics were combined and dried over sodium sulfate and filtered. Solvent was removed under vacuum to leave 1-(tert-butoxycarbonyl)-5-methylpiperidine-3-carboxylic acid (136C) as a white solid which was used without further purification. ESI-MS:m/z 266.4 (M+H)⁺.

embedded image

Enzene-1,2-diamine (928 mg, 8.58 mmol) was dissolved in N,N-dimethylforamide (6.6 mL). HOBt (1.16 g, 8.58 mmol), EDC (1.64 g, 8.58 mmol), and 1-(tert-butoxycarbonyl)-5-methylpiperidine-3-carboxylic acid (136C) (1.61 g, 6.6 mmol) were added and stirred overnight at room temperature. The solvent was removed under vacuum and the residue was partitioned between water (25 mL) and ethyl acetate (25 mL). The organic layer was separated and the aqueous solution was extracted with ethyl acetate (2×25 mL). The organics were combined and washed with 1N NaOH (25 mL). The organics were dried over sodium sulfate and filtered. Solvent was removed under vacuum and the residue containing tert-butyl 3-(2-aminophenylcarbamoyl)-5-methylpiperidine-1-carboxylate (136D) was taken into the next step without further purification. ESI-MS:m/z 334.4 (M+H)⁺.

embedded image

The residue (136D) was dissolved with acetic acid (15 mL) and heated to 80° C. for 4 hr. Solvent was removed under vacuum. The residue containing tert-butyl 3-(1H-benzo[d]imidazol-2-yl)-5-methylpiperidine-1-carboxylate (135E) was used in the next step with out further purification. ESI-MS:m/z 316.4 (M+H)⁺.

embedded image

Into a 10 mL round bottomed 136E and 25% trifluoroacetic acid in dichloromethane (5 mL) was added, and the mixture was stirred at room temperature for 3 hr. The solvent was removed under vacuum. The residue containing 2-(5-methylpiperidin-3-yl)-1H-benzo[d]imidazole (136F) was used in the next step without purification. ESI-MS:mh 216.4 (M+H)⁺.

embedded image

136F (137 mg, 634 μmol) was dissolved with 2:1 acetonitrile:dichloromethane (3.2 mL). (R)-3-(tert-butoxycarbonylamino)-4-(naphthalen-2-yl)butanoic acid (230 mg, 697 μmol) in 2:1 acetonitrile:dichloromethane (3.5 mL) was added. HOBt (94 mg, 697 umol) in DMF (3.5 mL) was added. Into a fritted syringe was added PS-carbodiimide resin (1.31 mmol/g, 968 mg). The amine, acid and HOBt solutions were taken up in the syringe and capped. The mixture was shaken overnight at room temperature. The solution was expelled into a round bottomed flask and the solvent was removed under vacuum. The residue containing tert-butyl (2R)-4-(3-(1H-benzo[d]imidazol-2-yl)-5-methylpiperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (136G) was taken into the next step without further purification. ESI-MS:m/z 527.4 (M+H)⁺.

embedded image

Into a 10 mL round bottomed flask was added 136G (158 mg, 298 μmol) and N,N-dimethylforamide (1.5 mL). NaI (67 mg, 447 μmol) and NaH (18 mg, 447 μmol, 60% disp.) were added in sequence. The mixture was stirred for 30 minutes at room temperature. 3-methoxy propyl bromide (68 mg, 447 μmol) was added at once and stirred overnight at room temperature. Solvent was removed under vacuum and the residue containing tert-butyl (2R)-4-(3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)-5-methylpiperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (136H) was taken into the next step without further purification. ESI-MS:m/z 599.6 (M+H)⁺.

embedded image

The residue 136H was dissolved in 25% trifluoroacetic acid and stirred at room temperature for 3 hr. Solvent was removed under vacuum and purified by preparatory LC/MS (25-35% CH₃CN in H₂O) to give (3R)-3-amino-1-(3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)-5-methylpiperidin-1-yl)-4-(naphthalen-2-yl)butan-1-one (246) as a TFA salt (13 mg, 9%). ESI-MS:m/z 499.5 (M+H)⁺.

Example 137
Synthesis of (R)-3-amino-4-(4-chlorophenyl)-1-((S)-3-hydroxy-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (247) and (R)-3-amino-4-(4-chlorophenyl)-1((R)-3-hydroxy-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (248)

embedded image

1H-benzo[d]imidazole (12.7 mmoles, 1.5 g) was added to an oven dried 200 mL round-bottomed flask equipped for stirring under nitrogen. DMF (20 mL) was added and the solution was cooled to 0° C. with an ice bath. To this cooled solution was added NaH (60% in mineral oil, 13.3 mmoles, 533 mg) in two portions. The resultant solution was allowed to stir at 0° C. for 30 minutes under nitrogen. 1-bromo-3-methoxypropane (14.0 mmoles, 2.14 g) was added and the solution was allowed to warm to room temperature and stirred for 1 hr. The reaction solution was then poured into ice-water, extracted with ethyl acetate, and washed once with saturated aqueous sodium chloride. The organic layer was collected and subsequently dried with anhydrous Na₂SO₄and filtered. This filtrate was collected, concentrated, and dried in-vacuo. This material was then purified by chromatography on silica gel (5-15% CH₃OH/CH₂Cl₂) to afford 1-(3-methoxypropyl)-1H-benzo[d]imidazole (137A) as a clear oil (9.62 mmoles, 1.83 g, 76% yield). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 2.10 (dt, J=12.57, 6.22 Hz, 2H) 3.29 (t, J=5.68 Hz, 2H) 3.34 (s, 3H) 4.31 (t, J=6.69 Hz, 2H) 7.23-7.34 (m, 2H) 7.37-7.45 (m, 1H) 7.78-7.83 (m, 1H) 7.89 (s, 1H). ESI-MS: m/z 191.4 (M+H)⁺.

embedded image

1-(3-methoxypropyl)-1H-benzo[d]imidazole (137A) (9.62 mmoles; 1.83 g) was added to an oven dried 250 mL round-bottomed flask equipped with an addition funnel and for stirring under nitrogen. Et₂O (75 mL) was added and the solution was cooled to −78° C. with an acetone/CO₂(s) bath. N-BuLi (2.5M in hexanes, 10.1 mmoles, 4.0 mL) was added drop-wise via syringe and the resultant solution was allowed to stir at −78° C. for 45 minutes. Tert-butyl 3-oxopiperidine-1-carboxylate (10.1 mmoles, 2.01 g) in END (25 mL) was then added drop-wise to the reaction solution at −78° C. via addition funnel and allowed to stir for 1 hr. The reaction solution was then allowed to warm to rt and stir for ihr. The reaction solution was then poured into ice-water, extracted with ethyl acetate, and washed once with saturated aqueous sodium chloride. The organic layer was collected and subsequently dried with anhydrous Na.2SO₄and filtered. The filtrate was collected, concentrated, and dried in-vacuo. The residue was then partially purified by chromatography on silica gel (5-15% CH₃OH/CH₂Cl₂) to afford tert-butyl 3-hydroxy-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (137E) as a mixture of products that was carried onto the next step without further purification. ESI-MS: m/z 390.4 (M+H)⁺.

embedded image

137B (9.62 mmoles, mixture from previous step) was added to a 25 mL round-bottomed flask equipped for stirring under nitrogen. HCl (4 M in dioxane, 10 mL) was then added and the solution was stirred at room temperature for 1 hr. The resultant solution was then extracted with Et(Mc and a 10% aqueous K₂CO₃solution. The organic layer was collected and dried with Na₂SO₄. This was then filtered, concentrated, and dried in-vacuo affording as an approximate 1/1 mixture of 3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-3-ol (137C) and 1-(3-methoxypropyl)-1H-benzo[d]imidazole that was used without further purification. ESI-MS: m/z 290.4 (M+H)⁺.

embedded image

The mixture containing (3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-3-ol (137C) (0.200 g of mixture) was weighed into a 20 mL vial. DMF (5 mL), (R)-3-(tert-butoxycarbonylamino)-4-(4-chlorophenyl)butanoic acid (0.381 mmoles, 0.120 g) and N-methylmorpholine (1.038 mmoles, 0.114 mL) were then added and the solution was allowed to stir at it for 5 min. HATU (0.415 mmoles, 0.158 g) was added and the resultant solution was stirred at room temperature for 3 hr. The reaction solution was then directly purified by preparative LC/MS. ESI-MS: m/z 585.4 (M+H)⁺. The resultant fractions were collected and the solvent was removed in-vacuo affording a clear oil. HCl (4 M in dioxane, 4 mL) was added and the solution was allowed to stir at room temperature for 3 hr. The solvent was removed in vacuo affording a mixture of the title diastereomers 247 and 248 as their HCl salts (0.324 mmoles, 169 mg, 94% yield).

These diastereomers were then separated by Berger PrepSFC Chromatography according to the following conditions: column: ChiralPak AD-H (5 μm, 10×250 mm), mobile phase: A: liquid CO₂B: 10 mM NH4OAc in EtOH; flow rate: 15 mL/min, gradient: 25% B, run time: 15 min., prep injection volume: 500 μL, total injections: 11, QC-anal injection volume: 500 μL affording the separated enantiomers.

Distomer: (R)-3-amino-4-(4-chlorophenyl)-14(8)-3-hydroxy-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (247) (61 mg, 34%). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.96-2.21 (m, 5H) 2.29-2.45 (m, 1H) 2.52-2.77 (m, 4H) 3.07-3.49 (m, 7H) 3.66-4.04 (m, 3H) 4.30-4.60 (m, 3H) 7.10-7.38 (m, 6H) 7.46-7.63 (m, 2H). ESI-MS: m/z 485.3 (M+H)⁺.

Eutomer: (R)-3-amino-4-(4-chlorophenyl)-1-((R)-3-hydroxy-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (247) (66.6 mg, 37%). 1H NMR (400 MHz, DMSO-d₆) δ ppm 1.91-2.43 (m, 5H) 2.52-2.79 (m, 4H) 3.11-3.31 (m, 6H) 3.36-3.48 (m, 2H) 3.67-4.08 (m, 2H) 4.23-4.58 (m, 4H) 7.12-7.28 (m, 4H) 7.29-7.37 (m, 2H) 7.46-7.60 (m, 2H) ESI-MS: m/z 485.3 (M+H)⁺.

Example 138
General Procedure for the Synthesis of N-Substituted Derivatives of (S)-3,4-diamino-1((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (138F and 138G)

embedded image

The amine group of (S)-3-amino-4-(tert-butoxycarbonylamino)hutanoic acid (138A) was protected with an Fmoc group according to standard Schotten-Baumen procedure yielding (S)-3-(((9H-fluoren-9-yl)methoxy)carbonylamino)-4-(tert-butoxycarbonylamino)butanoic acid (138B).

embedded image

Piperidine (R)-1-(3-methoxypropyl)-2-(piperidin-3-yl)-1H-benzo[d]imidazole (138C) (3.19 g, 11.3 mmol) was acylated with the protected butanoic acid 138B (5 g, 11.4 mmol) in N-methylmorpholine using the standard BOP coupling reaction similar to HATU procedure of Example 7, Step E yielding tert-butyl (S)-2-(9H-fluoren-9-ylamino)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutylcarbamate (1380) (7.9 g, 11.4 mmol). ESI-MS: m/z 696.6 (MH⁺).

Removal of the Bac group was accomplished by standard procedures (dioxane, 4 M Ha/dioxane, 20° C., 20 min; evapn.) yielding (S)-3-(9H-fluoren-9-ylamino)-4-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one dihydrochloride salt (138E) (10.4 mmol, 90% yield). ESI-MS: m/z 597.5 (MH+). ¹H NMR (400 MHz, MeOH-d₄) δ ppm 1.10-1.29 (m, 1H) 1.54-2.38 (m, 6H) 2.67-3.10 (m, 4H) 3.17-3.30 (m, 4H) 3.36-3.59 (m, 4H) 3.98-4.78 (m, 7H) 7.26-7.48 (m, 4H), 7.59-7.87 (m, 7H), 7.90-7.99 (m, 1 H). HPLC retention time, T=0.777 min, STDTFA-2 method.

Step C.

The preparation of the N-derivatization of (9H-fluoren-9-yl)methyl (S)-1-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (138E) were accomplished using one of the two procedures listed below:

embedded image

In a 4 mL vial was placed acid chloride or chloroformate or isocyanate or sulfonyl chloride (0.2 mmol, 1.6 eq), followed by a stock solution of amine 137E (67 mg, 0.112 mmol, 1 eq) in 0.8 mL of amylene stabilized chloroform. Then DIEA (0.05 mL, 0.31 mmol, 2.5 eq) was added to the vial, and the reaction mixture was stirred at ambient temperature for 1 hour. Reaction progress was monitored by LC/MS. Chloroform was then removed under vacuum (Savant at low temperature) and 0.6 mL of 10% solution of piperidine in DMF was added to the mixture. After reacting for 1 hr, the solvents were removed under vacuum (Savant at medium temperature). The residue was dissolved in 0.8 mL of DMSO, transferred to 96 well plate and purified using LC-MS based purification (50 mm×10 mm Phenomenex Gemini Column using a 10-100% acetonitrile-water gradient) to yield the desired analog (137F).

embedded image

where

R is alkyl, heteroalkyl, aryl, or heteroaryl

In a 4 mL vial was added acid (0.2 mmol, 1.6 eq) and a stock solution of amine 137E (67 mg, 0.112 mmol, 1 eq) in 0.5 mL of amylene stabilized chloroform, followed by stock solution of (benzotriazol-1-yloxy)-tris(dimethylamino)-phosphonium hexafluorophosphate (BOP) (66 mg, 0.15 mmol, 1.2 eq) in 0.3 mL of amylene stabilized chloroform. Then DIEA (0.05 mL, 0.31 mmol, 2.5 eq) was added to the vial, and the reaction mixture was stirred at ambient temperature for 1 hr. Reaction progress was monitored by LC/MS. Chloroform was then removed under vacuum (Savant at low temperature) and 0.6 mL of solution of 10% piperidine in DMF was added to the mixture. After 1 hour, solvents were removed under vacuum (Savant at medium temperature). The residue was dissolved in 0.8 mL of DMSO, transferred to 96 well plate and purified using LC-MS based purification (50 mm×10 mm Phenomenex Gemini Column using a 10-100% acetonitrile-water gradient) to yield the desired analog (138G).

Compounds that were prepared according to the general procedure outlined in Example 138 are listed in Table VI.

TABLE VI

Compound

ESI-MS:

No.
Structure/Name
m/z (M + H⁺)

249

embedded image

528.3

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-2-naphthamide

250

embedded image

523.6

1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(2-

methoxyphenyl)urea

251

embedded image

544.3

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-5-

phenylfuran-2-carboxamide

252

embedded image

560.4

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-5-

phenylthiophene-2-carboxamide

253

embedded image

523.5

1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(4-

methoxyphenyl)urea

254

embedded image

523.5

1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(3-methoxyphenyl)urea

255

embedded image

561.2

1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(3,4-dichlorophenyl)urea

256

embedded image

527.2

1-((S)-2-ainino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(3-chlorophenyl)urea

257

embedded image

527.1

1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(2-chlorophenyl)urea

258

embedded image

551.5

1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(2,3-

dihydrobenzo[b][1,4]dioxin-6-yl)urea

259

embedded image

560.0

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-4-

(thiophen-2-yl)benzamide

260

embedded image

562.0

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-5-(2-

fluorophenyl)furan-2-carboxamide

261

embedded image

560.0

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-4-

(thiophen-3-yl)benzamide

262

embedded image

546.3

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3,4-dichlorobenzamide

263

embedded image

518.3

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-

oxobutyl)benzofuran-2-carboxamide

264

embedded image

554.4

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-carboxamide

265

embedded image

577.2

1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(2-

(trifluoromethoxy)phenyl)urea

266

embedded image

533.1

1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(2,3-

dihydro-1H-inden-5-yl)urea

267

embedded image

612.0

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-5-(2,4-

dichlorophenyl)furan-2-carboxamide

268

embedded image

579.6

1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(5-tert-

butyl-2-methoxyphenyl)urea

269

embedded image

493.5

1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-phenylurea

270

embedded image

570.4

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-

phenoxybenzamide

271

embedded image

520.3

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-2,3-

dihydrobenzofuran-5-carboxamide

272

embedded image

585.2

1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(2-

phenoxyphenyl)urea

273

embedded image

553.2

1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(2,5-

dimethoxyphenyl)urea

274

embedded image

559.2

1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(2-

(difluoromethoxy)phenyl)urea

275

embedded image

589.2

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-5-(2-

nitrophenyl)furan-2-carboxamide

276

embedded image

612.0

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-5-(2,5-

dichlorophenyl)furan-2-carboxamide

277

embedded image

612.0

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-5-(2,3-

dichlorophenyl)furan-2-carboxamide

278

embedded image

570.4

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-4-

phenoxybenzamide

279

embedded image

553.2

1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(2,4-

dimethoxyphenyl)urea

280

embedded image

508.3

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-4-

methoxybenzamide

281

embedded image

548.3

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-4-

chlorobenzenesulfonamide

282

embedded image

536.4

methyl 3-((S)-2-amino-4-((R)-3-(1-(3-

methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-

4-oxobutylcarbamoyl)benzoate

283

embedded image

527.2

1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(4-

chlorophenyl)urea

284

embedded image

539.1

1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(2-

(methylthio)phenyl)urea

285

embedded image

537.5

1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(2-

ethoxyphenyl)urea

286

embedded image

535.1

1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(2-

propylphenyl)urea

287

embedded image

537.1

1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(2-

methoxy-5-methylphenyl)urea

288

embedded image

585.2

1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(3-

phenoxyphenyl)urea

289

embedded image

546.3

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-2,6-

dichlorobenzamide

290

embedded image

582.0

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-2,6-

dichlorobenzenesulfonamide

291

embedded image

569.2

1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(biphenyl-2-yl)urea

292

embedded image

537.5

1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(4-

methoxy-2-methylphenyl)urea

293

embedded image

506.3

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3,4-dimethylbenzamide

294

embedded image

616.4

ethyl 4-(5-((S)-2-amino-4-((R)-3-(1-(3-

methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-

4-oxobutylcarbamoyl)furan-2-yl)benzoate

295

embedded image

612.0

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-5-(3,5-

dichlorophenyl)furan-2-carboxamide

296

embedded image

578.4

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-5-(3-

chlorophenyl)furan-2-carboxamide

297

embedded image

589.2

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-5-(3-

nitrophenyl)furan-2-carboxamide

298

embedded image

512.3

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-chlorobenzamide

299

embedded image

571.2

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-2-

phenoxynicotinamide

300

embedded image

548.3

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-

chlorobenzenesulfonamide

301

embedded image

535.1

1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(2-isopropylphenyl)urea

302

embedded image

549.5

1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(2-tert-butylphenyl)urea

303

embedded image

560.0

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobuty)-3-(5-

methyl-1,2,4-oxadiazol-3-yl)benzamide

304

embedded image

562.0

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-5-(4-

fluorophenyl)furan-2-carboxamide

305

embedded image

582.0

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3,4-

dichlorobenzenesulfonamide

306

embedded image

548.3

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-2-

chlorobenzenesulfonamide

307

embedded image

553.2

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-2-

(propylthio)nicotinamide

308

embedded image

536.3

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-2,3-

dihydrobenzo[b][1,4]dioxine-6-carboxamide

309

embedded image

512.3

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-4-chlorobenzamide

310

embedded image

508.3

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-methoxybenzamide

311

embedded image

528.3

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-1-naphthamide

312

embedded image

480.2

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)propane-2-sulfonamide

313

embedded image

562.4

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-y l)-4-oxobutyl)-6-

(piperidin-1-yl)picolinamide

314

embedded image

536.3

methyl 4-((S)-2-amino-4-((R)-3-(1-(3-

methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-

4-oxobutylcarbamoyl)benzoate

315

embedded image

544.2

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-

methoxybenzenesulfonamide

316

embedded image

514.3

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-

oxobutyl)benzenesulfonamide

317

embedded image

478.3

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)benzamide

318

embedded image

496.3

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-fluorobenzamide

319

embedded image

498.4

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-2-cyclohexylacetamide

320

embedded image

512.3

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-2-chlorobenzamide

321

embedded image

544.3

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-4-

methoxybenzenesulfonamide

322

embedded image

581.2

1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(2,5-

dimethoxyphenethyl)urea

323

embedded image

499.1

1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-cyclohexylurea

324

embedded image

544.3

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-2-

methoxybenzenesulfonamide

325

embedded image

468.3

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)furan-2-carboxamide

326

embedded image

484.3

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-

oxobutyl)cyclohexanecarboxamide

327

embedded image

508.3

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-2-methoxybenzamide

328

embedded image

487.1

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-

oxobutyl)morpholine-4-carboxamide

329

embedded image

551.5

methyl 2-(3-((S)-2-amino-4-((R)-3-(1-(3-

methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-

4-oxobutyl)ureido)benzoate

330

embedded image

565.2

ethyl 2-(3-((S)-2-amino-4-((R)-3-(1-(3-

methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-

4-oxobutyl)ureido)benzoate

331

embedded image

470.4

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-

oxobutyl)cyclopentanecarboxamide

332

embedded image

485.6

1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-cyclopentylurea

333

embedded image

444.4

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-

oxobutyl)isobutyramide

334

embedded image

471.5

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-

oxobutyl)pyrrolidine-1-carboxamide

335

embedded image

480.5

N-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)propane-2-sulfonamide

336

embedded image

518.3

1-((S)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)-3-(2-cyanophenyl)urea

Example 139
General Procedure for the Synthesis of N-Substituted Derivatives of (9H-fluoren-9-yl)methyl (3S,4R)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carhonyppyrrolidin-3-ylcarbamate (139F and 139G)

embedded image

The amine group of Boc-pyrrolidine-amino acid, (3R,4S)-4-amino-1-(tert-butoxycarbonyl)pyrrolidine-3-carboxylic acid (139A), was protected with an Fmoc group according to standard Schotten-Baumen procedure yielding (3R,48)-4-(((9H-fluoren-9-yl)methoxy)carbonylamino)-1-(tert-butoxycarbonyl)pyrrolidine-3-carboxylic acid (139B). ESI-MS: m/z 453.3 (MH)⁺.

embedded image

(R)-1-(3-methoxypropyl)-2-(piperidin-3-yl)-1H-benzo[d]imidazole (138C) (3.02 g) was coupled to (3R,4S)-4-(((9H-fluoren-9-yl)methoxy)carbonylamino)-1-(tert-butoxycarbonyl)pyrrolidine-3-carboxylic acid (5 g) (138B) using the standard BOP coupling procedure from Example 138, Step C, Procedure B. The deprotection was performed according to standard procedures (TFA/CH₂Cl₂; evapn; EtOAc/satd NaHCO₃; dry; evapn.) to yield the free amine, (9H-fluoren-9-yl)methyl (3S,4R)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidin-3-ylcarbamate (139E): ESI-MS: m/z 608.6 (MH+). ¹H NMR (400 MHz, MeOH-d₄) δ ppm 1.66 (m, 1H) 1.7-2.3 (m, 5H) 4.21-4.25 (m, 2H) 7.1-7.6 (m, 8H). HPLC retention time, T=0.817 min, STDTFA-2 method.

Step C.

N-Derivatives of the free amine (9H-fluoren-9-yl)methyl (3S,4R)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidin-3-ylcarbamate (138E) were prepared using either Procedure A or B listed below:

embedded image

where

- X is C(O), OC(O), NC(O), or S(O)₂, and
- R is alkyl, heteroalkyl, aryl, or heteroaryl

Procedure A: In a 4 mL vial was placed acid chloride or chloroformate or isocyanate or sulfonyl chloride (0.2 mmol, 1.6 eq), followed by a stock solution of (9H-fiuoren-9-yl)methyl (3S,4R)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidin-3-ylcarbamate (139E) (75 mg, 0.124 mmol, 1 eq) in 0.8 mL of amylene stabilized chloroform. Then DIEA (0.05 mL, 0.31 mmol, 2.5 eq) was added to the vial, and the reaction mixture was stirred at ambient temperature for 1 hr. Reaction progress was monitored by LC/MS. Chloroform was then removed under vacuum (Savant at low temperature) and 0.6 mL of 10% solution of piperidine in DMF was added to the mixture. After 1 hr solvents were removed under vacuum (Savant at medium temperature). The residue was dissolved in 0.8 mL of DMSO, transferred to 96 well plate and purified using LC-MS based purification (50 mm×10 mm Phenomenex Gemini Column using a 10-100% acetonitrile-water gradient).

embedded image

where

- R is alkyl, heteroalkyl, aryl, or heteroaryl

In a 4 mL vial was added acid (0.2 mmol, 1.6 eq) and a stock solution of (9H-fluoren-9-yl)methyl (3S,4R)-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidin-3-ylcarbamate (139E) (75 mg, 0.124 mmol, 1 eq) in 0.5 mL of amylene stabilized chloroform, followed by stock solution of (benzotriazol-1-yloxy)-tris(dimethylamino)-phosphonium hexafluorophosphate (BOP) (66 mg, 0.15 mmol, 1.2 eq) in 0.3 mL of amylene stabilized chloroform. Then DIEA (0.05 mL, 0.31 mmol, 2.5 eq) was added to the vial, and the reaction mixture was stirred at ambient temperature for 1 hour. Reaction progress was monitored by LC/MS. Chloroform was then removed under vacuum (Savant at low temperature) and 0.6 mL of solution of 10% piperidine in DMF was added to the mixture. After 1 hour solvents were removed under vacuum (Savant at medium temperature). The residue was dissolved in 0.8 mL of DMSO, transferred to 96 well plate and purified using LC-MS based purification (50 mm×10 mm Phenomenex Gemini Column using a 10-100% acetonitrile-water gradient).

Compounds that were prepared according to the General Procedure outlined in Example 138 are listed in Table VII.

TABLE VII

Compound

ESI-MS:

No.
Structure/Name
m/z (M + H⁺)

337

embedded image

((3R,4S)-4-amino-1-(2,3-dihydrobenzo[b][1,4]dioxin-6- ylsulfony)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H- benzo[d]imidazol-2-yl)piperidin-1-yl)methanone
584

338

embedded image

5((3S,4R)-3-amino-4((R)-3-(1-3-methoxypropyl)-1H- benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidin-1- ylsulfonyl)-1H-benzo[d]imidazol-2(3H)-one
582

339

embedded image

((3R,4S)-4-amino-1-(4-bromo-2,6- dichlorophenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-3- methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1- yl)methanone
672

340

embedded image

((3R,4S)-4-amino-1-(2,4,6-trichlorophenylsulfonyl)pyrrolidin- 3-yl)((R)-3-(1(3-methoxypropyl)-1H-benzo[d]imidazol-2- yl)piperidin-1-yl)methanone
628

341

embedded image

((3R,4S)-4-amino-1-(naphthalen-2-ylsulfonyl)pyrrolidin-3- yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2- yl)piperidin-1-yl)methanone
576

342

embedded image

((3R,4S)-4-amino-1-(4-bromo-2- chlorophenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3- methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1- yl)methanone
638

343

embedded image

((3R,4S)-4-amino-1-(2,5-dichlorophenylsulfonyl)pyrrolidin-3- yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2- yl)piperidin-1-yl)methanone
594

344

embedded image

((3R,4S)-4-amino-1-(4-chloro-2,5- dimethylphenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3- methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1- yl)methanone
588

345

embedded image

((3R,4S)-4-amino-1-(2,4,5-trichlorophenylsulfonyl)pyrrolidin- 3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2- yl)piperidin-1-yl)methanone
628

346

embedded image

((3R,4S)-4-amino-1-(2-chlorophenylsulfonyl)pyrrolidin-3- yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2- yl)piperidin-1-yl)methanone
560.0

347

embedded image

((3R,4S)-4-amino-1-(2,6-dichlorophenylsulfonyl)pyrrolidin-3- yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2- yl)piperidin-1-yl)methanone
594

348

embedded image

((3R,4S)-4-amino-1-(biphenyl-4-ylsulfonyl)pyrrolidin-3- yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2- yl)piperidin-1-yl)methanone
602

349

embedded image

((3R,4S)-4-amino-1-(2-chloro-4- fluorophenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3- methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1- yl)methanone
578

350

embedded image

((3R,4S)-4-amino-1-(2,4-dichlorophenylsulfonyl)pyrrolidin-3- yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2- yl)piperidin-1-yl)methanone
594

351

embedded image

((3R,4S)-4-amino-1-(3-chlorophenylsulfonyl)pyrrolidin-3- yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2- yl)piperidin-1-yl)methanone
560

352

embedded image

((3R,4S)-4-amino-1-(5-phenylfuran-2-carbonyl)pyrrolidin-3- yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2- yl)piperidin-1-yl)methanone
556

353

embedded image

((3R,4S)-4-amino-1-(3-chloro-2- methylphenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3- methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1- yl)methanone
574

354

embedded image

((3R,4S)-4-amino-1-(naphthalen-1-ylsulfonyl)pyrrolidin-3- yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2- yl)piperidin-1-yl)methanone
576

355

embedded image

((3R,4S)-4-amino-1-(2,3-dihydrobenzofuran-5- ylsulfonyl)pyrrolidin-3-y1)((R)-3-(1-(3-methoxypropyl)-1H- benzo[d]imidazol-2-yl)piperidin-1-yl)methanone
568

356

embedded image

((3R,4S)-4-amino-1-(2-chloro-5- (trifluoromethyl)phenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3- methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1- yl)methanone
628

357

embedded image

((3R,4S)-4-amino-1-(3-methoxyphenylsulfonyl)pyrrolidin-3- yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2- yl)piperidin-1-yl)methanone
556.0

358

embedded image

((3R,4S)-4-amino-1-(3-phenoxybenzoyl)pyrrolidin-3-yl)((R)- 3-(1-(3-methoxypropy1)-1H-benzo[d]imidazol-2-yl)piperidin- 1-yl)methanone
582.4

359

embedded image

((3R,4S)-4-amino-1-(2-chloro-6- methylphenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3- methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1- yl)methanone
574

360

embedded image

((3R,4S)-4-amino-1-(1-methyl-1H-indol-5- ylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H- benzo[d]imidazol-2-yl)piperidin-1-yl)methanone
579

361

embedded image

((3R,4S)-4-amino-1-(3,4-dichlorophenylsulfonyl)pyrrolidin-3- yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2- yl)piperidin-1-yl)methanone
594.4

362

embedded image

((3R,4S)-1-(2-naphthoyl)-4-aminopyrrolidin-3-yl)((R)-3-(1-(3- methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1- yl)methanone
540.3

363

embedded image

((3R,4S)-4-amino-1-(2,3-dichlorophenyisulfonyl)pyrrolidin-3- yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2- yl)piperidin-1-yl)methanone
594

364

embedded image

((3R,4S)-4-amino-1-(3-(2-methylthiazol-4- yl)phenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3- methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1- yl)methanone
623

365

embedded image

((3R,4S)-4-amino-1-(3,4-dichlorobenzoyl)pyrrolidin-3-yl)((R)- 3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin- 1-yl)methanone
558.0

366

embedded image

((3R,4S)-4-amino-1-(2-phenoxynicotinoyl)pyrrolidin-3- yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2- yl)piperidin-1-yl)methanone
583.2

367

embedded image

(3S,4R)-3-amino-N-(3-methoxyphenyl)-4-((R)-3-(1-(3- methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1- carbonyl)pyrrolidine-1-carboxamide
535.3

368

embedded image

((3R,4S)-4-amino-1-(3-phenoxyphenylsulfonyl)pyrrolidin-3- y1)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2- yl)piperidin-1-yl)methanone
618

369

embedded image

((3R,4S)-4-amino-1-(4-methoxyphenylsulfonyl)pyrrolidin-3- yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2- yl)piperidin-1-yl)methanone
556.0

370

embedded image

((3R,4S)-4-amino-1-(4-chlorophenylsulfonyl)pyrrolidin-3- yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2- yl)piperidin-1-yl)methanone
560.0

371

embedded image

((3R,4S)-4-amino-1-(isopropylsulfonyl)pyrrolidin-3-yl)((R)-3- (1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1- yl)methanone
492.3

372

embedded image

((3R,4S)-4-amino-1-(3,4-dimethoxyphenylsulfonyl)pyrrolidin- 3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2- yl)piperidin-1-yl)methanone
586

373

embedded image

methyl 2-((3S,4R)-3-amino-4-((R)-3-(1-(3-methoxypropyl)- 1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidin-l- ylsulfonyl)benzoate
584

374

embedded image

((3R,4S)-4-amino-1-(4-tert-butylphenylsulfonyl)pyrrolidin-3- yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2- yl)piperidin-1-yl)methanone
582

375

embedded image

((3R,4S)-4-amino-1-(3-chlorobenzoyl)pyrrolidin-3-yl)((R)-3- (1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1- yl)methanone
524.3

376

embedded image

((3R,4S)-1-(1-naphthoyl)-4-aminopyrrolidin-3-yl)((R)-3-(1-(3- methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1- yl)methanone
540.3

377

embedded image

methyl 3-((3S,4R)-3-amino-4-((R)-3-(1-(3-methoxypropyl)- 1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidine- 1-carbonyl)benzoate
548.3

378

embedded image

(3S,4R)3-amino-N-(3-chlorophenyl)-4-((R)-3-(1-(3- methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1- carbonyl)pyrrolidine-1-carboxamide
539.1

379

embedded image

((3R,4S)-4-amino-1-(2-methoxyphenylsulfonyl)pyrrolidin-3- yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2- yl)piperidin-1-yl)methanone
556.0

380

embedded image

N-(4-((3S,4R)-3-amino-4-((R)-3-(1-(3-methoxypropyl)-1H- benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidin-1- ylsulfonyl)phenyl)acetamide
583

381

embedded image

((3R,4S)-4-amino-1-(4-methoxy-2- nitrophenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3- methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1- yl)methanone
601

382

embedded image

1-(4-((3S,4R)-3-amino-4-((R)-3-(1-(3-methoxypropyl)-1H- benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidin-1- ylsulfonyl)phenyl)pyrrolidin-2-one
609

383

embedded image

((3R,4S)-4-amino-1-(2,4-dimethylphenylsulfonyl)pyrrolidin-3- yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2- yl)piperidin-1-yl)methanone
554

384

embedded image

((3R,4S)-4-amino-1-(phenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1- (3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1- yl)methanone
526.3

385

embedded image

((3R,4S)-4-amino-1-benzoylpyrrolidin-3-yl)((R)-3-(1-(3- methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1- yl)methanone
490.3

386

embedded image

(3S,4R)-3-amino-N-cyclohexyl-4-((R)-3-(1-(3- methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1- carbonyl)pyrrolidine-1-carboxamide
511.5

387

embedded image

((3R,4S)-4-amino-1-(2-methoxybenzoyl)pyrrolidin-3-yl)((R)- 3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin- 1-yl)methanone
520.3

388

embedded image

(3S,4R)-3-amino-N-(4-chlorophenyl)-4-((R)-3-(1-(3- methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-l- carbonyl)pyrrolidine-1-carboxamide
539.1

389

embedded image

(3S,4R)-3-amino-N-(2-chlorophenyl)-4-((R)-3-(1-(3- methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1- carbonyl)pyrrolidine-1-carboxamide
539.1

390

embedded image

(3S,4R)-2-chlorophenyl 3-amino-4-((R)-3-(1-(3- methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1- carbonyl)pyrrolidine-1-carboxylate
ND

391

embedded image

4-((3S,4R)-3-amino-4-((R)-3-(1-(3-methoxypropyl)-1H- benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidin-1- ylsulfonyl)-3-chlorobenzonitrile
585

392

embedded image

((3R,4S)-4-amino-1-(1-methyl-1H-indol-4- ylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H- benzo[d]imidazol-2-yl)piperidin-1-yl)methanone
579

393

embedded image

((3R,4S)-4-amino-1-(3-fluorobenzoyl)pyrrolidin-3-yl)((R)-3- (1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1- yl)methanone
508.3

394

embedded image

((3R,4S)-4-amino-1-(4-methoxybenzoyl)pyrrolidin-3-yl)((R)- 3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin- 1-yl)methanone
520.3

395

embedded image

((3R,4S)-4-amino-1-(cyclopentanecarbonyl)pyrrolidin-3- yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2- yl)piperidin-1-yl)methanone
482.3

396

embedded image

1-((3S,4R)-3-amino-4-((R)-3-(1-(3-methoxypropyl)-1H- benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidin-1-yl)- 2-methylpropan-1-one
456.3

397

embedded image

l-((3S,4R)-3-amino-4-((R)-3-(1-(3-methoxypropyl)-1H- benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidin-1-yl)- 2-cyclohexylethanone
510.3

398

embedded image

((3R,4S)-4-amino-1-(2-chlorobenzoyl)pyrrolidin-3-yl)((R)-3- (1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1- yl)methanone
524.3

399

embedded image

(3S,4R)-3-amino-N-cyclopentyl-4-((R)-3-(1-(3- methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1- carbonyl)pyrrolidine-1-carboxamide
497.5

400

embedded image

(3S,4R)-3-amino-N-(2-methoxyphenyl)-4-((R)-3-(1-(3- methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1- carbonyl)pyrrolidine-1-carboxamide
535.1

401

embedded image

((3R,4S)-4-amino-1-(5-bromo-2- methoxyphenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3- methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-l- yl)methanone
634

402

embedded image

((3R,4S)-4-amino-1-(2- (trifluoromethyl)phenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3- methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1- yl)methanone
594

403

embedded image

2-((3S,4R)-3-amino-4-((R)-3-(1-(3-methoxypropyl)-1H- benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidin-1- ylsulfonyl)-4-methylbenzonitrile
565

404

embedded image

(3S,4R)-3-amino-4-((R)-3-(1-(3-methoxypropyl)-1H- benzo[d]imidazol-2-yl)piperidine-1-carbonyl)-N- phenylpyrrolidine-1-carboxamide
505.1

405

embedded image

((3R,4S)-4-amino-1-(cyclohexanecarbonyl)pyrrolidin-3- yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2- yl)piperidin-1-yl)methanone
496.3

406

embedded image

((3R,4S)-4-amino-1-(benzofuran-2-carbonyl)pyrrolidin-3- yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2- yl)piperidin-1-yl)methanone
530.3

407

embedded image

(3S,4R)-4-chlorophenyl 3-amino-4-((R)-3-(1-(3- methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1- carbonyl)pyrrolidine-1-carboxylate
540.3

408

embedded image

(3S,4R)-3-(trifluoromethyl)phenyl 3-amino-4-((R)-3-(1-(3- methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1- carbonyl)pyrrolidine-1-carboxylate
574.4

409

embedded image

((3R,4S)-4-amino-1-(3-(5-methyl-1,2,4-oxadiazol-3- yl)phenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3- methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1- yl)methanone
608

410

embedded image

((3R,4S)-4-amino-1-(2-methoxy-5- methylphenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3- methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1- yl)methanone
570

411

embedded image

((3R,4S)-4-amino-1-(2-methoxy-4- nitrophenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3- methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1- yl)methanone
601

412

embedded image

((3R,4S)-4-amino-1-(5-chloro-2- methoxyphenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3- methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1- yl)methanone
590

413

embedded image

((3R,4S)-4-amino-1-(2,5-dimethoxyphenylsulfonyl)pyrrolidin- 3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2- yl)piperidin-1-yl)methanone
586

414

embedded image

((3R,4S)-4-amino-1-(2,6-dichlorobenzoyl)pyrrolidin-3-yl)((R)- 3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin- 1-yl)methanone
558.0

415

embedded image

(3S,4R)-3-amino-N-(4-methoxyphenyl)-4-((R)-3-(1-(3- methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1- carbonyl)pyrrolidine-1-carboxamide
535.1

416

embedded image

((3R,4S)-4-amino-1-(4-chlorobenzoyl)pyrrolidin-3-yl)((R)-3- (1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1- yl)methanone
524.3

417

embedded image

((3R,4S)-4-amino-1-(pyrrolidine-1-carbonyl)pyrrolidin-3- yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2- yl)piperidin-1-yl)methanone
483.5

418

embedded image

((3R,4S)-4-amino-1-(2-(propylthio)nicotinoyl)pyrrolidin-3- yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazo]-2- yl)piperidin-1-yl)methanone
565.6

419

embedded image

((3R,4S)-4-amino-1-(3- (difluoromethoxy)phenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3- methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1- yl)methanone
592

420

embedded image

((3R,4S)-4-amino-1-(furan-2-carbonyl)pyrrolidin-3-yl)((R)-3- (1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1- yl)methanone
480.3

421

embedded image

((3R,4S)-4-amino-1-(3-methoxybenzoyl)pyrrolidin-3-yl)((R)- 3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin- 1-yl)methanone
520.3

422

embedded image

methyl 4-((3S,4R)-3-amino-4-((R)-3-(1-(3-methoxypropyl)- 1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidine- 1-carbonyl)benzoate
548.3

423

embedded image

((3R,4S)-4-amino-1-(morpholine-4-carbonyl)pyrrolidin-3- yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2- yl)piperidin-1-yl)methanone
499.1

424

embedded image

methyl 2-((3S,4R)-3-amino-4-((R)-3-(1-(3-methoxypropyl)- 1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidine- 1-carbonyl)benzoate
548.3

425

embedded image

((3R,4S)-4-amino-1-(2,6-dichlorophenylsulfonyl)pyrrolidin-3- yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2- yl)piperidin-1-yl)methanone
594

426

embedded image

((3R,4S)-4-amino-1-(2,6-difluorophenylsulfonyl)pyrrolidin-3- yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2- yl)piperidin-1-yl)methanone
562

427

embedded image

2-((3S,4R)-3-amino-4-((R)-3-(1-(3-methoxypropyl)-1H- benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidin-1- ylsulfonyl)benzonitrile
551

428

embedded image

((3R,4S)-4-amino-1-(3-fluorophenylsulfonyl)pyrrolidin-3- yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2- yl)piperidin-1-yl)methanone
544

429

embedded image

N-(3-((3S,4R)-3-amino-4-((R)-3-(1-(3-methoxypropyl)-1H- benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidin-1- ylsulfonyl)phenyl)acetamide
583

430

embedded image

((3R,4S)-4-amino-1-(3-(2-methylpyrimidin-4-yl) phenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3- methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1- yl)methanone
618

431

embedded image

((3R,4S)-4-amino-1-(3-(5-methyl-1,3,4-oxadiazol-2-yl) phenylsulfonyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)- 1H-benzo[d]imidazol-2-yl)piperidin-1-yl)methanone
608

Example 140
General Procedure for the Synthesis of Derivatives of (S)-3-amino-4-hydroxy-1-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)hutan-1-one (140E)

embedded image

The piperidine, ((R)-1-(3-methoxypropyl)-2-(piperidin-3-yl)-1H-benzo[d]imidazole) (140A), was acylated with the homoserine acid, ((S)-4-(benzyloxy)-3-(tert-butoxycarbonylamino)hutanoic acid) (140B) (3.4 g), using the standard BOP coupling procedure of Example 139, Step C, Procedure B. The deprotection of O-benzyl group 140C was performed according to standard hydrogenation procedure (20 wt % of 10% Pd—C, HOAc, H₂(1 atm), 20° C., 18-36 hrs) to yield the free alcohol tert-butyl (S)-1-hydroxy-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (140D). ESI-MS: m/z 475.5.

The benzyl ether amide material 1400 (3.16 g, 5.6 mmol) was dissolved in AcOH (10% soln; 32 mL) under nitrogen, and then 10% palladium on activated carbon (1.26 g, 20 wt %) was added. The reaction mixture was stirred vigorously under a balloon of hydrogen (kept full) at room temperature overnight. Reaction progress was monitored by LC/MS. Once completed (18-36 h), the black mixture was filtered through Celite with additional MeOH washing, and the solvents were evaporated to dryness. This residue was taken up in EtOAc (˜100 mL), washed with saturated NaHCO₃(3×30 mL), and saturated NaCl (2×15 mL), and dried (Na₂SO₄). The organic phase was filtered and then evaporated (up to 45° C.) and placed on full vacuum to yield tert-butyl (S)-1-hydroxy-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate 140E (1.3 g) as a clear foaming glass. ESI-MS: m/z 475.5 (MH+). ¹H NMR (400 MHz, MeOH-d₄) δ ppm 1.66 (m, 1H) 1.7-2.3 (m, 5H) 4.21-4.25 (m, 2H) 7.1-7.6 (m, 8H). HPLC retention time, T=0.725 min, STDTFA-2 method.

embedded image

Derivatives 140F were prepared using Mitsunobu conditions in a 0.115 mmol scale of 140E, followed by Boc-deprotection with mixture of TFA/CH₂Cl₂(1:1).

In a 4 mL vial was added the phenol (0.23 mmol, 2 eq), triphenylphosphine (60 mg, 0.23 mmol, 2 eq) and a stock solution of tert-butyl (S)-1-hydroxy-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (140E) (55 mg, 0.115 mmol, 1 eq) in 0.5 mL of toluene. To this solution at 0° C. was quickly added under nitrogen the diethylazodicarboxylate (40 mg, 0.23 mmol, 2.0 eq). The reaction mixture was stirred at ambient temperature overnight. Reaction progress was monitored by LC/MS. The reaction was diluted with EtOAc (2 mL) and washed with saturated NaHCO₃(2×1 mL), dried with (Na₂SO₄), filtered and evaporated yielding the N-protected compound.

To this residue was added 0.6 mL of solution of TFA/CH₂Cl₂(1:1). After 1 hour solvents were removed under vacuum (Savant at low temperature). The residue was dissolved in 0.8 mL of DMSO, transferred to 96 well plate and purified using LC-MS based purification (50 mm×10 mm Phenomenex Gemini Column using a 10-100% acetonitrile-water gradient) to yield 140F.

Compounds prepared according to the synthesis procedure outlined in Example 140 are listed in Table VIII.

TABLE VIII

Compound

ESI-MS:

No.
Structure/Name
m/z (M + H⁺⁾

432

embedded image

509

methyl 2-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutoxy)benzoate

433

embedded image

481

(R)-3-amino-4-(3-methoxyphenoxy)-1-((R)-3-(1-(3-

methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-

yl)butan-l-one

434

embedded image

491

(R)-4-(1H-benzo[d]imidazol-2-yloxy)-3-amino-1-((R)-3-(1-(3-

methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-

yl)butan-1-one

Table IX below lists other benzimidazole compounds prepared according to the schemes described above.

TABLE IX

Compound

ESI-MS:

No.
Structure/Name
m/z (M + H⁺)

435

embedded image

602.8

(R)-3-amino-4-(4-(2-((S)-3-hydroxypyrrolidin-1-yl)thiazol-4-

yl)phenyl)-1-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one

436

embedded image

594.8

1-(4′-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)biphenyl-4-

yl)imidazolidin-2-one

437

embedded image

527.7

(R)-3-amino-4-(4-(2-hydroxypyridin-4-yl)phenyl)-1-((R)-3-(1-

(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-

yl)butan-1-one

438

embedded image

581.7

6-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-2H-

benzo[b][1,4]oxazin-3(4H)-one

439

embedded image

581.8

(R)-3-amino-1-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4-(4-methyl-3,4-

dihydro-2H-benzo[b][1,4]oxazin-7-yl)phenyl)butan-1-one

440

embedded image

584.7

1-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-6-

fluoro-1H-benzo[d]imidazol-2(3H)-one

441

embedded image

612.7

1-(4′-((R)-2-amino-4-((R)-3-(4-fluoro-1-(3-methoxypropyl)-

1H-benzo[d]imidazol-2-yl)piperidin-l-yl)-4-

oxobutyl)biphenyl-4-yl)imidazolidin-2-one

442

embedded image

615.8

7-(4-((R)-2-amino-4-((R)-3-(4-fluoro-1-(3-methoxypropyl)-

1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-

2H-benzo[b][1,4]thiazin-3(4H)-one

443

embedded image

599.7

7-(4-((R)-2-amino-4-((R)-3-(4-fluoro-1-(3-methoxypropyl)-

1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl )phenyl)-

2H-benzo[b][1,4]oxazin-3(4H)-one

444

embedded image

545.7

(R)-3-amino-1-((R)-3-(4-fluoro-1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4-(2-hydroxypyridin-

4-yl)phenyl)butan-1-one

445

embedded image

540.7

N-(2-(2-((R)-1-((R)-3-amino-4-(4-(6-hydroxypyridin-3-

yl)phenyl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-

yl)ethyl)acetamide

446

embedded image

539.7

N-(2-(2-((R)-1-((R)-3-amino-4-(4-(6-aminopyridin-3-

yl)phenyl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-

yl)ethyl)acetamide

447

embedded image

594.8

3-(2-((R)-1-((R)-3-amino-4-(4-(4-methyl-3,4-dihydro-2H-

benzo[b][1,4]oxazin-7-yl)phenyl)butanoyl)piperidin-3-yl)-1H-

benzo[d]imidazol-1-yl)propanamide

448

embedded image

603.7

N-(2-(2-((R)-1-((R)-3-amino-4-(4-(2,2-

difluorobenzo[d][1,3]dioxol-5-yl)phenyl)butanoyl)piperidin-3-

yl)-1H-benzo[d]imidazol-1-yl)ethyl)acetamide

449

embedded image

581.7

N-(2-(2-((R)-1-((R)-3-amino-4-(4-(2,3-

dihydrobenzo[b][1,4]dioxin-6-yl)phenyl)butanoyl)piperidin-3-

yl)-1H-benzo[d]imidazol-1-yl)ethyl)acetamide

450

embedded image

540.7

N-(2-(2-((R)-1-((R)-3-amino-4-(4-(2-aminopyrimidin-5-

yl)phenyl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-

yl)ethyl)acetamide

451

embedded image

545.7

(R)-3-amino-1-((R)-3-(4-fluoro-1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4-(6-hydroxypyridin-

3-yl)phenyl)butan-1-one

452

embedded image

544.7

(R)-3-amino-4-(4-(6-aminopyridin-3-yl)phenyl)-1-((R)-3-(4-

fluoro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-

yl)piperidin-1-yl)butan-1-one

453

embedded image

599.7

(R)-3-amino-1-((R)-3-(4-fluoro-1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4-(4-methyl-3,4-

dihydro-2H-benzo[b][1,4]oxazin-7-yl)phenyl)butan-1-one

454

embedded image

608.7

(R)-3-amino-4-(4-(2,2-difluorobenzo[d][1,3]dioxol-5-

yl)phenyl)-1-((R)-3-(4-fluoro-1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one

455

embedded image

586.7

(R)-3-amino-4-(4-(2,3-dihydrobenzo[b][1,4]dioxin-6-

yl)phenyl)-1-((R)-3-(4-fluoro-1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one

456

embedded image

545.7

(R)-3-amino-4-(4-(2-aminopyrimidin-5-yl)phenyl)-1-((R)-3-

(4-fluoro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-

yl)piperidin-1-yl)butan-1-one

457

embedded image

596.7

methyl 4′-((R)-4-((R)-3-(1-(2-acetamidoethyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-2-amino-4-

oxobutyl)biphenyl-4-ylcarbamate

458

embedded image

583.7

5-(4-((R)-2-amino-4-((R)-3-(4-fluoro-1-(3-methoxypropyl)-

1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-

oxobutyl)phenyl)indolin-2-one

459

embedded image

585.7

6-(4-((R)-2-amino-4-((R)-3-(4-fluoro-1-(3-methoxypropyl)-

1H-benzo[d]imidazol-2-yl)piperidin-l-yl)-4-

oxobutyl)phenyl)indolin-2-one

460

embedded image

585.7

5-(4-((R)-2-amino-4-((R)-3-(4-fluoro-1-(3-methoxypropyl)-

1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-

oxobutyl)phenyl)benzo[d]oxazol-2(3H)-one

461

embedded image

540.7

N-(2-(2-((R)-1-((R)-3-amino-4-(4-(2-hydroxypyridin-4-

yl)phenyl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-

yl)ethyl)acetamide

462

embedded image

607.8

N-(2-(2-((R)-1-((R)-3-amino-4-(4′-(2-oxoimidazolidin-l-

yl)biphenyl-4-yl)butanoyl)piperidin-3-yl)-1H-

benzo[d]imidazol-1-yl)ethyl)acetamide

463

embedded image

584.7

(R)-3-amino-4-(4-(2-aminobenzo[d]oxazol-5-yl)phenyl)-1-

((R)-3-(4-fluoro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-

yl)piperidin-1-yl)butan-1-one

464

embedded image

610.8

N-(2-(2-((R)-1-((R)-3-amino-4-(4-(2-oxo-2,3-

dihydrobenzo[b][1,4]oxathiin-6-yl)phenyl)butanoyl)piperidin-

3-yl)-1H-benzo[d]imidazol-1-yl)ethyl)acetamide

465

embedded image

578.7

N-(2-(2-((R)-1-((R)-3-amino-4-(4-(2-oxoindolin-5-

yl)phenyl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-

yl)ethyl)acetamide

466

embedded image

578.7

N-(2-(2-((R)-1-((R)-3-amino-4-(4-(2-oxoindolin-6-

yl)phenyl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-

yl)ethyl)acetamide

467

embedded image

580.7

N-(2-(2-((R)-1-((R)-3-amino-4-(4-(2-oxo-2,3-

dihydrobenzo[d]oxazol-5-yl)phenyl)butanoyl)piperidin-3-yl)-

1H-benzo[d]imidazol-1-yl)ethyl)acetamide

468

embedded image

579.7

5-(4-((R)-2-amino-4-((R)-3-(4-fluoro-1-(3-methoxypropyl)-

1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-

oxobutyl)phenyl)benzo[d]oxazol-2(3H)-one

469

embedded image

594.7

(R)-3-amino-4-(4-(2-aminobenzo[d]oxazol-5-yl)phenyl)-1-

((R)-3-(4-fluoro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-

yl(piperidin-l-yl)butan-l-one

470

embedded image

575.1

N-(2-(2-((R)-1-((R)-3-amino-4-(4-(2-aminopyrimidin-5-

yl)phenyl)butanoyl)piperidin-3-yl)-4-chloro-1H-

benzo[d]imidazol-1-yl)ethyl)acetamide

471

embedded image

553.7

N-(2-(2-((R)-1-((R)-3-amino-4-(4-(6-aminopyridin-3-

yl)phenyl)butanoyl)piperidin-3-yl)-4-methyl-1H-

benzo[d]imidazol-1-yl)ethyl)acetamide

472

embedded image

554.7

N-(2-(2-((R)-1-((R)-3-amino-4-(4-(2-aminopyrimidin-5-

yl)phenyl)butanoyl)piperidin-3-yl)-4-methyl-1H-

benzo[d]imidazol-1-yl)ethyl)acetamide

473

embedded image

554.7

N-(2-(2-((R)-1-((R)-3-amino-4-(4-(6-hydroxypyridin-3-

yl)phenyl)butanoyl)piperidin-3-yl)-4-methyl-1H-

benzo[d]imidazol-1-yl)ethyl)acetamide

474

embedded image

617.7

N-(2-(2-((R)-1-((R)-3-amino-4-(4-(2,2-

difluorobenzo[d][1,3]dioxol-5-yl)phenyl)butanoyl)piperidin-3-

yl)-4-methyl-1H-benzo[d]imidazol-1-yl)ethyl)acetamide

475

embedded image

608.8

N-(2-(2-((R)-1-((R)-3-amino-4-(4-(4-methyl-3,4-dihydro-2H-

benzo[b][1,4]oxazin-7-yl)phenyl)butanoyl)piperidin-3-yl)-4-

methyl-1H-benzo[d]imidazol-1-yl)ethyl)acetamide

476

embedded image

526.6

N-(2-(2-((R)-1-((R)-3-amino-4-(4-(6-hydroxypyridin-3-

yl)phenyl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-

yl)ethyl)acetamide

477

embedded image

595.7

N-(2-(2-((R)-1-((R)-3-amino-4-(4-(2,3-

dihydrobenzo[b][1,4]dioxin-6-yl)phenyl)butanoyl)piperidin-3-

yl)-4-methyl-1H-benzo[d]imidazol-1-yl)ethyl)acetamide

478

embedded image

575.1

N-(2-(2-((R)-1-((R)-3-amino-4-(4-(6-hydroxypyridin-3-

yl)phenyl)butanoyl)piperidin-3-yl)-4-chloro-1H-

benzo[d]imidazol-1-yl)ethyl)acetamide

479

embedded image

574.1

N-(2-(2-((R)-1-((R)-3-amino-4-(4-(6-aminopyridin-3-

yl)phenyl)butanoyl)piperidin-3-yl)-4-chloro-1H-

benzo[d]imidazol-1-yl)ethyl)acetamide

480

embedded image

525.7

3-(2-((R)-1-((R)-3-amino-4-(4-(6-aminopyridin-3-

yl)phenyl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-

yl)propanamide

481

embedded image

526.6

3-(2-((R)-1-((R)-3-amino-4-(4-(2-aminopyrimidin-5-

yl)phenyl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-

yl)propanamide

482

embedded image

580.7

3-(2-((R)-1-((R)-3-amino-4-(4-(4-methyl-3,4-dihydro-2H-

benzo[b][1,4]oxazin-7-yl)phenyl)butanoyl)piperidin-3-yl)-1H-

benzo[d]imidazol-1-yl)propanamide

483

embedded image

589.6

3-(2-((R)-1-((R)-3-amino-4-(4-(2,2-

difluorobenzo[d][1,3]dioxol-5-yl)phenyl)butanoyl)piperidin-3-

yl)-1H-benzo[d]imidazol-1-yl)propanamide

484

embedded image

567.7

3-(2-((R)-1-((R)-3-amino-4-(4-(2,3-

dihydrobenzo[b][1,4]dioxin-6-yl)phenyl)butanoyl)piperidin-3-

yl)-1H-benzo[d]imidazol-1-yl)propanamide

485

embedded image

509.7

3-(2-((R)-1-((R)-3-amino-4-(biphenyl-4-yl)butanoyl)piperidin-

3-yl)-1H-benzo[d]imidazol-1-yl)propanamide

486

embedded image

566.7

3-(2-((R)-1-((R)-4-(4′-acetamidobiphenyl-4-yl)-3-

aminobutanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-

yl)propanamide

487

embedded image

539.7

3-(2-((R)-1-((R)-3-amino-4-(4′-methoxybiphenyl-4-

yl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-

yl)propanamide

488

embedded image

510.6

3-(2-((R)-1-((R)-3-amino-4-(4-(pyridin-4-

yl)phenyl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-

yl)propanamide

489

embedded image

544.1

3-(2-((R)-1-((R)-3-amino-4-(4′-chlorobiphenyl-4-

yl)butanoyl)piperidin-3-yl)-1H-benzo[d]imidazol-1-

yl)propanamide

490

embedded image

570.7

(R)-3-amino-4-(4-(2,3-dihydrobenzofuran-5-yl)phenyl)-1-((R)-

3-(4-fluoro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-

yl)piperidin-1-yl)butan-1-one

491

embedded image

585.7

N-(4′-((R)-2-amino-4-((R)-3-(4-fluoro-1-(3-methoxypropyl)-

1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-

oxobutyl)biphenyl-4-yl)acetamide

492

embedded image

558.7

(R)-3-amino-1-((R)-3-(4-fluoro-1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidin-1-yl)-4-(4′-methoxybiphenyl-

4-yl)butan-1-one

493

embedded image

566.74

(R)-3-amino-4-(4-(2,3-dihydrobenzofuran-5-yl)phenyl)-l-((R)-

3-(1-(3-methoxypropyl)-4-methyl-1H-benzo[d]imidazol-2-

yl)piperidin-1-yl)butan-1-one

494

embedded image

564.73

(R)-3-amino-4-(4-(benzofuran-5-yl)phenyl)-1-((R)-3-(1-(3-

methoxypropyl)-4-methyl-1H-benzo[d]imidazol-2-

yl)piperidin-1-yl)butan-1-one

495

embedded image

579.74

5-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-4-methyl-

1H-benzo[d]imidazol-2-yl)piperidin-l-yl)-4-

oxobutyl)phenyl)indolin-2-one

496

embedded image

611.81

7-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-4-methyl-

1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-

2H-benzo[b][1,4]thiazin-3(4H)-one

497

embedded image

595.74

7-(4-((R)-2-amino-4-((R)-3-(1-(3-rnethoxypropyl)-4-methyl-

1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-

2H-benzo[b][1,4]oxazin-3(4H)-one

498

embedded image

593.77

5-(4-((R)-2-amino-4-((R)-3-(1-(3-methoxypropyl)-4-methyl-

1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutyl)phenyl)-

1-methylindolin-2-one

499

embedded image

564.73

(R)-4-(4-(1H-indazol-5-yl)phenyl)-3-amino-1-((R)-3-(1-(3-

methoxypropyl)-4-methyl-1H-benzo[d]imidazol-2-

yl)piperidin-1-yl)butan-1-one

500

embedded image

579.75

(R)-3-amino-4-(4-(3-amino-1H-indazol-5-yl)phenyl)-1-((R)-3-

(1-(3-methoxypropyl)-4-methyl-1H-benzo[d]imidazol-2-

yl)piperidin-1-yl)butan-1-one

501

embedded image

565.7

3-(2-((R)-1-((R)-3-amino-4-(4-(2,3-dihydrobenzofuran-5-

yl)phenyl)butanoyl)piperidin-3-yl)-4-methyl-1H-

benzo[d]imidazol-1-yl)-N-methylpropanamide

Table X below lists azabenzimidazole compounds prepared according to the schemes described above.

TABLE X

ESI-MS:

Compound
Structure/Name
m/z (M + H⁺)

502

embedded image

520.07

(3R)-3-amino-1-(3-(5-chloro-3-(3-methoxypropyl)-3H-

imidazo[4,5-b]pyridin-2-yl)piperidin-1-yl)-4-(naphthalen-2-

yl)butan-1-one

503

embedded image

515.65

(3R)-3-amino-1-(3-(5-methoxy-3-(3-methoxypropyl)-3H-

imidazo[4,5-b]pyridin-2-yl)piperidin-1-yl)-4-(naphthalen-2-

yl)butan-1-one

504

embedded image

542.68

(R)-3-amino-4-(4-(6-hydroxypyridin-3-yl)phenyl)-1-((R)-3-(3-

(3-methoxypropyl)-7-methyl-3H-imidazo[4,5-b]pyridin-2-

yl)piperidin-1-yl)butan-1-one

505

embedded image

525.69

(R)-3-amino-4-(biphenyl-4-yl)-1-((R)-3-(3-(3-methoxypropyl)-

7-methyl-3H-imidazo[4,5-b]pyridin-2-yl)piperidin-1-yl)butan-

1-one

Table XI below lists another pyrrolidine compound prepared according to the schemes described above.

TABLE XI

ESI-MS:

Compound
Structure/Name
m/z (M + H⁺)

506

embedded image

474.65

3-((3S,4R)-3-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-

benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidin-l-

yl)benzonitrile

Example 141
SFC Separation of Racemic Mixtures

embedded image

Racemic mixture of tert-butyl (2R)-4-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(4-chlorophenyl)-4-oxobutan-2-ylcarbamate were separated into steroisomeric components of tert-butyl (R)-4-((R)-3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(4-chlorophenyl)-4-oxobutan-2-ylcarbamate (140A) and tert-butyl (R)-44(S)-3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(4-chlorophenyl)-4-oxobutan-2-ylcarbamate (14013) by supercritical fluid chromatography under the following conditions:

- Column: ChiralPak AD-H (5 um, 21×250 mm)
- Mobile Phase:
  - A: liquid CO,
  - B: IPOH
- Flow Rate: 45 mLJmin
- Gradient: 20% IPA
- Prep injection volume: 1000 μL
- Total injections: 12
- Anal injection volume: 100 μL
- Run Time: 20 min.

The ee ratio of each of the fractions is >99%. ESI-MS: m/z 469.3 (M+H)⁺.

Example 142
Regioisomer LC/MS Separation

A mixture of (R)-tert-butyl 3-(4-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate and (R)-tert-butyl 3-(7-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (18.39 mmole, 7.50 g) was separated by LC/MS under the following conditions:

- Instrument: Waters ZQ LC/MS Prep System
  - ZQ 2000 single quadrupole mass detector
  - 2767 sample manager for injection and collection
  - 2525 binary gradient pump and 515 isocratic pump
  - 2487 UV detector and AllTech 2000 ELSD detector
  - Controlled by MassLynx 4.1 software with FractionLynx program
- MS Method: (PrepScan200-800Pos or AnalScan200-800Pos)
  - Mass Range: 200-800
  - Ion mode: positive
- Column: Gemini 5 um 75×30 mm. Mobile phase: A-10 mM NH₄HCO₃in H₂O; B-10 mM
  - NH₄HCO₃in 20/80 H₂O/CAN. Flow rate: 50 mLJmin. Total run time: 8 min.
  - Gradient: 75-85% B in 6 min
- Prep injection: batch 1-250 uL, batch2-210 uL
- Total injections: 75
- Product purified:
  - (R)-tert-butyl 3-(4-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (142A) (3.02 g).
  - (R)-tert-butyl 3-(7-chloro-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate (142B) (1.00 g).

embedded image

Example 143
Synthesis of 34(3S,4R)-3-amino-4-((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carbonyl)pyrrolidin-1-yl)benzonitrile (507)

embedded image

The compound was synthesized according general scheme 35. To a mixture of the intermediate, (9H-fluoren-9-yl)methyl 4-(3-(1-(3-methoxypropyl)-4,5-dimethyl-1H-imidazol-2-yl)piperidine-1-carbonyl)pyrrolidin-3-ylcarbamate (15c, general scheme 15, 49.0 mg, 0.081 mmol) and 3-iodobenzonitrile (25.3 mg, 1.5 eq) in 2 ml acetonitril was added (E)-2-(diphenylphosphoryl)benzaldehyde oxime (5.2 mg, 20% mol), cesim carbonate (55.4 mg, 2.1 eq) and copper (1) oxide (0.6 mg, 5% mol). The reaction mixture was heated at 80° C. for 18 hrs. The mixture was filtered and filtrate was concentrated and purified on preparative HPLC to give the product as light brown solid (10.4 mg, 26%); MS: MH+=487.4 (RT=1.90 min STDTFA-2 method).

Example 144
Synthesis of ((3R,4S)-4-amino-1-(4-nitrophenyl)pyrrolidin-3-yl)((R)-3-(1-(3-methoxypropyl)-1H-benzo[d]limidazol-2-yl)piperidin-1-yl)methanone (508)

embedded image

To a solution of the intermediate 15c (9H-fluoren-9-yl)methyl 4-(3-(1-(3-methoxypropyl)-4,5-dimethyl-1H-imidazol-2-yl)piperidine-1-carbonyl)pyrrolidin-3-ylcarbamate (also see Example 139, 50.0 mg, 0.082 mmol) in 2 mL DMF was added 1-fluoro-4-nitrobenzene (12 uL, 0.112 mmol) and potassium carbonate (200 mg). The mixture was heated at 100° C. for 4 hrs. The reaction mixture was filtered and purified by preparative HPLC (5 to 50% CH3CN/water) to give 10.0 mg product, MS: MH+=507.2, RT=4.44 min.

Example 145
Synthesis of (R)-3-amino-4-(4-(2-aminopyrimidin-5-yl)phenyl)-1-((R)-3-(1-(2-fluoroethyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)butan-1-one (509)

embedded image

To a solution of Compound 513 (Example 5, 300 mg, 0.555 mmol) in 5 mL of DMF at 0° C. was added NaI (92 mg, 0.61 mmol), NaH (60%, 29 mg, 0.72 mmol). The mixture was stirred at 0° C. for 30 mins. 1-Fluoro-2-iodoethane (97 mg, 0.72 mmol) was added, the reaction was warmed to room temperature and stirred overnight. It was poured into 20 mL crushed ice and extracted with DCM (3×25 mL), the combined organic layer was dried over MgS₂O₄and concentrated. The resulting residue was purified by preparative HPLC using 15-45% CH₃CN/water). tert-Butyl (R)-1-(4-bromophenyl)-4-((R)-3-(1-(2-fluoroethyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate (145A) was obtained after lyophilizing as white solid w=146 mg (45%).

Suzuki coupling of 145A with 2-aminopyrimidin-5-ylboronic acid (145E) was carried out analogously to the synthesis of Compound 613 (Example 6, Step B). The crude Boc-protected intermediate was de-protected with TFA using procedure similar to that for the synthesis of Compound 72 from Compound 6B (Example 6, Step C). The crude product was purified by preparative HPLC using 15% CH₃CN/water as mobile phase. Compound 509 was obtained in 14.4% yield over two steps (17.8 mg), MS: MH⁺=502.4.

Example A
Expression of Preprorenin and Purification of Prorenin

The sequence of human wild-type renin is known in the art; see, Imai, T. et al., Proc. Natl. Acad. Sci. USA 1983, 80, 7105-7409. It is noted that the fragment of the renin protein useful for the assay comprises amino acid residues 67-406 of human renin (active renin). To prepare active renin, a fragment longer than active renin, a preprorenin (e.g., comprising residues 1-406), may be expressed and from which a prorenin (e.g., comprising residues 23-406) may be recovered. The prorenin may later be cleaved to obtain active renin.

Expression of human preprorenin (residues 1-406) can be conducted using a FreeStyle 293 Expression System (Invitrogen Corp.), wherein the plasmid DNA for human prorenin expression (pcDNA3.1(+)/hREN) is used to conduct transient expression in FreeStyle 293-F cells. After transfection of the plasmid DNA, the cells are subjected to shaking at 37° C., 8% CO₂and 125 rpm for 3 days.

The prorenin protein is then accumulated and purified by salting out. Powdered ammonium sulfate is added to the culture medium and dissolved to make a 40% saturation of the salt. The resulting precipitate can be collected by centrifugation and discarded. Ammonium sulfate is added to the remaining solution and dissolved to make an 80% saturation of salt. The resulting precipitate can be collected by, for example, centrifugation. The prorenin protein is recovered by dissolving the precipitate in buffer.

The concentrated liquid is subjected to gel filtration chromatography using, for example, HiLoad 16/60 Superdex 200 pg (Amersham Biosciences, Inc.) equilibrated with 20 mM Tris-hydrochloric acid (pH 8.0) containing 0.15 M sodium chloride, at a flow rate of 1.4 mIJmin, to obtain 3.6 mg of purified prorenin (residues 24-406).

Example B
Purification of Active Renin

To 3.6 mg of prorenin (residues 24-406, as prepared in Example A) dissolved in 5.2 mL of 0.1 M Tris-hydrochloric acid (pH 8.0), is added 12 μg of trypsin (Roche Diagnostics Corp.), and the mixture is allowed to react at 28° C. for 55 minutes to carry out activation of renin. After the reaction, 0.4 mL of immobilized trypsin inhibitor (Pierce Biotechnology, Inc.) is added to remove the trypsin used in the activation, by adsorption. The reaction liquid containing the active renin is concentrated using Vivaspin 20 (molecular weight of the fraction 10,000; Vivascience, Inc.), and diluted with 20 mM Tris-hydrochloric acid (pH 8.0). The diluted liquid is fed to a TSKgel DEAE-5 PW column (7.5 mm I.D.×75 mm, Tosoh Corp.) equilibrated with 20 mM Tris-hydrochloric acid (pH 8.0) at a flow rate of 1 mL/min to adsorb the active renin (residues 67 406). The column is washed with the buffer solution used for the equilibration, and then elution is carried out by means of a linear concentration gradient of sodium chloride from 0 M to 0.3 M, to obtain 1.5 mg of purified active renin (residues 67-406).

Example C
Establishment of Renin Expressing Vector

A plasmid DNA to express human renin in HEIC293 cells can be prepared as follows. PCR is carried out using human renal cDNA (Clontech Laboratories, Inc., Marathon Ready cDNA) as the template and using two synthetic DNAs (5′-AAGCTTATGGATGGATGGAGA-3′ (S EQ ID NO: 1) and 5′-GGATCCTCAGCGGGCCAAGGC-3′ (S EQ ID NO: 2)), and the obtained fragment is cloned using TOPO TA Cloning Kit (Invitrogen Corp.). The obtained fragment is subcloned into pcDNA3.1(+) that has been cleaved by HindIII and BamHI, to obtain a plasmid DNA for human preprorenin expression (pcDNA3.1(+)/hREN).

Example D
Assaying the In Vitro Enzymatic Activity of Renin Inhibitors

Solutions of test compounds in varying concentrations mM final concentration) are prepared in dimethyl sulfoxide (DMSO) and then diluted into assay buffer comprising 50 mM Hepes, 1 mM EDTA, 1 mM DTT, 0.1 mg/mL BSA, 0.01% Brij35, pH 7.4. Alternatively, the assay can be performed with a high BSA concentration, wherein the buffer contains an additional 2% BSA.

Recombinant human renin (3 nM final concentration) is added to the dilutions and pre-incubated with the compounds for 10 minutes at 37° C. As described in Examples A-C above, human renin can be obtained by expressing preprorenin (residue 1-406) in mammalian cells, treating the prorenin (residues 24-406) contained in the culture supernatant with trypsin, and isolate the active form (residues 67-406). After pre-incubation, the reaction is initiated with of substrate QXL520-γ-Abu-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Thr-Lys (HiLyteFluo488)-Arg-OH (Anaspec, San Jose, Calif.). The final DMSO in the assay is 5%. The total volume of the reaction mixture is 20 μL, which can be placed on Greiner 384-well small volume plates.

Renin activity may be determined via fluorescence (excitation λ=485 nm; emission X=538 nm), e.g., on a Molecular Devices SPECTROmax GEMINI XPS. The fluorescence intensity is determined upon the addition of substrate and determined again after incubation at 37° C. for one hour. The fluorescence intensity of a blank (no inhibition) using vehicle alone is also determined. Renin activity is linearly proportional to the change in fluorescence observed (final-initial).

The percent inhibition of renin at a given compound concentration is defined as:

100%×[1−(F_compound/F_blank)]

where F_compoundis the observed fluorescence at a given concentration of test compound and F_blankis the observed fluorescence in the presence of vehicle alone.

The pIC₅₀value (negative log of the molar concentration of the compound that produces 50% inhibition) of a test compound is calculated by non-linear least squares curve fitting of the equation:

Percent Inhibition=100%/(1+(10^−pIC50/10 log [I]))

to percent inhibition versus compound concentration. The 50% inhibitory concentration (IC₅₀) of a test compound is calculated by raising 10 to the negative pIC₅₀(10^−pIC50).

IC₅₀values for selected compounds of the present invention are given in Table XII.

TABLE XII

IC₅₀of Exemplified Compounds Against Renin

Compound No.
1C₅₀(nM)

1
>1,000

3
>1,000

4
>1,000

5
>1,000

6
>1,000

7
>1,000

8
>1,000

9
>1,000

10
>1,000

11
>1,000

12
>1,000

13
>1,000

14
>1,000

15
>1,000

16
>1,000

17
>1,000

18
>1,000

19
>1,000

20
>1,000

21
>1,000

23
>1,000

24
100-1,000

25
>1,000

26
>1,000

27
>1,000

28
>1,000

29
>1,000

30
>1,000

31
>1,000

32
>1,000

33
>1,000

34
>1,000

35
>1,000

36
>1,000

37
>1,000

38
>1,000

39
>1,000

40
>1,000

41
>1,000

42
>1,000

43
>1,000

44
>1,000

45
>1,000

46
>1,000

47
>1,000

48
>1,000

49
>1,000

50
>1,000

51
>1,000

52
>1,000

53
>1,000

54
>1,000

55
>1,000

56
>1,000

57
>1,000

58
>1,000

59
>1,000

60
>1,000

61
>1,000

62
>1,000

63
>1,000

64
>1,000

65
>1,000

66
>1,000

67
>1,000

68
>1,000

69
>1,000

70
>1,000

71
>1,000

72
<100

73
100-1,000

74
<100

75
100-1,000

76
100-1,000

77
100-1,000

78
>1,000

79
100-1,000

80
100-1,000

81
100-1,000

82
>1,000

83
>1,000

84
100-1,000

85
>1,000

86
100-1,000

87
100-1,000

88
>1,000

89
>1,000

90
<100

91
100-1,000

92
100-1,000

93
>1,000

94
>1,000

95
100-1,000

96
100-1,000

97
<100

98
<100

99
100-1,000

100
100-1,000

101
>1,000

102
>1,000

103
>1,000

104
100-1,000

105
<100

106
<100

107
>1,000

108
100-1,000

109
100-1,000

110
100-1,000

111
100-1,000

112
>1,000

113
100-1,000

114
>1,000

115
100-1,000

116
100-1,000

118
<100

119
100-1,000

120
>1,000

121
>1,000

122
<100

123
<100

124
<100

125
<100

126
<100

127
<100

128
<100

129
<100

130
<100

131
<100

132
<100

133
<100

134
<100

135
<100

136
<100

137
<100

138
<100

139
<100

140
<100

141
100-1,000

142
<100

143
<100

144
<100

145
<100

146
<100

147
<100

148
<100

149
<100

150
<100

151
<100

152
<100

153
<100

154
<100

155
<100

156
<100

157
<100

158
<100

159
<100

160
<100

161
<100

162
<100

163
<100

164
<100

165
<100

166
100-1,000

167
<100

168
<100

169
<100

170
<100

171
<100

172
<100

173
<100

174
<100

175
<100

176
<100

177
<100

178
<100

179
<100

180
<100

181
<100

182
<100

183
<100

184
<100

185
<100

186
<100

187
<100

188
<100

189
<100

190
<100

191
<100

192
<100

193
<100

194
<100

195
<100

197
<100

198
<100

199
<100

200
<100

201
<100

202
<100

203
100-1,000

204
100-1,000

205
<100

206
<100

207
100-1,000

208
<100

209
100-1,000

210
100-1,000

211
<100

212
<100

213
100-1,000

214
<100

mixture of 215 & 216
<100

mixture of 217 & 218
<100

219
<100

220
<100

221
<100

222
<100

mixture of 223 & 224
<100

226 mixture of 225 & 226
<100

mixture of 227 & 228
<100

229
<100

231
100-1,000

232
100-1,000

233
100-1,000

234
>1,000

235
100-1,000

236
<100

237
100-1,000

238
<100

239
100-1,000

240
>1,000

241
100-1,000

242
>1,000

243
>1,000

244
>1,000

245
>1,000

246
>1,000

247
>1,000

248
>1,000

249
<100

250
<100

251
<100

252
<100

253
<100

254
<100

255
<100

256
<100

257
<100

258
<100

259
<100

260
<100

261
<100

262
100-1,000

263
100-1,000

264
100-1,000

265
100-1,000

266
100-1,000

267
100-1,000

268
100-1,000

269
100-1,000

270
100-1,000

271
100-1,000

272
100-1,000

273
100-1,000

274
100-1,000

275
100-1,000

276
100-1,000

277
100-1,000

278
100-1,000

279
100-1,000

280
100-1,000

281
100-1,000

282
100-1,000

283
100-1,000

284
100-1,000

285
100-1,000

286
100-1,000

287
100-1,000

288
100-1,000

289
100-1,000

290
100-1,000

291
100-1,000

292
100-1,000

293
100-1,000

294
100-1,000

295
100-1,000

296
100-1,000

297
100-1,000

298
100-1,000

299
100-1,000

300
100-1,000

301
100-1,000

302
100-1,000

303
100-1,000

304
100-1,000

305
100-1,000

306
100-1,000

307
100-1,000

308
100-1,000

309
100-1,000

310
100-1,000

311
100-1,000

312
100-1,000

313
100-1,000

314
100-1,000

315
100-1,000

316
100-1,000

317
100-1,000

318
100-1,000

319
100-1,000

320
100-1,000

321
100-1,000

322
100-1,000

323
>1,000

324
>1,000

325
>1,000

326
>1,000

327
>1,000

328
>1,000

329
>1,000

330
>1,000

331
>1,000

332
>1,000

333
>1,000

334
>1,000

335
100-1,000

337
>1,000

338
<100

339
100-1,000

340
100-1,000

341
100-1,000

342
100-1,000

343
100-1,000

344
100-1,000

345
100-1,000

346
100-1,000

347
100-1,000

348
100-1,000

349
100-1,000

350
100-1,000

351
100-1,000

352
100-1,000

353
100-1,000

354
100-1,000

355
100-1,000

356
100-1,000

357
100-1,000

358
100-1,000

359
100-1,000

360
100-1,000

361
100-1,000

362
100-1,000

363
100-1,000

364
100-1,000

365
100-1,000

366
100-1,000

367
100-1,000

368
100-1,000

369
100-1,000

370
100-1,000

371
100-1,000

372
100-1,000

373
100-1,000

374
100-1,000

375
100-1,000

376
100-1,000

377
100-1,000

378
100-1,000

379
100-1,000

380
100-1,000

381
100-1,000

382
100-1,000

383
100-1,000

384
>1,000

385
>1,000

386
>1,000

387
>1,000

388
>1,000

389
>1,000

390
>1,000

391
>1,000

392
>1,000

393
>1,000

394
>1,000

395
>1,000

396
>1,000

397
>1,000

398
>1,000

399
>1,000

400
>1,000

401
>1,000

402
>1,000

403
>1,000

404
>1,000

405
>1,000

406
>1,000

407
>1,000

408
>1,000

409
>1,000

410
>1,000

411
>1,000

412
>1,000

413
>1,000

414
>1,000

415
>1,000

416
>1,000

417
>1,000

418
>1,000

419
>1,000

420
>1,000

421
>1,000

422
>1,000

423
>1,000

424
>1,000

425
100-1,000

426
100-1,000

427
>1,000

428
100-1,000

429
<100

430
100-1,000

431
>1,000

432
>1,000

433
>1,000

434
100-1,000

435
<100

436
<100

437
<100

438
<100

439
<100

441
<100

442
<100

443
<100

444
<100

445
100-1,000

446
100-1,000

447
100-1,000

448
100-1,000

449
100-1,000

450
100-1,000

451
<100

452
<100

453
<100

454
<100

455
<100

456
<100

457
<100

458
<100

459
<100

460
<100

461
100-1,000

462
100-1,000

463
<100

464
<100

465
<100

466
100-1,000

467
100-1,000

468
100-1,000

469
100-1,000

470
100-1,000

471
100-1,000

472
100-1,000

473
100-1,000

474
100-1,000

475
100-1,000

476
100-1,000

477
100-1,000

478
100-1,000

479
<100

480
100-1,000

481
100-1,000

482
100-1,000

483
100-1,000

484
>1,000

485
>1,000

486
100-1,000

487
100-1,000

488
100-1,000

489
>1,000

490
<100

491
<100

492
<100

493
<100

494
<100

495
<100

496
<100

497
<100

498
<100

499
<100

500
<100

501
100-1,000

502
>1,000

503
100-1,000

504
100-1,000

505
<100

506
100-1,000

507
100-1,000

508
100-1,000

509
100-1,000

Number	Name	Date	Kind
6448271	Lubisch et al.	Sep 2002	B1
6476050	Aquila et al.	Nov 2002	B2

Number	Date	Country
WO0168604	Sep 2001	WO
WO02068420	Sep 2002	WO
WO03051840	Jun 2003	WO
WO03075921	Sep 2003	WO
WO03087304	Oct 2003	WO
WO2004058264	Jul 2004	WO
WO2004082638	Sep 2004	WO
WO2006007540	Jan 2006	WO
WO2006007998	Jan 2006	WO
WO2006044509	Apr 2006	WO
WO2006104280	May 2006	WO
WO2006098519	Sep 2006	WO
WO2007056170	May 2007	WO
WO2007082554	Jul 2007	WO
WO2008003736	Jan 2008	WO

Renin inhibitors

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

US Classifications

Field of Search

US

International Classifications

Term Extension

Abstract

Description

Claims

RELATED APPLICATIONS

US Referenced Citations (2)

Foreign Referenced Citations (15)

Provisional Applications (1)